

Advances in VIRUS RESEARCH

VOLUME 49

Cumulative Subject Index
Volumes 25 – 47



ACADEMIC PRESS

Advances in
VIRUS RESEARCH

VOLUME 49

Cumulative Subject Index
Volumes 25–47

ADVISORY BOARD

DAVID BALTIMORE

ROBERT M. CHANOCK

PETER C. DOHERTY

H. J. GROSS

B. D. HARRISON

PAUL KAESBERG

BERNARD MOSS

ERLING NORRBY

AKIRA OYA

J. J. SKEHEL

R. H. SYMONS

M. H. V. VAN REGENMORTEL

Advances in VIRUS RESEARCH

Edited by

KARL MARAMOROSCH FREDERICK A. MURPHY

Department of Entomology
Rutgers University
New Brunswick, New Jersey

School of Veterinary Medicine
University of California, Davis
Davis, California

AARON J. SHATKIN

Center for Advanced Biotechnology and Medicine
Piscataway, New Jersey

VOLUME 49

Cumulative Subject Index
Volumes 25–47

ACADEMIC PRESS
San Diego London Boston
New York Sydney Tokyo Toronto

This book is printed on acid-free paper. ∞

Copyright © 1997 by ACADEMIC PRESS

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, Massachusetts 01923), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-1997 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters.

0065-3527/97 \$25.00

Academic Press

a division of Harcourt Brace & Company

525 B Street, Suite 1900, San Diego, California 92101-4495, USA

<http://www.apnet.com>

Academic Press Limited

24-28 Oval Road, London NW1 7DX, UK

<http://www.hbuk.co.uk/ap/>

International Standard Book Number: 0-12-039849-4

PRINTED IN THE UNITED STATES OF AMERICA

97 98 99 00 01 02 MM 9 8 7 6 5 4 3 2 1

CONTENTS

CONTENTS OF VOLUMES 25-47	vii
SUBJECT INDEX	1
CONTRIBUTOR INDEX	207

This Page Intentionally Left Blank

CONTENTS OF VOLUMES 25–47

VOLUME 25

Translation of Plant Virus Messenger RNAs J. G. ATABEKOV AND S. YU. MOROZOV	1
The Closteroviruses: A Distinct Group of Elongated Plant Viruses M. BAR-JOSEPH, S. M. GARNSEY, AND D. GONSALVES	93
Host Passage Effects with Plant Viruses C. E. YARWOOD	169
Vector Cell Monolayers and Plant Viruses L. M. BLACK	191
The Structural Properties and Identification of Insect Viruses K. A. HARRAP AND C. C. PAYNE	273
Adenovirus Proteins and Their Messenger RNAs LENNART PHILIPSON	357
Adeno-associated Viruses K. I. BERNS AND W. W. HAUSWIRTH	407
Envelope Antigens of Oncoviruses ANATOLI D. ALTSTEIN AND VICTOR M. ZHDANOV	451

VOLUME 26

Processing of Adenovirus Nuclear RNA to mRNA JOSEPH R. NEVINS AND SELINA CHEN-KIANG	1
Persistent Viral Infections as Models for Research in Virus Chemotherapy G. STREISSLE	37
Viruses as Probes for Development and Differentiation WARREN MALTZMAN AND ARNOLD J. LEVINE	65
The Biology and Ecology of Strains of an Insect Small RNA Virus Complex P. D. SCOTTI, J. F. LONGWORTH, N. PLUS, G. CROIZIER, AND C. REINGANUM	118
Tobacco Mosaic Virus: Model for Structure and Function of a Simple Virus L. HIRTH AND K. E. RICHARDS	145
Plant–Virus Interactions Related to Resistance and Localization of Viral Infections ILAN SELA	201

VOLUME 27

Diagnostic Virology Using Electron Microscopic Techniques	
ANNE M. FIELD	1
Studies of Japanese Encephalitis in China	
C. H. HUANG	71
<i>Plantago</i> as a Host of Economically Important Viruses	
JOHN HAMMOND	103
Penetration of Viral Genetic Material into Host Cell	
A. G. BUKRINSKAYA	141
Comparative Biology and Evolution of Bacteriophages	
DARRYL C. REANNEY AND HANS-W. ACKERMANN	205
Mechanisms of Viral Tumorigenesis	
RAYMOND V. GILDEN AND HARVEY RABIN	281

VOLUME 28

Genetic Engineering with Plant Viruses, and Their Potential as Vectors	
R. HULL AND J. W. DAVIES	1
The Molecular Biology of Coronaviruses	
LAWRENCE S. STURMAN AND KATHRYN V. HOLMES	35
Sternorrhynchous Vectors of Plant Viruses: Virus-Vector Interactions and Transmission Mechanisms	
KERRY F. HARRIS	113
Granulosis Viruses, with Emphasis on the GV of the Indian Meal Moth, <i>Plodia interpunctella</i>	
R. A. CONSIGLI, K. A. TWEETEN, K. K. ANDERSON, AND L. A. BULLA, JR.	141
Virus Structure: High-Resolution Perspectives	
STEPHEN C. HARRISON	175
Viroids	
T. O. DIENER	241
Chickenpox Virus	
MICHAEL J. TAKAHASHI	285
Mosquitoes and the Incidence of Encephalitis	
PAUL R. GRIMSTAD	357

VOLUME 29

Prions: Novel Infectious Pathogens	
STANLEY B. PRUSINER	1
Molecular Biology of Wound Tumor Virus	
DONALD L. NUSS	57
The Application of Monoclonal Antibodies in the Study of Viruses	
MICHAEL J. CARTER AND VOLKER TER MEULEN	95
Monoclonal Antibodies against Plant Viruses	
EVAMARIE SANDER AND RALF G. DIETZGEN	131
Immunosorbent Electron Microscopy for Detection of Viruses	
DAVID KATZ AND ALEXANDER KOHN	169

The Entomopoxviruses	
BASIL M. ARIF	195
Use of Protoplasts and Separate Cells in Plant Virus Research	
EVAMARIE SANDER AND GABRIELE MERTES	215
Vibriophages and Vibriocins: Physical, Chemical, and Biological Properties	
S. N. CHATTERJEE AND M. MAITI	263
Plant Virus-Specific Transport Function and Resistance of Plants to Viruses	
J. G. ATABEKOV AND YU. L. DOROKHOV	313

VOLUME 30

An Unusual Replication Strategy of an Animal Iridovirus	
K. G. MURTI, R. GOORHA, AND A. GRANOFF	1
Mosquito Cell Cultures and the Study of Arthropod-Borne Togaviruses	
AKIRA IGARASHI	21
The High-Voltage Electron Microscope in Virology	
H. M. MAZZONE, G. WRAY, AND W. F. ENGLER	43
New Antiviral Compounds	
G. STREISSLE, A. PAESSENS, AND H. OEDIGER	83
The Molecular Biology of Geminiviruses	
JOHN STANLEY	139
The Role of Avian Retroviral LTRs in the Regulation of Gene Expression and Viral Replication	
GRACE JU AND BRYAN R. CULLEN	179
Marek's Disease Virus	
SHIRO KATO AND KANJI HIRAI	225
Bunyavirus Pathogenesis	
IAN M. PARSONSON AND DALE A. MCPHEE	279

VOLUME 31

Ambisense RNA Genomes of Arenaviruses and Phleboviruses	
DAVID H. L. BISHOP	1
The Molecular Basis of Antigenic Variation in Influenza Virus	
GILLIAN M. AIR AND W. GRAEME LAVER	53
Epitope Mapping of Flavivirus Glycoproteins	
FRANZ X. HEINZ	103
Regulation of Adenovirus mRNA Formation	
S. J. FLINT	169
Regulation of Protein Syntheses in Virus-Infected Animal Cells	
MARILYN KOZAK	229
Latency of Insect Viruses	
J. D. PODGWAITE AND H. M. MAZZONE	293
Plant Viruses in Rivers and Lakes	
RENATE KOENIG	321
Antibody-Dependent Enhancement of Viral Infectivity	
JAMES S. PORTERFIELD	335

Virus-Related Pathology: Is the Continued Presence of the Virus Necessary? J. HUPPERT AND T. F. WILD	357
Nonpersistent Viruses: Epidemiology and Control B. RACCAH	387

VOLUME 32

Toward New Viral Vaccines for Man ERLING NORRBY	1
Retroid Virus Genome Replication WILLIAM S. MASON, JOHN M. TAYLOR, AND ROGER HULL	35
Viral Oncogenes, <i>v-yes</i> and <i>v-erbB</i> , and Their Cellular Counterparts KUMAO TOYOSHIMA, TADASHI YAMAMOTO, SADAAKI KAWAI, AND MITSUAKI YOSHIDA	97
Hepatitis A A. G. COULEPIS, B. N. ANDERSON, AND I. D. GUST	129
Cryptic Plant Viruses GUIDO BOCCARDO, VITTORIA LISA, ENRICO LUISONI, AND ROBERT G. MILNE	171
Molecular Studies of Brome Mosaic Virus Using Infectious Transcripts from Cloned cDNA PAUL AHLQUIST, ROY FRENCH, AND JOZEF J. BUJARSKI	215
Adeno-Associated Viruses: An Update KENNETH I. BERNS AND ROY A. BOHENZKY	243

VOLUME 33

Domains of Virus Glycoproteins MILTON J. SCHLESINGER AND SONDR A SCHLESINGER	1
Flavivirus Replication Strategy E. G. WESTAWAY	45
The Autonomously Replicating Parvoviruses of Vertebrates SUSAN F. COTMORE AND PETER TATTERSALL	91
Regulation of Translation by Poliovirus NAHUM SONENBERG	175
Disease Induction by Plant Viruses L. C. VAN LOON	205
The Dianthoviruses: A Distinct Group of Isometric Plant Viruses with Bipartite Genome C. HIRUKI	257
Banana Bunchy Top: An Economically Important Tropical Plant Virus Disease JAMES L. DALE	301
Approaches to the Study of Vector Specificity for Arboviruses—Model Systems Using Cultured Mosquito Cells VICTOR STOLLAR	327

VOLUME 34

Initiation of Viral DNA Replication THOMAS J. KELLY, MARC S. WOLD, AND JOACHIM LI	1
Vaccinia: Virus, Vector, Vaccine ANTONIA PICCINI AND ENZO PAOLETTI	43
The pre-S Region of Hepadnavirus Envelope Proteins A. ROBERT NEURATH AND STEPHEN B. H. KENT	65
Archaeobacterial Viruses WOLF-DIETER REITER, WOLFRAM ZILLIG, AND PETER PALM	143
The Lentiviruses: Maedi/Visna, Caprine Arthritis-Encephalitis, and Equine Infectious Anemia WILLIAM P. CHEEVERS AND TRAVIS C. MCGUIRE	189
Poliovirus Neurovirulence VINCENT R. RACANIELLO	217
The Molecular Biology of Influenza Virus Pathogenicity HANS-DIETER KLENK AND RUDOLF ROTT	247
Measurement of the Affinity of Antiviral Antibodies P. ANNE UNDERWOOD	283

VOLUME 35

Synthesis and Processing of Avian Sarcoma Retrovirus RNA C. MARTIN STOLTZFUS	1
The Viral and Cellular Forms of the Abelson (<i>abl</i>) Oncogene NAOMI ROSENBERG AND OWEN N. WITTE	39
Molecular Structure, Biology, and Genetics of Prions STANLEY B. PRUSINER	83
Bacteriophage $\phi 6$: A Unique Virus Having a Lipid-Containing Membrane and a Genome Composed of Three dsRNA Segments LEONARD MINDICH	137
Baculovirus Vectors for Expression of Foreign Genes C. YONG KANG	177
Rotavirus and Adult Diarrhea HUNG TAO	193
Viral-Bacterial Synergistic Interaction in Respiratory Disease LORNE A. BABIUK, M. J. P. LAWMAN, AND H. BIELEFELDT OHMANN	219
African Swine Fever CHARLES A. MEBUS	251
Carrier-Mediated Delivery of Antiviral Agents PETER G. CANONICO, MEIR KENDE, AND BJARNE GABRIELSEN	271

VOLUME 36

Biology and Molecular Biology of Furoviruses ALAN A. BRUNT AND K. E. RICHARDS	1
<i>Drosophila</i> Retrotransposons: Interactions with Genome G. ECHALIER	33

Virus Entry into Animal Cells MARK MARSH AND ARI HELENIUS	107
Toward Understanding the Molecular Basis for Attenuation of Picornaviruses JEFFREY I. COHEN	153
Molecular Determinant of Rotavirus Neutralization and Protection SUZANNE M. MATSUI, ERICH R. MACKOW, AND HARRY B. GREENBERG	181
Rabies Virus Epitopic Variation: Use in Ecologic Studies JEAN S. SMITH	215
Molecular Pathogenesis of Sindbis Virus Encephalitis in Experimental Animals DIANE E. GRIFFIN	255
Structure of Potyvirus Coat Proteins and Its Application in the Taxonomy of the Potyvirus Group D. D. SHUKLA AND C. W. WARD	273
Industrial Production of Viral Pesticides T. R. SHIEH	315

VOLUME 37

Oncogenes, Protooncogenes, and Signal Transduction: Toward a Unified Theory? ROBERT W. STORMS AND HENRY R. BOSE, JR.	1
Mechanisms of Viral-Mediated <i>Trans</i> -Activation of Transcription JOSEPH R. NEVINS	35
The Role of Viral and Cellular Nuclear Proteins in Herpes Simplex Virus Replication DAVID M. KNIPE	85
Human Papillomaviruses and Carcinomas DENISE A. GALLOWAY AND JAMES K. MCDUGALL	126
Cytoplasmic Polyhedrosis Viruses—Reoviridae SERGE BELLONCIK	173
The Paramyxoviridae: Aspects of Molecular Structure, Pathogenesis, and Immunity RAIJA VAINIONPÄÄ, RAYMOND MARUSYK, AND AIMO SALMI	211
The Outbreak of Poliomyelitis in Finland in 1984-1985: Significance of Antigenic Variation of Type 3 Polioviruses and Site Specificity of Antibody Responses in Antipolio Immunizations TAPANI HOVI	243
Eastern Equine Encephalomyelitis Virus: Epidemiology and Evolution of Mosquito Transmission THOMAS W. SCOTT AND SCOTT C. WEAVER	277
Electrotransfection of Plant Protoplasts with Viral Nucleic Acids TADAOKI HIBI	329

VOLUME 38

Molecular Biology of Rotaviruses A. R. BELLAMY AND G. W. BOTH	1
--	---

Molecular Biology of Varicella Zoster Virus JEFFREY M. OSTROVE	45
Structure and Function of the RNA Polymerase of Vesicular Stomatitis Virus AMIYA K. BANERJEE AND DHRUBAJYOTI CHATTOPADHYAY	99
Control of Expression and Cell Tropism of Human Immunodeficiency Virus Type 1 JEROME A. ZACK, SALVATORE J. ARRIGO, AND IRVIN S. Y. CHEN	125
Interferon-Induced Proteins and the Antiviral State PETER STAEHEL I	147
Expression of a Plant Virus-Coded Transport Function by Different Viral Genomes JOSEPH G. ATABEKOV AND MIKHAIL E. TALIANSKY	201
Structural and Functional Properties of Plant Reovirus Genomes DONALD L. NUSS AND DAVID J. DALL	249
Regulation of Tobamovirus Gene Expression WILLIAM O. DAWSON AND KIRSI M. LEHTO	307
The "Merry-Go-Round": Alphaviruses between Vertebrate and Invertebrate Cells HANS KOBLET	343
Emergence, Natural History, and Variation of Canine, Mink, and Feline Parvoviruses COLIN R. PARRISH	403

VOLUME 39

Human Immunodeficiency Virus Structure: Implications for Antiviral Design EDWARD ARNOLD AND GAIL FERSTANDIG ARNOLD	1
Abortive Infection and Malignant Transformation by Adenoviruses: Integration of Viral DNA and Control of Viral Gene Expression by Specific Patterns of DNA Methylation WALTER DOERFLER	89
Paramyxoviridae: Transcription and Replication MARK S. GALINSKI	129
Genomic Segment Reassortment in Rotaviruses and Other Reoviridae ROBERT F. RAMIG AND RICHARD L. WARD	163
Hepatitis A Virus and Hepatitis A Infection BRUCE C. ROSS, DAVID A. ANDERSON, AND IAN D. GUST	209
Problems and Prospects for Preparation of Killed Antiviral Vaccines E. I. BUDOWSKY	255
Pathogenesis of Theiler's Murine Encephalomyelitis Virus MASAHITO YAMADA, ANDREAS ZURBRIGGEN, AND ROBERT S. FUJINAMI	291
Satellite RNA for the Biocontrol of Plant Disease PO TIEN AND GUSUI WU	321

VOLUME 40

Regulation of Gene Expression in the Human Immunodeficiency Virus Type 1 BRYAN R. CULLEN	1
---	---

Immortalizing Genes of Epstein–Barr Virus TIM MIDDLETON, TONI A. GAHN, JENNIFER M. MARTIN, AND BILL SUGDEN	19
Molecular Biology of Non-A, Non-B Hepatitis Agents: Hepatitis C and Hepatitis E Viruses GREGORY R. REYES AND BAHIGE M. BAROUDY	57
The 5'-Untranslated Region of Picornaviral Genomes VADIM I. AGOL	103
Effects of Defective Interfering Viruses on Virus Replication and Pathogenesis <i>in Vitro</i> and <i>in Vivo</i> LAURENT ROUX, ANNE E. SIMON, AND JOHN J. HOLLAND	181
Structure and Function of the HEF Glycoprotein of Influenza C Virus GEORG HERRLER AND HANS-DIETER KLENK	213
Bunyaviridae: Genome Organization and Replication Strategies MICHÈLE BOULOY	235

VOLUME 41

Human Herpesvirus 6: The Virus and the Search for Its Role as a Human Pathogen PHILIP E. PELLETT, JODI B. BLACK, AND MASAHIRO YAMAMOTO	1
The Pestiviruses VOLKER MOENNIG AND PETER G. W. PLAGEMANN	53
Lactate Dehydrogenase-Elevating Virus, Equine Arteritis Virus, and Simian Hemorrhagic Fever: A New Group of Positive-Strand RNA Viruses PETER G. W. PLAGEMANN AND VOLKER MOENNIG	99
Translational Suppression in Retroviral Gene Expression DOLPH L. HATFIELD, JUDITH G. LEVIN, ALAN REIN, AND STEPHEN OROSZLAN	193
Molecular Biology and Genetics of Neurodegenerative Diseases Caused by Prions STANLEY B. PRUSINER	241
Cucumber Mosaic Virus PETER PALUKAITIS, MARILYN J. ROOSSINCK, RALF G. DIETZGEN, AND RICHARD I. B. FRANCKI	282
New Plant Virus Problems in Developing Countries: A Corollary of Agricultural Modernization L. BOS	349
Prospects for Oral Vaccination Using Recombinant Bacteria Expressing Viral Epitopes FLORIAN SCHÖDEL	409

VOLUME 42

Antiviral Agents: Characteristic Activity Spectrum Depending on the Molecular Target with Which They Interact ERIC DE CLERCQ	1
--	---

Interferon-Induced Antiviral Actions and Their Regulation	
GANES C. SEN AND RICHARD M. RANSOHOFF	57
Human Immunodeficiency Virus Vaccines	
DANI P. BOLOGNESI	103
Synthetic Peptides as Diagnostic Tools in Virology	
PAULI LEINIKKI, MATTI LEHTINEN, HEIKKI HYÖTY, PÄIVI PARKKONEN, MARJA-LEENA KANTANEN, AND JUHA HAKULINEN	149
Virus Infection of Polarized Epithelial Cells	
SIMON P. TUCKER AND RICHARD W. COMPANS	187
Pathogenesis of Virus-Induced Demyelination	
JOHN K. FAZAKERLEY AND MICHAEL J. BUCHMEIER	249
Reovirus Receptors	
GORDON J. SAUVÉ, H. URI SARAGOVÍ, AND MARK I. GREENE	325
Biology of Coxsackie A Viruses	
TIMO HYYPIÄ AND GLYN STANWAY	343
Pathophysiology of Rabies Virus Infection of the Nervous System	
HENRI TSIANG	375

VOLUME 43

New, Emerging, and Reemerging Infectious Diseases	
FREDERICK A. MURPHY	1
Regulation of Human Immunodeficiency Virus Infection: Implications for Pathogenesis	
BETH ANN ANTONI, STEVEN B. STEIN, AND ARNOLD B. RABSON	53
Geographic-Specific Genotypes or Topotypes of Human T-Cell Lymphotropic Virus Type I as Markers for Early and Recent Migrations of Human Populations	
RICHARD YANAGIHARA	147
Recent Developments in Hepatitis Delta Virus Research	
DAVID W. LAZINSKI AND JOHN M. TAYLOR	188
Toroviruses of Animals and Humans: A Review	
MARION KOOPMANS AND MARIAN C. HORZINEK	233
Molecular Studies of Genetic RNA-RNA Recombination in Brome Mosaic Virus	
JOZEF J. BUJARSKI, PETER D. NAGY, AND STANISLAW FLASINSKI	275
New Developments in Fungal Virology	
SAID A. GHABRIAL	303

VOLUME 44

Pararetroviruses and Retroviruses: A Comparative Review of Viral Structure and Gene Expression Strategies	
HELEN M. ROTHNIE, YVAN CHAPDELAINÉ, AND THOMAS HOHN	1

Molecular Biology of Rubella Virus TERYL K. FREY	69
Rotaviruses: Immunologic Determinants of Protection against Infection and Disease PAUL A. OFFIT	161
Human Immunodeficiency Virus Type 1 Associated CD4 Downmodulation ROMAS GELEZIUNAS, STEPHANE BOUR, AND MARK A. WAINBERG	203
Antisense Treatment of Viral Infection J. LINDSAY WHITTON	268
The Structure, Function, and Regulation of Papillomaviral Genes in Infection and Cervical Cancer LUBOMIR P. TUREK	306
Equine Herpesviruses 2 and 5: Comparisons with Other Members of the Subfamily Gammaherpesvirinae CATHERINE T. AGIUS AND MICHAEL J. STUDDERT	357
The Molecular Biology of Tombusviridae MARCELLO RUSSO, JÖZSEF BURGYN, AND GIOVANNI P. MARTELLI	382
SpV1 and SpV4, Spiroplasma Viruses with Circular Single-Stranded DNA Genomes, and Their Contribution to the Molecular Biology of Spiroplasmas J. RENAUDIN AND J. M. BOVE	429

VOLUME 45

Apoptosis in Viral Infections ENAL S. RAZVI AND RAYMOND M. WELSH	1
Modification of Membrane Permeability by Animal Viruses LUIS CARRASCO	61
Membrane Fusion and the Alphavirus Life Cycle MARGARET KIELIAN	113
Equine Herpesviruses 4 (Equine Rhinopneumonitis Virus) and 1 (Equine Abortion Virus) BRENDAN S. CRABB AND MICHAEL J. STUDDERT	153
Bovine Herpesvirus 1 (BHV-1): Biology, Pathogenesis, and Control SURESH K. TIKOO, MANUEL CAMPOS, AND LORNE A. BABIUK	191
Feline Immunodeficiency Virus as a Model for Development of Molecular Approaches to Intervention Strategies against Lentivirus Infections JOHN H. ELDER AND TOM R. PHILLIPS	225
Characterization of Genome Structure and Establishment of Vector Cell Lines for Plant Reoviruses ICHIRO UYEDA, IKUO KIMURA, AND EISHIRO SHIKATA	249
Bacteriophage PRD1: A Broad Host Range dsDNA Tectivirus with an Internal Membrane DENNIS H. BAMFORD, JAVIER CALDENTY, AND JAANA K. H. BAMFORD	281

VOLUME 46

Poliovirus Assembly and Encapsidation of Genomic RNA DAVID ANSARDI, DONNA C. PORTER, MARIE J. ANDERSON, AND CASEY D. MORROW	1
---	---

Genome Rearrangements of Rotaviruses	
ULRICH DESSELBERGER	71
Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Early Events in Reverse Transcription	
ERIC J. ARTS AND MARK A. WAINBERG	99
Hepadnaviruses: Current Models of RNA Encapsidation and Reverse Transcription	
DOROTHY A. FALLOWS AND STEPHEN P. GOFF	167
Cell Types Involved in Replication and Distribution of Human Cytomegalovirus	
BODO PLACHTER, CHRISTIAN SINZGER, AND GERHARD JAHN	197
Varicella-Zoster Virus: Aspects of Pathogenesis and the Host Response to Natural Infection and Varicella Vaccine	
ANN M. ARVIN, JENNIFER F. MOFFAT, AND REBECCA REDMAN	265
Anatomy of Viral Persistence: Mechanisms of Persistence and Associated Disease	
JUAN CARLOS DE LA TORRE AND MICHAEL B. A. OLDSTONE	313
The Iridoviruses	
TREVOR WILLIAMS	347
Molecular Biology of Luteoviruses	
M. A. MAYO AND V. ZIEGLER-GRAFF	415

VOLUME 47

Marburg and Ebola Viruses	
HEINZ FELDMANN AND HANS-DIETER KLENK	1
Molecular Characterization of Pestiviruses	
GREGOR MEYERS AND HEINZ-JÜRGEN THIEL	53
Principles of Molecular Organization, Expression, and Evolution of Closteroviruses: Over the Barriers	
A. A. AGRANOVSKY	119
Comparison of the Replication of Positive-Stranded RNA Viruses of Plants and Animals	
KENNETH W. BUCK	159
Trans-Activation of Cellular Genes by Hepatitis B Virus Proteins: A Possible Mechanism of Hepatocarcinogenesis	
WOLFGANG H. CASELMANN	253
Autonomous Parvovirus and Densovirus Gene Vectors	
JOE CORSINI, BORIS AFANASIEV, IAN H. MAXWELL, AND JONATHAN O. CARLSON	303
Virus-Induced Immunopathology	
BARRY T. ROUSE	353
Geographic and Molecular Epidemiology of Primate T Lymphotropic Retroviruses: HTLV-I, HTLV-II, STLV-I, STLV-PP, and PTLV-L	
ANTOINE GESSAIN AND GUY DE THÉ	377

This Page Intentionally Left Blank

INDEX

*Boldface numerals indicate volume numbers***A**

- 2'-5'A analogs, antiviral activities, **30:120-123**
 viral mRNA degradation, **30:121**
- AAV, *see* Adeno-associated virus
- AAV-2, human herpesvirus 6 and, **41:18**
- Abaca bunchy top virus, **33:309-310**
- Abelson disease
 carboxy terminus, **35:72**
 lymphoid differentiation, **35:74**
 mutations within protein tyrosine kinase-conserved region, **35:73-74**
 pathology, **35:42-43**
- Abelson murine leukemia virus
 cell transformation by, **26:88-90**
 conditional transformation mutants, **35:72-73**
 early research, **35:40-41**
 genetics, **35:67-75**
 Ab-MLV-P160 vs. Ab-MLV-P120, **35:70-71**
 carboxy terminus, **35:71-72**
 conserved regions, **35:68-69**
gag sequences, **35:69-70**
 lymphoid transformation, **35:69**
 MoMLV, **35:67**
- hematopoietic transformation, **35:55-67**
- B lymphopoiesis, **35:55-57**
 establishment and progression of transformed state, **35:63-67**
 Ig gene structure, **35:57-58**
 interaction with hematopoietic lineages, **35:62-63**
 lymphoid differentiation markers, **35:58-60**
 transformant and target cell, **35:50-62**
- in vitro* transformation of lymphoid cells, **35:44-45**
 Ig gene structure, **35:57-58**
 lymphoid differentiation markers, **35:58-60**
 isolation, **35:41-42**
 oncogene structure
 activation of transforming potential, **35:53-55**
 molecular cloning, **35:50-51**
 protein expression, **35:46-50**
 splicing patterns, **35:51-53**
 3T3 cells *in vitro*, **35:43-44**
 Ts, **35:74**
- Aberrant ratio, in plants, and viral infection, **33:242**
- Ab-MLV, *see* Abelson murine leukemia virus
- Abortion
 equine abortion virus, **45:157-158**
 protozoal, in cattle, **43:46**
- Abortive infections, with parvoviruses, **33:168**
- Abortive replication, adeno-associated viruses, **25:422-425**
- Abscissic acid, viral infections and, **33:237-240**
- Abutilon mosaic virus, whitefly-transmitted, **30:143**
- AC 20, subculture, loss of susceptibility to, **25:215-216**
- N*-Acetylgalactosamine, HEF glycoprotein of influenza C virus and, **40:223**
- N*-Acetylneuraminic acid, HEF glycoprotein of influenza C virus and, **40:216, 221, 225**
- Acetyltransferases, influenza C virus HEF glycoprotein, **40:222-223, 228**
- Acidification, vacuolar, inhibitors, **45:119-121**
- Acidity
 archaeobacterial viruses and, **34:178**
 lentiviruses and, **34:193**
- AcNPV, *See* *Autographa californica* nucleopolyhedrosis virus
- 2'-5' A cores
 antiviral activities, **30:12**
 3'-methylated analogs, antiviral, **30:123**

- Acquired immunodeficiency syndrome
see also Human immunodeficiency virus
 and defective interfering viruses,
 40:188, 195
 development, 43:57–58
 feline and simian, 43:45–46
 HIV structure and, 39:3–5, 16, 24, 56
 glycoproteins, 39:43, 46–50
pol gene products, 39:25, 28, 30, 39
 human herpesvirus 6 and, 41:2–4, 15, 35
 killed antiviral vaccines and, 39:284
 lactate dehydrogenase-elevating virus
 and, 41:119, 182
 lentiviruses and, 34:189, 191
 lesions of demyelination, 42:250
 poliovirus and, 34:218
 translational suppression by retro-
 viruses and, 41:193
 viral demyelination, 42:284–285
- Acquisition, in nonpersistent virus trans-
 mission, 31:392–393
- Actinomycin C, effect on plant virus rep-
 lication, 29:254–255
- Actinomycin D
 effects
 BMV replication, 29:339
 30K protein synthesis, 38:330
 plant virus replication, 29:254–255
 tobacco mosaic virus vRNP polypep-
 tides, 29:351
 inhibition of arenaviruses, 31:9
 pestiviruses and, 41:77
 positive-strand RNA viruses and,
 41:158, 164, 179
- Acutely transforming defectives, defec-
 tive interfering viruses and, 40:194
- Acyclic nucleoside phosphonates, 42:23–27
- Acyclovir
 carrier-mediated delivery, 35:273, 288–
 289
 macromolecular carriers, 35:290–291
 prodrugs, 35:275–280
 clinical application, 30:126
 HIV structure and, 39:4, 30
 HSV inhibition, 30:95–98
in vitro and *in vivo*, 30:96–97
 human herpesvirus 6 and, 41:24–25
 specificity for herpesviruses, 42:16–18
 treatment of chickenpox, 28:335–336
- Adenine arabinoside, chickenpox treat-
 ment, 28:335
- 3-Adenin-9-yl-2-hydroxypropanoic acid,
 42:5, 8
- Adeno-associated virus, 25:407–444,
 47:306–311
 coat proteins, 32:250
 comparison with autonomous par-
 voviruses, 32:291–292
 defective-interfering particles, 32:265,
 282
 defectiveness, adenovirus-transformed
 cells and, 25:434–435
 DNA synthesis and, 25:431–432
 helper requirements and, 25:435
 herpesvirus as a helper, 25:433–434
 RNA synthesis and, 25:432–433
 discovery, 32:244
 DNA replication, 32:260–266
 DNA polymerase and, 32:265–266
 steps of, model, 32:253, 261–263
 terminal repeat efficiency, wild-type
 and mutants, 32:263–265
 future study, 32:293
 gene vectors, 47:317–320
 genomic linear ssDNA, 32:243, 245
 inverted terminal repeat, 32:248–
 249
 mutations, 32:252–258
 nucleotide sequence, 32:246–247
 ORFs, 32:249–250
 RNA transcripts, 32:249–250
 location, 32:256
 as mRNAs, 32:256–258
 protein-coding, 32:256–258
 splicing, 32:256–258
 genomic organization, 47:308–309
 host range, 32:244–245
 infection, DNA replication
 inhibitory effects, 25:435–438
 penetration, 25:418–420
 infectious, generation during transduc-
 ing virus production, 47:325–326
 inhibition
 adenovirus
 infection *in vivo*, mouse, 32:280
 oncogenicity *in vivo*, hamster,
 32:280–282
 replication *in vitro*, 32:277–279
 rodent cell transformation *in vitro*,
 32:282–285

- herpesvirus oncogenicity, **32:285–287**
 SV40 replication *in vitro*, **32:279–280**
- latent infection
 adenovirus required for
 growth, **32:268–269**
 rescue, **32:274–277**
 DNA integration, **32:269–274**
 cloned into bacterial plasmids,
32:271–272
 cotransfected with SV40 DNA,
32:272–274
 history, **25:438–439**
 in tissue culture, **25:439–442**
 lytic infection, **25:435–436**
 oncolytic effects, **47:316**
 packaging cell lines, **47:326–327**
 protein
 antigenic properties, **25:418**
 physical characteristics, **25:416–418**
 protein synthesis, **32:266–268**
 replication
 dependence on helper viruses,
32:243–244, 251–252
 genome parts critical for, **32:252–255**
 transcription, **32:255–260**
 initiation by promoters, **32:256**
in vitro, **25:427–429**
 regulation by helper viruses, **32:258**
 self-regulation, **32:258–260**
 mutation effects, **32:259–260**
 translation, **25:429–431**
 vectors for DNA cloning, **32:288–290**
 eukaryotic gene expression, **32:291**
 prokaryotic gene expression, **32:289–290**
 viral oncogenicity, adenovirus and,
25:436–437
 herpesvirus and, **25:437–438**
 virion assembly, **25:429–431**
 structure, **25:409–416**
- Adenocarcinoma, vibriocin-sensitive,
29:304
- 5-Adenosyl homocysteine hydrolase inhibitor, **30:100**
- S-Adenosylhomocysteine hydrolase inhibitors, **42:5, 7–10**
 mechanism of action, **42:8–9**
 susceptibility of virus replication, **42:8**
- viruses sensitive to, **42:8**
- S-Adenosylmethionine, viral replication
 and, **33:339–343, 360, 362**
- Adenovirus
 AAV inhibitory effects
 infection *in vivo*, mouse, **32:280**
 oncogenicity *in vivo*, hamster,
32:280–282
 replication *in vitro*, **32:277–279**
 rodent cell transformation *in vitro*,
32:282, 285
 abortive infection and, **39:89–95**
 animal cells and, **36:113, 136–138**
 apoptosis induced by, **45:15–16**
 assembly, **25:393–396**
 attachment proteins, **27:191**
 cell penetration by, **27:152, 191–192**
 cellular receptors for, **27:191**
 DNA replication, **34:1–3, 33**
 origin, **34:4–7**
 protein, **34:7–9**
 reaction, **34:3–4**
 SV40, **34:10**
 early proteins, **25:360–364**
 purification, **25:376–379**
 effects on AAV latent infection
 growth induction, **32:268–269**
 rescue possibility, **32:274–277**
 E2 promoter interactions, **37:53–54**
 gene expression control, **26:29–31**
 helper functions for AAV replication
E1a gene product, **32:251**
 early region 4, **32:251**
 early region 2a, **32:251**
 hepadnavirus and, **34:104**
 hexon polymerization, **29:117**
 immunocomplexes with antibodies,
29:186
 immunosorbent electron microscopy,
29:187
 infection, and HIV expression, **43:112**
 mammalian cells, gene expression and,
25:357–360
- mRNA
 biogenesis, **26:1–31**
 late promoter, **26:13–15**
 methylation, **26:23–24**
 poly(A) addition, **26:18–23**
 processing, **26:19–28**
 speculations, **25:396–400**
 splicing, **26:24–28**

- Adenovirus (*cont.*)
 mRNA (*cont.*)
 structure, **26:10–13**
 oncodna viruses
 DNA persistence, **39:104–110**
 integrative recombination, **39:110–111**
 oncogenicity
 genome regions E1a and E1b, role in, **32:282–283**
 serotype differences, **32:283**
 picornaviral genomes and, **40:145–146**
 polypeptides
 intermediate, **25:382–384**
 late, **25:390–391**
 structural, **25:369**
 taxonomic, **29:104**
 protein mRNAs, **25:357–400**
 replication, interferon-induced inhibition, **38:181–182**
 sequence-specific methylation, **39:111–114**
 eukaryotic promoters, **39:122–123**
 inverse correlations, **39:114**
 promoter inactivation, **39:123–124**
 reversal of inhibition, **39:117–119**
 spreading, **39:119–122**
 in vitro methylation, **39:114–117**
 species specificity
 DNA replication, **39:97–99**
 hamster cells, **39:95–97, 99–100**
 major late promoter, **39:100–102**
 partial complementation, **39:102–103**
 structural proteins, molecular weight, **25:370**
 transcription units, **26:3–10**
 early type, **26:5–8**
 late type, **26:8–10**
 nascent chain analysis, **26:3–4**
 structural aspects, **26:10–19**
 termination, **26:16–18**
 tumor antigens, **25:375–376**
 vaccinia and, **34:45**
 Adenovirus gene expression, regulation
 in infected cells, **31:262–265**
 mRNA
 stability, **31:216–218**
 transport from nucleus to cytoplasm, **31:211–216**
 transcription
 activation of late genes, **31:199–204**
 control signals, **31:179–187**
 E1A protein-mediated activation, **31:188–195**
 early to late transition, **31:199–204**
 enhancer elements, **31:183–187**
 pre-early to early transition, **31:188–195**
 promoter sites, **31:179–183**
 repression of early transcription, **31:195–199**
 transcription unit expression during, **31:170–179**
 during transcript processing, **31:204–211**
 polyadenylation, **31:205–207**
 splicing, **31:207–211**
 Adenovirus genes
 E1A in, **37:38–41**
 transcription, **37:38–41**
 Adenovirus type 2, **39:90, 94–95**
 oncodna viruses, **39:109**
 sequence-specific methylation, **39:115–117**
 species specificity, **39:97, 100–103**
 Adenovirus type 5, **39:90, 94–95, 102–103**
 Adenovirus type 12, **39:89–94**
 oncodna viruses, **39:106, 109–111**
 sequence-specific methylation, **39:111–114**
 species specificity, **39:95–103**
 Adherence, bacterial, **35:222–224**
 Adhesins, viral-bacterial synergistic interaction and, **35:222–223**
 Adrenocorticotrophic hormone, stress and, **35:234**
 ADRV, *see* Adult diarrhea rotavirus
 Adsorption
 antiviral antibody affinity and, **34:295, 302**
 archaeobacterial viruses and
 Halobacterium phages, **34:165–167**
 Halobacterium salinarium phage Hs1, **34:163–164**
 Sulfolobus virus-like particle SSV1, **34:177**
 bacteriophage ϕ 6, **35:163–164**
 influenza virus and, **34:251, 264, 274**
 plant viruses to particulate matter in waters, **31:324–326**

- Adult diarrhea rotavirus
 characterization
 antigenic relationship, 35:202–205
 classification, 35:205–206
 MAbs, 35:207–208
 molecular cloning, 35:207
 morphology, 35:194
 passage trials, 35:206
 RNA analysis, 35:194–202
 source of samples, 35:206–207
 clinical manifestations, 35:213–215
 diagnosis, 35:215–217
 epidemiological features, 35:208–213
 age distribution, 35:209–211
 morbidity and mortality, 35:208–209
 seasonal distribution, 35:209
 seroepidemiology, 35:210, 212–213
 sex distribution, 35:209
 waterborne nature, 35:210–211
 general considerations, 35:193–194
 prevention, 35:216–217
 treatment, 35:216–217
- Aedes aegypti* dengovirus vectors, 47:334–335
- Aedes albopictus*
 CPE(+) and CPE(-) clones, 33:333–339
 togavirus-infected cells
 cytopathology, 30:27–28
 defective-interfering particles, 30:25–26
 diagnostic antigen preparation, 30:35
 drug-resistant cell mutants, 30:28–29
 high virus-producing clones, 30:26–27
 isolation
 contaminating viruses, 30:36
 insect viruses, 30:34–35
 togaviruses, 30:29–34
 morphology, 30:22–23
 persistent infection, 30:23–25
 virus attenuation during, 30:35–36
- AEV, *see* Avian erythroblastosis virus
- Africa, HTLV-II occurrence, 47:405, 407–409
- African swine fever
 clinical signs, 35:256–259
 acute and subacute forms, 35:257–259
 chronic form, 35:259
 incubation period, 35:257
 peracute form, 35:257
 subclinical form, 35:259
 diagnosis, 35:265–268
 disinfectants for, 35:253
 epidemiology, 35:253–256
 husbandry, 35:256
 pork products, 35:254–255
 transmission, 35:255–256
 vectors, 35:253–254
 wild pigs, 35:256
 etiology, 35:252–253
 general considerations, 35:251–252
 geographical distribution, 35:252
 gross pathology, 35:259–260
 hog cholera vs., 35:263
 immunology, 35:263–265
 lesions
 fetal, 35:260
 histologic, 35:260–263
- Agallia constricta* van Duzee, 29:73
- Agallia quadripunctata*, cellular tests, 25:231–232
- Agalliopsis novella*, 29:73
- Agar double diffusion test, 29:148, 151
- Age
 hepatitis A virus and, 39:212, 216–218
 human herpesvirus 6 and, 41:27–28
 lactate dehydrogenase-elevating virus and, 41:151
- Age-dependent poliomyelitis
 ecotropic proviral content, 41:141–143
 mice, 41:102, 123
 motor neuron infection, 41:126–129
 motor neuron protection, 41:134–141
 MuLV, 41:128–134
 pathology, 41:124–126
- Agglutination
 HEF glycoprotein of influenza C virus and, 40:213, 224–226, 231
 influenza virus and, 34:262
 vaccinia and, 34:58
- Aging, pneumonia and, 35:235–236
- Agricultural modernization, *see* Plant viruses in developing countries
- Agriculture, infectious disease problems, 43:26–28
- Agrobacterium tumefaciens*, 29:88, 256
 satellite RNA for biocontrol, 39:332–333
- AIDS, *see* Acquired immunodeficiency syndrome

- Aino virus, congenital abnormalities in cattle, **30:295**
- Akabane disease, **43:19**
- Akabane virus
 experimental infection of chicken embryo, **30:295, 297**
 fetal pathology, domestic ruminants, **30:291–295**
 transplacental infection, **30:299–301**
 glycoproteins, proteolytic enzyme effects, **30:305**
 virion proteins, **30:303**
- Alanine aminotransferase
 hepatitis A virus, **39:212–213, 239–240**
 hepatitis C virus, **40:74, 77–79, 81**
 hepatitis E virus, **40:86**
- Albumin
 as antiviral drug carrier, **30:123–124**
 conjugates, carrier-mediated drug delivery and, **35:292**
 hepatitis C virus and, **40:78**
- Alcohol dehydrogenase, *Drosophila*, retrotransposons and, **36:83–84**
- Aldehydes
 cucumber mosaic virus and, **41:291–292, 294, 296**
 killed antiviral vaccines and, **39:260**
- Aleutian disease virus, antiviral antibody affinity and, **34:307**
- Aleyrodidae, as plant-virus vectors, **28:135–137**
- Alfalfa, sweet clover necrotic mosaic virus and, **33:293–294**
- Alfalfa cryptic virus, mixture of two viruses, **32:180**
- Alfalfa mosaic virus, **25:48–54, 33:211, 220, 222, 246**
 aphid transmission, **28:118**
 capsid proteins, **47:204–205**
 description, **31:389**
 genome organization, **41:305–306, 313**
 immunization of mice, **29:136**
 MAb-determined antigenic properties, **29:150**
 MAbs, **29:134**
Plantago hosts and occurrence, **27:116, 130**
 positive hybridomas, **29:143**
 protoplast infection, **29:227–228, 231, 235**
 pseudorecombinants, **33:211**
 replication, inhibition, **29:254–255**
 RNA₁, **25:53–54**
 RNA₃, **25:50–53**
 RNA₄, **25:50**
 RNA replication, **47:213**
 translation of RNAs *in vitro*, **25:50**
 tri-partite genome, **47:204**
 virus-host plant relationships, **41:328–329**
- Algae
 blue-green, cyanobacteria disease, **43:40**
 eukaryotic, isometric viruses from, **31:323–324**
- Alien genotypes, plant viruses in developing countries and, **41:353, 367**
- Alimentary canal, polarized epithelial cells, **42:217–225**
- Alkalinity, archaeobacterial viruses and, **34:180**
- Alkylation, DNA replication and, **34:13**
- Alleles, neurodegenerative diseases caused by prions and, **41:255–256, 258**
- Alligatorweed stunting disease, **25:116–117**
- Alphaherpesviruses, characterization, **44:357**
- Alpha-like virus supergroup
 replication proteins, **47:191–197**
 RNA synthesis, **47:212–213**
 sequences required for subgenomic RNA synthesis, **47:227–229**
 3' structural elements, **47:217–218**
 tRNA-like sequences in RNA, **47:215–217**
- Alphaviruses, **45:113–146**
 animal cells and
 endocytosis, **36:119, 121**
 entry, **36:130–132, 134**
 receptors, **36:117**
 asymmetry in positive- and negative-strand accumulation, **47:234**
 budding, **45:128–131**
 cellular receptors for, **27:147–148**
 cucumber mosaic virus and, **41:305**
 cytopathic effects, **38:371–373**
 endocytic uptake and low-pH-triggered fusion, **45:117–119**

- entry and fusion, molecular events
 during, 45:137–143
 effects on spike protein dimerization,
 45:139
 E2/p62 subunit alterations, 45:139–
 140
 E1 subunit alterations, 45:140–141
 events following receptor binding,
 45:138
 fusion event summary, 45:142
 truncated E1 studies, 45:142–143
 entry inhibition, temperature and,
 45:121
 exit from cell, 45:128–131
 pathway, cholesterol role, 45:136–
 137
 genomic coding strategies, 44:144–145
 glycoproteins, 33:8–19
 cytoplasmic domain, 33:10–11
 ectodomain, 33:12–13
 transmembrane domain, 33:11–12
 host range
 determinants, 33:11
 and tissue tropism, 45:114–115
 infection, cholesterol and sphin-
 gomyelin role, 45:135–136
 influenza virus and, 34:270
 interactions with plasma membrane
 receptor, 45:115–117
 in mosquito cells, 38:348–350
 nucleocapsid, 38:346–347
 phylogenetic tree of replicases, 44:146–
 147
 positive-strand RNA viruses and,
 41:101, 112, 146, 180
 Sindbis virus encephalitis and, 36:255–
 259, 268
 structure
 spike protein, 45:125–126
 virus particle, 45:122–124
 taxonomy, 38:344–345
 translational suppression by retro-
 viruses and, 41:210
 vacuolar acidification inhibitors,
 45:119–121
 between vertebrate and invertebrate
 cells, 38:343–389
 viral RNA and protein synthesis,
 45:126–128
 virion, 38:345–348
 Alphavirus fusion, 38:373–387
 ATP in C6/36 and BHK cells and,
 38:382–383
 cholesterol and sphingomyelin role,
 45:135–136
 comparison with influenza virus,
 45:143–145
 conformational changes and, 38:377–
 380
 course of events
 after infection, 38:375
 after lowering pH, 38:375–376
 endosomal, 38:374
 energy and potential and, 38:382–389
 fusogenic sequence, 38:381–382
 identification of SPV fusogenic protein
 in, 38:380–381
 intracellular pH
 in C6/36 and BHK cells and,
 38:384–385
 with other viruses/cells and, 38:385
 ion fluxes and concentrations and,
 38:385–386
 membrane potential and, 38:386
 mutants, 45:133–135
 properties, 45:131–133
 from within, 38:374–375
 from without, 38:373–374
 Alphavirus replication machinery,
 38:350–371
 adsorption in, 38:350–351
 cleavage of p62 to E3 and E2 in,
 38:366–368
 entry in, 38:354–356
 fatty acid acylation in, 38:365–366
 glycan processing in, 38:364–365
 maturation in, 38:368–371
 oligomerization in, 38:361–362
 penetration in, 38:351–352
 phosphorylation in, 38:366
 posttranslational modifications in,
 38:363–368
 protein import to RER in, 38:359–361
 SFV component synthesis in, 38:356–
 359
 transport pathway in, sorting problem
 and, 38:362–363
 uncoating in, 38:351–356
 ALV, *see* Avian leukosis virus
 Alveolar macrophage functions, virus-in-
 duced impairment of, 35:227–229
 Alzheimer's disease, 29:11, 13, 47

- Alzheimer's disease (*cont.*)
 prions and, **35:124–126**
 senile plaques, **29:22**
- α -Amanitin
 inhibition of arenaviruses, **31:9**
 vaccinia and, **34:46**
- Amantadine
 influenza virus and, **34:255**
 M2 function inhibition, **45:88–89**
 side effects, **35:274**
 as virus uncoating inhibitor, **27:163, 165**
- Amantadine hydrochloride
 effect on LCM infections, **26:57–58**
 formula, **26:51**
- Ambisense RNA viruses, coding
 arenaviruses, **31:10–18**
 bunyaviruses, **31:40**
 phleboviruses, **31:40–41**
- Ambisense segments, Bunyaviridae and,
40:255–256, 258–259
- Amino acids
 adenovirus and, **39:95, 117**
 animal cells and, **36:136**
 archaeobacterial viruses and, **34:180–182**
 Bunyaviridae and, **40:243, 246, 249–254**
 cucumber mosaic virus and, **41:298, 324, 334**
 genome organization, **41:302, 305–306, 309, 313**
 virus particle, **41:286–287**
- defective interfering viruses and,
40:191, 194, 197–198
- DNA replication and, **34:17, 31**
- Drosophila* retrotransposons and
 intracellular cycles, **36:63**
 organization, **36:50, 56–59**
- Epstein-Barr virus and, **40:28, 37–39, 43**
- furoviruses and, **36:20**
- HEF glycoprotein of influenza C virus
 and, **40:214, 222, 225–227, 229–231**
- hepadnavirus and, **34:66–67**
 characterization, **34:79–83, 85–86, 89–90**
 epitopes, **34:114–115, 119, 121, 127**
 pre-S sequences, **34:97, 105, 111**
- hepatitis A virus and, **39:223, 232, 241–245**
- hepatitis C virus and
 cloning, **40:66–67, 69–73**
 prevention, **40:79**
- hepatitis E virus and, **40:89**
- HIV-1 and, **40:6, 12–13**
- HIV structure and, **39:11**
 glycoproteins, **39:40, 42, 44, 47**
pol gene products, **39:28, 31–32, 38**
 regulatory proteins, **39:51–52, 54–56**
- human herpesvirus 6 and, **41:17, 19**
- influenza virus and, **34:274**
 components, **34:250–251, 255–256**
 genetic resistance, **34:273**
 pathogenicity, **34:264, 266, 270**
- neurodegenerative diseases caused by
 prions and, **41:244–246, 248, 250, 258, 269**
- oral vaccination and, **41:412–413, 434**
- Paramyxoviridae and, **39:132–134, 147–148**
- pestiviruses and, **41:78–80, 90**
- picornaviral genomes and, **40:107, 149–150, 158**
- picornaviruses and
 genome, **36:163–165**
 protein analysis, **36:160–161**
 recombinants, **36:170–171**
 revertants, **36:166–168**
 RNA, **36:173**
- poliovirus and, **34:228, 237**
- positive-strand RNA viruses and,
41:100
 equine arteritis virus, **41:164, 167**
 lactate dehydrogenase-elevating virus,
41:112, 141, 146, 149, 153
- potyvirus coat protein and, **36:307**
 genome organization, **36:276, 279**
 structure, **36:280–287, 289**
 taxonomy, **36:291, 294, 296–299, 304**
- rotaviruses and
 neutralization, **36:195, 199–201**
 protection, **36:190**
 surface proteins, **36:205**
- simian hemorrhagic fever virus,
41:179
- Sindbis virus encephalitis and, **36:256, 268–269**
 structure, **36:257–259**
 virulence, **36:262–263, 265–267**

- Theiler's murine encephalomyelitis virus and, **39:293–294, 296, 309, 311**
- TMV coat protein, symptoms and, **33:218–219**
- translational suppression by retroviruses and, **41:196**
- readthrough suppression, **41:198–200, 205–206, 209**
- ribosomal frameshifting, **41:212, 216–217, 230**
- vaccinia and, **34:48**
- Amino acid sequence
- BMV3/CAT product, N-terminal, **32:231**
- changes in variants of neuraminidase, **31:78**
- EGFR, human, **32:108–109**
- erbB* protein, chicken, **32:108–109**
- gene products of *src* family, kinase domain, **32:109–114**
- HA1 polypeptide of influenza B strains, **31:65**
- influenza B virus variants, **31:66**
- at N terminus of neuraminidases, **31:81–82**
- p90^{gag-yes} and p60^{src}, comparison, **32:103–104**
- ε-Aminocaproic acid, influenza virus attachment inhibition, **30:85**
- 5'-Amino-5'-deoxythymidine, antiviral activity, **30:104**
- 2-Amino-5-(2'-sulfamoylphenyl)-1,3,4-thiadiazole, antiviral activity, **30:115**
- virus assembly and, **30:115**
- Aminotransferase, hepatitis A virus and, **39:212–214, 219, 239–240**
- Ammonium pentatungstodiantimonate antiviral activity, **30:115**
- effect on LCM infections, **26:57–59**
- formula, **26:51**
- Ammonium thiocyanate, antiviral antibody affinity and, **34:303**
- AMP (adenosine 5'-monophosphate), HSV inhibition, **30:93–94**
- Amyloid, **29:42, 45**
- plaques, in prion diseases, **29:21–22**
- PrP, **35:112–116**
- neurodegenerative diseases caused by prions and, **41:248–249, 252, 261, 264–265, 270**
- Amyloid β-protein gene, **35:126**
- Amyotrophic lateral sclerosis, **29:12, 47**
- Anal carcinomas
- epidemiology, **37:153–154**
- human papillomaviruses and, **37:134**
- Anemia, lentiviruses and, **34:202, 205**
- Anemone mosaic virus, *Plantago* hosts and occurrence, **27:113**
- Angioimmunoblastic lymphadenopathy, human herpesvirus 6 and, **41:34**
- Angiomatosis, bacillary epithelioid, **43:41**
- Animal cells, **36:39, 107–109, 138**
- early interactions, **36:109–110**
- endocytosis, **36:117–121**
- advantages, **36:122–123**
- penetration, **36:121–122**
- enveloped viruses
- alphaviruses, **36:130–132**
- flaviviruses, **36:132–133**
- herpesviruses, **36:135–136**
- orthomyxoviruses, **36:134**
- paramyxoviruses, **36:134**
- retroviruses, **36:134–135**
- rhabdoviruses, **36:133**
- macromolecule transport, **36:110–111**
- membrane fusion, **36:130**
- fusion proteins, **36:123–126**
- influenza HA, **36:126–129**
- nonenveloped viruses, **36:136**
- adenovirus, **36:137–138**
- picornaviruses, **36:136–137**
- reovirus, **36:138**
- receptors, **36:111–117**
- Anogenital carcinomas, epidemiology, **37:153–154**
- Antennapedia, picornaviral genomes and, **40:147**
- Antibiotic resistance
- bacteriophage, **27:236**
- oral vaccination and, **41:428–429**
- Antibiotic therapy, prophylactic, in animal feed, **35:238**
- Antibodies
- AAV, low titer in cervical cancer patients, **32:286–287**
- ADRV and, **35:212–213**
- animal cells and
- endocytosis, **36:119**
- enveloped viruses, **36:131, 133**
- receptors, **36:111, 116**
- anti-V3, **42:123**

- Antibodies (*cont.*)
- antiviral, *see* Antiviral antibody affinity
 - biology, **41:24**, **26**, **28–38**
 - Bunyaviridae and, **40:246**, **248–249**
 - carrier-mediated delivery of antiviral agents and, **35:293–295**
 - cucumber mosaic virus and, **41:291–296**, **306**
 - decoration, **29:170**, **173–174**
 - defective interfering viruses and, **40:192**, **197**
 - equine arteritis virus and, **41:155**, **157**, **159–163**, **176–178**
 - HAV
 - coproantibodies IgA, short period, **32:133**
 - IgG, gradual development, **32:133**
 - IgM, early appearance, **32:133**
 - HEF glycoprotein of influenza C virus and, **40:220**
 - hepadnavirus, **34:69**
 - characterization, **34:86**, **90**
 - diagnosis, **34:129–132**
 - epitopes, **34:113–116**, **118–123**
 - genetic restriction, **34:123–126**
 - pre-S sequences, **34:95**, **97–99**, **104–108**, **110–113**
 - T-cell recognition, **34:128**
 - vaccine, **34:132–133**
 - hepatitis A virus, **39:213**, **215–216**
 - epidemiology, **39:219**
 - prevention, **39:237–238**, **240–241**
 - replication in cell culture, **39:228**, **230**
 - hepatitis C virus
 - cloning, **40:66**, **74–75**
 - infectious agent, **40:60**
 - prevention, **40:79**, **83**
 - replication, **40:77**
 - hepatitis E virus, **40:90**, **94**
 - HIV structure and, **39:5**, **32**, **55**
 - gag* gene products, **39:23–24**
 - glycoproteins, **39:39**, **43–44**, **46**, **48–50**
 - human herpesvirus 6, **41:3**, **15**, **21**
 - influenza virus and, **34:252**
 - lactate dehydrogenase-elevating virus
 - age-dependent poliomyelitis, **41:132**, **134**, **136–140**, **144**
 - mice, **41:106**, **111–113**, **115–118**, **121–124**
 - molecular properties, **41:145**, **152**
 - lentiviruses and
 - structure, **34:192–193**
 - virus-host cell interaction *in vivo*, **34:200**, **202–207**
 - monoclonal, *see* Monoclonal antibodies
 - neurodegenerative diseases caused by
 - prions and, **41:261**
 - oral vaccination and, **41:410–416**, **438**
 - epitope presentation systems, **41:425–427**
 - foreign antigens in *Salmonella*, **41:417**, **422–423**
 - Paramyxoviridae and, **39:152**
 - pestiviruses and, **41:84–86**, **89–90**
 - border disease virus, **41:66–67**
 - bovine viral diarrhea virus, **41:61**
 - properties, **41:76**, **80**
 - picornaviruses and, **36:153**, **174–175**
 - protein analysis, **36:158**, **160–161**
 - poliovirus and, **34:222**
 - potyvirus coat protein and, **36:299–304**, **306**
 - rabies viruses and, **36:223**, **248**
 - response
 - to bacteria, anti-isotypic, **35:233–234**
 - to paramyxoviridae, **37:229–231**
 - rotaviruses and, **36:182**, **39:182–183**, **187–190**
 - neutralization, **36:183–187**, **192–194**, **198**, **201**
 - protection, **36:188–190**
 - surface proteins, **36:202–204**, **206–207**
 - rotavirus-specific, **44:170–172**
 - Sindbis virus encephalitis and, **36:258**
 - synthetic peptides, reaction with influenza virus hemagglutinin, **31:73–74**
 - Theiler's murine encephalomyelitis virus and, **39:293–295**, **305**, **307**, **309**
 - vaccinia and, **34:57–58**, **60**
- Antibody-dependent cell-mediated cytotoxicity
- lactate dehydrogenase-elevating virus and, **41:116**
 - simian hemorrhagic fever virus and, **41:177**

- Antibody-dependent enhancement
 antibody specificity
 FcR for IgG subclasses, 31:344–345
 IgG for viral determinants, 31:345–347
 species specificity of FcR, 31:344
 in dengue viruses, 31:337–339
 early studies on, 31:336–337
 effects of macrophage activation, 31:349–351
 flavivirus epitopes involved in, 31:151–159
 in macrophage-like cell lines, 31:339
 mechanisms, 31:341–347
 complement receptors, 31:342–343
 Fc receptors, 31:341–342
 viral specificity, 31:343–344
 viral replication/restriction, 31:347–349
 and viral vaccines, 31:352
in vivo, 31:351–352
 yellow fever virus type-specific and, cross-reactive MAbs, 31:155
- Anticomplement immunofluorescence, human herpesvirus 6 and, 41:25
- Antigenic drift, influenza virus type A, 31:62
- Antigenic epitopes, synthetic peptides, 42:152–153
- Antigenicity, of parvovirus nonstructural polypeptides, 33:128–132
- Antigenic relationships
 ADRV, 35:202–205
 asinine herpesvirus 3 with other viruses, 45:169–173
 coronaviruses, 28:94–95
 flaviviruses
 MAbs, 31:109–117
 dengue virus, 31:113–117
 yellow fever virus, 31:109–113
 polyclonal sera, 31:107–108
 serological subgroups, 31:107–108
 parvoviruses, 38:418–423
 toroviruses, 43:252–253
- Antigenic structure, parvoviruses, 33:104–106
- Antigenic variation
 flaviviruses
 epitopes involved in, 31:118–121
 St. Louis encephalitis virus type-specific epitope, 31:120
- hemagglutinin, structure, 31:58–74
 antibodies to synthetic peptides and, 31:73–74
 antigenic drift, 31:62
 antigenic sites at low pH, changes in, 31:71–73
 carbohydrate effect on antigenic sites, 31:73
 epitopes on, structure, 31:69–71
 host cell selection of antigenic variants, 31:68
 in influenza virus type B, 31:64–67
 receptor-cloaking variants, 31:68–69
 variants selected with MAbs, 31:62–64
- influenza virus, antigenic shift mechanism, 31:57–58
- matrix protein, 31:89–90
- neuraminidase
 antigenic variants of, 31:76–79
 crystals complexed with MAbs, 31:83–87
 deletions in, 31:79–80
 homology in, 31:80, 83
 relationship among subtypes, 31:80
 structure, 31:74–87
 nonstructural proteins, 31:90–91
 nucleoprotein, 31:88–89
 polymerase proteins, 31:91
- Antigens
 Ab-MLV and, 35:59–60
 alterations, epidemic spread and, 32:4–5
 animal cells and
 enveloped viruses, 36:131, 135
 receptors, 36:112–113, 116
 antiviral antibody affinity and, 34:283–285, 307–308
 measurement
 direct, 34:287–288, 295–299, 301
 relative, 34:302, 304–305, 307
 BP-1, 35:59–60
 cell surface, in MDV vaccinal immunity, 30:269
 cellular, virus modification of, 31:366–368
 cucumber mosaic virus and, 41:290–296

- Antigens (*cont.*)
- defective interfering viruses and,
 - 40:182, 187, 198
 - from dengue virus-infected mosquito cells, 30:35
 - detection with synthetic peptides, 42:178
 - DNA replication and, 34:33
 - adenovirus, 34:2
 - bovine papilloma virus, 34:28
 - Epstein-Barr virus, 34:29, 31
 - SV40, 34:10–20
 - e, mediating host immune responses, 46:174–175
 - Epstein-Barr virus and
 - EBNA-2, 40:28–34
 - genome, 40:24–27
 - latent membrane protein, 40:36
 - target cell, 40:21, 23
 - equine arteritis virus and, 41:156, 159–160, 163
 - HBV, 35:179–180
 - aggregates, immunogenicity, 32:23, 28
 - HEF glycoprotein of influenza C virus and, 40:217, 220–221
 - hepadnavirus and, 34:66–69
 - characterization, 34:93
 - diagnosis, 34:129–132
 - epitopes, 34:115, 118–121, 123, 127–128
 - genome organization, 34:69
 - pre-S sequences, 34:97, 102, 104, 106, 109–110
 - replication, 34:75
 - hepatitis A virus and, 39:210, 216, 219, 224
 - prevention, 39:238–239
 - replication in cell culture, 39:226, 230, 232
 - hepatitis C virus and, 40:57, 90
 - cloning, 40:63–64, 73, 77
 - infectious agent, 40:61
 - prevention, 40:79–81, 84
 - replication, 40:77–79
 - HIV-1 and, 40:3
 - HIV structure and, 39:3, 7
 - gag* gene products, 39:23–24
 - glycoproteins, 39:39, 46–49
 - human herpesvirus 6 and, 41:3–4, 10, 18
 - biology, 41:25–27, 29, 32, 36–37, 39
 - HVT-specific, 30:241–244, 249–251
 - glycoprotein A, 30:244–248
 - glycoprotein B, 30:244–248
 - nuclear, 30:250
 - influenza virus and, 34:248
 - components, 34:250–251, 253–255
 - interactions with TcR, 45:36–38
 - killed antiviral vaccines and, 39:273–275, 278, 280–283
 - lactate dehydrogenase-elevating virus and, 41:152
 - age-dependent poliomyelitis, 41:128, 141
 - mice, 41:106, 110, 116–118, 120–123
 - lentiviruses and
 - structure, 34:192–196, 198
 - virus-host cell interaction *in vivo*, 34:203–208
 - MATSA, in lymphoblastoid cell lines
 - detection, 30:257
 - epitopes, 30:258, 260
 - H-D heterophile antigen as component of, 30:258–259
 - properties, 30:258
 - MDV-specific, 30:241–244, 249–251
 - glycoprotein A, 30:244–248
 - glycoprotein B, 30:248–249
 - induction by latent viral DNA, 30:262, 264–266
 - nuclear, 30:250
 - neutralizing immunogenic sites, identification
 - glycosylation role, 32:13–14
 - MAbs and, 32:11–13
 - progress, 32:7–8
 - protein fragment evaluation, 32:8–9
 - recombinant DNA technology, 32:10–11
 - synthetic peptide use, 32:9–10
 - oral vaccination and, 41:409–413, 415–417, 438
 - bacteria as carriers, 41:431, 437
 - epitope presentation systems, 41:424–428
 - foreign antigens in *Salmonella*, 41:417–423
 - genetic stabilization, 41:428–430
 - pestiviruses and, 41:54, 67, 72–76, 84–87, 89–90

- bovine viral diarrhea virus, **41:61**,
63–66
properties, **41:72–76**
picornaviruses and, **36:158**, **160**
poliovirus and, **34:217**, **228**, **237**
potyvirus coat protein and, **36:175**,
299–304
quantitation, **29:97–99**
rabies viruses and, **36:217**
Africa, **36:240**, **243**, **246–249**
Europe, **36:239–240**
Latin America, **36:237–238**
North America, **36:223**, **226–227**
rotaviruses and, **39:166–168**
comparison to other reoviruses,
39:192–193
future studies, **39:197–198**
neutralization, **36:184**, **187**, **194**,
201–202
protection, **36:204**
studies, **39:181–184**
vaccination, **39:189**
simian hemorrhagic fever virus and,
41:177
Sindbis virus encephalitis and, **36:262**
Theiler's murine encephalomyelitis vi-
rus and, **39:298**, **300–301**, **303–310**
Thy-1, **35:59–60**
vaccinia and, **34:61**
genome, **34:47**
vector, **34:50**, **53**, **55**, **57–58**, **60**
variation, *see* Antigenic variation
virus envelope, methods of studying,
25:459–463
- Anti-HIV agents, **42:1–2**
dideoxynucleoside analogs, **42:27–30**
HIV-1 reverse transcriptase inhibitors,
42:31–35
sulfated polysaccharides, **42:2–5**
- Anti-idiotypic MAbs, pestiviruses and,
41:86
- Antisense treatment, viral infection,
44:267–294
advantages
preciseness of target site selection,
44:269
reduction in drug-resistant viral
variants, **44:269–270**
antisense RNA, **44:290–292**
approaches, **44:272–273**
beginnings of technology, **44:268–269**
- effects
mammalian systems, **44:292–294**
nonmammalian systems, **44:292**
exogenously applied oligonucleotides,
44:285–290
in vivo action, **44:271–272**
potential toxicity, **44:271**
ribozymes, *see* Ribozymes
- Antisera
against cryptic viruses, **32:185**
reaction with dsRNA in plants,
32:182
cucumber mosaic virus and, **41:290–**
291
- Antiviral agents, **42:1–36**
acyclic and carbocyclic guanosine anal-
ogs, **42:16–19**
acyclic nucleoside phosphonates,
42:23–27
- S-adenosylhomocysteine hydrolase in-
hibitors, **42:5**, **7–10**
- carrier-mediated delivery
antibodies and, **35:293–295**
Ara-A, **35:280–284**
ribavirin, **35:284–286**
to CNS, **35:286–289**
general considerations, **35:271–275**
immunomodulators and, **35:301–306**
conjugated interferons, **35:305–**
306
emulsions, **35:302–303**
liposomes, **35:303–305**
microencapsulation, **35:301–302**
liposomes and, **35:295–298**, **303–**
305
macromolecular carriers and,
35:289–293
peptide carriers, **35:289–293**
prodrugs, **35:275–286**
vaccines, **35:298–301**
emulsions, **35:299–300**
liposomes, **35:300–301**
microencapsulation, **35:298–299**
viral-bacterial synergistic interaction
in respiratory disease and,
35:239–241
- dideoxynucleoside analogs, **42:27–31**
effect on viral gp120/cellular CD4 in-
teraction, **42:4–5**
IMP dehydrogenase inhibitors, **42:13–**
16

- Antiviral agents (*cont.*)
- OMP decarboxylase/CTP synthetase inhibitors, **42:10–13**
 - sulfated polysaccharides, **42:2–6**
 - thymidine analogs, **42:20–23**
- Antiviral antibody affinity, **34:283–285, 307–308**
- measurement
- direct
 - definitions, **34:285–286**
 - equations, **34:286–288**
 - liquid-phase, **34:288–295, 297**
 - solid-phase, **34:295–297**
 - valency, **34:297–302**
 - relative, **34:302, 305**
 - antibody binding, **34:303–306**
 - antibody competition, **34:304–305**
 - dissociative methods, **34:302–303**
 - virus competition, **34:306–307**
- Antiviral compound inhibitors
- attachment, **30:84–85**
 - macromolecular synthesis
 - purine nucleosides, **30:92–100**
 - pyrimidine nucleosides, **30:100–105**
 - ribovirin, **30:105–107**
 - various compounds, **30:107–112**
 - maturation and assembly, **30:112–115**
 - penetration, **30:85–88**
 - replication early stages, **30:90–91**
 - uncoating, **30:88–89**
- Antiviral compounds
- 2'-5'A analogs, **30:120–123**
 - assay for activity, **26:49**
 - characteristics, **26:48–49**
 - effects
 - infected cell cultures, **26:49–56**
 - virus persistence, **26:49–56**
 - formulae, **26:51**
 - interferon type I inducers, **30:116–120**
 - high-molecular weight, **30:117**
 - low molecular weight, **30:117–120**
 - interferon type II inducers, **30:120**
 - for plant viruses, **26:213–217**
 - activity measurement, **26:213–214**
 - resistance and, **26:214–217**
 - resistance to, **26:55–56**
 - targeting with
 - liposomes, **30:124–125**
 - MAbs, **30:125**
 - protein carriers, **30:123–124**
 - retrograde axonal transport, **30:125–126**
 - with unknown mechanism of action, **30:115–116**
- Antiviral drugs
- human herpesvirus 6 and, **41:24–25**
 - translational suppression by retroviruses and, **41:233**
- Antiviral factor
- chemical nature, **26:221–222**
 - discovery and general activity, **26:217–219**
 - interferon, **26:226–229**
 - localization and resistance, **26:229–230**
 - mode of action, **26:225–226**
 - purification, **26:219–220**
 - stimulation, **26:222–225**
 - from TMV-infected plants, **26:217–230**
- Ape
- Creutzfeldt-Jakob disease in, **29:7–8, 10–11**
 - kuru in, **29:7–8, 10**
- Aphidicolin
- archaeobacterial viruses and, **34:144**
 - DNA replication and, **34:7**
 - parvovirus gene expression and, **33:140–142**
- Aphididae as plant-virus vectors, **28:114–133**
- circulative viruses, **28:120–121**
 - feeding behavior, **28:131–132**
 - helpers for, **28:118–120**
 - plant effects, **28:122**
 - transmission participants, **28:116–123**
 - transmission types, **28:114–116**
 - vector-plant interactions, **28:127–131**
 - vector-virus interaction, **28:123–127**
- Aphids
- alarm pheromones, application of, **31:419**
 - cell culture, **25:262–264**
 - cucumber mosaic virus and, **41:331, 333–337**
 - numbers, and models for describing nonpersistent virus spread, **31:415–416**
 - plant viruses in developing countries and
 - crop improvement, **41:361, 372, 374–375, 377**
 - remedial action, **41:383, 389–391**

- spread of banana bunchy top virus and, 33:317
- transmission of closteroviruses, 25:118–120
- as vectors for nonpersistent virus transmission, 31:394–395
- Aphid-transmissible monopartite closteroviruses, genome organization and functions of gene products, 47:129–135
- Aphis*, cucumber mosaic virus and, 41:333–335
- Aphthovirus*, picornaviral genomes and, 40:104–105
- Aphthoviruses, 39:294–295
- picornaviral genomes and cis-acting elements, 40:126
- phenotype, 40:157
- RNA replication, 40:154
- structure, 40:105–106, 108–109
- trans-acting factors, 40:132
- Apolipoprotein-B synthesis, 35:120–122
- Apoptosis, 45:1–50
- altered surface properties, 45:6, 8
- analysis, 45:3, 5–8
- Bcl-2, protective effect, 45:49
- cell cycle role, 45:9–10, 48–49
- cell shrinkage, 45:5–6
- cellular genes and proteins in, 45:10–15
- bcl-2*, 45:13–15
- c-fos*, 45:11
- c-myc*, 45:10
- p53, 45:11–12, 49
- pRb, 45:13
- definition, 45:2
- detection *in situ*, 45:5, 7
- Fas/Apo-1 system, 45:34–35
- Fas/TNF receptor, functions, 45:49
- immunological memory impairment, 45:47
- interrelationship between cell proliferation and cell death, 45:48
- killing mechanism by cytotoxic lymphocytes, 45:23–26
- in LCMV model, 45:38–44
- lymphocytes, 45:32–34
- nuclear changes during, 45:3–4
- nuclear DNA fragmentation during, 45:3, 5
- protease role, 45:49–50
- subdiploid DNA content, 45:5–6
- target susceptibility to CTL-mediated DNA fragmentation, 45:26–28
- T lymphocyte
- activation-induced, 45:35–36
- EBV-induced infectious mononucleosis, 45:44–45
- HIV infection, 45:45–47
- virus-induced, 45:15–23
- adenoviruses, 45:15–16
- baculoviruses, 45:16–17
- chicken anemia virus, 45:17–18
- Epstein–Barr virus, 45:18–19
- HIV, 45:19–21
- influenza virus, 45:21
- papovaviruses, 45:21
- parvoviruses, 45:22
- Sindbis virus, 45:22
- spongiform encephalopathies, 45:22–23
- viral integration into apoptosis gene, 45:23
- virus-infected cell lysis by TNF- α , 45:28–30
- virus-infected targets mediated by B cells, 45:30–32
- Apple mosaic virus
- diagnosis, with MAb, 29:161
- immunization of mice, 29:136
- MAb-determined antigenic properties, 29:150–151
- Apple stem grooving virus, 25:113–114
- A protein, tobacco mosaic virus, 26:148–150
- Aprotinin, influenza attachment inhibition, 30:85
- Ara-A, *see* Vidarabine
- Arabidopsis thaliana*
- defective interfering viruses and, 40:204
- protoplast isolation, 29:224
- 9 β -D-Arabinofuranosyladenine, and derivatives, HSV inhibition, 30:92–94
- Arabis mosaic virus, 33:216
- immunization of mice, 29:136
- MAb-determined antigenic properties, 29:152–153
- MAbs, 29:134
- Plantago* hosts and occurrence, 27:114, 126–127
- positive hybridomas, 29:140–142, 144

- Arachidonic acid derivatives, respiratory defense mechanisms and, **35:236–237**
- Arachis*, plant viruses in developing countries and, **41:367, 369**
- Arboviruses
 Bunyaviridae and, **40:235, 262**
 definition, **33:328**
 mosquito transmission, **37:277–279**
- Archaeobacterial viruses, **34:143–147, 184–185**
- Halobacterium halobium* bacteriophage Φ H
 genetic variability, **34:150–153**
 lysogens, **34:153–157**
- Halobacterium halobium* bacteriophage Φ N, **34:162–163**
- Halobacterium* phages
 Hh1, **34:165–166**
 Hh3, **34:166–167**
 Ja1, **34:164–165**
 S45, **34:167–168**
- Methanobrexibacter smithii*, **34:168**
 properties, **34:147–149**
 transcription, **34:157–162**
- Sulfolobus* virus-like particle SSV1
 components, **34:179–181**
 DNA, **34:177–179**
 features, **34:174–177**
 transcription, **34:181–184**
- Thermoproteus tenax*
 properties, **34:168–171**
 virus TTV1, **34:171–173**
 virus TTV2, **34:173–174**
 virus TTV3, **34:173–174**
 virus TTV4, **34:174**
- Arenaviridae
 distribution, **31:3**
 isolation from rodents, **31:3–4**
 members, **31:2–5**
 vertebrate hosts, **31:3**
- Arenaviruses, **42:234**
 Bunyaviridae and, **40:244, 264**
 genetic attributes, **31:10**
 glycoproteins, surface projections, **31:5**
 infection cycle, **31:9–10**
 large protein L, **31:7**
 nucleocapsid protein N, **31:7**
 particle, schematic representation, **31:6**
 ribosomes, **31:8–9**
- RNA
 L and S species, **31:8**
 S species, ambisense coding arrangement, **31:10–18**
 implications, **31:14–16**
 origin, **31:16–18**
- RNA polymerase activities, **31:7–8**
 shape, **31:5**
 size, **31:5**
 structural components, **31:5–9**
 structural proteins of, **31:5**
 viral envelope, **31:5–6**
- Arginine
 HEF glycoprotein of influenza C virus and, **40:222**
 influenza virus and
 components, **34:252**
 pathogenicity, **34:265–266, 268–270**
- Arildone
 HIV structure and, **39:21**
 uncoating inhibition, **27:165–166**
 HSV, **30:89**
 poliovirus, **30:88–89**
- Arima clones, hepatitis C virus and, **40:75–76**
- Arthritis
 following rubella virus infection, **44:73**
 lentiviruses and, **34:189–190**
 virus-host cell interaction *in vivo*, **34:201, 203–204**
 rheumatoid, **29:47**
 Sindbis virus encephalitis and, **36:255**
- Arthropathy, chronic, following rubella virus vaccination, **44:73–74**
- Arthropod-borne viruses, *see also* Bunyaviruses; Togaviruses
 animals, vectors, **31:305–306**
 Bunyaviridae and, **40:235, 246, 262**
 plants, vectors, **31:306–307**
- Arthropods, viral transmission, **43:13**
- Arthropod vectors, transmission by, **42:216–217**
- ASF, *see* African swine fever
- Asialofetuin, as antiviral drug carrier, **30:124**
- Asinine herpesvirus 3, antigenic relationships with other viruses, **45:169–173**
- L-Asparaginase, effect on persistent viral infections, **26:57–58**

- Aspartyl protease PR, HIV structure and, **39:2**, 5
pol gene products, **39:24–29**, 39
Aspergillus japonicus, macerating enzyme, **29:219**
 Aster ringspot virus, *Plantago* host and occurrence, **27:114**
 Aster yellows, *Plantago* hosts and occurrence of, **27:116**
 Astrocytes, **42:253–254**, 258–259
 Astrocytic foot processes, **42:258**
 Astrocytosis, prion diseases and, **35:89**, 91–92
 Astroviruses, **29:188**, 193, 43:25
 ASV, *see* Avian sarcoma virus
 Ataxia
 feline panleukopenia virus and, **38:412**, 414
 lentiviruses and, **34:201**
 ATF factor, in *trans*-activation of transcription, **37:61–63**, 67–68
 ATP (adenosine 5'-triphosphate)
 archaeobacterial viruses and, **34:178**
 cap binding proteins and, **33:178**, 180–184
 DNA replication and, **34:18–19**
 Epstein-Barr virus and, **40:39**
 neurodegenerative diseases caused by prions and, **41:270**
 picornaviral genomes and, **40:130–132**, 140
 ATPase, DNA replication and, **34:18–19**
 Attachment, rubella virus, **44:105–106**
 Attachment proteins, **27:148–150**, 167–168, 175–176, 178–181, 185, 187, 189–192, 196
 Attenuation, transcription by parvovirus and, **33:145**
 AUG
 Bunyaviridae and, **40:250**, 252–253
 picornaviral genomes and, **40:107–108**
 cis-acting elements, **40:114–117**, 124, 126, 128
 evolution, **40:158**
 mRNAs, **40:143**, 145, 147, 149–151
 trans-acting factors, **40:131–133**, 137
 translation initiation, **40:140–142**
 Australia, banana bunchy top virus infection control, **33:314–318**
 New South Wales, **33:319–322**
 Queensland, **33:321–322**
 Australia antigen, **47:253**
 Autoantibodies, Theiler's murine encephalomyelitis virus and, **39:308**
 Autocatalytic processing, hepatitis delta virus, **43:203–204**
Autographa californica nucleopolyhedrosis virus, **35:178–179**
 recombinant, foreign DNA sequences, **35:189**
 Autoimmunity
 induction by paramyxoviridae, **37:234–235**
 virus-related, **47:365–367**
 lymphocytic choriomeningitis virus-type species infection-induced, **31:9**
 modification of cellular antigens, **31:366–368**
 molecular mimicry, **31:368–369**
 polyclonal lymphocyte activation, **31:365–366**
 Autonomization, gene activation by, **25:12**
 Autoradiography, vaccinia and, **34:57–58**
 Auxins, viral infections and, **33:239–240**
 Auxotrophs, oral vaccination and, **41:432–435**
Avena sativa, leaf protoplasts, virus infection, **29:227**
 Avian erythroblastosis virus
 mutants *td*-130, transforming only fibroblasts, **32:107**
 kinase domain deleted, **32:107–108**
 transforming erythroblasts and fibroblasts *in vitro*, **32:104**
 v-erbB gene
 identification as oncogene, **32:104–106**
 nucleotide sequence, **32:107**
 Avian influenza viruses, **42:221–222**
 Avian leukemia virus, HIV-1 and, **40:1–2**
 Avian leukosis virus
 delayed B-cell lymphoma induction, **30:205–206**
 c-myc expression, **30:207–209**
 enhancer insertion, **30:207**
 LTR role, **30:206–209**

- Avian leukosis virus (*cont.*)
 delayed B-cell lymphoma induction
 (*cont.*)
 LTR transcriptional activity after insertion, **30:212**
 between preproinsulin II gene and 3' LTR provirus, **30:213–214**
 promoter insertion, **30:207**
 transcriptional interference between *c-myc* and LTR, **30:212–213**
 molecular clones
 isolation, **30:184**
 LTR, heterogeneity, **30:185**
 RNA, splice sites in, **35:20, 22**
 spliced mRNA and, **35:24**
- Avian retroviral LTR
 cis-acting elements in, **35:4–9**
 detection in ASV, **30:182–183**
 generation during viral replication, **30:182**
 DNA provirus integration and, **30:195–196**
 reverse transcription-replication and, **30:193–205**
 nucleotide sequences
 analogies with transposons, **30:191–192**
 endogenous retroviruses, **30:188–191**
 exogenous retroviruses, **30:187–191**
 in oncogenesis
 transcriptional activity after integration, **30:211–212**
 transcriptional interference in transformed cells, **30:212–214**
 tumor induction and, **30:205–211**
 retroviral transcript polyadenylation and, **30:204–205**
 transcriptional control region, **30:195–203**
 activities in natural variants, **30:200–204**
 enhancer elements, **30:198–199, 203–204**
 initiator region, **30:197–198**
 location, **30:196–197**
 promoter element, **30:199–200**
- Avian sarcoma retrovirus RNA, *see* Rous sarcoma virus RNA
- Avian sarcoma virus
 LTR detection, **30:182–183**
 molecular clones
 isolation, **30:184**
 LTR, heterogeneity, **30:185–186**
- Avian sarcoma virus Y73
 discovery, **32:100**
 genome, nucleotide sequence, **32:102–103**
 p90 induction in cells, **32:100–104**
yes gene, comparison with *src*, **32:102–104**
- Avian type C virus, envelope, antigenic properties, **25:464–466**
- Avidity, antiviral antibody affinity and, **34:283**
- Axonal transport, retrograde, antiviral drugs coupled with horseradish peroxidase, **30:125–126**
- 5-Azacytidine, adenovirus and, **39:117, 124**
- 6-Azauridine, **42:10–12**
- 3'-Azido-3'-deoxythymidine, *see* Zidovudine
- 3'-Azido-2',3'-dideoxynucleosides, **42:28**
- 8-Azidopurines, binding of viral protein to chromatin and, **33:245**
- Azidothymidine, *see* Zidovudine
- AZT, *see* Zidovudine

B

- BABIM, *see* Bis(5-amidino-2-benzimidazolyl)-methane
- Baboon endogenous virus, translational suppression by retroviruses and, **41:201**
- Baby hamster kidney cells
 adenovirus and, **39:95, 97–103, 110**
 animal cells and, **36:116, 119, 123**
 ATP in, fusion and, **38:383**
 BHK21, equine arteritis virus and, **41:158, 164**
 intracellular pH of, fusion and, **38:384–385**
 picornaviruses and, **36:157**
- Bacillary epithelioid angiomatosis, **43:41**
- Bacille Calmette-Guérin, oral vaccination and, **41:430–431, 437–438**
- Bacilliform viruses, *Plantago* hosts and occurrence of, **27:116, 130–131**
- Bacillus*, **29:266, 294**

- Bacillus acidocaldarius*, archaeobacterial viruses and, **34:178**
- Bacteria
- DNA replication and, **34:21**
 - hepatitis A virus and, **39:214, 221, 236–237**
 - HIV structure and, **39:29, 31**
 - influenza virus and, **34:274**
 - components, **34:254**
 - pathogenicity, **34:265, 268–270**
 - pathogens, new, emerging, and reemerging, **43:35–41**
 - poliovirus and, **34:230**
 - recombinant, oral vaccination with, **41:409–438**
 - vaccinia and, **34:48**
- Bacterial adherence, **35:222–224**
- Bacterial-viral synergy
- bovine herpesvirus role, **45:204–206**
 - in respiratory disease, **35:219–243**
- Bacteriocins, *see also* Colicins; Vibriocins
- as diagnostic tool for sensitive cancer cells, **29:304, 306**
 - evolution, **27:243**
 - high-molecular-weight type, **29:303**
 - host range, **29:301**
 - properties, **27:244**
 - therapeutic use, **29:304, 306**
- Bacteriophage $\phi 6$
- cDNA copies, **35:159–162**
 - genomic organization, **35:157–159**
 - life cycle, **35:138–141, 163–172**
 - adsorption, **35:163–164**
 - membrane assembly, **35:168–172**
 - nucleocapsid entry through cytoplasmic membrane, **35:164–165**
 - phage membrane fusion with host outer membrane, **35:164**
 - protein synthesis in infected cells, **35:167–168**
 - replication, **35:165–167**
 - transcription, **35:165–167**
 - molecular cloning, **35:153–157**
 - mutations, **35:151–153**
 - structure, **35:138–139**
 - unique aspects, **35:137–138**
 - virion, **35:141–151**
 - amino acid composition, **35:144**
 - composition, **35:141–144**
 - membrane, **35:144–146**
 - nucleocapsids, **35:146–151**
 - protein content, **35:142–144**
 - visualization, **35:147–151**
- Bacteriophage PRD1, **45:281–316**
- CAT expression, **45:297**
 - characteristics, **45:282**
 - DNA packaging, **45:313–314**
 - DNA penetration, **45:299–301**
 - DNA replication, **45:301–311**
 - DNA-binding proteins, **45:307–308**
 - essential proteins, **45:303–304**
 - inverted terminal repeat sequences, **45:309–311**
 - mechanism, **45:301–302**
 - in vitro* studies, **45:304–307**
 - gene localization, **45:294–295**
 - genome
 - cloning, **45:290–291**
 - sequencing, **45:291–295**
 - transcriptional regulation, **45:295–299**
 - known proteins, **45:314–316**
 - life cycle, **45:283**
 - lysis, **45:314**
 - marker rescue analysis, **45:294–295**
 - particle assembly, **45:312–313**
 - phage nonsense mutant isolation, **45:289–290**
 - physical and genetic map, **45:291**
 - P-plasmid-encoded receptor, **45:299–301**
 - protein amino acid composition, **45:295–296**
 - Raman difference spectroscopy, **45:287–289**
 - structural characteristics, **45:282**
 - subviral particles, **45:284–287**
 - virion
 - organization, **45:311–312**
 - physical and chemical properties, **45:284–289**
- Bacteriophages
- antibiotic resistance genes, **27:236**
 - basic properties, **27:210**
 - coat proteins, **27:230–233**
 - comparative biology, **27:205–280**
 - defective, evolutionary position, **27:243–247**
 - distribution, **27:211–219**
 - in eukaryotes, **27:259–260**
 - evolution
 - DNA/DNA interactions, **27:234–239**

- Bacteriophages** (*cont.*)
 evolution (*cont.*)
 modular, **27:239–242**
 morphological, **27:247–254**
 by point mutations, **27:233–234**
 filamentous, structure, **28:230–235**
 fundamental groups, **27:209**
 genetic maps, **27:221**
 genome economy in morphogenesis, **27:247–248**
 high-voltage electron microscopy, **30:70–71**
 lytic proteins, **45:98–101**
 morphological variation, **27:248–249**
 nucleic acids
 comparative anatomy, **27:219–233**
 heteroduplex comparisons, **27:226–229**
 hybridization, **27:229**
 restriction endonuclease patters, **27:229**
 sequence comparison, **27:224–226**
 origins, **27:260–261**
 patterns of macromolecular synthesis, **27:230**
 plasmids and, **27:263–265**
 self-assembly, **27:247–248**
 systematics, **27:208–211**
 virus relationship, **27:254–260**
- Bacteriorhodopsin**, archaeobacterial viruses and, **34:146**
- Baculoviruses**
 base composition, **25:289**
 Bunyaviridae and, **40:253, 260, 264**
Choristoneura biennis, **29:204–205**
 conformation, **25:289**
 DNA, **25:290–297, 29:205–206**
 genomes
 base composition, **29:205**
 size, **29:205–206**
 high-voltage electron microscopy, **30:71–75**
 homology studies and, **25:299**
 inclusion body protein, **25:320–324**
 induced apoptosis, **45:16–17**
 morphology, **25:278–281**
 nature and strandedness, **25:289**
 nucleic acid, **29:205–206**
 particles, virus-associated enzymes, **25:325–327**
 pesticide production and, **36:315–316**
 restriction endonuclease analysis, **25:297–299**
 serological properties, **25:335–338**
 structural proteins, properties, **25:321–323**
 virus particle proteins, **25:324**
- Baculovirus** vectors, foreign gene expression
 detection of foreign DNA sequences, **35:189**
 gene expression in, **35:190–191**
 general considerations for, **35:177–178**
 insect cells and, **35:178–181**
 propagation, **35:189**
 recombinant baculovirus construction, **35:185–191**
 transfection and selection, **35:186–189**
 transfer vector construction, **35:181–185**
- Badnaviruses**
 capsid structure, **44:50**
 characteristics, **44:6**
 genomic promoters, **44:25**
 Pol translation, **44:43–44**
 regulatory function, **44:16**
 splicing, **44:25–26**
 translational control, **44:39–40**
- Bafilomycin A**
 proton-ATPase inhibition, **45:67**
 vacuolar acidification inhibition, **45:120**
- Banana**
 cucumber mosaic virus, **41:335**
 distribution, **33:302–303**
- Banana bunchy top virus**
 characteristics
 diagnosis of infected plants, **33:311–312**
 epidemiology, **33:313**
 host range and varietal susceptibility, **33:309**
 symptoms, **33:306–307**
 virus etiology, **33:310–311**
 virus strains, **33:309–310**
 control in Australia, **33:314–318**
 New South Wales, **33:319–321**
 Queensland, **33:321–322**
 geographical history, **33:303–306**
 limited research, **33:301–302**
- Barley**
 facultative resistance, **29:346**

- plant viruses in developing countries
 - and, **41:360, 366**
 - virus complementation, **29:341–342**
- Barley mosaic virus, **33:220–221, 246**
- Barley stripe mosaic hordeivirus, transport function, **38:221–222**
- Barley stripe mosaic virus, **33:221, 242**
 - furoviruses and, **36:21**
 - as helper virus, **29:341–342**
 - infection, detection, **29:245**
 - protoplast infection, **29:227**
- Barley yellow dwarf virus, **33:213, 215, 302, 311**
 - heterologous encapsidation, **46:447**
 - MAbs, **29:134**
 - P5 protein, **46:432**
 - protoplast infection, **29:227**
 - RNA translation, **46:439–440**
 - strains, MAb-determined antigenic properties, **29:151–152**
 - translational suppression by retroviruses and, **41:214**
 - transport function complementation, **29:337**
- Basal membrane, **42:188–190**
- Bat, rabies viruses and, **36:217**
 - epizootiology, **36:217, 222–223**
 - Europe, **36:239**
 - Latin America, **36:237**
 - North America, **36:228–229, 232–236**
- B-cell lymphoma
 - ALV delayed induction, **30:205–206**
 - viral LTR role in
 - transcriptional interference, **30:212–214**
 - transformed phenotype maintenance, **30:212**
- B cells
 - Ab-MLV
 - differentiation, **35:56–58**
 - precursors, **35:58–62**
 - defective interfering viruses and, **40:196**
 - Epstein-Barr virus, **40:19–20, 47–48**
 - EBNA-1, **40:41**
 - EBNA-2, **40:31–32**
 - genome, **40:24–27**
 - latent membrane protein, **40:34–37**
 - target cell, **40:21–24**
 - hepadnavirus and, **34:114**
 - HIV structure and, **39:7**
 - human herpesvirus 6 and, **41:3, 9–10, 33, 36**
 - hybrid clone, **29:132**
 - immature, sensitivity to apoptosis, **45:33**
 - lactate dehydrogenase-elevating virus
 - and, **41:114, 117–124**
 - mediation of virus-infected target apoptosis, **45:30–32**
 - oral vaccination and, **41:411, 423, 426–427**
 - pestiviruses and, **41:57**
 - responses
 - bovine herpesvirus infection, **45:209–210**
 - rotavirus, **44:165–167**
 - serotype and structural specificities, **44:168–169**
- BCG, *see* Bacille Calmette–Guérin
- Bcl-2
 - apoptosis role, **45:33–34**
 - protective effect against apoptosis, **45:49**
- Bcr* gene, Ab-MLV and, **35:54–55**
- BCTV, *see* Beet curly top virus
- Bean-BCMV interrelations, genetics and, **33:230–232**
- Bean common mosaic virus, in developing countries, **41:370–372**
- Bean golden mosaic virus
 - complementation with helper virus, **29:334**
 - DNA, protoplast infection with, **29:241**
 - genomic DNA, nucleotide sequence, **30:151–156**
 - Phaseolus vulgaris* infection
 - phloem-restricted, **30:142**
 - replication in nucleus, **30:141, 164**
 - protoplast infection, **29:228**
 - transport function, **38:223–224**
 - whitefly-transmitted, **30:141**
- Bean pod mottle virus
 - HIV structure and, **39:23**
 - protoplast infection, **29:229, 232, 234–235**
- Bean summer death virus
 - Orosius argentatus* as vector, **30:144**
 - properties, **30:144–145**
- Bean yellow mosaic virus, **33:235**
- Bee chronic paralysis virus group, **25:315, 318**

- Bee chronic paralysis virus group (*cont.*)
 serological properties, **25:342**
- Beet cryptic virus, mixture of two viruses, **32:180–181**
- Beet curly top virus
Circulifer tenellus as vector, **30:144**
 host passage effects, **25:179–180**
Plantago hosts and occurrence, **27:114, 125**
 properties, **30:144–145**
- Beet mild yellows virus, *Plantago* host and occurrence, **27:114, 126**
- Beet necrotic yellow vein virus, **36:1, 3, 27–28**
 cytopathology, **36:9, 11**
 molecular biology, **36:18–23, 25**
 natural occurrence, **36:3, 6–7**
 particle dimensions, **36:17–18**
 purification, **36:16–17**
 transport function, **38:222–223**
 vectors, **36:12–13, 15**
- Beet ringspot virus, *Plantago* hosts and occurrence, **27:115**
- Beet soil-borne virus, furoviruses and, **36:7, 12, 17, 28**
- Beet western yellows virus, **29:152, 33:236, 239, 311**
 agroinfection experiments, **46:425**
 heterologous encapsidation, **46:447**
 infection diagnosis, **46:451**
 P5 protein, **46:431–434**
 protein roles, deduction by mutagenesis, **46:434–435**
 replication, **46:449–450**
 ribosomal frameshift, **46:436–437**
 RNA translation, **46:439**
 subgenomic mRNA synthesis, **46:440–442**
- Beet yellows closterovirus, ORFs, **47:196**
- Beet yellow stunt virus, **25:105**
 genome organization and functions of gene products, **47:135**
- Beet yellows virus, **29:318, 33:236**
 characteristics, **25:476–477**
 CP homologs, **47:125**
 genome organization and functions of gene products, **47:129–133**
 nucleotide and amino acid sequences, **47:133**
 ORFs, **47:130, 132–133**
 particle structure, **47:124–127**
- Plantago* hosts and occurrence, **27:112, 119–120**
 3'-proximal genes, **47:144–146**
 ribosomal frameshifting, **47:140–144**
 transmission, **47:121, 124**
- Behavioral factors, new, emerging, and reemerging diseases, **43:23–26**
- Bemisia tabaci*, see Whitefly
- Berberine chloride, **29:282**
- Berne virus, **43:234, 236**
 E protein, **43:246–247**
 matrix protein, **43:247**
 morphology and morphogenesis, **43:238–240**
 N protein, **43:244–245**
 polymerase protein, **43:247**
 positive-strand RNA viruses and, **41:149, 167**
 P protein, **43:245–246**
 seroepidemiology, **43:255–256**
 structural proteins, **43:243–247**
- β genes
 mechanism, **37:100–101**
 transactivation of, **37:100–101**
- Betaherpesviruses, **44:357–358**
- β proteins, nuclear localization, in HSV
 DNA replication, **37:106–108**
- Betula*, protoplasts, **29:220**
- BHK cells, see Baby hamster kidney cells
- Biocontrol
 agents, protective effects, **39:326–330**
 plant disease, with satellite RNA, **39:321–338**
- Biotypes, pestiviruses and, **41:71, 91**
- Bird seed, *Plantago* seed use in, **27:111**
- Birnaviridae, with dsRNA, characteristics, **32:207**
- Bis(5-amidino-2-benzimidazolyl)methane respiratory syncytial virus penetration inhibition, **30:87–88**
 as virus uncoating inhibitor, **27:163, 166**
- 1,2-Bis(5-ethoxy-2-benzimidazolyl)-1,2-ethandiol
 effect on FMD virus, **26:52–54**
 formula, **26:51**
- BK virus, immunosorbent electron microscopy, **29:176–177**
- Bluetongue virus, **29:122**
 activation, **29:64**
 VP2, detection, **29:106**

- B lymphoblastoid cells, Epstein-Barr virus and, 40:36–37, 47
- B lymphoblasts, Epstein-Barr virus and, 40:23–24, 29, 33, 47
- B lymphopoiesis, Ab-MLV and, 35:55–57
- BMV, *see* Brome mosaic virus
- Bone marrow
 hepadnavirus and, 34:98
 lactate dehydrogenase-elevating virus and, 41:108
 lentiviruses and, 34:206, 208
- Border disease virus, 41:54, 66, 68, 84–85
 clinical picture, 41:66–67
 cytopathogenic, 47:98–99
 pathology, 41:67–68
 properties, 41:74, 76
 sheep, 47:53, 57
- Bordetella pertussis*, 35:222
- Borna disease virus, 46:333, 335–336
- Bovine coronavirus, HEF glycoprotein of influenza C virus and, 40:229, 231
- Bovine enterovirus, picornaviral genomes and, 40:160
- Bovine herpesvirus, 45:191–218
 B cell responses, 45:209–210
 classification, 45:192–193
 DNA immunization, 45:217–218
 encoded proteins, 45:193–194
 eradication, 45:218
 genome organization, 45:193–194
 glycoproteins, 45:194–198
 nomenclature, 45:196
 host responses to infection, 45:207–213
 latency, 45:203–204
 macrophage responses, 45:210–211
 natural killer and natural killer-like responses, 45:211–212
 pathogenesis, 45:202–203
 polymorphonuclear neutrophils in infection, 45:206, 212–213
 replication, 45:195
 role in viral bacterial synergy, 45:204–206
- T-cell responses, 45:207–209
- vaccines
 conventional, 45:213–214
 live vectors, 45:216–217
 subunit, 45:214–216
- viral replication, 45:201–202
- virion structure, 45:192
- virus-encoded enzymes, 45:198–201
 deoxyuridine triphosphatase, 45:199
 DNA polymerase, 45:199–200
 ribonucleotide reductase, 45:199
 thymidine kinase, 45:198–199
- Bovine herpesvirus 1, 35:228–230
 lymphocyte function and, 35:231–232
 vaccine, 35:239
- Bovine leukemia virus
 gp 51, structural analysis, 29:111
 protein, functional areas, 29:107–108
 translational suppression by retroviruses and, 41:220, 228
- Bovine papillomavirus
 DNA replication and, 34:2, 20–22, 33
 gene products, 34:24–25
 regulation, 34:25–29
 sequence elements, 34:22–24
 hepadnavirus and, 34:102
 transformation studies, 37:142–144
- Bovine papillomavirus type 1, 44:307–308
 E2, functional domains, 44:338
 gene expression regulation by viral gene products, 44:340–341
 genome structure, 44:309–310
 transcription, 44:327–328
- Bovine parainfluenza virus type 3, 39:132–133
 genome organization, 39:135–136, 138
 transcription, 39:144, 147
- Bovine respiratory torovirus, 43:234, 237
- Bovine spongiform encephalopathy, 43:42–45
 epidemic, prions and, 41:242, 257–259, 262
- Bovine viral diarrhea virus, 41:54, 58, 66, 84–87, 89, 91, 47:53, 56–57
 biological significance of cellular insertions, 47:70–71
 cIns insertion, 47:83–85
 clinical picture, 41:59–63
 comparisons to pestiviruses, 41:68, 71
 difference from other pestiviruses, 47:101–102
 identification of cellular sequences in the genome, 47:68–70
 nucleotide sequences, 47:66–68
 homology with CSFV, 47:69
 pair #1, analysis, 47:71–72
 pathology, 41:63–66

- Bovine viral diarrhea virus (*cont.*)
 properties, 41:72, 74–82
 ubiquitin-coding sequences, 47:73–83
 comparison with cp BVDV strains,
 47:76–79
 function of ubiquitin insertions,
 47:79–83
 pair #14, 47:73–74
 pair III-C/III-NC, 47:75–76
 pair TGAC/TGAN, 47:74–75
 pair 190/VM, 47:73–74
 prevalence, 47:83
 without cellular insertions, 47:85–96
 CP7, 47:94–96
 CP9, 47:91–92
 CP13 DI, 47:92–93
 defective interfering particles,
 47:90–94
 double duplication, 47:85–88
 dwarfs, 47:90–94
 mucosal disease, induction and DI
 particles, 47:93–94
 N^{pro} gene, duplicated, protein pro-
 cessing, 47:88–90
 Pe515CP and CP6, 47:85–87
 without genome rearrangement, 47:96
- Bovine virus B223, rotaviruses and,
 39:185–186
- b proteins, from virus-infected plants,
 26:230–232
- Bragg reflections, iridoviruses, 46:371
- Brain
 ASF and, 35:261–263
 functional alterations in rabies,
 42:398–403
 lactate dehydrogenase-elevating virus
 and, 41:106, 122
 lentiviruses and, 34:202, 204–205
 poliovirus and
 neurovirulence, 34:226, 235–236,
 238
 pathogenesis, 34:220–221
 Theiler's murine encephalomyelitis
 virus and, 39:296, 298, 303, 305,
 308
- Brain stem, poliovirus and
 neurovirulence, 34:225, 234–235
 pathogenesis, 34:221
- Brain tissue, virus detection in, 27:33–38
- Brassica rapa*, leaf protoplasts, virus in-
 fection, 29:227, 234, 240
- Brassica sinensis*, leaf protoplasts, virus
 infection, 29:227
- Breakage and religation model, illegiti-
 mate recombination, 43:292
- Breast-feeding, HTLV-I-infected moth-
 ers, 43:150–151
- Breast milk, virus detection in, 27:32
- Breda virus, 43:234, 236
 persistence of infection in herd,
 43:259–260
- Breeders' lines, plant viruses in develop-
 ing countries and, 41:352–353, 363,
 382–383
- Breeding, plant viruses in developing
 countries and, 41:397
 agricultural modernization, 41:351–
 352
 remedial action, 41:382, 388–389, 391–
 394
- Breeding programs, plant viruses in de-
 veloping countries and, 41:361, 363,
 379
- Bremia lactucae*, plant viruses in devel-
 oping countries and, 41:375
- Brevdensovirus*, 47:313
- Broad bean mottle virus, structure,
 28:211–213
- Broad bean necrosis virus, 36:1, 28
 cytopathology, 36:9–10
 natural occurrence, 36:5
 purification, 36:15
 vectors, 36:12
- Broad bean wilt virus
 aphid transmission, 28:118
Plantago host and occurrence, 27:116,
 129–130
- Bromelain
 HEF glycoprotein of influenza C virus
 and, 40:248–249
 lentiviruses and, 34:194
- Brome mosaic bromovirus
 genome organization, 41:305–306, 309,
 313
 virus-host plant relationships, 41:328
 virus particle, 41:287
- Brome mosaic virus, *see also* RNA–RNA
 recombination, brome mosaic virus
 asymmetry in positive- and negative-
 strand accumulation, 47:234
- CAT gene insertion and expression,
 32:227–233

- complementation experiment with tobacco mosaic virus, **29:342–343**
- facultative resistance to, **29:340**
- genomic ssRNA
- RNA3
 - deletion of sequences required for replication, **32:223–224**
 - 5' terminal structure, **32:220**
 - three components, **32:216–218**
 - functions, **32:218**
 - serwing as mRNA, **32:217**
 - helper virus promoting transport over nonhosts, **29:341–342**
 - intercistronic region, **47:225–226**
 - molecular biology, **43:277–279**
 - previous recombination studies, **43:279–280**
 - protoplast infection, **29:226–228, 231–232, 234**
 - recombinants in barley, **32:234–238**
 - replication
 - complexes, **47:214**
 - inhibition, **29:254**
 - replication proteins, **47:191–193**
 - resistance to, **29:339**
 - RNA, **29:328**
 - protoplast infection with, **29:236–239**
 - 3'-terminal strands, **47:226**
 - 5'-terminal strands, **47:222–223**
 - RNA-dependent RNA polymerase, **47:206**
 - sequences required for subgenomic RNA synthesis, **47:227–229**
 - single coat protein, **32:217**
 - structure, **28:211–213**
 - subgenomic RNA, **32:217**
 - transcripts from cloned cDNA, infectivity, **32:218–220**
 - increase in presence of 5' cap, **32:220–222**
 - reduction by nonviral 5' bases, **32:220–222**
 - stimulation by nonviral 3'-end, **32:222–223**
 - tRNA-like sequence, **47:215–217**
- Bromodeoxyuridine, DNA replication and, **34:26**
- 5-Bromo-2'-deoxyuridine, DNA replication by parvovirus and, **33:149–150**
- E-5-12-Bromovinyl- β -D-arabino-furanosyluracil, antiviral activity, **30:103**
- (*E*)-5-(2-Bromovinyl)-2'-deoxyuridine, **42:20–23**
- antiviral activity, **30:100–102**
 - clinical treatment
 - HSV I, **30:126–127**
 - varicella-zoster virus, **30:126–127**
 - viral DNA polymerase and, **30:101**
- Bromoviruses, **25:54–58**
- transport function, **38:216–218**
- Bronchioalveolar lavage, respiratory defense mechanisms and, **35:225**
- Budding
- alphavirus, **45:128–131**
 - hepadnaviruses, **44:48**
 - nuclear membrane, in HSV replication, **37:114–115**
 - rubella virus, **44:131–134**
 - Sindbis virus mutant, **33:350–351**
 - single-shelled rotavirus particles, **38:17–18**
- Bunyamwera virus, **40:235, 238**
- genome organization, **40:243–244, 246, 252, 263**
 - glycoproteins, proteolytic enzyme effects, **30:305**
 - human infection, **30:286–287**
 - neurotropic in newborn mice, **30:287**
 - structure, **40:242**
 - virion proteins, **30:303**
- Bunyaviridae, **40:235–237, 263–264**
- arthropod-borne, classification, **30:279**
 - Bunyavirus* genus, proposed serological classification of, **31:22–23**
 - coding strategy, **31:40**
 - genetic attributes, **31:34–38**
 - California serogroup, **31:34–35, 37**
 - epizootiology, **31:35**
 - intertypic recombinant virus formation, **31:37**
 - La Crosse, and *Aedes triseriatus*, relationship, **31:35**
 - L and M RNA mutants, **31:34**
 - reassortants, **31:34–35**
 - genetic properties, **31:18–38**
 - genome organization, **40:243**
 - glycoproteins, **31:19**
 - hierarchy of relationships among, **31:42–43**
 - hierarchy of virus relationships, **31:36**

- Bunyaviridae (*cont.*)
infection cycle, 31:38–40
 release of nucleocapsid into cell cytoplasm, 31:39
 translation of viral-complementary mRNA species, 31:39
 transmission, 31:38
 virus dispersal, 31:39–40
interactions with host cells, 40:262–263
L RNA segment, 40:243–244
major structural components, differences between, 31:19–20
morphogenesis, 40:260–262
M RNA segment, 40:244–251
Nairovirus genus, proposed serological classification of, 31:27
nucleocapsids, 31:20
particle, schematic representation of, 31:19
Phlebovirus genus, proposed serological classification of, 31:30–31
protein species characteristic of, 31:20
replication, 40:255
 mRNA molecules, 40:255–256
 transcription, 40:256–260
RNA species, 31:19–21
size and shape, 31:18–19
S RNA segment, 40:251–254
structural properties, 31:18–38
structure, 40:237–242
unassigned groups, proposed serological classification of, 31:33
Uukuvirus genus, proposed serological classification of, 31:29
viral morphologies and structural components, 31:18–21
Bunyavirus, 40:235, 237, 263
 genome organization, 40:243, 246–248, 252
 structure, 40:237, 240–241
Bunyaviruses, 40:235, 42:229
 coding assignments
 La Crosse virus, S RNA species, 31:24
 snowshoe hare virus, L and M RNA species, 31:25
 S RNA species, 31:24
 coding strategy of, 31:40–41
 genome organization, 40:245, 251
 genomic RNA, structure, 30:302
 glycoproteins, surface virion, 30:305–306
 invertebrate hosts, 30:308–309
 morphology, 31:18–21
 particle, schematic representation, 31:19
 picornaviruses and, 36:173
 proposed serological classification of, 31:22–23
 reassortants
 gene products, pathogenesis and, 30:302–304
 generation, 30:302–304
 RNA species characteristic of, 31:19
 serogroups, pathogenic
 Bunyamwera, 30:286–287, 297
 California, 30:287–290, 297–298
 members, characteristics, 30:280–286
 Simbu, 30:290–302
 structural and genetic properties, 31:21, 24–25
 structure, 40:238, 242
 study, MAbs in, 29:103
 transmission, 31:25
 vertebrate hosts, 30:306–307
Burdock yellows virus, 25:105–107
Burkitt's lymphoma
 DNA replication and, 34:29, 31
 Epstein-Barr virus and, 27:300–304, 40:20, 28, 30–32, 41
 human herpesvirus 6 and, 41:34
Butylated hydroxytoluene, antiviral activity, 30:116
N-Butyldeoxynojirimycin, anti-HIV-1 activity, 44:237
BVDU, *see* (*E*)-5-(2-Bromovinyl)-2'-deoxyuridine
BYDV-PAV, 44:421–422
- C
- c-Abl* gene, Ab-MLV and, 35:50–55
Calcium
 Epstein-Barr virus and, 40:35
 HEF glycoprotein of influenza C virus and, 40:218
 influenza virus and, 34:265
 intracellular, role in HIV gene expression control, 43:105

- vaccinia and, **34:51**
- Calicivirus, **29:193**
- California encephalitis virus
encephalitis induction
in humans, **30:287**
in newborn mice, **30:289–290**
transmission, host role, **30:307**
- CaMV, *see* Cauliflower mosaic virus
- Cancer therapy, parvoviruses, **47:315–316**
- Canine distemper, **42:278–280**, **282**
in black-footed ferret, **43:47**
- Canine distemper virus, **39:133**, **135–136**, **147–148**
F component, immunity induction, **32:23–25**
- Canine myocarditis, canine parvovirus and, **38:414–415**
- Canine parvovirus, **38:403–441**, **47:305**
historical background, **38:406–407**
mutants, **38:427–429**
oncolytic effects, **47:316**
properties, mapping, **38:436–439**
strains, natural variation, **38:424–427**
- Canine parvovirus disease, **43:29–30**
- Cannibalism
and kuru, **29:13–15**
and scrapie, **29:14–15**
- Cap binding factor
p220 as subunit, **31:259–260**
p220 cleavage of eIF-3 and, **31:260–261**
- Cap binding protein complex
eIF-4A component, function, **33:182–184**
function, **33:180–182**
role in shutoff of host mRNA translation, **33:184–185**, **191**
inactivation of complex by infection, **33:185–187**
mechanism of inactivation, **33:187–188**
poliovirus mediation of p220 cleavage, **33:188–191**
- Cap binding proteins
identification, **33:177–178**
structural complexity, **33:179–180**
- Cap binding proteins II, components, **33:179–180**
- Cap independence, picornaviral genomes and, **40:145–147**
- Capping
enzymes, positive-stranded RNA viruses, **47:187–190**
and methylation, of RSV RNA, **35:14–17**
- Caprine arthritis–encephalitis virus, **34:189–191**
structure, **34:191–196**
virus–host cell interaction *in vitro*, **34:196–200**
virus–host cell interaction *in vivo*, **34:200–205**
- Capsid protein
carmovirus, **44:401**
hepatitis A virus and, **39:223–224**, **241**
HIV structure and, **39:18**, **20–24**, **45**
interaction with poliovirus RNA, **46:51–52**
oral vaccination and, **41:412–413**
poliovirus
myristylation, **46:18–19**
targeted, **46:43**
rotaviruses and, **39:186**
spiroplasma virus, SpV4, **44:440–443**
as target of host defense machinery, **43:342–343**
Theiler's murine encephalomyelitis virus and, **39:296**, **309**
- Totivirus*
heterogeneity, **43:328–329**
phosphorylation, **43:329–332**
VP4, poliovirus, **46:9**
- Capsids, *see also* Complementation system
assembly, HIV structure and, **39:22–24**
effect on RNA replication, **47:203–205**
empty, poliovirus, **46:25–29**, **55–56**
iridoviruses, **46:367–369**
mutations affecting RNA encapsidation, poliovirus, **46:47–52**
myristylation, poliovirus, functional significance, **46:37–38**
parvovirus, polypeptides, **33:98–104**
precursor, poliovirus, proteolytic cleavage, **46:44–47**
relationship with genome organization, closteroviruses, **47:150–152**
structures, pararetroviruses and retroviruses, **44:48–50**
- Caput, Ab-MLV and, **35:42–43**

- Carbobenzoxyleucylchloromethyl ketone, inhibition of poliovirus protein cleavage, **30:113**
- Carbocyclic adenosine, **42:7, 9**
- Carbocyclic 3-deazaadenosine, **42:5, 7**
- Carbodine, antiviral activity, **30:104–105**
- Carbohydrate
addition, effect on influenza hemagglutinin antigenic sites, **31:73**
animal cells, **36:113, 125**
hepadnavirus, **34:91, 128**
influenza virus, **34:251, 264**
oncovirus envelope, **25:453–454**
Sindbis virus encephalitis, **36:257, 259**
- Carborundum powder, leaf treatment, **29:218–219**
- Carboxylic ionophores, acidification inhibition, **45:120**
- 10-Carboxymethyl-9-acridone, interferon type I inducer, **30:118**
- Carboxymethyl germanium sesquioxide, interferon type II inducer, **30:120**
- Carboxypeptidases, influenza virus and, **34:265**
- Carboxy terminus, Ab-MLV and, **35:50–51, 65, 71–72**
- Carcinogenesis, oncovirus envelope antigen role, **25:481**
- Carcinoma
anal
epidemiology, **37:153–154**
human papillomaviruses and, **37:134**
anogenital, epidemiology, **37:153–154**
cervical
epidemiology, **37:153–154**
human papillomaviruses and, **37:130**
genital
epidemiology, **37:153–154**
human papillomaviruses and, **37:130**
hepatocellular, **40:81, 83, 47:269–272**
human papillomaviruses in, **37:158–159**
laryngeal, human papillomaviruses and, **37:135**
oral, human papillomaviruses and, **37:135**
- Cardiac glands, stomach, **42:219**
- Cardiolipin, animal cells and, **36:128**
- Cardioviruses, **39:293–294**
picornaviral genomes and, **40:104–105, 154, 157, 161**
cis-acting elements, **40:125–127**
structure, **40:105–106, 108–109**
trans-acting factors, **40:132–133**
translational inhibition by, **33:196–198**
- Carlaviruses
aphid transmission, **28:117**
description, **31:389**
Plantago host, **27:112, 119**
- Carmo-like virus supergroup
formation of multivesicular bodies, **47:213–214**
replication proteins, **47:197–199**
sequences required for subgenomic RNA synthesis, **47:229–230**
3'-terminal structures, **47:220–221**
- Carmovirus
capsid protein, functions, **44:401**
genome expression, **44:390–391**
genome organization, **44:386–387**
8K and 9K proteins, functions, **44:401**
28K and 88K proteins, functions, **44:400**
sequence similarity with tombusviridae, **44:388–389**
taxonomic structure, **44:431**
- Carnation etched ring virus, MAbs, **29:134**
- Carnation mottle virus
genome organization, **44:386–387**
identification, **31:323**
immunosorbent electron microscopy, **29:176**
Plantago host and occurrence, **27:115**
- Carnation necrotic fleck virus, **25:107–108**
genome organization, **47:135**
- Carnation ringspot virus
distribution, **33:257–258**
occurrence in other plants, **33:259–260**
purification, **33:261**
- Carnation vein mottle virus
immunosorbent electron microscopy, **29:187**
Plantago host and occurrence, **27:112**
- Carriers, oral vaccination and, **41:427–428, 430–438**
- Carrot red leaf virus, **46:447**
- Carrot yellow leaf virus, **25:108**
- Cascade appearance, early and intermediate proteins, **25:374**

- Cassava latent virus
 coat protein, **30:156–158**
 genomic DNA
 coding regions, **30:153–156**
 expression during infection, **30:160**
 nucleotide sequence, **30:151–153**
 structure, **30:147–151**
 transcription, **30:157–159**
 ultrastructure, **30:167**
Nicotiana benthamiana infection
 defective particles, **30:169–170**
 in nucleus, **30:141**
 phloem-restricted, **30:142**
 replication cycle, **30:166–168**
 transport function, **38:223–224**
 whitefly-transmitted, **30:141**
- CAT, *see* Chloramphenicol acetyltransferase
- Cat, Creutzfeldt-Jakob disease in, **29:7–8**
- Catalysis
 HIV structure and, **39:23, 34, 39**
 influenza virus and, **34:253–254**
 lentiviruses and, **34:194**
- Cations
 divalent, pH and, **45:73–74**
 monovalent, membrane potential and, **45:71–73**
- Cat scratch disease, **43:40–41**
- Cattle
 bovine viral diarrhea, **47:53, 56–57**
 mucosal disease, **47:56**
 protozoal abortion, **43:46**
- Cauliflower mosaic virus, **33:222–223, 246**
 capsid structure, **44:49–50**
 DNA
 protoplast infection with, **29:241**
 structure, **32:38–39, 46–47**
 functional polycystronic messages, **32:232**
 furoviruses and, **36:16**
 genes I–VI and gene products, **32:56–57**
 comparison with retrovirus genes, **32:58–59**
 immunosorbent electron microscopy, **29:174–175**
 protoplast infection, **29:227–232, 243**
 reverse transcription
 discovery and pathway, **32:47–49**
 DNA synthesis and, **32:68–71**
 RNA packaging, **44:54–55**
 as vector for dihydrofolate reductase gene, **32:225–226**
- Caulimoviruses, *see also* Pararetroviruses
 aphid transmission, **28:117**
 capsid structure, **44:49–50**
 characteristics, **44:5–6**
 description, **31:389**
 DNA, **28:8–10**
 genetic engineering, **28:23–24**
 genomic RNA
 packaging and unpackaging, **32:71–74**
 transcription, **32:82–84**
 control by sequence elements, **32:83–84**
 host regulation of viral transcription during infection, **44:24–25**
 integration, random, **32:76**
 list, **28:6**
Plantago host and occurrence, **27:114, 124**
 Pol translation, **44:43**
 properties, **28:7**
 regulatory function, **44:16–17**
 replication, **28:11**
 as retroid viruses, **32:35–37**
 RNA, **44:23–24**
 packaging, **44:54**
 19S promoter, **44:23**
 35S promoter, **44:22–23**
 transcription in, **28:10–11**
 translational control, **44:36–39**
 translational strategy, **32:84–85**
 transport function, **38:212–214**
- CB medium, **25:202**
- CD3, human herpesvirus 6 and, **41:10–12**
- C6/36 cells
 ATP in, fusion and, **38:382–383**
 intracellular pH, fusion and, **38:384–385**
 SFV-infected, fusion at low pH, **38:376–377**
- CD4, **44:203–246**
 animal cells and, **36:111–112, 135**
 association
 gp160, **44:243–244**
 p56^{ck}, **44:217–219, 223–224**
 CD4⁺, CTLs, **42:126–127**

- CD4 (*cont.*)
 cell surface
 depletion, HIV-1 infection and, 44:243
 downregulation, 44:225–230
 cytoplasmic tail, role in endocytosis and HIV-1 entry, 44:219–221
 D1 and D2 domains, 44:214–217
 Epstein-Barr virus and, 40:40
 gp120 binding to, 44:224–225
 HIV-1, 40:2, 5
 factors involved, 44:232–233
 Nef, 44:245–246
 virion protein U, 44:244–245
 HIV-1 receptor, 38:137–139
 HIV structure and, 39:2, 7, 15, 24, 55
 glycoproteins, 39:39–41, 43–47, 50
 human herpesvirus 6 and, 41:10–11, 34–35
 interaction
 gp120, 42:115–116
 MHC II, 44:212
 oral vaccination and, 41:412, 415, 417
 role
 T cell activation, 44:221–223
 thymic development, 44:212–214
- CD8
 Epstein-Barr virus and, 40:40
 foreign antigens in *Salmonella*, 41:417, 422–423
 human herpesvirus 6 and, 41:10–11, 35
 lactate dehydrogenase-elevating virus and, 41:121, 144
 oral vaccination and, 41:412, 415–417, 437–438
- CD2 antigen, Epstein-Barr virus and, 40:36
- CD21 antigen, Epstein-Barr virus and, 40:29
- CD23 antigen, Epstein-Barr virus and, 40:21, 23, 29, 31–32
- CD2 molecule, 43:101
- CD4 receptor, interaction with glycoprotein gp120, sulfated polymer effect, 42:4–5
- Celery yellow vein virus, *Plantago* host and occurrence, 27:115
- Cell culture
 leafhopper
 AC20 cell line, 25:212–215
 established lines, 25:208–212
 media, 25:201–208
 prions, 35:111–112
 virus diagnosis in, 27:42–43
 virus persistence in, 26:38–42
 cell cycle, 26:39
 cell-specific factors, 26:38–39
 interferon in, 26:39–40
 mechanism, 26:38–42
 virus-specific factors, 26:40–41
- Cell cycle
 parvovirus infection and, 33:140
 role in apoptosis, 45:9–10, 48–49
 virus persistence in cell culture, 26:39
- Cell-free isolation, chickenpox virus, 28:290
- Cell-free replication, adeno-associated viruses, 25:421–422
- Cell function disruption, 31:373–379
 inhibition of luxury functions, 31:375–376
 receptor function, 31:374–375
- Cell fusion, pathology and, 25:239–241
- Cell-infecting unit, 25:251–253
- Cell lines, *see also* Lymphoblastoid cell lines
 BHK, *see* Baby hamster kidney cells
 chicken embryo, influenza virus and, 34:259, 272
 Chinese hamster ovary, hepadnavirus and, 34:103
 HeLa, 29:301, 304
 picornaviral genomes and, 40:120–121, 127, 134, 136
 macrophage-like, antibody-dependent enhancement and, 31:339
 MDCK, *see* Madin–Darby canine kidney cells
 packaging, parvoviruses, 47:326–327
 susceptibilities to viruses, 25:229
 3T3, Ab-MLV and, 35:43–44, 50, 68–72
 without virus expression after virus infection, 31:377–379
- Cell proliferation
 effect on target susceptibility to CTL-mediated DNA fragmentation, 45:26–28
 relationship with cell death, 45:48
- Cell receptors, *see also* Fc receptors
 function, disruption, 31:374–375

- mediating antibody-dependent enhancement, **31:341–342**
MHC specificity, **44:213**
for viruses, **27:143–148, 167–168, 181, 183–185, 191, 193–194**
- Cells, closterovirus-infected, structure, **25:126–136**
- Cell-sparing effects, defective interfering viruses and, **40:191–192**
- Cell storage
liquid nitrogen and, **25:228–229**
temperature and, **25:228**
- Cell surface molecules, virus receptors, **26:66, 42:325–326**
- Cellular stress, and HIV expression, **43:106–107**
- Cellulose, hepadnavirus and, **34:95–96**
- Cellulysin, **29:219, 225**
- Celosia argentea*, cucumber mosaic virus and, **41:335**
- Central nervous system, **35:84**
Bunyaviridae and, **40:264**
carrier-mediated delivery of antiviral agents, **35:286–289**
coxsackie A viruses, **42:348**
cytomegalovirus effect, **46:217–218**
defective interfering viruses and, **40:187**
demyelination, **42:250**
immunology, **42:256–259**
influenza virus and, **34:259**
invasion by bunyaviruses
Bunyamwera serogroup, mouse, **30:297**
California serogroup, human, mouse, **30:297–298**
Simbu serogroup, human, **30:298–299**
stages of human infection, **30:299**
- lactate dehydrogenase-elevating virus and, **41:123, 126, 137–139, 143–144**
- lentiviruses and, **34:202, 204**
- neurodegenerative diseases caused by prions and, **41:241, 244, 257, 259, 269, 271**
- pestiviruses and, **41:55, 64, 69**
- poliovirus and, **34:217, 240, 242–243**
neurovirulence, **34:222, 230, 235–236, 238**
pathogenesis, **34:220–221**
rabies virus, **42:391–393, 397**
reovirus receptor, **42:337–338**
- Sindbis virus encephalitis and, **36:260–261, 267**
structure and functional organization, **42:252–256**
- Theiler's murine encephalomyelitis virus and, **39:292, 313**
demyelination, **39:304, 306–309**
pathogenicity, **39:309–310**
pathology, **39:296–298, 303**
vaccinia and, **34:61**
viral entry, **42:254**
viral persistence, **46:335**
- C-erbB* gene, in signal transduction, **37:6**
- Cereal, furoviruses and, **36:3–6**
- Cerebrospinal fluid, **42:256**
Theiler's murine encephalomyelitis virus and, **39:307**
virus detection in, **27:32**
- Certification, plant viruses in developing countries and, **41:386–387**
- Cervical cancer
AAV antibody low titer, **32:286–287**
induction by HSV type, **32:2, 285**
- Cervical carcinoma
epidemiology, **37:153–154**
human papillomaviruses and, **37:130**
integration of human papillomaviral DNA fragments, **44:325–327**
papillomavirus gene regulation, **44:347**
- c-fgr*
Epstein-Barr virus and, **40:23, 31–32, 40**
human, characteristics, **32:118**
c-src, activation and modification by *v-src*, **32:99–100**
c-yes, four genes, human, **32:117–119**
- Chemical delivery system, antiviral agents, **35:286–289**
- Chemotherapy, *see also* Antiviral agents
antiviral, **26:37–64, 35:239–241**
- Chenopodium hybridum*, leaf protoplasts, virus infection, **29:227**
- Chenopodium quinoa*
isometric viruses infectious to, **31:323**
satellite RNA for biocontrol and, **39:324, 333–334**
- Cherry leaf roll virus, **33:212–213**
Plantago hosts and occurrence, **27:115**

- Chestnut blight fungus
 alignment of cysteine and histidine residues, **43:366–367**
 dsRNA
 defective, role in hypovirulence, **43:368–369**
 origin and structure, **43:361–362**
 genome organization and expression strategy, **43:362–368**
 hypovirulence
 molecular basis, **43:371–373**
 reo-like viruses associated with, **43:369–371**
 and positive-sense RNA viruses, **43:365–368**
 relation between strains NB58 and HYPV-713, **43:364–365**
- Chicken anemia virus, induced apoptosis, **45:17–18**
- Chickenpox, *see also* Varicella-zoster virus
 chemotherapy, **28:334–345**
 clinical aspects, **28:332–333**, **38:46–47**
 congenital and neonatal, **28:333–334**
 immunization
 active, **28:340–345**
 passive, **28:338–340**
 during infancy, and transferred maternal immunity, **28:345–347**
- Chickenpox virus, **28:285–356**
 cell-free virus isolation, **28:290**
 definition and classification, **28:286–287**
 DNA, **28:299–303**
 experimental hosts, **28:326–327**
 glycoproteins, synthesis in infected cells, **28:296–297**
 immune response
 cell-mediated, **28:320–326**
 in humans, **28:315–326**
 isolation and propagation in cell culture, **28:288–290**
 pathogenesis of disease by, **28:328–330**
 possible persistence of viral genome in cultured cells, **28:312–323**
 purification, **28:291–296**
 replication in cultured cells, **28:303–312**
 electron microscopy, **28:307–311**
 enzyme induction, **28:305–307**
 fluorescent antibody staining, **28:303–305**
 simian varicella viruses compared to, **28:327–328**
 thermal stability, **28:291**
 viral particles and glycoproteins excreted by infected cells, **28:311–312**
- Chikungunya virus, in mosquito cells
 attenuation during persistent infection, **30:35–36**
 contaminating mutant, **30:36**
- Children
 in day-care centers, hepatitis A transmission, **32:137**
 leukemic, vaccination, **28:343–344**
 rotavirus diarrhea, **43:25**
 rotavirus immune response, **44:176–178**
- Chimpanzee
 Creutzfeldt-Jakob disease, **29:11**
 hepatitis delta virus
 cDNA-transfected, **43:191–192**
 infected, **43:191**
 HIV vaccine trials, **42:127–129**
- China, Japanese encephalitis in, **27:71–101**
- Chlamydia pneumoniae*, **43:39**
- Chloramphenicol acetyltransferase, **39:100–101**, **114–116**, **119**
 coinoculated with BMV RNA1 and RNA2, **32:230**
- Drosophila* retrotransposons and, **36:54**, **75–77**
 expression improvement, **32:233**
 hepadnavirus and, **34:90**, **105**
 induction in barley protoplasts by BMV RNA3/CAT hybrids, **32:227–233**
 picornaviral genomes and, **40:118–119**
 vaccinia and, **34:48**, **50**
- Chloriridovirus*
 classification, **46:351**, **363**
 hybridization complexes, **46:357**, **359**
- Chloris striate mosaic virus
Nesoclutha pallida as vector, **30:143**
 properties, **30:144**
- Chloroform, **29:282–283**
- Chloroplast pigment protein, **29:42**
- Chlorosis
 cucumber mosaic virus and, **41:319**, **323–324**, **334–335**

- furoviruses and, **36:4–9**
 viral infection and, **33:235–236**
- Chlorotic leaf spot virus, immunosorbent
 electron microscopy, **29:175**
- Chlorpromazine, prions and, **35:117–118**
- Cholera, **43:10–11**
 bacteriophages, **29:265**
- Choleraphage ϕ 149, **29:270–272**, **277**,
286
 mode of action on classical and El Tor
 biotypes, **29:277–278**
- Cholera toxin, CT-B, oral vaccination
 and, **41:426–428**
- Cholesterol
 animal cells and, **36:129**, **132**
 HIV structure and, **39:14**
 role in alphavirus
 exit pathway, **45:136–137**
 virus fusion and infection, **45:135–**
136
- Chromatin
 adenovirus and, **39:91**, **109**
 DNA replication and, **34:10**, **16**
Drosophila retrotransposons and, **36:83**
 host, association of viral protein with,
33:243–247
 structure, role in HIV expression inhi-
 bition, **43:118**
- Chromatography
 cucumber mosaic virus and, **41:287**
 DNA replication and, **34:8–9**
 translational suppression by retro-
 viruses and, **41:208**
- Chromosomes
 adenovirus and, **39:97**
 oncodna viruses, **39:104**, **106**, **109**
 sequence-specific methylation,
39:117, **122**, **124**
 alterations, mechanisms of, **31:361–**
363
 archaeobacterial viruses and, **34:172**,
179
 chicken, MVD DNA location, **30:261–**
263
 DNA replication and, **34:23–24**
Drosophila retrotransposons and,
36:34, **91–92**, **94**, **96**
 insertional mutagenesis, **36:79**, **84–**
85, **89–90**
 organization, **36:59**
 scattered repetition, **36:35–44**
 transcription, **36:69**, **71**, **74**, **76**
 Epstein-Barr virus, **40:43–44**, **46**
 HIV structure and, **39:3**, **39**
 influenza virus and, **34:273**
 integration, **41:430**, **437**
 killed antiviral vaccines and, **39:256**
 lentiviruses and, **34:199**
 neurodegenerative diseases caused by
 prions and, **41:244**, **248**
 oral vaccination and, **41:429**
 translational suppression by retro-
 viruses and, **41:193–194**
 virus-induced cytogenic changes,
31:360–361
- Chronic disease, Theiler's murine en-
 cephalomyelitis virus and, **39:298–**
303
- Chronic fatigue syndrome, human her-
 pesvirus 6 and, **41:37**
- Chronic myelogenous leukemia, *abl* on-
 cogene and, **35:54**, **65–66**
- Chronic wasting disease, **29:9**, **35:84**
 amyloid plaques, **29:21**
 deer and elk, **43:45**
 natural host, **29:6**
 prions and, **41:242**
- α -Chymotrypsin, and tick-borne encephal-
 itis virus, **31:140**
- Cicadulina* spp., see Leafhopper
- Circulifer tenellus*, see Leafhopper
- Circumsporozoite antigens, oral vaccina-
 tion and, **41:423**, **430**
- Cirrhosis, hepatitis C virus and, **40:83**
- Cis-acting elements
 picornaviral genomes and, **40:156**, **162**
 mRNAs, **40:143**, **145**, **147–148**, **150–**
151
 negative control, **40:127–129**
 positive control, **40:117–126**
 RNA replication, **40:151**, **153**
 structure, **40:108**
 translation control, **40:114–117**
 translation initiation, **40:139–143**
 in RSV *gag* gene, **35:9–12**
 in RSV LTR region, **35:4–9**
- Cis-acting factors, adenovirus and, **39:94**,
117
- Cis-acting repressing sequence, HIV
 structure and, **39:53**
- Cis-acting sequences
 HIV-1 and, **40:2**, **6**

- Cis-acting sequences (*cont.*)
 translational suppression by retroviruses and, 41:218–224
- Citrus, plant viruses in developing countries and, 41:369–370, 376, 381
- Citrus exocortis viroid, 33:223, 233
- Citrus exocortis virus, MAbs, 29:134
- Citrus leaf rugose virus, MAbs, 29:134
- Citrus tristeza virus, 25:108–111
 genome organization and functions of gene products, 47:134–135
 particle structure, 47:125
 3'-proximal genes, 47:144–145
 ribosomal frameshifting, 47:140–144
- Classical swine fever virus, 47:53, 58
 cytopathogenic, 47:99–101
 defective interfering particles, 47:100–101
 nucleotide sequences, 47:66–68
 homology with BVDV, 47:69
- Clathrin, animal cells and, 36:117, 119, 131
- Cleavage
 maturation, using complementation system, poliovirus, 46:52–53
 Paramyxoviridae and, 39:142–144
 parvoviral DNA, 33:160
 proteolytic, capsid precursor, poliovirus, 46:44–47
- Clones
 adenovirus and, 39:91, 94, 97–98
 animal cells and, 36:112
 biology, 41:26, 36–37
 Bunyaviridae and, 40:260, 263–264
 genome organization, 40:243–244, 250–254
 structure, 40:238, 240
 cucumber mosaic virus and, 41:283, 323–324, 334
 defective interfering viruses and, 40:188, 194, 200, 202, 205
 DNA replication and
 adenovirus, 34:4–5
 bovine papilloma virus, 34:21–22, 24, 26, 28
 Epstein-Barr virus, 34:31
 SV40, 34:12
- Drosophila* retrotransposons and insertional mutagenesis, 36:79, 89
 intracellular cycles, 36:65
 organization, 36:53
 scattered repetition, 36:39–40, 46
 transcription, 36:67
 Epstein-Barr virus and, 40:20, 22–24, 34
 furoviruses and, 36:18
 HEF glycoprotein of influenza C virus and, 40:214, 221
 hepadnavirus and, 34:69, 104
 hepatitis A virus and, 39:210, 219
 genome, 39:242, 244, 246
 replication in cell culture, 39:230
 hepatitis C virus and, 40:58, 94–95
 infectious agent, 40:59–62
 organization, 40:62–67, 69–70, 73–76
 prevention, 40:79–80
 replication, 40:79
 hepatitis E virus and
 expression, 40:91
 organization, 40:87–90
 prevention, 40:94
 HIV structure and, 39:30–31, 56
 human herpesvirus 6 and, 41:3
 influenza virus and, 34:256, 264, 273
 lactate dehydrogenase-elevating virus and, 41:110
 lentiviruses and, 34:193–194
 molecular biology, 41:16–17, 23
 neurodegenerative diseases caused by prions and, 41:244–245, 256
 oral vaccination and, 41:414, 429
 Paramyxoviridae and, 39:132, 134–138, 147
 pesticide production and, 36:326
 picornaviral genomes and, 40:152, 157
 picornaviruses and, 36:170
 poliovirus and, 34:218, 239
 potyvirus coat protein and, 36:301
 rotaviruses and, 36:204, 39:178, 197
 satellite RNA for biocontrol and, 39:333
 Sindbis virus encephalitis and, 36:263, 267
 translational suppression by retroviruses and, 41:199, 201
 vaccinia and, 34:43, 60
 genome, 34:46–47
 vector, 34:50–51, 58
- Closterovirus, 25:94–95, 47:119–153
 aphid-borne, 25:106, 118–120, 28:118
 atypical, 25:113–116
 biological patterns and cytopathic effects, 47:121–124

- control, **25:157–159**
- evolution of genomes
- packaging constraints and, **47:150–152**
 - replicase and, **47:147–150**
- expression
- papain-like proteinase, **47:139–140**
 - peculiarities, **47:146–147**
 - 3'-proximal genes, subgenomization, **47:144–146**
 - ribosomal frameshifting, **47:140–144**
- genome organization and functions of gene products
- beet yellow stunt virus, **47:135**
 - beet yellows virus, **47:129–133**
 - carnation necrotic fleck virus, **47:135**
 - citrus tristeza virus, **47:134–135**
 - general outlook, **47:138–139**
 - other closteroviruses, **47:136, 138**
 - whitefly-transmissible mono- and bipartite closteroviruses, **47:135–137**
- geographical distribution, **25:95–99**
- infected cell, structure, **25:126–136**
- particle structure, **47:124–129**
- assembly mechanism, **47:128–129**
 - flexibility, **47:125**
- Plantago* hosts and occurrence, **27:112, 119–120**
- serology, **25:152–157**
- taxonomy, **47:120–121**
- transmission by vectors, effect of host plants and environment, **25:122–124**
- virus strains, effect on epidemiology, **25:124–126**
- Clover, plant viruses in developing countries and, **41:361**
- Clover primary leaf necrosis virus, **33:212**
- Clover witches broom, *Plantago* hosts and occurrence, **27:116**
- Clover yellows virus, **25:112**
- Clumping, **29:170, 173**
- C-myc* gene, cis-acting elements and, **35:12**
- CNS, *see* Central nervous system
- Coat protein
- AAV
 - characteristics, **32:250**
 - posttranslational modification, **32:267–268**
 - activation of virus genome, **25:48–50**
 - bacteriophages, **27:230–233**
 - cryptic viruses of plants, **32:177**
 - estimated M_r , **32:204**
 - cucumber mosaic virus and, **41:321, 337**
 - antigenic properties, **41:292–293**
 - genome organization, **41:309, 312, 314**
 - virus-host plant relationships, **41:328–329**
 - virus particle, **41:286–288, 290**
 - virus-vector relationships, **41:333–334**
- dianthoviruses
- aggregation, **33:283**
 - properties, **33:266–267, 278–279**
- leafhopper-transmitted MSV, **30:161–162**
- plant viruses, **33:218–219, 245**
- synthesis, **32:267–268**
- tobacco mosaic virus, **26:147–154**
- tobamovirus
- effects on gene expression, **38:332**
 - synthesis, **38:331**
- virion, **25:148–150**
- whitefly-transmitted geminiviruses, **30:156–158**
- Coat protein gene
- cymbidium ringspot virus, transformation with, **44:418**
- tobamovirus
- deletions, **38:331**
 - function, **38:315**
- Cobra- α -neurotoxoid, antiviral activity, **30:111**
- Coding strategy, parvovirus genome
- nonstructural polypeptides, **33:127–137**
 - structural polypeptides, **33:122–127**
 - transcription, **33:117–119**
 - translation, **33:119–122**
- Codons
- alternate stop, translational suppression by retroviruses, **41:204–207**
 - leaky scanning, **31:238–239**
 - non-AUG, translation from, **44:35–36**
 - reinitiation and, **31:241–243**
 - terminator, suppression of, **31:244**
 - translation initiation at other than AUG, **31:239–241**
- Coinfection, rotaviruses and, **39:166–171, 176, 187**

- Cola chlamydantha*, plant viruses in developing countries and, 41:356
- Colicins, *see also* Bacteriocins; Vibriocins
definition, 29:298
vibriocin typing by, 29:305
- Collagen, Epstein-Barr virus and, 40:35
- Colorado red node virus, *Plantago* host and occurrence, 27:114
- Commelina diffusa*, cucumber mosaic virus and, 41:335
- Commercial plant propagation material, developing countries and agricultural modernization, 41:352–353
crop improvement, 41:372
remedial action, 41:380, 382–384, 389, 393
- Commercial stock, plant viruses in developing countries and, 41:352
- Comovirus, 25:58–60
transport function, 38:214–215
- Comparative biology, bacteriophages, 27:205–280
- Competition
rotaviruses and, 39:169–171
translational inhibition by picornaviruses and, 33:195–196, 198
- Complement
hepatitis A virus and, 39:213, 216
HIV structure and, 39:43
- Complementarity
Paramyxoviridae and, 39:137, 145, 150
picornaviral genomes and, 40:151
- Complementary DNA
Bunyaviridae and, 40:236, 243, 250, 252–253
copies, bacteriophage $\phi 6$, 35:159–162
cucumber mosaic virus and, 41:283, 296, 322–324, 334
defective interfering viruses and, 40:200, 206
DNA replication and, 34:22–24, 26–28
Epstein-Barr virus and, 40:32
frameshifting, luteoviruses, 46:437–438
furoviruses and, 36:24
HAV RNA, 32:151–158
hepadnavirus and, 34:103
hepatitis A virus and, 39:210, 219, 232
genome, 39:242, 244, 246
prevention, 39:241
hepatitis C virus and
cloning, 40:64, 69–70, 74–76
prevention, 40:80
hepatitis delta virus
transfected cell lines, 43:193–194
transfected chimpanzees and woodchucks, 43:191–192
hepatitis E virus and, 40:87–91, 93
infectious clones of RNA viruses
application, 32:215–216
BMV with phage 7 promoters, 32:219–220
for WCCV RNA, 32:185
influenza virus and, 34:273
lentiviruses, 34:195
neurodegenerative diseases caused by prions and, 41:244
neurovirulence, 34:230, 233, 236
Paramyxoviridae and, 39:147
pestiviruses and, 41:77, 85
picornaviral genomes and, 40:152–153, 157
picornaviruses and, 36:168, 170, 175
poliovirus and, 34:218, 240
positive-strand RNA viruses and, 41:146, 148–150, 165
probes
ADRV, 35:216
coxsackie A viruses, 42:345
rotaviruses and, 36:195, 39:197
satellite RNA for biocontrol and, 39:322, 333
Sindbis virus encephalitis and, 36:163, 267
Theiler's murine encephalomyelitis virus and, 39:301, 311, 313
- Complementation
adenovirus and, 39:90, 102–103
phenomenological nonspecificity of viral transfer factor on, 38:231–238
rotaviruses and, 39:173–174, 176, 191
transport function, between related and unrelated viruses, 38:231–238
between viroid and viruses, lack of, 38:238
- Complementation system, poliovirus encapsidation study, 46:39–53
assembly phenotypes, 46:42
capsid mutations, 46:47–52
affecting RNA encapsidation, 46:47–52

- capsid precursor, proteolytic cleavage, **46:44–47**
- capsid proteins, **46:43–44**
- maturation cleavage, **46:52–53**
- nucleating role of RNA genome, **46:43**
- P1 precursors, **46:39, 42–43**
- Complement factors, respiratory defense mechanisms and, **35:237**
- Complement fixation, **29:99**
- for serological relationships between flaviviruses, **31:107**
- test, for chickenpox antigens, **28:314–315**
- Complement receptors, mediation of antibody-dependent enhancement, **31:341–342**
- Complex trapping-blocking ELISA, pestiviruses and, **41:86**
- Concanamycins, proton-ATPase inhibition, **45:67**
- Concanavalin A
- animal cells and, **36:113**
- lactate dehydrogenase-elevating virus and, **41:118–119, 121–122**
- Condyloma acuminata
- epidemiology, **37:153–154**
- papillomavirus and, **37:128, 130**
- Conformation, parvovirus RNA, **33:145–147**
- Congenital rubella syndrome, **44:71–72, 74–75**
- Conjunctivitis, **42:348**
- Consultative Group on International Agricultural Research (CGIAR), developing countries and, **41:350, 364, 395**
- Continuous-flow electrotransfector, **37:334–336**
- Continuous translation, virus strategy, **38:205**
- Contraviruses, **47:313–314**
- Copia*, *Drosophila* retrotransposons and, **36:34–35, 91, 93–94, 96**
- insertional mutagenesis, **36:77, 79–80, 83**
- intracellular cycles, **36:62–63, 66**
- organization, **36:47, 50–51, 53, 56–69**
- scattered repetition, **36:37–47**
- transcription, **36:67–70, 74–75**
- Copy-choice recombination, rotaviruses and, **39:198–199**
- Cord blood lymphocytes, human herpesvirus 6 and
- biology, **41:27, 38**
- discovery, **41:3**
- growth properties, **41:8, 10–12**
- molecular biology, **41:19–20, 25**
- Core cordycepin analogs, antiviral activity, **30:122–123**
- Corn lily fleck virus, **33:242**
- Corn stunt mycoplasma, immunosorbent electron microscopy, **29:172**
- Corona-like virus supergroup, replication proteins, **47:203**
- Coronaviruses, **28:35–112, 47:361**
- adsorption, penetration, and uncoating, **28:60–63**
- animal cells and, **36:125**
- antigenic relationships among, **28:94–95**
- avian, **28:49–51**
- emergence, **28:37–38**
- E1 protein, **28:71–72, 92–94**
- E2 protein, **28:72–74, 87–92**
- equine arteritis virus and, **41:164, 166–168**
- gastrointestinal tract, **42:222–223**
- glycoproteins, **33:30–31**
- oligosaccharides, **28:51–54**
- structure and biological activities, **28:87–94**
- growth and purification, **28:41–43**
- HEF glycoprotein of influenza C virus and, **40:222, 229–231**
- host-derived components, **28:57–58**
- influenza virus and, **34:270**
- intracellular synthesis and transport of proteins, **28:68–74**
- lactate dehydrogenase-elevating virus and, **41:146, 149**
- mammalian, **28:44–49**
- members, **28:38**
- molecular biology, **28:35–112**
- mouse hepatitis virus, **42:261–265**
- mutants, **28:83–84**
- N protein, **28:71**
- persistent infection, **28:85**
- positive-strand RNA viruses and, **41:181**
- replication, **28:60–87**
- diagram, **28:61**
- host regulation, **28:85–87**

- Coronaviruses (*cont.*)
 replication (*cont.*)
 summary, **28:60**
 RNA transcription in, **28:74–79**
 sequences required for subgenomic
 RNA synthesis, **47:230–233**
 structural proteins, **28:43–54**
 structure, **28:39–41**
 taxonomic relationship with torovirus,
 43:234–235
 3'-terminal structures, **47:221–222**
 translational suppression by retro-
 viruses and, **41:221**
 viral genome, **28:54–56**
 viral lipids, **28:56–57**
 viral mRNAs, **28:63–68**
 virion assembly and cytopathic effects,
 28:79–83
 virion structure and organization,
 28:39–60
 virion subunits, **28:58–60**
- Corticosteroids
 hepatitis C virus and, **40:80**
 lentiviruses and, **34:202**
- Corticosterone, lactate dehydrogenase-
 elevating virus and, **41:121–122**
- Corticoviridae, basic properties, **27:210**
- Cortisol levels, stress and, **35:234–235**
- Corynebacterium diphtheriae*, **29:306**
- Cotton
 pesticide production and, **36:317–
 318**
 plant viruses in developing countries
 and, **41:373**
- Counterimmune electrophoresis
 for ADRV, **35:210, 212, 216**
 rotavirus in human stools, **29:180**
- COUP-TF, **43:74**
- Cowpea
 facultative resistance, **29:340–341**
 plant viruses in developing countries
 and, **41:367, 375**
 protoplasts
 isolation, **29:217–219**
 virus infection, **29:228**
- Cowpea chlorotic mottle bromovirus, ge-
 nome organization, **41:305**
 virus-host plant relationships, **41:328**
- Cowpea chlorotic mottle virus, **33:211–
 212**
 protoplast infection, **29:227, 232, 234**
 stimulation by poly-D-lysine,
 29:230–231
 replication proteins, **47:193**
 RNA, **47:193, 223**
 protoplast infection with, **29:236–
 237, 239**
 structure, **28:211–213**
- Cowpea mosaic virus, **33:207, 210, 213,
 220–222, 224**
 facultative resistance, **29:340**
 membranous vesicle arrays, **47:212**
 proteolytic activity, **29:316**
 protoplast infection, **29:228–231, 235**
 replication, inhibition, **29:254–255**
 resistance to, **29:239**
 RNA, **29:330**
 protoplast infection with, **29:237**
 RNA polymerase, **29:328**
 translocation protein, **29:252**
- Coxsackie A virus, **42:343–371**
 capsid proteins, **42:355, 357–358**
 carboxy-terminal extension, **42:363,
 369–370**
 clinical manifestations and epidemiol-
 ogy, **42:346–349**
 cross-reactive epitopes, **42:359**
 diagnostic procedures, **42:334–336**
 disease entities caused by, **42:344**
 duplication and transposition of se-
 quences, **42:368–369**
 evolution, **42:367–368**
 future prospects, **42:369–371**
 genetic diversity and evolution,
 42:364–369
- ICAM-1, **42:361–362**
- immature muscle cells and infection,
 42:352
- independent genetic lineages, **42:368**
- molecular relationships, **42:364–365**
- nonstructural proteins, **42:359**
- pathogenesis, **42:349–353**
- relationship between classification and
 sequence identity, **42:366**
- replication cycle, **42:361–364**
- RGD sequence, **42:362–363, 369–370**
- sequences flanking predicted cleavage
 sites, **42:359–361**
- 3'-untranslated region, **42:355–356**
- 5'-untranslated region, **42:354–355**
- virion structure, **42:353–361**
 genomic RNA, **42:354–356**

- viral proteins, 42:355, 357–361
- virus RNA in tissues, 42:351
- Coxsackie B virus
 - B4 variants, 29:119
 - interacting with CD8⁺ T cells, 47:355
 - murine model, 47:356–357
- Coxsackie virus, 29:122
 - discrimination between serotypes, 42:349
 - picornaviral genomes and, 40:105, 108, 116, 122, 124, 137
 - picornaviruses and, 36:154–155, 157, 170
- C promoter, 44:20–21
- C protein, rubella virus, 44:122–123
- Creutzfeldt-Jakob disease, 29:3, 5–6, 10–12, 15, 24, 43
 - adaptation process, 29:25
 - agent
 - possible spiroplasma, 29:43
 - resistance to radiation, 29:12
 - sizes, 29:33
 - distribution, 29:12
 - duration of illness, 29:8
 - epidemiology, 29:13
 - fibrils found with, 29:43
 - incubation period, 29:7, 21
 - genes controlling, 29:23
 - natural host, 29:6
 - pathogenesis, 29:18
 - lack of immune response in, 29:19–21
 - plaques, 29:11, 21–22, 45
 - and prions, 41:241–243, 257
 - familial diseases, 41:259–261
 - transgenic mice, 41:262, 269
- Cricket paralysis virus
 - in cultured cell lines, 26:132–134
 - discovery, 26:118–119
 - ecological studies, 26:139–141
 - host range, 26:125–129, 31:302–304
 - properties, 26:119–124
 - quantitative studies, 26:134–137
 - resistance, 26:129–132
 - serological studies, 26:124–125
 - transmission, 26:137–139
- Crimean–Congo hemorrhagic fever, 43:18
- Cropping, plant viruses in developing countries and, 41:354–361
 - protected, 41:358–359
- Crops, plant viruses in developing countries and
 - improvement, 41:351, 354
 - cropping, 41:354–361
 - crop protection, 41:372–375
 - genetic upgrading, 41:361–372
 - intensification, 41:375–377
 - management, 41:378–379
 - protection, 41:351, 372–375
 - rehabilitation, 41:353
- Cross-hybridization, human herpesvirus 6 and, 41:16–17
- Cross-immunofluorescence
 - dengue MAbs, specificity, 31:114
 - flaviviruses and yellow fever E protein-specific MAbs, 31:111
- Cross-linking, of parvovirus capsid polypeptides, 33:102
- Cross-neutralization, pestiviruses and, 41:73, 75, 85
- Cross-reactivity
 - cucumber mosaic virus and, 41:296
 - human herpesvirus 6 and, 41:3, 26, 36
 - positive-strand RNA viruses and, 41:152, 173, 177
- Crown-gall disease, 29:88
- Cryphonectria parasitica*, see Chestnut blight fungus
- Cryptic infection, parvovirus and, 33:168
- Cryptic self-hypothesis, 47:366–367
- Cryptic viruses, plants
 - cellular location, 32:191–193
 - coat proteins, 32:177
 - estimated M_r , 32:204
 - comparison with
 - dsRNAs from healthy plants, 32:208–209
 - male plant sterility factor, 32:208
 - other viruses with dsRNA, 32:207–208
 - cultivar infection, 32:194–195
 - distribution throughout plants, 32:193
 - future study, 32:210–211
 - genomic dsRNA, 32:171, 177
 - agar gel double immunodiffusion, 32:182
 - estimated M_r , 32:177, 200–201, 203
 - identification methods, 32:202
 - polyacrylamide gel electrophoresis, 32:182–185
 - segment length, 32:203–204

- Cryptic viruses, plants (*cont.*)
 history, **32:171–173**, 177
 hosts and properties, **32:174–176**
 identification in hosts, methods,
32:179–180
 identity with temperate viruses, **32:173**
 interrelationships, serology, **32:205–207**
 low concentration in hosts, **32:171**, 177
 measurements, **32:199–200**
 morphology, **32:177–178**
 as normal viruses, not virus-like particles, **32:209–210**
 physicochemical properties, **32:198–199**
 purification
 clarification, **32:196**
 concentration, **32:196**
 density gradient centrifugation,
32:196–197
 extraction, **32:195**
 stability and yield, **32:195**
 serological tests
 agar gel diffusion, **32:186**
 decoration with antibodies, **32:187**
 ELISA, **32:187–188**
 immunosorbent electron microscopy,
32:186–187
 symptomless, **32:171**, 178, 188–189
 transmission
 graft failure, **32:172**, 179, 190–191
 mechanical, failure, **32:172**, 179
 sap, failure, **32:191**
 seed, high degree in various hosts,
32:172, 179, 189–190
 by vectors, failure, **32:179**, 191
 unrecognizable by electron microscopy,
32:185–186
 in various hosts, nomenclature,
32:180–181
- Cryptotopes, **29:147**, 151, 157–158
 antibodies, **29:145**
- CTL, *see* Cytotoxic T cells
- Cubic bacteriophages, distribution,
27:217–219
- Cucumber, plant viruses in developing
 countries and, **41:381**, 385
- Cucumber chlorotic spot virus
 genome organization and functions of
 gene products, **47:136**
 ribosomal frameshifting, **47:141–144**
- Cucumber green mottle mosaic virus,
 protoplast infection, **29:227**
- Cucumber mosaic virus, **29:114**, **33:212**,
 215, 236, 238, 243, 245, 312, **41:282–283**, 338
 antigenic properties
 immunogenicity, **41:290–291**
 serology, **41:293–296**
 variation, **41:291–293**
 defective interfering viruses and,
40:204–206
 in developing countries, **41:372**
 in double infection with potato virus
 X, **29:336**
 epidemiology
 control strategies, **41:336–338**
 field spread, **41:334–336**
 facultative resistance to, **29:340**
 genome organization, **41:296–297**
 gene functions, **41:313–316**
 nucleotide sequence, **41:297–313**
 host passage effect, **25:177–179**
 immunosorbent electron microscopy,
29:176, 187, 190
Plantago host and occurrence, **27:114**,
 124–125
 protoplast infection, **29:227–228**, 232
 pseudorecombinants, symptoms and,
33:212
 replication
 complexes, **47:185–186**
 inhibition, **29:254**
 proteins, **47:192–193**
- RNA
 protoplast infection with, **29:239**
 3'-terminal strands, **47:224**
 5'-terminal strands, **47:223–224**
 satellite-like RNAs, **25:70–72**
 satellite RNA for biocontrol and,
39:337–338
 construction of control agents,
39:323–325
 field applications, **39:325–326**
 fungal disease, **39:330**, 332
 protective effects in crops, **39:326–330**
 transgenic plants, **39:333–335**
 satellite RNAs, **41:316–317**
 distribution, **41:320–323**
 replication, **41:317–319**
 structure, **41:317**

- symptom modification, 41:319–320
 - satellites and, 33:216, 223
 - sequences required for subgenomic RNA synthesis, 47:228–229
- taxonomy, 41:284–285
- virus-host plant relationships
 - cytopathology, 41:324–325
 - replicase, 41:329–331
 - replication, 41:325–329
 - seed transmission, 41:331–332
 - symptomatology, 41:323–324
- virus particle
 - coat protein, 41:286–288
 - particle composition, 41:285–286
 - purification, 41:285
 - reassembly, 41:290
 - structure, 41:288–290
- virus-vector relationships, 41:331, 333–334
- Cucumber necrosis virus
 - defective interfering RNA, 44:404–405
 - sequences required for subgenomic RNA synthesis, 47:229–230
- Cucumber pale fruit viroid, protoplast infection with, 29:241
- Cucumis sativus*, leaf protoplasts, virus infection, 29:227
- Cucumoviruses
 - aphid transmission, 28:117–118
 - description, 31:389
 - identification, 31:323
 - Plantago* host and occurrence, 27:114, 124–125
 - transport function, 38:216–218
- Cucurbit aphid-borne yellows virus, subgenomic mRNA synthesis, 46:440–442
- Culex melanonconion*, in EEE virus transmission, 37:295–298
- Culex quinquefasciatus*, as vectors of encephalitis, 33:330
- Culex tarsalis*, variants, vector efficiency, 33:329
- Culex tritaeniorhynchus*, Japanese encephalitis virus isolation from, 27:73
- Culicoides* spp., see Midges
- Culiseta melanura*
 - EEE virus transmission, 37:287–295
 - infections with EEE
 - evolution, 37:315–319
 - experimental, 37:298
 - other mosquito-virus interactions and, 37:306–307
 - pathological changes during, 37:312–315
 - rapid transmission, 37:307–312
 - timing and distribution, 37:302–306
- Cultural practices, plant viruses in developing countries and, 41:374–375, 377
- Cyanobacteria disease, 43:40
- Cyclaridine, HSV inhibition, 30:94
- Cyclaridine-5'-methoxyacetate, HSV inhibition, 30:94
- Cyclic AMP
 - control of *trans*-activation of transcription, 37:67–68
 - oral vaccination and, 41:434
 - in transport function of plant viruses, 38:227–228
- 2,3-Cyclic nucleotide 3'-phosphodiesterase, pestiviruses and, 41:68
- Cycloleucine, 35:15–16
- replication of Sindbis virus and, 33:340, 360
- Cyclopentenylcytosine, 42:11–13
- Cyclopentylcytosine, 42:11–12
- Cyclophosphamide
 - age-dependent poliomyelitis and, 41:124, 128–129, 133–137, 139, 143
 - lactate dehydrogenase-elevating virus and, 41:115–116, 119, 151
- Cymbidium ringspot virus, 40:199, 202–203
 - coat protein gene, transformation with, 44:418
 - defective interfering RNA, 44:402–404, 407–408
 - replication proteins, 47:198
 - satellite RNA, 44:412–414
- Cysteine
 - hepadnavirus and, 34:82
 - Paramyxoviridae and, 39:148–149
 - potyvirus coat protein and, 36:282, 286
- Cystic fibrosis transmembrane protein, 47:320
- Cystoviridae
 - basic properties, 27:210
 - with dsRNA, characteristics, 32:207
- Cytidine, DNA replication and, 34:3

- Cytokines
 HIV expression
 activation, **43:102–104**
 inhibition, **43:119–120**
 human herpesvirus 6 and, **41:38**
 lactate dehydrogenase-elevating virus
 and, **41:120–121, 124**
 as proinflammatory participants,
47:355
 role in immune response to bovine her-
 pesvirus, **45:205–206**
- Cytokinins, viral infection and, **33:237,**
239–240
- Cytolysis, lentiviruses and, **34:196**
- Cytolytic T cells, oral vaccination and,
41:412, 417, 422
- Cytomegalovirus, **39:95, 117, 119,**
46:197–241
 diagnosis using synthetic peptides,
42:172
 and HIV expression, **43:108–110**
 human herpesvirus 6 and, **41:2–3, 5**
 biology, **41:26, 28, 33, 35–37**
 molecular biology, **41:17–20, 24**
 human infection determinants,
46:198–216
 cell culture systems, **46:200–201**
 cell differentiation, **46:213**
 gene expression
 early phase, **46:210**
 late, **46:211**
 permissive culture cells, **46:199–**
212
 IE2 protein functions, **46:204–205**
 immediate early gene location,
46:202–204
 initial events, **46:214–215**
 MAbs, **46:206–207**
 noninfectious enveloped particles,
46:211–212
 nonpermissive, **46:212–214**
 polypeptides, immunoblot analyses,
46:207–209
 replication
 cycle, **46:199, 202**
 permissive culture cells, **46:199–**
212
 strain variabilities, **46:216**
 tegument proteins, **46:215**
 virion protein role in initiating in-
 fection, **46:215**
- infection
 hematopoietic system and circulating
 cells, **46:228, 231–232**
 latent, **46:236–241**
 cell culture models, **46:239–241**
 latency site, **46:238–239**
 murine, as model, **46:237–238**
 tissue cells, **46:219–220, 224–230**
 inhibition by
 DFMO, **30:110–111**
 MGBF, **30:110–111**
 MAbs, **29:101**
 organ tropism, **46:216–219**
 spread and pathogenesis, cell types in,
46:234–236
 transmission modes, **46:232–234**
- Cytopathic effects
 cucumber mosaic virus and, **41:283,**
324–325
 hepatitis A virus and, **39:227–228**
 human herpesvirus 6 and, **41:10**
 lentiviruses and, **34:196, 198**
 positive-strand RNA viruses and,
41:158, 172–173, 175, 182
- Cytopathogenicity
 influenza virus and, **34:248**
 low, in viral persistence, **26:44**
- Cytopathogenic pestiviruses, **41:54, 71,**
89, 91
 bovine viral diarrhea virus, **41:61, 65–**
66
 properties, **41:79, 81–82**
- Cytopathology
 dianthoviruses, **33:286–289**
 electron microscopy, **33:287–289**
 light microscopy, **33:286–287**
 equine herpesvirus 2, **44:366–367**
 luteoviruses, **46:450**
- Cytoplasm
 adenovirus mRNA transport from nu-
 cleus, **31:211–216**
 animal cells and, **36:139**
 early interactions, **36:110**
 endocytosis, **36:119, 121–123**
 macromolecule transport, **36:111**
 membrane fusion, **36:125**
 nonenveloped viruses, **36:137**
 receptors, **36:112**
 cucumber mosaic virus and, **41:324,**
327, 329
 DNA replication and, **34:17**

- Drosophila* retrotransposons and
 intracellular cycles, **36:62–63**
 scattered repetition, **36:43**
 transcription, **36:68–70**
 hepatitis A virus and, **39:224, 227**
 HIV structure and, **39:4, 16, 29, 54**
 human herpesvirus 6 and, **41:5, 7, 11**
 influenza virus and, **34:252–253, 256**
 lentiviruses and, **34:191**
 neurodegenerative diseases caused by
 prions and, **41:253, 270**
 oral vaccination and, **41:416, 424**
 poliovirus and, **34:219**
 potyvirus coat protein and, **36:277, 291**
 Sindbis virus encephalitis and, **36:257–**
 259
 Theiler's murine encephalomyelitis vi-
 rus and, **39:303**
 vaccinia and, **34:44–45, 51, 60**
- Cytoplasmic domain
 alphavirus glycoprotein, **33:12–13**
 influenza virus hemagglutinin, **33:7–8**
 rabies virus, **33:19–22**
 Rous sarcoma virus, **33:24–25**
 vesicular stomatitis virus, **33:19–22**
- Cytoplasmic membrane, virus producing
 cells, envelope antigens and, **25:463–**
 464
- Cytoplasmic polyhedrosis virus, **29:59–**
 60, 64, 198, 210, 37:173–206
 antigenic characteristics, **37:184**
 base composition and, **25:300**
 cell susceptibility to, **37:201, 203–205**
 cell-virus interactions, insects and cell
 cultures in, **37:185–285**
 characteristics, **37:178–205**
 conformation, **25:300–305**
 homology studies, **25:305**
 inclusion body protein, **25:327**
 infections from
 mixed, **37:200–203**
 specificity of, **37:185–187**
 introduction to, **37:173–174**
 morphogenesis of, **37:174–178**
 morphology, **25:281–283**
 nature and strandedness, **25:299–300**
 particles, structure and composition,
 37:178–182
 pathogenesis, **37:174–178**
 persistence, **37:197–200**
 polyhedra, **37:182–184**
 propagation, **37:197–200**
 replication
 factors influencing, **37:201, 203–205**
 in larvae and insect cell culture,
 37:187–205
 nucleic acid synthesis in, **37:197**
 polyhedrin crystallization in,
 37:192–197
 protein and antigen synthesis in,
 37:187, 191–192
- RNA, **25:302–303**
 serological properties, **25:338–339**
 structural proteins, **25:302–303**
 structure and composition, **37:178–184**
 transcriptase activity, **29:64**
 virus-associated enzymes, **25:328**
 virus particle protein, **25:327–328**
- Cytosine
 archaeobacterial viruses and, **34:163**
 picornaviruses and, **36:166–167**
- Cytosine arabinoside, **35:290**
 in treatment of chickenpox, **28:335**
- Cytoskeleton, viral interactions affecting
 cell function, **46:337–338**
- Cytosol
 animal cells and, **36:108**
 enveloped viruses, **36:131**
 membrane fusion, **36:129**
 nonenveloped viruses, **36:138**
 signal transduction across, **37:16–18**
- Cytotoxicity
 assays, varicella-zoster virus, **46:282–**
 283
 hepatitis delta virus, **43:220–221**
- Cytotoxic T cells, **42:125–127**
 ASF and, **35:265**
 lactate dehydrogenase-elevating virus
 and, **41:116, 140–141, 178**
 oral vaccination and, **41:415–417, 422–**
 423, 437–438
 protective immunity to equine her-
 pesviruses, **45:178**
- D**
- DAS-ELISA, **29:161–162**
 cucumber mosaic virus and, **41:292–**
 296
- DA strain of Theiler's murine encephalomyelitis virus, **39:292**

- DA strain of Theiler's murine encephalomyelitis virus (*cont.*)
 demyelination, **39:304–305**, **308–309**
 pathogenicity, **39:310–312**
 pathology, **39:296–303**
 virology, **39:295–296**
- Datura fastuosa*, cucumber mosaic virus and, **41:335**
- Dauca carota*, protoplast isolation, **29:224–225**
- Day-care centers
 hepatitis A transmission, **32:137**
 virus diarrhea and, **43:24–25**
- Dazaifu IV
 genes, **46:388–389**
 repetitive DNA, **46:390**
- 3-Deazaadenosine, antiviral activity, **30:95**
- 3-Deazaaristeromycin, antiviral activity, **30:95**
- 3-Deazaneplanocin A, **42:7**
- Decoration, antibody halo effect, **29:170**, **173–174**
- Deer, chronic wasting disease, **43:45**
- Defective interference, Paramyxoviridae and, **39:144–145**, **151**
- Defective interfering particles
 BVDV, **47:90–94**
 CSFV, **47:100–101**
 mucosal disease induction, **47:93–94**
 poliovirus, **46:31–32**, **40**
 togaviruses in mosquito cells, **30:25–26**
- Defective interfering viruses, **40:181–183**, **206**
 amplification, **40:183–184**
 animals and humans, **40:189**
 DNA viruses, **40:196–197**
 retroviruses, **40:194–196**
 RNA viruses, **40:189–194**
 satellite viruses, **40:197–198**
 assays, **40:184–185**
 cell protection, **40:185**
 cycling phenomenon, **40:185–186**
 disease processes, **40:187–189**
 host cell type, **40:184**
 plants, **40:198–199**
 cymbidium ring spot virus, **40:202–203**
 RNAs, **40:205–206**
 symptoms, **40:203–205**
 tomato bushy stunt virus, **40:201–202**
 turnip crinkle virus, **40:199–201**
- Defective particles, geminiviruses, **30:169–171**
- Defense mechanisms, respiratory, **35:224–227**
- Defensins, oral vaccination and, **41:434**
- Degradation
 archaeobacterial viruses and, **34:178**
 hepadnavirus and, **34:75**
 lentiviruses and, **34:192**
- Delayed growth marker, poliovirus and, **34:228**, **233**
- Delayed-type hypersensitivity reactions, **47:358–360**
 immune deviation, **47:368**
 Theiler's murine encephalomyelitis virus, **39:305–306**
- Deletions
 archaeobacterial viruses and
Halobacterium halobium, **34:150–153**
Thermoproteus tenax, **34:173**
 parvovirus DNAs, **33:109–110**
- Delta antigen
 autonomously functioning domains, **43:211**
 large, **43:225**
 post-transcriptional modifications, **43:219–220**
 unique amino acids, role in hepatitis delta virus, **43:218–219**
- N terminus, **43:217**
 properties associated with, **43:214–215**
 small, in hepatitis delta virus genome replication, **43:202–203**
- Dementias, prions and, **35:124–126**
- Demyelinating diseases, **42:249–251**
- Demyelination
 chemicals inducing, **42:260–261**
 lentiviruses and, **34:202**
 nonviral experimental, **42:259–261**
 Theiler's murine encephalomyelitis virus and, **39:292**, **304**, **313**
 cellular immunity, **39:306–307**
 humoral immune response, **39:307–308**
 immunogenetics, **39:304–305**
 immunosuppression, **39:305–306**
 infection of nude mice, **39:308–309**

- pathology, **39:296, 298–303**
 virus-induced, *see* Viral demyelination
 Dendrobium vein necrosis virus, **25:117**
 Dengue, vector control failure, **43:14–16**
 Dengue hemorrhagic fever, **47:365**
 dengue shock syndrome antibody-dependent enhancement, **31:152**
 Dengue virus
 antibody-dependent enhancement and, **31:337–339**
 antigenic relationships, **31:113–116**
 MAbs, **29:101–102**
 MAb specificity, cross-immunofluorescence, **31:114**
 in mosquito cells
 diagnostic antigen preparation and, **30:35**
 isolation, **30:29–31**
 mutant detection, **30:34**
 oral vaccination and, **41:418, 422**
 polyclonal sera, serotypes, **31:113**
 specificity of, immunofluorescence, **31:114–115**
 types 2 and 3, mixed infection, **29:104**
 Dengue 2 virus
 epitopes on, topological model, **31:125**
 MAbs, **31:145, 156**
 replication in U-937 human monocytes, **31:153**
 serological subgrouping, **31:108**
 Density gradients, virus diagnosis in, **27:44–45**
 Dengoviruses, **47:312–315**
 base composition, **25:311**
 conformation, **25:311–313**
 DNA, **25:312**
 gene vectors, **47:333–335**
 genomic organization, **47:311, 313**
 homology studies, **25:313**
 mediated gene delivery, **47:338**
 nature and strandedness, **25:311**
 NS1 gene, **47:314**
 potential vectors, **47:335**
 restriction endonuclease analysis, **25:313**
 serological properties, **25:340**
 structural proteins, **25:331**
 2-Deoxy-D-glucose, antiviral activity, **30:113–114**
 glycosylation inhibition and, **30:113–114**
 Deoxynucleoside 5'-triphosphate, HIV-1 reverse transcriptase binding site, **46:116–119**
 Deoxypyrimidine kinase
 chickenpox virus-induced, **28:305–306**
 varicella zoster virus-induced, **38:68–71**
 Deoxyuridine triphosphatase
 in bovine herpesvirus, **45:199**
 feline immunodeficiency virus, **45:234–235**
 Desmotubules, **29:315**
 Developing countries, plant viruses in, *see* Plant viruses in developing countries
 Development, viruses in study of, **26:65–116**
 Dexamethasone, lactate dehydrogenase-elevating virus and, **41:115–116, 125**
 Dextran sulfate, **42:2–5**
 DFMO, *see* α -Difluoromethylornithine
 Diabetes mellitus, **29:47**
 insulin-dependent, in congenital rubella syndrome patients, **44:74–75**
 Diagnostic tools, human herpesvirus 6 and, **41:24–27**
 Diagnostic virology, **27:1–69**
 1,5-Diaminoanthraquinones, interferon type I induction, **30:118**
Dianthovirus, **44:421**
 Dianthoviruses
 cytopathology, **33:286–289**
 electron microscopy, **33:282–289**
 light microscopy, **33:286–287**
 diseases caused in plants, **33:258–260**
 ecological studies, **33:291–294**
 genome reassortment studies
 aggregation of coat protein, **33:283**
 bipartite genome, **33:281**
 electrophoretic mobility, **33:285**
 infectivity, **33:281–283**
 serological specificity, **33:283, 285**
 symptomatology, **33:285–286**
 host range and symptomatology
 experimental studies, **33:277–278**
 natural isolates, **33:276–277**
 members
 carnation ringspot virus, **33:257–258**
 red clover necrotic mosaic virus, **33:258**

- Dianthoviruses (*cont.*)
 members (*cont.*)
 sweet clover necrotic mosaic virus,
 33:258
 properties, 33:257, 265–266
 electron microscopy, 33:263–265
 protein and nucleic acid, 33:266–268
 purification, 33:260–263
 replication, 33:278–281
 serological studies
 MAbs, 33:272–276
 polyclonal antibodies, 33:269–272
 transmission by vectors, 33:289–291
 transport function, 38:218–219
- Diarrhea, *see also* Adult diarrhea ro-
 tavirus
 ASF and, 35:258
 rotaviruses and, 36:182, 43:25
 neutralization, 36:194
 protection, 36:188–189
 surface proteins, 36:205
 viral, day care and, 43:24–25
- 1,5-Dichloroflavan, rhinovirus direct in-
 activation, 30:91
- 2-(3,4-Dichlorophenoxy)-5-nitro-
 benzonitril, picornavirus early repli-
 cation inhibition, 30:91
- 2',3'-Didehydro-2',3'-dideoxynucleosides,
 42:28
- Didemins, antiviral activities, 30:110
- Dideoxynucleoside analogs, 42:27–31
 2',3'-Dideoxyuridine, 42:28–30
- Differentiating agents, and HIV expres-
 sion, 43:104–106, 119–120
- Differentiation, virus use in studies of,
 26:65–116
- α -Difluoromethylornithine, human cyto-
 megalovirus inhibition, 30:110–111
 polyamine biosynthesis and, 30:110
- 9-(3,4-Dihydroxybutyl)guanine, antiviral
 activity, 30:99
- S-9-(2,3-Dihydroxypropyl)adenine, 42:5, 7
 antiviral activity, 30:99–100
- 4'5-Dihydroxy-3,3',7-trimethoxyflavone,
 human picornavirus early replication
 inhibition, 30:90
- Diisopropyl fluorophosphate, HEF gly-
 coprotein of influenza C virus and,
 40:221, 223, 225, 229
- Dimerization, hepatitis delta virus,
 43:216–217
- o*-Diphenolic compounds, enzymatically
 oxidized, HSV attachment inhibition,
 30:84–85
- Diphtheria, archaeobacterial viruses and,
 34:144
- Direct immunofluorescent test, ASF and,
 35:266–267
- Disease control, plant viruses in develop-
 ing countries and, 41:374, 377, 392,
 396
- Dissociation, antiviral antibody affinity
 and, measurement
 direct, 34:295–297
 relative, 34:302–304
- Disulfide bonds, potyvirus coat protein
 and, 36:285–286
- Divided-genome virus, 25:314
 serological properties, 25:341
 structural proteins, 25:331–332
- DNA
 adeno-associated viruses, 25:409–
 416
 adenovirus and, 39:89–95
 oncodna viruses, 39:104–111
 sequence-specific methylation,
 39:113–124
 species specificity, 39:95–103
 animal cells and, 36:112, 134
 antiviral antibody affinity and, 34:302
 archaeobacterial viruses and, 34:144–
 145, 147, 185
Halobacterium halobium, 34:147,
 150–158, 160–163
Halobacterium phages, 34:164–167
Methanobrexibacter smithii, 34:168
Sulfolobus virus-like particle SSV1,
 34:177–183
Thermoproteus tenax, 34:171–174
 bacteriophages, unusual bases in,
 27:222–223
- Baculovirus, properties, 25:290–297
 binding factors, papillomavirus, tran-
 scription, 44:331–333
 bovine herpesvirus, 45:193–194
 caulimoviruses, 28:8–10
 chickenpox virus, 28:299–303
 cloning in AAV, 32:288–290
 bacterial neomycin resistance gene
 expression, 32:289–290
 possibilities for mammalian genet-
 ics, 32:291

- prokaryotic CAT gene expression, **32:289**
- cloning in retroviruses, **32:287–288**
- complementary, *see* Complementary DNA
- covalently closed circular formation, **46:191–192**
- hepadnaviruses, **46:170–172**
- cucumber mosaic virus and, **41:305, 322**
- defective interfering viruses and, **40:182, 184–186, 188**
 - animals and humans, **40:189, 194–197**
- Densoviruses, **25:312**
- double-stranded
 - plant viruses, **28:5–12**
 - retroid viruses
 - integration, **32:74–76**
 - RNA transcription from, **32:76–84**
- Drosophila* retrotransposons and, **36:34, 91–92, 96–97**
 - insertional mutagenesis, **36:77, 79, 84–85, 89**
 - intracellular cycles, **36:60, 63–67**
 - organization, **36:51–52, 54–55, 59**
 - scattered repetition, **36:36–37, 39, 41, 44–45**
 - transcription, **36:67, 70–71**
- Epstein-Barr virus and, **40:20, 22, 47–48**
 - EBNA-1, **40:41–47**
 - genome, **40:24, 26**
- fragmentation
 - apoptosis, **45:3, 5, 24–25**
 - CTL-mediated, target susceptibility, **45:26–28**
- fragment integration in cervical carcinomas, **44:325–327**
- FV3
 - circular permutation, **30:5–8**
 - methylation, **30:4**
 - terminal redundancy, **30:5–8**
- gag* gene products, **39:29–31, 34–36**
- geminiviruses, structure, **30:145–151**
- hepadnavirus and, **34:66, 68**
 - characterization, **34:86, 95**
 - diagnosis, **34:130**
 - expression, **34:102–106**
 - genome organization, **34:69–70**
 - immunogenicity, **34:107**
 - mRNA transcription, **34:75**
 - pre-S sequences, **34:97–100**
 - replication, **34:71–72, 75**
 - sequence data, **34:78–82**
 - vaccine, **34:134–135**
- hepatitis C virus and, **40:64, 74, 80**
- hepatitis E virus and, **40:89**
- HIV-1 and, **40:2, 4–5**
- HIV genome, organization, **43:60–61**
- HIV structure and, **39:4, 9, 16, 21, 39**
- host chromosomal, *Spiroplasma citri* in, **44:450–453**
- human herpesvirus 6 and
 - biology, **41:26, 28–29, 32–35, 37**
 - discovery, **41:3–4**
 - growth properties, **41:12–13**
 - molecular biology, **41:16–18, 23**
 - structure, **41:4–5, 7**
- human papillomaviruses, replication, **37:140–141**
- HVT
 - homology with MDV serotypes, **30:234–237**
 - latent in lymphoblastoid cell lines, **30:260–261**
 - during passage in cultured cells, **30:240–241**
 - properties, **30:227–231**
- immunization to bovine herpesvirus, **45:217–218**
- influenza virus and, **34:273**
- invertebrate iridoviruses, restriction endonuclease profile, **46:354–357**
- iridovirus, **25:307–309**
- killed antiviral vaccines and, **39:261, 264–265**
- lactate dehydrogenase-elevating virus and, **41:118, 132–133, 144, 146**
- leafhopper-transmitted MSV
 - coding and intergenic regions, **30:160–163**
 - nucleotide sequence, **30:160–161, 163**
 - small encapsitated fragment, **30:163–164**
- lentiviruses and
 - virus-host cell interaction *in vitro*, **34:197–199**
 - virus-host cell interaction *in vivo*, **34:208**

- MDV
 latent in lymphoblastoid cell lines, **30:260–266**
 oncogenicity-related fragments in MDV I, **30:237–240**
 physical map, **30:232–233**
 properties, **30:227–231**
 serotypes, homology, **30:233–237**
 methylation
 iridoviruses, **46:376–377**
 role in HIV expression inhibition, **43:118–119**
 transcription, **46:380**
 neurodegenerative diseases caused by prions and, **41:244**
 as oligodeoxynucleotide target, **44:286–287**
 oral vaccination and, **41:438**
 packaging, PRD1, **45:313–314**
 parvoviruses, **33:97–98, 103, 105, 139, 142**
 packaging, **33:164**
 replication, **33:149–162**
 structure and sequence, **33:106, 111**
 penetration, PRD1, **45:299–301**
 pesticide production and, **36:315, 341**
 pestiviruses and, **41:77**
 picornaviruses and, **36:175**
 plant, viral infection and, **33:242–243**
 poliovirus and, **34:221, 230**
 polymerization, RNA- and DNA-dependent, **46:107, 131–133**
 priming and synthesis, hepadnaviruses minus strand, **46:184–189**
 plus strand, **46:189–191**
 proviral
 avian retroviruses
 integration into host DNA, **30:195–196**
 transcription, **30:196–203**
 HIV-1 dsDNA, **46:101, 104**
 repetitive, iridoviruses, **46:390–391**
 replication
 adeno-associated viruses, **25:420–421**
 iridoviruses, **46:375–376**
 ribozymes cleaving, **44:284**
 rotaviruses and, **39:176, 179**
 satellite RNA for biocontrol and, **39:333**
 sequences, foreign, in recombinant AcNPV, **35:189**
 single-stranded
 AAV, **32:243–245**
 adenovirus oncogenicity inhibition, **32:280–285**
 integration into cellular DNA, **32:269–274**
 inverted terminal repeat, **32:248–249, 252–255, 263–265**
 nucleotide sequence, **32:246–247**
 ORFs, **32:249–250, 255**
 replication, **32:260–266**
 plant viruses, **28:13**
 torsion-induced bends, HIV-1 reverse transcription, **46:115**
 translational suppression by retroviruses and, **41:193–194, 198**
 tumor, transfection, in HPV transformation, **37:148–149**
 vaccinia and, **34:43–45**
 genome, **34:45–46, 48–49**
 vector, **34:52–53, 55–56, 58**
 varicella zoster virus, **38:52–53**
 viral, replication, **37:102–112**
 whitefly-transmitted geminiviruses
 nucleotide sequences, **30:151–156**
 coding regions, **30:153–156**
 common region, **30:152–153**
 homology, **30:143, 152**
 transcription, **30:157–159**
 DNA-binding factors, regulation of interferon genes, **42:64, 66–67**
 DNA-binding proteins, **29:42**
 DNA replication and adenovirus, **34:8–9**
 SV40, **34:19–20**
 PRD1, **45:307–308**
 DNA footprinting, *gag* gene of RSV and, **35:10**
 DNA polymerase
 AAV, **32:265–266**
 in bovine herpesvirus, **45:199–200**
 CaMV, **32:69–70**
 DNA-dependent, closteroviruses, **47:149**
 DNA replication and, **34:7–8, 20**
Drosophila, retrotransposons and, **36:58, 64**
 hepadnaviruses, **32:43, 34:69, 71, 75**
 HIV structure and, **39:4, 34–35, 37**
 human herpesvirus 6 and, **41:18, 21–23, 26**

- induction by
 chickenpox virus, **28:306–307**
 HVT, **30:251**
 MDV, **30:251**
 varicella zoster virus, **38:71–72**
- lentiviruses and, **34:194**
- parvovirus infection and, **33:150–152**
- vaccinia and, **34:44, 48, 51**
- viral, inhibition by
 acyclovir, **30:98**
 BVDU, **30:101**
 2'-nordeoxyguanosine, **30:98–99**
 trisodium phosphonoformate, **30:108**
- DNA replication, initiation of, **34:1–2, 32–34**
- adenovirus, **34:2–3**
 origin, **34:4–7**
 protein, **34:7–9**
 reaction, **34:3–4**
- bovine papilloma virus, **34:20–22**
 gene products, **34:25, 44**
 regulation, **34:25–29**
 sequence elements, **34:22–24**
- Epstein-Barr virus, **34:29–32**
- SV40, **34:10–12**
 mechanism, **34:16–20**
 origin, **34:12–16**
- DNase
 DNA replication and, **34:9**
- Epstein-Barr virus, **40:43**
- hepatitis C virus, **40:80**
- hepatitis E virus, **40:89**
- HIV-1, **40:5**
- induction by
 chickenpox virus, **28:306**
 varicella zoster virus, **38:74**
- DNA synthesis
 FV3
 concatemer production, **30:12–13**
 sites and sizes, **30:10–12**
- hepadnaviruses, **32:43–45, 63–67**
 plus-strand synthesis, **32:64–66**
- induction, **45:9**
- retroviruses, tRNA role, **32:37, 39–40**
- reverse transcription
 actinomycin D effect, **32:70**
 CaMV, **32:47–49, 68–71**
 minus-strand synthesis, **32:68–69**
- DNA viruses, replication, interferon-induced inhibition, **38:177–182**
- Dodder, virus transmission and, **33:291**
- Dodder latent virus, *Plantago* host and occurrence, **27:116**
- Dog, rabies viruses and, **36:215–216**
 Asia, **36:250**
 epizootiology, **36:217**
 Europe, **36:238–239**
 Latin America, **36:237–238**
 North America, **36:235**
- Dolichos enation mosaic virus, **29:319**
 as helper virus, **29:341–342**
- Dot-blot test, for ADRV, **35:216**
- Double-stranded RNA, **42:85–86**
 activated inhibitor pathway, **43:199**
 ADRV and, **35:193–194**
 banana bunchy top virus, **33:310–311**
- Birnaviridae, **32:207**
- chestnut blight fungus, origin and structure, **43:361–362**
- cryptic viruses, **32:171, 177, 182–185, 200–204**
- Cystoviridae, **32:207**
- defective, hypovirulence role, **43:368–369**
- dianthoviruses and, **33:278–280**
- in healthy plants, **32:208–209**
- inhibition
 dependent pathways, **42:93–95**
 host protein synthesis by poliovirus infection, **33:191–192**
- L-A, **43:340–342**
- La France disease
 molecular characterization, **43:375–377**
 packaging, **43:377–378**
- male sterility factor, plants, **32:208**
- Mycoviruses groups A-F, **32:207–208**
- plant viruses and, **33:217**
- positive-stranded RNA viruses, **47:184**
- Reoviridae, **32:207**
- satellite, *Totivirus*, encoding killer toxins
 smut killer system, **43:356–360**
 yeast killer system, **43:347–356**
- TAR, **43:96**
- Totivirus*
 replication, **43:311–313**
 required host genes, **43:336–339**
 unencapsidated, hypovirus, *see* Chestnut blight fungus
- Douglas fir tussock moth, pesticide production and, **36:316–317**

- Downy mildew, satellite RNA for bio-control and, **39:329–330**
- Driselase, **29:219, 224–225**
- Drosophila*
- adenovirus and, **39:123**
 - translational suppression by retroviruses and, **41:211, 214**
- Drosophila C virus*
- in cultured cell lines, **26:132–134**
 - discovery, **26:119**
 - ecological studies, **26:139–141**
 - host range, **26:125–129, 31:304–305**
 - properties, **26:119–124**
 - quantitative studies, **26:134–137**
 - resistance to, **26:129–132**
 - transmission, **26:137–139**
- Drosophila melanogaster*
- picornaviral genomes and, **40:147**
 - and virus-like particles, **31:311–313**
- Drosophila* retrotransposons, **36:34–35**
- copia*, **36:67–70**
- development, **36:71–74**
 - modulation, **36:75–77**
 - peculiarities, **36:70–71**
- fluid component, **36:91**
- higher organisms, **36:97**
- insertional mutagenesis, **36:77–78**
- excess function, **36:84–85**
 - interference, **36:85–86**
 - loss of function, **36:78–84**
 - overproduction, **36:85**
 - phenotype, **36:87**
 - suppression, **36:87–91**
- intracellular cycles, **36:60**
- DNA circles, **36:64–66**
 - extrachromosomal linear copies, **36:66–67**
 - replication, **36:67**
 - reverse transcriptase, **36:64**
 - virus-like particles, **36:60–64**
- nomadic elements, **36:92–97**
- organization, **36:47–50**
- internal sequences, **36:55–60**
 - long terminal repeats, **36:50–55**
- rearrangement, **36:91–92**
- scattered repetition, **36:35–38**
- cultured cel lines, **36:45–47**
 - environmental stresses, **36:41–42**
 - hybrid dysgenesis, **36:42–45**
 - insertion sites, **36:38–40**
 - rate, **36:40–41**
 - transcription, **36:67**
- Drugs
- antiviral
 - human herpesvirus 6 and, **41:24–25**
 - translational suppression by retroviruses and, **41:233**
 - HIV structure and, **39:4–5**
- DS element, Epstein-Barr virus and, **40:44–46**
- Duck hepatitis B virus, **43:222**
- DNA nucleotide sequence near 5'-end, **32:64–65**
 - genomic RNA organization, **32:38–39, 51–55**
 - hepadnavirus and, **34:66**
 - characterization, **34:79, 85, 90**
 - genome organization, **34:69**
 - pre-S sequences, **34:97, 110**
 - replication, **34:71–72, 75**
 - vaccine, **34:133**
 - picornaviral genomes and, **40:143**
 - replication not only in hepatocytes, **32:82**
 - reverse transcription pathway, **32:43–45**
- Dysentery, winter, *see* Winter dysentery
- Dyspnea, lentiviruses and, **34:201**
- E**
- E1A protein
- blocking interferon action, **42:92–93**
 - dependent *trans*-activation of transcription, **37:38–63**
 - characteristics, **37:38–41**
 - promoter targets for, **37:41–51**
 - transcription factors involved in, **37:51–63**
 - as promoter-bound activator in *trans*-activation of transcription, **37:68–69**
- Early events
- flavivirus replication, **33:51–52**
 - parvovirus life cycle, **33:137–139**
- Eastern equine encephalomyelitis, disease characteristics and occurrence, **28:385–389**
- Eastern equine encephalomyelitis virus, **37:277–320**
- epidemiology, **37:279–284**

- infections, experimental, **37:298–319**
 introduction, **37:277–279**
 replication, **37:284–286**
 structure, **37:284–286**
 transmission, **37:286–298**
 in Central America, **37:295–298**
 in North America, **37:286–295**
 rapid, significance of, **37:307–312**
 in South America, **37:296–298**
- Eastern spruce budworm, entomopox-virus, **29:195, 210**
- Ebola hemorrhagic fever, **47:3–9**
 new emerging and reemerging, **47:9–10**
- Ebola virus, **47:15**
- E1B promoter, in *trans*-activation of transcription, **37:42–43**
- EBV, *see* Epstein-Barr virus
- Ecdysterone, *Drosophila* retrotransposons and, **36:76–77**
- Echinocloa ragged stunt virus, characteristics, **38:252–253**
- Echinocystis lobata*, cucumber mosaic virus and, **41:331**
- Echovirus 11, **42:364**
- Eclar, pesticide production and, **36:316–317, 341**
- Ecological studies, of dianthoviruses, **33:291–294**
- Economic loss, plant viruses in developing countries and, **41:390–391**
- Ectodomain
 alphavirus glycoprotein
 fusion activity, **33:10–11**
 host range determinants, **33:11**
 influenza virus hemagglutinin
 fusion activity, **33:4–6**
 host range determinants, **33:11**
 receptor binding site, **33:6**
 rabies virus
 oligosaccharide sites, **33:14–16**
 receptor binding activity, **33:17**
 receptor binding and fusogenic activity, **33:16–17**
- Rous sarcoma virus glycoprotein, **33:23–24**
- vesicular stomatitis virus
 oligosaccharide sites, **33:14–16**
 receptor binding and fusogenic sites, **33:16–17**
- Edeine, Bunyaviridae and, **40:257**
- EDTA
 archaeobacterial viruses and, **34:172**
 cucumber mosaic virus and, **41:288, 294**
- E2F binding site, in viral *trans*-activation of transcription and, **37:55–59**
- E2F factor, in *trans*-activation of transcription, **37:63–67**
- E4F factor
 regulated promoters in *trans*-activation of transcription and, **37:59–60**
 in *trans*-activation of transcription, **37:64–67**
- e1* gene, hepatitis C virus and, **40:71, 73**
- e2* gene, hepatitis C virus and, **40:73**
- e2* gene product, hepatitis C virus and, **40:72**
- E4 gene product, human papillomaviruses, **37:141–142**
- EGF, *see* Epidermal growth factor
- EGFR, *see* Epidermal growth factor receptor
- Eggplant mottled crinkle virus, immunosorbent electron microscopy, **29:179**
- Eggs, *Salmonella enteritidis* in, **43:28**
- Ehrlichiosis, human, **43:37**
- Electrode chamber in electrotransfection, **37:333**
- Electron density
 human herpesvirus 6 and, **41:4, 7**
 pestiviruses and, **41:71–72**
- Electron microscopy
 ADRV and, **35:194–199, 216**
 animal cells and, **36:109, 125**
 archaeobacterial viruses and
 Halobacterium halobium, **34:147–148**
 Halobacterium salinarum phage HS1, **34:163**
 Thermoproteus tenax, **34:172**
 Bunyaviridae and, **40:237, 239, 260**
 cassava latent virus ultrastructure, **30:167**
 cucumber mosaic virus and, **41:288, 324**
 defective interfering viruses and, **40:185**
 detection of rotaviruses, **29:180**
 DNA replication and
 adenovirus, **34:3**

- Electron microscopy (*cont.*)
 DNA replication and (*cont.*)
 bovine papilloma virus, **34:22–23**
 SV40, **34:16**
Drosophila retrotransposons and, **36:47, 60**
 equine arteritis virus and, **41:160**
 furoviruses and, **36:17**
 FV3
 DNA structure, **30:7**
 in infected cell, **30:9**
 HEF glycoprotein of influenza C virus and, **40:218–219**
 hepadnavirus and, **34:90**
 hepatitis A virus and, **39:213, 215, 221–222**
 hepatitis C virus and, **40:60, 77–78**
 high-voltage, *see* High-voltage electron microscopy
 HIV structure and, **39:8, 14, 17**
 human herpesvirus 6 and, **41:4–5, 7, 20**
 HVT
 DNA, **30:230–231**
 virion, **30:228–229**
 immunoelectron, *see* Immunoelectron microscopy
 influenza virus, **34:252**
 neuraminidase, **31:75**
 structure, **31:54**
 lactate dehydrogenase-elevating virus and, **41:105–106, 110–112, 128, 133, 145**
 lentiviruses and, **34:191**
 MDV
 DNA, **30:230–231**
 virion, **30:118–119**
 neurodegenerative diseases caused by prions and, **41:271**
 pestiviruses and, **41:71–72**
 picornaviral genomes and, **40:110**
 potyvirus coat protein and, **36:288**
 purified dianthoviruses, **33:263–265**
 rabies viruses and, **36:248**
 rotaviruses and, **36:206**
 simian hemorrhagic fever virus and, **41:178**
 Sindbis virus encephalitis and, **36:262**
 squash leaf curl virus ultrastructure, **30:146**
 Theiler's murine encephalomyelitis virus and, **39:297, 301, 303**
 torovirus, **43:261–262**
 use in diagnostic virology, **27:1–69**
 comparison with other methods, **27:49–53**
 safety, **27:53–54**
 techniques, **27:15–21**
 vaccinia and, **34:43**
 Electropherotype, rotaviruses and, **39:171–172, 178, 192, 194**
 Electrophoresis
 archaeobacterial viruses and, **34:147, 165, 167**
 cucumber mosaic virus and, **41:286–288**
 DNA replication and, **34:13**
 hepadnavirus and, **34:66, 106**
 hepatitis A virus and, **39:230**
 human herpesvirus 6 and, **41:15, 19, 21**
 lentiviruses and, **34:192**
 pestiviruses and, **41:76, 78, 80–81**
 rotaviruses and, **39:166, 178–180, 183**
 satellite RNA for biocontrol and, **39:324–325**
 simian hemorrhagic fever virus and, **41:179**
 Theiler's murine encephalomyelitis virus and, **39:293**
 translational suppression by retroviruses and, **41:200**
 vaccinia and, **34:46**
 Electrophoretic mobility, reassortants of dianthoviruses and, **33:285**
 Electrotransfection, plant protoplasts with viral nucleic acids, **37:329–341**
 apparatus, **37:332–336**
 applications and prospects in plant virology, **37:339–341**
 frequency, factors affecting, **37:336–339**
 introduction, **37:329–330**
 methods, **37:332**
 principles, **37:330–331**
 ELISA, *see* Enzyme-linked immunosorbent assay
 Elk, chronic wasting disease, **29:6, 9, 43:45**
 Elm mottle virus, *Plantago* hosts and occurrence, **27:115**

- Elongated viruses, plant, **31:322–323**
- Elongation, frameshifting during, **31:243–244**
- Emerging viruses, positive-strand RNA viruses and, **41:182**
- Emulsion, carrier-mediated drug delivery and
immunodilator, **35:302–303**
vaccine, **35:299–300**
- Encapsidation, *see also* Complementation system
Bunyaviridae and, **40:242, 263**
cucumber mosaic virus and, **41:297, 329**
genome organization, **41:312, 314**
satellite RNAs, **41:317–318**
virus particle, **41:285, 288**
defective interfering viruses and, **40:184, 198, 202, 206**
heterologous, luteoviruses, **46:447–448**
RNA, **46:30–34**
capsid mutations affecting, poliovirus, **46:47–52**
hepadnaviruses, **46:176–180**
requirements for, poliovirus, **46:31**
signals, **46:32–33**
subcellular location, **46:33–34**
- Encapsidation signal, *Totivirus*, **43:316, 318**
- Encephalitis, **39:297**
antiviral antibody affinity and, **34:302–303**
induction by
Bunyamwera virus, human, **30:287**
California virus
human, **30:287**
mouse, **30:289–290**
La Crosse virus
human, **30:287–289**
mouse, **30:290**
- lentiviruses and, **34:189–190**
virus-host cell interaction *in vivo*, **34:201, 204, 207**
- mosquito-borne, **28:357–438**
Asian and Australasian disease types, **28:381–385**
diagnosis, **28:380–381**
disease pathology, **28:379–380**
Eastern equine encephalitis, **28:406–412**
- Jamestown Canyon encephalitis, **28:412–419**
- Japanese encephalitis, **28:381–383**
- LaCrosse encephalitis, **28:406–412**
- Murray Valley encephalitis, **28:383–385**
public concern about, **28:379**
research needs, **28:421–424**
Rocio encephalitis, **28:419–421**
Saint Louis encephalitis, **28:400–406**
transmission modes, **28:359–360**
in the U.S., **28:385–421**
vector competence and virus transmission, **28:359–378**
- Venezuelan equine encephalomyelitis, **28:395–400**
- Western equine encephalomyelitis, **28:389–395**
- rabies viruses and, **36:248–249**
- Sindbis virus, *see* Sindbis virus encephalitis
- tick-borne, **43:17–18**
- Encephalomyelitis
with demyelination, **42:250–251**
experimental allergic, **42:259–260**
postinfectious, **42:281–282**
Sindbis virus and, **36:256, 258–261**
- Encephalomyelitis virus, eastern equine, **37:277–320**
- Encephalomyocarditis virus, **39:293–294, 311**
interferon-induced antiviral actions, **42:82**
picornaviral genomes and, **40:104, 106**
cis-acting elements, **40:117, 125–126, 128**
evolution, **40:160–161**
phenotype, **40:157–158**
structure, **40:106, 109–110**
transacting factors, **40:132–134, 138, 141**
translation initiation, **40:140, 142**
replication, interferon-induced inhibition, **38:185–186**
- Endangered species, pathogens, new, emerging, and reemerging, **43:47**
- Endocrine disorders, virus-induced, **31:359**
- Endocytosis
animal cells and, **36:108, 117–121, 139**
advantages, **36:122–123**

- Endocytosis (*cont.*)
 animal cells and (*cont.*)
 early interactions, **36:109**
 enveloped viruses, **36:131–136**
 macromolecule transport, **36:111**
 membrane fusion, **36:126**
 nonenveloped viruses, **36:136–138**
 penetration, **36:121–122**
 receptors, **36:112, 117**
 CD4 cytoplasmic tail role, **44:219–221**
 lactate dehydrogenase-elevating virus
 and, **41:108, 110**
 phorbol ester-induced, **44:226, 229**
 poliovirus and, **34:219**
 virus entry into cells by, **27:151–154**
- Endoglycosidase H
 Bunyaviridae and, **40:261**
 digestion, prion proteins and, **35:103**
- Endonuclease
 adenovirus and, **39:98, 102, 114, 122**
 archaeobacterial viruses and, **34:181–182**
Drosophila retrotransposons and,
36:58–59
 lentiviruses and, **34:194–195**
- Endoplasmic reticulum
 furoviruses and, **36:10**
 hepadnavirus and, **34:99**
 influenza virus and, **34:249, 254**
 maturation of rotavirus in, **38:17–18**
 NS28 in, orientation of, **38:24–25**
 retention of rotavirus glycoprotein
 VP7 in, **38:21–23**
 rough, of alphaviruses, protein import
 into, **38:359–361**
 Sindbis virus encephalitis and, **36:258, 260**
- Endoproteases, influenza virus and,
34:265
- Endosomes, influenza virus and, **34:252**
- Endothelium
 hepadnavirus and, **34:97**
 poliovirus and, **34:220**
- Enhancer sequence, parvovirus DNA
 and, **33:116–117**
- Enterically transmitted NANBH, **40:57–58, 85, 95**
 cloning, **40:87, 89**
 infectious agent, **40:85–87**
 prevention, **40:93–94**
- Enterovirus
 conservation of amino acids, **42:168–169**
 hepatitis A virus and, **39:226–227**
 picornaviral genomes and, **40:104–105**
 polypeptides, functions, **42:353**
 serological properties, **25:341**
 structural proteins, **25:332**
 Theiler's murine encephalomyelitis vi-
 rus and, **39:292–294**
- Entomopoxvirus, **29:195–213**
 acidic deoxyribonuclease, **29:203**
Aedes aegyptis, **29:197**
 alkaline protease, **29:204–205**
Amsacta moorei, **29:195–196, 198, 200–204, 206, 208–209**
Anomala cuprea, **29:197**
Aphodius tasmaniae, **29:197**
 base composition, **25:305–306**
Camptochironomus tentans, **29:197**
Chironomus attenuatus, **29:197**
Chironomus decorus, **29:210**
Chironomus luridus, **29:195, 197**
Chironomus near decorus, **29:206**
Choristoneura biennis, **29:195–196, 199, 201–202, 206**
Choristoneura diversana, **29:196**
Choristoneura fumiferana, **29:195, 206**
 conformation, **25:306**
 components, **29:200–206**
Demodena boranensis, **29:196**
Dermolepida alborhirtum, **29:197**
 DNA-dependent RNA polymerase,
29:204
Euxoa auxiliaris, **29:196, 201–203, 206**
Figulus sublaevis, **29:197**
Geotrupes silvaticus, **29:197**
Goeldichironomus holoprasinus,
29:197, 206
 halo, **29:200**
 host range, **29:196–198**
 inclusion body, enzymes, **29:203–205**
 infection, **29:206–209**
 in larvae, **29:207–208**
 adsorption, **29:207**
 maturation, **29:207–208**
 morphogenesis, **29:207–208**
 nonoccluded particles, **29:208**
 occlusion, **29:208**
 penetration, **29:207**

- Melanoplus sanguinipes*, **29**:197, 201–203, 206
- Melolontha melolontha*, **29**:195–196, 198
- morphology, **25**:283, **29**:196–197
- multiplication, **29**:206–209
- nature and strandedness, **25**:305
- neutral deoxyribonuclease, **29**:203–204
- nucleotide phosphohydrolase, **29**:203
- Oncopera alboguttata*, **29**:210
- Operophtera brumata*, **29**:196
- Oreopsyche angustella*, **29**:196
- Othnonius batesi*, **29**:196, 206, 210
- in pest control, **29**:209–210
- Phyllopertha horticola*, **29**:197
- polyadenylic acid polymerase, **29**:204
- serological properties, **25**:339
- spindles, **29**:198, 200–201
- structural features, **29**:198–200
- structural proteins, **25**:329–330, **29**:201–203
- in tissue culture cells, **29**:208–209
- virion, **29**:198–200
- components, **29**:201–202
- enzymes, **29**:203–205
- env*
- for coat proteins
- hepadnaviruses, **32**:54
- MoMLV, **32**:51
- HIV-1 and, **40**:2, 11
- HIV structure and, **39**:10–11, 39, 53
- HTLV-I sequence and functional conservation, **43**:157–160
- retrovirus replication and, **35**:3–4
- RSV
- intron sequences in, **35**:22–26
- spliced mRNAs and, **35**:20–22, 24, 26
- Envelope antigen
- methods of studying in oncovirus, **25**:458
- immunoelectron microscope, **25**:462
- oncovirus, **25**:451–482
- precursors, **25**:456–458
- purification, **25**:458–459
- Enveloped viruses, cell penetration by, **27**:167–187
- Envelope glycoproteins, HIV structure and, **39**:11, 14, 17
- gene products, **39**:19, 39–40, 42, 47–50
- Envelope proteins, hepadnavirus, *see* Hepadnavirus envelope proteins
- Envelopes, pararetroviruses and retroviruses, **44**:47–48
- Environment
- cucumber mosaic virus and, **41**:331, 336
- effect on nonpersistent virus spread, **31**:398–400
- lactate dehydrogenase-elevating virus and, **41**:125, 153
- Enviroxime, rhinovirus inhibition, **30**:109–110
- Env protein, **45**:238–240
- HIV-1, **40**:2
- Enzeco AP 650, **29**:219
- Enzootics, rabies viruses and, **36**:218–219, 222–223
- Latin America, **36**:237–238
- North America, **36**:223–228, 232–233, 235–236
- Enzymatic activities, iridoviruses, **46**:385–386
- Enzyme immunoassay
- HIV sensitivity and specificity, **42**:165–166
- human herpesvirus 6 and, **41**:25–26
- Enzyme-linked immunosorbent assay, **29**:97–99, 108, 118, 144, 163, 170, 188, 193
- ADRV and, **35**:215–216
- antiviral antibody affinity and, **34**:302, 304–305
- ASF and, **35**:267
- chickenpox-virus antibodies, **28**:317–318
- competition, **29**:147
- cryptic virus detection in plants, **32**:187–188
- cucumber mosaic virus and, **41**:292–296
- dianthoviruses and, **33**:269–272
- equine arteritis virus and, **41**:161
- vs. immunosorbent electron microscopy, **29**:175–177
- indirect, **29**:147–148
- detection of Tobamo viruses, **29**:155–156
- lactate dehydrogenase-elevating virus and, **41**:118, 122–123, 152

- Enzyme-linked immunosorbent assay (*cont.*)
 multilayered sandwich, **29:147**
 vs. PA-CGT, **29:180**
 pestiviruses and, **41:85–86**
 in plant virology, **29:132**
 plant viruses in developing countries and, **41:380**
 rotavirus, in human stools, **29:180**
 sensitivity, **29:191–192**
 simian hemorrhagic fever virus and, **41:176–177**
 torovirus
 advantages and disadvantages, **43:263–264**
 antibody detection, **43:266**
 virus antigen in protoplasts, **29:246**
- Enzymes
 archaeobacterial viruses and, **34:145**
Halobacterium halobium, **34:152, 154, 163**
Methanobrexibacter smithii, **34:168**
Sulfolobus virus-like particle SSV1, **34:178**
 Bunyaviridae and, **40:244, 247, 255, 258**
 cucumber mosaic virus and, **41:296, 313**
 defective interfering viruses and, **40:190**
 DNA replication and, **34:4, 23–24**
 HEF glycoprotein of influenza C virus and, **40:214, 217, 221–225**
 hepadnavirus and, **34:104, 130**
 hepatitis C virus and, **40:69**
 hepatitis E virus and, **40:86, 89**
 HIV-1 and, **40:2**
 HIV structure and, **39:4, 6, 16, 42**
 human herpesvirus 6 and, **41:19, 21–24**
 induced by varicella zoster virus, **38:68–74**
 influenza virus and
 components, **34:254, 257**
 pathogenicity, **34:262, 265**
 killed antiviral vaccines and, **39:276–278, 284**
 lactate dehydrogenase-elevating virus and, **41:107–109, 111, 124, 133**
 neurodegenerative diseases caused by prions and, **41:269**
 Paramyxoviridae and, **39:134**
 pestiviruses and, **41:68, 77, 84–85**
 picornaviral genomes and, **40:107, 132, 134, 143, 147**
 protease, **39:25, 27**
 reverse transcriptase, **39:29–36, 38**
 translational suppression by retroviruses and, **41:194, 228**
 vaccinia and, **34:44**
 genome, **34:46–47**
 vector, **34:55**
 Eosinophils, Epstein-Barr virus and, **40:31**
- Epidemic development, plant viruses and crop improvement, **41:356–357, 359–360, 366, 369**
 crop protection, **41:375**
 remedial action, **41:377, 388, 390–391**
- Epidemic hemorrhagic fever, Hantaan viruses and, **31:32**
- Epidemiology
 banana bunchy top virus, **33:313**
 cucumber mosaic virus and, **41:290, 334–338**
 hepatitis A virus, **39:210–212**
 age distribution, **39:216–217**
 characterization, **39:221**
 duration of infectivity, **39:218–219**
 epidemic waves, **39:216**
 patterns of infection, **39:217–218**
 routes of infection, **39:220–221**
 seasonal patterns, **39:216**
 human herpesvirus 6 and, **41:27–28, 39**
 neurodegenerative diseases caused by prions and, **41:257**
- nonpersistent viruses
 models for description, **31:413–417**
 spread
 environmental effect, **31:398–400**
 forms, **31:409–413**
 vectors
 biology, **31:394–398**
 characteristics, **31:392–394**
 incidence, monitoring methods, **31:400–409**
 livetrapping and evaluation of, **31:405–407**
 virus incidence, monitoring methods, **31:400–409**

- dependence on number of aphids, 31:415–416
- infection incidence, 31:408–409
- in soybeans, 31:416–417
- pestiviruses and, 41:69–70, 74, 91
- plant viruses in developing countries and, 41:351, 377, 396
- positive-strand RNA viruses and, 41:157, 163, 182
- Epidermal growth factor
 - Epstein-Barr virus and, 40:39–40
 - interaction with receptor, 37:5–7
- Epidermal growth factor receptor
 - amino acid sequence, homology with *erbB* protein, 32:108–109
 - tyrosine kinase activity, 32:112
- Epidermodysplasia verruciformis
 - epidemiology, 37:153
 - human papillomaviruses and, 37:134
- Episomal elements, adenovirus and, 39:104, 117
- Epithelial cells
 - airway, viral replication and, 35:228
 - arrangement and shape, 42:194
 - defective interfering viruses and, 40:196
 - Epstein-Barr virus and, 40:20, 35–36, 38, 47
 - human papillomavirus interaction with, 37:128
 - membranous, 42:210, 220–221, 224–225
 - oral vaccination and, 41:409–410, 414
 - pestiviruses and, 41:58, 63–64
 - polarized, *see* Polarized epithelial cells
 - roles, 42:187–188
 - secretion, viral infections and, 35:224
 - types, 42:193–194
- Epithelial tissues, properties, 42:193–195
- Epithelium
 - DNA replication and, 34:31
 - hepadnavirus and, 34:97
 - influenza virus and, 34:254
 - poliovirus and, 34:220, 226
- Epitopes
 - animal cells and, 36:113
 - antigenic, synthetic peptides, 42:152–153
 - antiviral antibody affinity and, 34:284
 - measurement
 - direct, 34:287–288, 293–294, 298–301
 - relative, 34:303–307
- Bunyaviridae and, 40:245
- continuous, prediction, 42:154–155
- false-positive reactivity, 42:156–157
- flavivirus
 - antibody-dependent enhancement and, 31:151–159
 - antigenic variations, 31:118–121
 - blocking antibodies, 31:148–149
 - chemical modification, 31:137–139
 - dengue 2 virus, topological model, 31:125
 - functional activities, virus-specific dissociation, 31:149–151
 - functional characterization, 31:144–148
 - on nonstructural glycoprotein NV3, 31:159–160
 - passive protection, 31:144–148
 - protein fragmentation, 31:139–144
 - structural characterization, 31:137–144
 - topological mapping, 31:123–127
 - cooperative effects between antibodies, 31:128–137
 - MAB binding and functional assays, 31:129–134
 - models, 31:123–128
 - type-specific, St. Louis encephalitis virus strains, 31:120
 - virus strains, 31:150–151
 - virus types, 31:149–150
- gp41 immunodominant domain, 42:159–161
- HEF glycoprotein of influenza C virus and, 40:217, 220, 222, 226
- hepadnavirus and
 - characterization, 34:90
 - immunogenicity, 34:106–111, 113
 - pre-S sequences, 34:97, 101, 105
 - vaccine, 34:133–134
- hepatitis A virus and, 39:224
- hepatitis C virus and, 40:80, 84
- hepatitis E virus and, 40:90, 93–94
- HIV structure and, 39:7, 21, 47–48
- lactate dehydrogenase-elevating virus and, 41:115, 138, 144–145, 152–153

- Epitopes (*cont.*)
 lentiviruses and
 structure, **34:194–195**
 virus-host cell interaction *in vivo*,
 34:206–207
 location, luteoviruses, **46:445**
 mapping, **29:110**
 by overlapping peptides, **42:155–156**
 oral vaccination and, *see* Oral vaccination with recombinant bacteria
 Paramyxoviridae and, **39:133–134**
 pestiviruses and, **41:75, 86**
 potyvirus coat protein and, **36:299–300, 303–305**
 reaction of antibody with, **29:99**
 rotaviruses and, **39:183, 186, 198**
 neutralization, **36:186, 192–195, 198–199, 201**
 protection, **36:190**
 surface proteins, **36:203–204**
 Sindbis virus encephalitis and, **36:258–259, 262**
 Theiler's murine encephalomyelitis virus and, **39:309, 313**
- Epizootics
 equine arteritis virus, **41:155–156, 163, 182**
 simian hemorrhagic fever virus and, **41:168–169, 171–173, 175–176, 178, 182**
- Epizootiology, rabies viruses and
 Africa, **36:240, 246–248**
 North America, **36:217–218, 223–224, 236**
 bat, **36:222–223, 228, 299**
 enzootics, **36:218–220**
 interspecies transmission, **36:219, 221**
 rat, **36:230–231**
 terrestrial species, **36:224, 228**
 transmission, **36:232–236**
- E2 promoter, in *trans*-activation of transcription, **37:43–45**
- E3 promoter, in *trans*-activation of transcription, **37:45–46**
- E4 promoter, in *trans*-activation of transcription, **37:46–47**
- E1 protein
 coronaviruses, **28:71–72**
 structure and biological activities, **28:92–94**
 as papillomavirus replication factor, **44:312–313**
- E2 protein
 coronaviruses, **28:72–74**
 structure and biological activities, **28:87–92**
 as papillomavirus replication factor, **44:313–315**
- E protein, Berne virus, **43:246–247**
- Epstein-Barr virus
 acute lymphoproliferative disease from, **27:306–318**
 animal cells and, **36:112, 119, 136**
 apoptosis induced by, **45:18–19**
 association with diseases, **44:370–371**
 bacteriophages in, **27:259–260**
 as cofactor in AIDS progression, **43:110–111**
 defective interfering viruses and, **40:196**
 detection of structural change, **29:118**
 diagnosis using synthetic peptides, **42:169–172**
 diseases associated with, **27:300–324**
 DNA replication and, **34:2, 29–33**
 encoded RNAs, immortalizing genes, **40:33**
 entry in oropharynx, **42:218**
 experimental infection by, **27:304–305**
 genomic DNA, homology with MDV and HVT, **30:235–237**
 hepatitis C virus and, **40:61**
 and HIV expression, **43:110–111**
 human herpesvirus 6 and, **41:2–3, 5, 9**
 biology, **41:26, 33, 36–37**
 immortalizing genes, **40:19–20, 47–48**
 characteristics, **40:22–24**
 EBNA-1, **40:40–47**
 EBNA-2, **40:27–34**
 genome, **40:24–27**
 infection of B lymphocytes, **40:21–22**
 latent membrane protein, **40:34–40**
 target cell, **40:20–21**
 infectious mononucleosis, T cell apoptosis, **45:44–45**
 latency of, **26:71–72**
 MAbs, **29:101**
 new cell surface marker, **29:114**
 properties, **27:255**
- Epstein-Barr virus nuclear antigen 1
 DNA replication and, **34:29, 31–32**

- immortalizing genes and, **40:25–27, 33, 40–48**
- Epstein-Barr virus nuclear antigen 2, immortalizing genes and, **40:24–34, 40, 45, 47**
- Epstein-Barr virus nuclear antigen leader protein, immortalizing genes and, **40:24, 26, 28, 33**
- Equilibrium, antiviral antibody affinity and, **34:283–284**
 measurement, direct, **34:286, 288, 292–293, 295, 297–298**
- Equine abortion virus, **45:153–181**
 abortion, **45:157–158**
 antigenic relationship with equine rhinopneumonitis virus and AHV3, **45:169–173**
 cultivation, **45:173–174**
 epidemiology, **45:159–162**
 experimental animal models, **45:176**
 genetic relationship with equine rhinopneumonitis virus, **45:168–169**
 genital disease, **45:158**
 genome, **45:162–165**
 hypothetical view of origins, **45:169, 172**
 laboratory diagnosis, **45:174–176**
 latency, **45:159**
 myeloencephalitis, **45:158**
 proteins/glycoproteins, **45:165–168**
 subtype designations, **45:154**
 vaccines, **45:177–180**
- Equine arteritis virus, **41:100–101, 145, 149**
 bucyrus strain, **41:155–156, 158, 161–163, 166**
 common properties of positive-strand RNA viruses, **41:178–181**
 emerging viruses, **41:182**
 host immune response, **41:160–163**
 pathogenesis, **41:155–158**
 replication, **41:158–160**
 viral strains, **41:163**
 virion properties, **41:163–168**
- Equine herpesvirus, **45:155, 165–168**
- Equine herpesviruses 2 and 5, **44:357–373**
 epidemiology, **44:371–372**
 genome structure and composition, **44:361–363**
 growth characteristics in cell culture, **44:365–368**
 cytopathology, **44:366–367**
 host range, **44:366**
 replication, **44:367**
 transformation, **44:367–368**
 heterogeneity of isolates, **44:364–365**
 identification
 as equine herpesvirus, **44:364–365**
 as gammaherpesviruses, **44:361**
 pathogenesis and clinical features, **44:368–371**
 proteins, **44:363–364**
- Equine infectious anemia virus, **34:189–191**
 structure, **34:191, 193–195**
 virus-host cell interaction *in vitro*, **34:197–200**
 virus-host cell interaction *in vivo*, **34:201–206**
- Equine rhinopneumonitis virus, **45:153–181**
 antigenic relationship with equine abortion virus and AHV3, **45:169–173**
 cultivation, **45:173–174**
 epidemiology, **45:159–162**
 experimental animal models, **45:176**
 genetic relationship with equine abortion virus, **45:168–169**
 genital disease, **45:158**
 genome, **45:162, 164–165**
 laboratory diagnosis, **45:174–176**
 latency, **45:159**
 proteins/glycoproteins, **45:165–168**
 respiratory disease, **45:156**
 vaccines, **45:177–180**
- Erythrocytes
 HEF glycoprotein of influenza C virus and, **40:213–214, 223–226, 229, 231**
 influenza virus and, **34:254, 262**
 killed antiviral vaccines and, **39:280**
 lentiviruses and, **34:205–206**
 vaccinia and, **34:58**
- Erythrophagocytosis, lentiviruses and, **34:203, 205**
- Erythropoiesis, lentiviruses and, **34:205–206**
- Escherichia coli*, **29:266, 301, 305**
 adenovirus and, **39:111**
 archaeobacterial viruses and, **34:157, 166, 175**

Escherichia coli (cont.)

- DNA replication and, **34:19, 31**
- Drosophila* retrotransposons and, **36:53, 66, 93**
- hepadnavirus and, **34:103, 105**
- hepatitis C virus and, **40:64**
- hepatitis E virus and, **40:89**
- HIV structure and, **39:31, 34–37**
- human herpesvirus 6 and, **41:20**
- oral vaccination and, **41:410, 414**
- bacteria as carriers, **41:431, 436–437**
- epitope presentation systems, **41:424–425**
- pestiviruses and, **41:77**
- rotaviruses and, **36:204**
- Theiler's murine encephalomyelitis virus and, **39:294**
- translational suppression by retroviruses and, **41:216, 219–220, 224–225, 230**
- Esophagus, **42:219**
- ET1.1
 - hepatitis C virus and, **40:63**
 - hepatitis E virus and, **40:88–90**
- ETEC, oral vaccination and, **41:427**
- 4'-Ethoxy-2'-hydroxy-4,6'-dimethoxy-chalcone, rhinovirus direct inactivation, **30:90–91**
- Ethylene, symptom production and, **33:235–236, 239**
- Ethyleneimines, killed antiviral vaccines and, **39:258, 282–283**
- Ethyl ether, **29:283**
- 5-Ethyl-1-ethoxymethyl-6[(3,5dimethylphenyl)thio]uracil, **42:31–33**
- 5-Ethyluridine-deoxyriboside
 - effect on persistent viruses, **26:54–55**
 - formula, **26:51**
- 5-Ethynyl- β -D-ribofuranosylimidazole-4-carboxamide, **42:13–14, 16**
- Etiology
 - banana bunchy top virus, **33:310–311**
 - lactate dehydrogenase-elevating virus, **41:124–125**
 - neurodegenerative diseases caused by prions, **41:271**
- Eubacteria, archaeobacterial viruses and, **34:144–145, 184**
- Halobacterium* phages, **34:166**
- Sulfolobus* virus-like particle SSV1, **34:177–178, 184**

Eukaryotes

- adenovirus and, **39:93, 114–115, 122–123**
- animal cells and, **36:107**
- archaeobacterial viruses and, **34:143–145, 178, 184**
- DNA replication and, **34:1, 33**
- adenovirus, **34:2**
- bovine papilloma virus, **34:21, 26**
- Epstein-Barr virus, **34:30**
- SV40, **34:10, 19**
- Drosophila* retrotransposons and, **36:34, 97**
- insertional mutagenesis, **36:78, 83, 88**
- organization, **36:52**
- scattered repetition, **36:41**
- transcription, **36:76**
- HIV structure and, **39:21**
- Theiler's murine encephalomyelitis virus and, **39:293**
- vaccinia and, **34:43**
- genome, **34:46, 49**
- vector, **34:57**
- Eukaryotic initiation factor 2, **43:96**
- Eukaryotic transcription activators, **38:117–118**
- Evolution
 - Bunyaviridae and, **40:251**
 - HIV structure and, **39:38**
 - picornaviral genomes and, **40:158–162**
 - rotaviruses and, **39:166–167, 177, 192, 194, 198**
- Exanthem subitum, human herpesvirus 6 and, biology, **41:27–32, 38–39**
- molecular, **41:21–22, 24**
- Excision, adenovirus and, **39:92–93**
- Experimental allergic encephalitis, lactate dehydrogenase-elevating virus and, **41:117, 123**
- Experimental allergic encephalomyelitis, **39:306, 42:259–260**

F

- Factor VIII, hepatitis C virus, **40:60, 74**
- False-positive reactivity, synthetic peptides, **42:156–157**
- Familial diseases, neurodegenerative diseases caused by prions and, **41:259–261**

- Fas/TNF receptor, functions, **45:49**
- FA strain of Theiler's murine encephalomyelitis virus, **39:292, 295**
- Fatal immunodeficiency syndrome, defective interfering viruses and, **40:194**
- Fatty acids
 Bunyaviridae and, **40:261**
 DNA replication and, **34:18**
 HEF glycoprotein of influenza C virus and, **40:218**
 influenza virus and, **34:249**
- Fc receptors
 lactate dehydrogenase-elevating virus and, **41:113, 121**
 mediation of antibody-dependent enhancement, **31:341-342**
- Feces, virus detection in, **27:27-32**
- Feline ataxia, feline panleukopenia virus and, **38:412, 414**
- Feline immunodeficiency virus, **43:45-46, 45:225-243**
 genome organization, **45:227-242**
 Env proteins, **45:238-240**
 Gag proteins, **45:230-232**
 LTR, **45:227-230**
 map, **45:237**
 ORF 2, **45:236-238**
 Pol proteins, **45:232-235**
 Rev proteins, **45:240-242**
 uncharacterized small ORFs, **45:242**
 Vif proteins, **45:235-236**
- Feline leukemia virus, **46:333**
 defective interfering viruses and, **40:194-195**
 translational suppression by retroviruses and, **41:199, 207**
- Feline panleukopenia virus, **38:403-441**, *see also* Parvoviruses
 historical background on, **38:405**
- Feline sarcoma virus, *abl* oncogene and, **35:53**
- Feline type C virus, envelope, antigenic properties, **25:471**
- Ferret
 black-footed, canine distemper, **43:47**
 chronic wasting disease, **29:9**
 kuru, **29:7**
 scrapie, **29:9**
- Ferritin, picornaviral genomes and, **40:151**
- Fescue cryptic virus, mixture of two viruses, **32:181**
- Fetus
 Akabane virus infection, domestic ruminants, **30:209-301**
 parvovirus diseases in, **38:412, 414-415**
- Fever
 hemorrhagic
 Crimean-Congo, **43:18**
 dengue, **31:152, 47:365**
 Ebola, **47:3-10**
 lentiviruses and, **34:202, 205**
- FIAC, *see* 2'-Fluoro-2'-deoxy-5-iodo-1 β -D-arabinosylcytosine
- Fibrin, lentiviruses and, **34:203**
- Fibroblasts
 DNA replication and, **34:31**
 Epstein-Barr virus and, **40:21-22, 24, 34-35, 38**
 hepadnavirus and, **34:102**
 influenza virus and, **34:266**
 lentiviruses and, **34:190, 196-199**
 murine, **29:301, 304**
 poliovirus and, **34:226**
- Fibronectin, respiratory defense mechanisms and, **35:225-227**
- Fibrosis, lentiviruses and, **34:202**
- Fifth disease, **43:26**
- Fijivirus, **45:258, 260**
 characteristics, **38:252**
 genome organization, **38:291**
- Filamentous bacteriophages
 distribution, **27:217-219**
 morphological variation in, **27:249-252**
- Filoviruses, **47:1-42**
 Biological Level 4 agents, **47:1**
 clinical syndrome, **47:32-33**
 diagnosis, **47:34-36**
 epidemiology, **47:2-17**
 Ebola hemorrhagic fever, **47:3-9**
 Marburg hemorrhagic fever, **47:2-7**
 molecular evolution, **47:15-17**
 new emerging and reemerging of Ebola hemorrhagic fever, **47:9-10**
 reservoir, **47:11-14**
 Reston hemorrhagic fever, **47:10-11**
 transmission, **47:6, 14-15**
 genome, **47:16-18, 20**
 immunology, **47:38-39**

- Filoviruses (*cont.*)
- morphology, 47:17–19
 - pathology
 - experimental animals, 47:37–38
 - humans, 47:38
 - pathophysiology, 47:39–42
 - patient management and prevention of infection, 47:36–37
 - prevalence of filovirus-reactive antibodies, 47:12
 - replication, 47:28–32
 - assembly and exit, 47:32
 - cell culture growth, 47:28–29
 - transcription, translation, and genome replication, 47:30–31
 - virus entry, 47:29–30
 - replication cycle, 47:20–21
 - viral proteins
 - GP, 47:24–26
 - L protein, 47:27
 - nonstructural, 47:27–28
 - NP, 47:20–22
 - VP24, 47:26–27
 - VP30, 47:26
 - VP35, 47:23
 - VP40, 47:23
- Fingerprinting
- oligonucleotide, topotypes for dengue 2 virus, 31:118
 - T1 RNase, lactate dehydrogenase-elevating virus, 41:153
- Flagellin, oral vaccination and, 41:424–425
- Flaviviruses, 47:58
- animal cells and, 36:132–133
 - antibody enhancement, 29:121
 - antigenic relationships, 31:107–117
 - cooperative effects between antibodies, 31:128–137
 - on dengue 2 virus, topological model, 31:125
 - functional activities, virus-specific dissociation of, 31:149–151
 - functional assays for MAbs, 31:129–134
 - functional characterization, 31:144–151
 - hemagglutinin inhibition, 31:144–148
 - models, 31:123–128
 - neutralization titers, 31:144–148
 - on nonstructural glycoprotein NV3, 31:159–160
 - passive protection, 31:144–148
 - protein fragmentation, 31:139–144
 - structural characterization, 31:132–144
 - topological mapping, 31:123–137
 - virus strains, 31:150–151
 - virus types, 31:149–150
- diagnosis, MAbs in, 29:101
- epitopes
- antibody-dependent enhancement and, 31:151–159
 - binding assays for MAbs, 31:129–134
 - blocking antibodies, 31:148–149
 - chemical modification, 31:137–139
 - conformational change, 31:137–139
- genomic RNA, 31:103–104
- hepatitis C virus and, 40:95
- cloning, 40:67, 69–73
 - prevention, 40:84
- hepatitis E virus and, 40:91
- historical background, 33:45–46
- lipid envelope, 31:104
- MAbs, 31:109–117
- mutants, 33:80–81
- nucleocapsid, 31:104
- pestiviruses and, 41:83, 90
- positive-strand RNA viruses and, 41:100–101, 145, 180–181
- replication
- early events, 33:51–52
 - glycosylation of virus-specified proteins, 33:58–61
 - identification of virus-specified proteins, 33:53–58
 - intracellular location of proteins and possible function, 33:61–65
 - persistent infection, ts mutants and interfering particles, 33:79–82
 - preliminary overview, 33:50–51
 - strategy of viral RNA synthesis, 33:74–77
 - translation strategy, 33:65–74
 - viral messenger RNA, 33:52–53
 - virus maturation and release, 33:77–79
- ribonucleic acid polymerase, 33:65, 76
- serological subgroups, 31:107–108
- strains, variations among, 31:117–123

- genomes, genetic evolution, **31:118**
 geographically defined variations,
 31:118
 mutation frequencies, **31:117**
 topotypes identified with oli-
 gonucleotide fingerprinting,
 31:118
 type-specific epitopes of St. Louis en-
 cephalitis virus, **31:120**
 vaccines, **31:121–123**
 structural composition, schematic,
 31:105
 structural proteins of mature virions,
 31:104–105
 structure of virion
 morphology and composition, **33:46–**
 47
 proteins, **33:48–50**
 RNA, **33:47–48**
- Flexal virus, antibodies to, **31:4**
- Fluorescein isothiocyanate, **29:245**
- Fluorescence
 cucumber mosaic virus and, **41:294**
 human herpesvirus 6 and, **41:3–4, 20,**
 25–26, 28
 lactate dehydrogenase-elevating virus
 and, **41:106, 111, 152**
 pestiviruses and, **41:84–85**
- Fluorescent-activated cell sorter, **29:144**
- Fluorescent antibody, chickenpox-virus,
 induced membrane antigen, **28:316–**
317
- 3'-Fluoro-3'-deoxyadenosine, **42:9–10**
- 2'-Fluoro-2'-deoxy-5-iodo-1 β -D-ar-
 abinosylcytosine
 anti-herpes, clinical trial, **30:127**
 antiviral activity, **30:102–103**
- 5-Fluorodeoxyuridine, **35:290**
- 3'-Fluoro-2',3'-dideoxynucleosides, **42:28**
- (RS)-9-(3-Fluoro-2-phosphonylmethoxy-
 propyl)adenine, **42:24, 26**
- p*-Fluorophenylalanine, formula, **26:51**
- Food and Agricultural Organization,
 plant viruses in developing countries
 and, **41:350, 391, 393–395**
- Foot-and-mouth disease virus, **29:116,**
39:293–295, 311
 antiviral compound effect on, **26:52–54**
 assembly, **29:116–117**
 oral vaccination and, **41:412–413**
 picornaviral genomes and, **40:104**
 cis-acting elements, **40:116, 128**
 evolution, **40:160–161**
 phenotype, **40:157**
 structure, **40:106–107, 109–110, 114**
 trans-acting factors, **40:133**
 picornaviruses and, **36:155, 161, 163**
 synthetic peptides as vaccines, **32:27**
 VP1 fragments, immunogenicity, **32:9**
- Foot pad response, antiviral compound
 effect on, **26:58–59**
- Formaldehyde, killed antiviral vaccines
 and, **39:257–258**
- Formalin
 equine arteritis virus and, **41:162**
 lactate dehydrogenase-elevating virus
 and, **41:114–115, 138, 152**
- Fos* complex in signal transduction, with-
 in nucleus, **37:18–20**
- Fowl plague virus, influenza virus and,
34:258–259
- Fox, rabies viruses and, **36:216**
 epizootiology, **36:218–219, 221, 223**
 Europe, **36:238–239**
 North America, **36:224, 226–227, 234–**
236
 process assurance, **36:323–326**
 process description, **36:326–333**
 virus replication, **36:332, 334–340**
- Frameshift
 during elongation, **31:243–244**
 equine arteritis virus and, **41:167**
 mutations
 complementation, **43:293–295**
 conversion to wt sequences, **43:295**
 ribosomal, *Totivirus*, **43:320–323**
 sequence repetitions and additions,
 43:295–296
 ribosomal, **41:196–197, 202, 210–233**
 translational, **46:435–438**
- FR element, Epstein-Barr virus and,
40:42, 44–46
- Friend leukemia virus
 gp, **29:70, 114**
 in persistently infected cells, **29:113**
- Frog virus 3
 DNA synthesis
 concatemer production, **30:12–13**
 sites and sizes, **30:10–12**
 genomic DNA
 methylation, **30:4**
 sequence organization, **30:4–8**

- Friend leukemia virus (*cont.*)
 genomic DNA (*cont.*)
 sequence organization (*cont.*)
 circular permutation, 30:5–8
 size and composition, 30:4
 high-voltage electron microscopy, 30:69–70
 mRNA synthesis
 host RNA polymerase II and, 30:13–14
 methylation pattern, 30:14
 virion proteins and, 30:14–15
 replication strategy, 30:15–17
 vertebrate cell infection, 30:8–9
 virion
 composition, 30:2–3
 morphology, 30:2
- F1-R virions, 42:208
- Fujinami sarcoma virus, LTR
 enhancer sequences, 30:203–204
 structure, 30:191
 transcriptional activity, 30:201–202
- Fulminant hepatitis, 39:210, 212–213
- Fundic glands, 42:219
- Fungal disease, satellite RNA for bio-control and, 39:329, 335–337
- Fungi
 antibiotic production, effect of viral infection, 29:256–257
 induced resistance to, 29:255
 pathogenic, virulence, 33:224–225
 transmission of dianthoviruses and, 33:290
- Furazolidone, 29:282
- Fusion
 activity
 alphavirus glycoproteins, 33:10–11
 influenza virus hemagglutinin, 33:4–6
 alphavirus
 comparison with influenza virus, 45:143–145
 events during, 45:142
 properties, 45:131–133
 from within, 38:374–375
 from without, 38:373–374
 DNA replication and, 34:31
 HEF glycoprotein of influenza C virus and, 40:226–228
 hepadnavirus and
 characterization, 34:90
 diagnosis, 34:129–130
 epitopes, 34:118
 genome organization, 34:69
 pre-S sequences, 34:105, 109–110
 vaccine, 34:133
 influenza virus and, 34:274
 components, 34:251–252, 254, 257
 pathogenicity, 34:261, 265–268
 lentiviruses and, 34:196
 virus penetration by, 27:154–159
- Fusion proteins
 animal cell membrane, 36:123–126
 Bunyaviridae, 40:245
 influenza virus hemagglutinin, 29:117
 Paramyxoviridae, 39:130, 140
- Fusogenic process
 HIV, 42:116
 rabies virus, 33:16–17
 vesicular stomatitis virus, 33:16–17
- Fv-1* locus, in mice, 26:75–76
- FV3 virus, *see* Frog virus 3

G

- Gag* gene
 Ab-MLV, 35:46–47, 69–70
 retrovirus replication and, 35:3–4
- RSV
 cis-acting elements in, 35:9–12
 sequences, 35:11
 spliced mRNAs and, 35:20–22, 24, 26
- gag* gene
 for core proteins
 hepadnaviruses, AUG role, 32:53–54
 MoMLV, 32:50–51, 71–72
 HIV-1 and, 40:2
 HIV infection regulation, 43:91–92
 HIV structure and, 39:17, 53
 gene products, 39:17–24
 genome structure, 39:10–11
 HTLV-I sequence and functional conservation, 43:157–160
 translational suppression by retroviruses and, 41:194, 196–197
 cis-acting sequences, 41:219–221, 223–224
 readthrough suppression, 41:187–204, 207–209

- ribosomal frameshifting, 41:211–212, 214, 216, 230–231
- gag-pol* core
 - pararetroviruses, 44:10–11
 - retroviruses, 44:8–9
- Gag–Pol precursors, 44:48–49
- Gag:Pol ratio, regulation, 44:44–45
- Gag protein
 - expression, 44:51
 - feline immunodeficiency virus, 45:230–232
- gag* protein
 - HIV-1 and, 40:2
 - HIV structure and, 39:5–6, 16, 55
- Galactocerebroside, Theiler's murine encephalomyelitis virus and, 39:308
- Galactose, HEP glycoprotein of influenza C virus and, 40:225
- β -Galactosidase
 - expression, RSV-infected cells and, 35:13
 - hepadnavirus and
 - characterization, 34:90
 - diagnosis, 34:130
 - epitopes, 34:118–119
 - pre-S sequences, 34:105, 110
 - vaccinia and, 34:50, 55
- galE*, oral vaccination and, 41:432–433, 435
- γ genes, synthesis, in HSV replication, 37:112–113
- Gamma globulin
 - ADRV and, 35:212–213
 - as clumping antibody, 29:193
 - hepatitis A prevention, 32:158–159
- Gammaherpesviruses, 44:358
 - equine herpesvirus 2 and 5, 44:361
 - genome compositions, 44:360–361
- Ganciclovir, 42:17–19
 - human herpesvirus 6 and, 41:24–25
- Gangliosides
 - role in rabies virus, 42:380–382
 - as virus receptors, 27:146–147
- GAP, in signal transduction, 37:15–16
- Gastroenteritis, rotaviruses, 39:165, 44:170, 174
- Gastrointestinal tract, as portal of entry, 42:221–222
- GCDI gene, picornaviral genomes and, 40:150
- GCN genes, picornaviral genomes and, 40:150
- GCN4 protein, picornaviral genomes and, 40:149–151
- GDP, picornaviral genomes and, 40:131
- GDVII, Theiler's murine encephalomyelitis virus and, 39:292, 295–297, 303, 310–311, 313
- Gel diffusions, virus diagnosis in, 27:44
- Gel mobility shift assays, *gag* gene of RSV, 35:10
- Geminiviruses
 - agricultural importance, 30:139
 - composition, 30:145–146
 - genomic DNA, structure, 30:145–151
 - group members, 30:140–141
 - leafhopper-transmitted
 - dicotyledonous plant infection, 30:144–145
 - genomic DNA, 30:160–164
 - monocotyledonous plant infection, 30:143–144
 - list, 28:12
 - Plantago* host and occurrence, 27:114, 125
 - properties, 28:14, 30:140
 - replication
 - within cell nucleus, 30:164
 - defective particles, 30:169–171
 - recombination and pseudorecombination, 30:171–172
 - stages, 30:165–168
 - structure, 30:146–147
 - transport function, 38:223–225
 - whitefly-transmitted
 - dicotyledonous plant infection, 30:141–143
 - genomic DNA, 30:151–160
- Gene activation, by autonomization, 25:12
- Gene banks, plant viruses in developing countries and, 41:352–353, 371, 391
 - accessions, 41:353
- Gene expression
 - adenovirus, 26:29–31
 - mRNA stability, regulation, 31:216–218
 - mRNA transport from nucleus to cytoplasm, regulation, 31:211–216

- Gene expression (*cont.*)
- adenovirus (*cont.*)
 - transcription
 - E1A protein-mediated activation of, 31:188–195
 - early, repression of, 31:195–199
 - early to late transition, 31:199–204
 - expression during infection, 31:170–179
 - late genes, activation of, 31:199–204
 - pre-early to early transition, 31:188–195
 - units, 31:170–179
 - transcriptional control signals
 - enhancer elements, 31:183–187
 - promoter sites, 31:179–183
 - transcriptional regulation, 31:170–204
 - transcript processing regulation during, 31:204–211
 - polyadenylation, 31:105–207
 - splicing, 31:207–211
 - baculovirus vectors and, 35:190–191
 - cucumber mosaic virus and, 41:319, 328
 - foreign, baculovirus vectors and, *see* Baculovirus vectors, foreign gene expression
 - hepatitis B virus, 47:272
 - in heterologous cells, retroviral LTR effects, 30:216–217
 - human herpesvirus 6 and, 41:35–36, 38
 - neurodegenerative diseases caused by prions and, 41:246, 259
 - oral vaccination and, *see* Oral vaccination with recombinant bacteria in parvoviruses, 33:139–149
 - regulation by interferons, 42:71–81
 - cis-acting sequences, 42:78–79
 - interferon-inducible genes, 42:71–72
 - interferon receptors, 42:72–73
 - signal transduction, 42:73–78
 - trans-acting factors, 42:79–81
 - retroviral, translational suppression in, *see* Translational suppression by retroviruses
 - varicella zoster virus, 38:75–86
 - genetic analyses and, 38:80–81
 - trans-activation in, 38:76, 78–79
- Gene-for-gene concept, host-virus interactions and, 33:224–226
- Gene function, cucumber mosaic virus and, 41:313–316
- Gene mapping, vaccinia and, 34:45–48
- Gene products
 - α , in HSV replication
 - combinatorial effects, 37:101
 - properties and functions, 37:101
 - E1a* of adenovirus, AAA replication and, 32:251
 - erB*-coded from AEV
 - amino acid sequence, 32:107–109
 - identification, 32:104–106
 - p90^{gag-yes} of avian sarcoma virus Y73, 32:100–104
 - amino acid sequence
 - homology with p60^{src}, 32:103–104
 - kinase domain, 32:110
 - phosphoaminoacids, identification, 32:101
 - tyrosine kinase activity, 32:101
 - p60^{src} of RSV
 - amino acid sequence, 32:103
 - homology with v-*erbB*, 32:107
 - kinase domain, 32:110
 - tyrosine kinase activity, 32:100
 - rep*-coded of AAV, 32:266–267
 - ros*-coded, homology with insulin receptor, 32:112
 - src* family, 32:109–114
 - effects on cell proteins, 32:114–116
 - kinase domain, amino acid sequences, 32:113
 - v-*fgr*-coded, kinase domain, amino acid sequence, 32:110
- General Agreement on Tariffs and Trade, plant viruses in developing countries and, 41:389
- Gene replacement therapy, 47:303–304
- Genes, *see also* Oncogenes; Proto-oncogenes
 - bcl-2*, in apoptosis, 45:13–15
 - CAT, prokaryotic
 - AAV as vector for, 32:289
 - from plasmids, insertion into BMV RNA3, 32:227–230
 - expression in presence of BMV RNA1 and 2, 32:230–233

- cellular transforming type, in tumor viruses, **27:296–299**
- c-fos*, in apoptosis, **45:11**
- c-myc*
 in ALV-induced B-cell lymphoma, **30:207–209**
 LTR effect on expression, **30:212–213**
- dihydrofolate reductase of CaMV, expression in turnip, **32:225–226**
- EGFR, human
 identity with *c-erbB-1*, **32:120–121**
 location on chromosome, **32:7, 119**
 as proto-oncogene for *v-erbB*, **32:112, 119–120**
- human papillomavirus, expression regulation, **37:139–140**
- iridoviruses, **46:388–390**
- I-VI of CaMV, **32:56–57**
- KEX*, **43:353**
- KRE*, **43:354**
- MAK*, **43:336–338**
- mouse α -globin, effect on HSV-TK gene expression, **30:215**
- mRNAs, late, synthesis, in HSV replication, **37:112–113**
- neomycin resistance, bacterial, AAV as vector for, **32:289–290**
- N^{Pro}, duplicated, BVDV, **47:88–90**
- papillomavirus
E5, **44:316–317**
E6, **44:317–318, 321–324**
E7, **44:317–321**
- PET18*, **43:337–338**
- 3'-proximal, subgenomization, closteroviruses, **47:144–146**
- rat preproinsulin II in recombinant, clones, effect of ALV LTR, **30:213–214**
- reverse transcriptase, domains on retronid virus genomes, **32:59–61**
- SKI*, **43:339–340**
- TK of HSV in recombinant vectors, **30:215**
 transcriptional interference with mouse α -globin gene, **30:215**
- tobamovirus
 coat protein, function, **38:315**
 effects of genome organization on, **38:332–334**
- expression
 regulation, **38:318–334**
 subgenonuc RNA promotor/leader sequence effect, **38:326–329**
- internal, regulation, **38:322–332**
 translational, **38:323–326**
- 30K, **38:315, 330–331**
- 126K/183K, function, **38:315–318**
- proximal 5', regulation, **38:320**
- varicella zoster virus, **38:82–83**
- viruses
 differentiation effects on expression of, **26:66**
 organization, **26:100–105**
- X, in mammalian hepadnaviruses, **32:54–55, 58**
- Gene sequence, flavivirus, **33:66–67**
- Genetic analysis, parvoviruses, **38:434–436**
- Genetic contents, plant viruses in developing countries and, **41:353**
- Genetic diversity, plant viruses in developing countries and, **41:353, 357, 382**
- Genetic engineering
 oral vaccination and, **41:412–413**
 with plant viruses, **28:1–33**
 cloning viral nucleic acids in prokaryotes, **28:19–22**
 infectivity of cloned viral nucleic acid, **28:22–23**
 manipulation of caulimovirus DNA, **28:23–24**
 principles and aims, **28:2–4**
 recipients for chimeric nucleic acid, **28:27–28**
 types of virus, **28:5**
 vector construction in, **28:25–27**
- Genetic erosion, plant viruses in developing countries and, **41:352, 357**
- Genetic linkage, lactate dehydrogenase-elevating virus and, **41:131–132**
- Genetic makeup, plant viruses in developing countries and, **41:361, 378**
- Genetic maps, of bacteriophages, **27:221**
- Genetic material of viruses, host-cell penetration, **27:141–204**
- Genetic purity, plant viruses in developing countries and, **41:386–387**
- Genetic resistance, cucumber mosaic virus and, **41:337**

- Genetic resources, plant viruses in developing countries and, 41:352–353, 378, 393–395
- Genetics
- Ab-MLV, 35:67–75
 - cucumber mosaic virus and, 41:306, 322
 - human herpesvirus 6 and, 41:19
 - neurodegenerative diseases caused by prions and, 41:255–256, 258–262, 264, 271
 - oral vaccination and, 41:411, 415, 431, 438
 - virus and host, viral demyelination, 42:286–291
- Genetic stabilization, oral vaccination and, 41:428–430
- Genetic upgrading, plant viruses in developing countries and
- crop improvement, 41:361–372
 - remedial action, 41:378–379
- Genetic variants, positive-strand RNA viruses and, 41:153, 182
- Gene transfer, *Spiroplasma* virus, SpV1, 44:453–455
- Genital carcinomas
- epidemiology, 37:153–154
 - human papillomaviruses and, 37:130
- Genital disease, equine herpesviruses, 45:158
- Genital warts, papillomavirus and, 37:128, 130
- Genitourinary tract, virus infection, 42:230–232
- Genogroup, rotaviruses and, 39:167–168, 192
- Genome
- adenovirus and, 39:90–93, 95
 - DNA methylation, 39:119–124
 - oncodna viruses, 39:104–111
 - sequence-specific methylation, 39:111, 113–114, 116–117
 - species specificity, 39:97–98, 102–103
 - bipartite, dianthoviruses, 33:281
 - BMV, three components, 32:206–210, 213–214
 - Bunyaviridae and, 40:236
 - morphogenesis, 40:263
 - replication, 40:255, 258, 260
 - structure, 40:238–239, 241–242
 - cryptic viruses, characterization, 32:200–204
 - cucumber mosaic virus and, 41:283–285, 293, 335
 - gene functions, 41:313–316
 - nucleotide sequence, 41:297–313
 - satellite RNAs, 41:320–322
 - virus-host plant relationships, 41:328, 330
 - defective interfering viruses and, 40:181–188
 - animals and humans, 40:189–191, 193–196, 198
 - plants, 40:198–203
 - FV3, 30:4–8
 - geminiviruses, replication, 30:164–172
 - HBV, antigen-coding part, 32:25–26
 - hepatitis A virus and, 39:210, 226
 - gene localization, 39:244
 - molecular cloning, 39:242
 - nucleotide sequences, 39:244–247
 - prevention, 39:241–242
 - hepatitis C virus and, 40:58
 - cloning, 40:62–71, 73, 75
 - infectious agent, 40:59–61
 - prevention, 40:79–81
 - replication, 40:77, 79
 - hepatitis E virus and, 40:89–93
 - HIV-1 and, 40:14
 - HIV structure and, 39:3, 13, 16
 - pol* gene products, 39:29, 35
 - structure, 39:10–11
 - human herpesvirus 6 and, 41:15–19
 - human papillomaviruses, structure, 37:135–137
 - killed antiviral vaccines and, 39:260, 263
 - changes in virion immunogenicity, 39:273, 278, 281–282
 - kinetics of inactivation, 39:264–266
 - neurodegenerative diseases caused by prions and, 41:244, 256
 - Paramyxoviridae, 39:129, 132, 134–135
 - replication, 39:150–152
 - structure, 37:217–220
 - transcription, 39:141–142, 144–146, 149
 - parvoviruses, coding strategy, 33:117–137
 - pestiviruses and, 41:53–54, 75–83, 90

- picornaviral, *see* Picornaviral genomes, 5'-untranslated region
- plant reovirus, structural and functional properties, **38:249–302**
- poliovirus type 3, attenuation-induced mutants, **32:16–18**
- positive-strand RNA viruses and, **41:100**
- common properties, **41:180–181**
- equine arteritis virus, **41:155, 158, 163–168**
- lactate dehydrogenase-elevating virus, **41:144–150, 153**
- simian hemorrhagic fever virus, **41:178–180**
- satellite RNA for biocontrol and **32:1322**
- cucumber mosaic virus and, **39:325**
- transgenic plants, **39:332, 335**
- Theiler's murine encephalomyelitis virus and, **39:293, 311**
- tobamoviruses, ability to manipulate, **38:312–313**
- translational suppression by retroviruses and, **41:194, 197–199, 204–205**
- wound tumor virus, function, defective interfering RNAs and, **38:272–276**
- Genome-linked virus proteins, positive-stranded RNA viruses, **47:190–191**
- Genomic map
- adenovirus
- early polypeptides, **25:368–373**
- intermediate mRNA, **25:380–382**
- late mRNA, **25:384–388**
- Genomic organization
- AAV, **32:243–258**
- bacteriophage $\phi 6$, **35:157–159**
- Bunyaviridae, **40:242–254**
- cucumber mosaic virus, **41:296–297**
- Fijivirus, **38:291**
- geminiviruses, **30:148–164**
- hepatitis A virus, **39:242–243**
- Paramyxoviridae, **39:135–141**
- parvoviruses, **33:111–117, 38:430–432**
- Phytoreovirus, **38:260–291**
- retroid viruses, **32:38–39, 49–62**
- rice dwarf virus, **38:288–290**
- tobamoviruses, **38:308–312**
- effect on gene expression, **38:332–334**
- wound tumor virus, **38:260–288**
- sequence, **38:269–272**
- Genomic segment reassortment in rotaviruses, *see* Rotaviruses, genomic segment reassortment
- Genotypes
- HTLV-I
- geographic molecular subtypes, **47:389**
- geographic-specific, **43:160–162**
- lactate dehydrogenase-elevating virus and, **41:132, 143**
- neurodegenerative diseases caused by prions and, **41:256**
- plant viruses in developing countries and
- agricultural modernization, **41:351, 353**
- crop improvement, **41:355–356, 359–361**
- crop protection, **41:374–375**
- genetic upgrading, **41:361, 363, 365, 367, 369, 371**
- intensification, **41:376**
- rotaviruses and, **39:186, 193**
- Geographical distribution
- African swine fever, **35:252**
- closterovirus, **25:95–99**
- hepatitis A epidemiology, **32:135–136**
- Germiston virus, Bunyaviridae and, **40:246, 252, 257, 261**
- Germplasm, plant viruses in developing countries and
- agricultural modernization, **41:352–353**
- crop improvement, **41:363–364, 367, 369–371**
- genome organization, **41:397**
- remedial action, **41:379–389, 391–396**
- Gerstmann-Sträussler syndrome, **29:5, 11, 35:83–84, 89**
- features, **29:6**
- prions and, **41:241–243, 257, 259, 269**
- Getah virus, in mosquito cells
- isolation, **30:32**
- mutant detection, **30:32–33**
- Gibberellins, viral infection and, **33:238–240**
- GL424 cells, hepatitis C virus and, **40:78**
- Gliosis, lentiviruses and, **34:202**
- β -globin gene, splicing, **35:32**

- Glomerulitis, lentiviruses and, **34:202**
- Glucocorticoid receptor, genital human papillomavirus transcription, **44:334**
- Glucocorticosteroids, MoMLV-induced tumors and, **35:41–42**
- Glucolipid, archaeobacterial viruses and, **34:173**
- Glucosamine, antiviral activity, **30:113–114**
glycosylation inhibition and, **30:113–114**
- Glutamic acid
archaeobacterial viruses and, **34:181**
influenza virus and, **34:264**
- Glutamine
influenza virus and, **34:264**
translational suppression by retroviruses and, **41:206–209**
- Glutamine–glycine dipeptide sites, cleavage, poliovirus, **46:12–13**
- Glycan, hepadnavirus and, **34:91**
- Glyceraldehyde-3-phosphate dehydrogenase, hepadnavirus and, **34:103**
- Glycine, influenza virus and, **34:264**
- Glycine max*
cell culture protoplasts, virus infection, **29:229**
protoplasts
auxin requirement, **29:224**
isolation, **29:225**
- Glycolipids
influenza virus and, **34:254**
prion proteins and, **35:104**
- Glycoprotein
alphavirus, **33:8–10**
cytoplasmic domain, **33:10–11**
ectodomain, **33:12–13**
transmembrane domain, **33:11–12**
archaeobacterial viruses and, **34:144**
bovine herpesvirus, **45:194–198**
Bunyaviridae and, **40:264**
bunyavirus-specific, **30:305–306**
coronaviruses, **33:30–31**
equine arteritis virus and, **41:164**
equine herpesviruses, **45:165–168**
filoviruses, **47:24–26**
flavivirus, epitope mapping, **31:103–163**
NV3, epitopes on, **31:159–160**
protein fragmentation, **31:139–144**
structural, **31:104–105**
gene products, **39:39–50**
genome organization, **40:245–246, 248–251**
HEF, influenza C virus, **40:213–231**
hepadnavirus and, **34:83, 85**
herpesviruses, **33:31–32**
HIV-1, **40:2**
envelope, **44:234–235**
HIV gp41, membrane permeability, **45:82–85**
HIV structure and, **39:3, 14**
human herpesvirus 6 and, **41:4, 12, 21**
HVT-specific, **30:244–248**
influenza virus and
components, **34:249, 251, 254–257**
pathogenicity, **34:270–271**
influenza virus neuraminidase, **33:28–29**
killed antiviral vaccines and, **39:258, 277, 280**
lactate dehydrogenase-elevating virus and
age-dependent poliomyelitis, **41:138, 144**
mice, **41:111–112, 114, 124**
molecular properties, **41:145–146**
lentiviruses and
structure, **34:193, 195**
virus-host cell interaction *in vivo*, **34:204–206**
MDV-specific, **30:244–249**
morphogenesis, **40:260–262**
nonenveloped viruses, **33:32**
nonstructural, filoviruses, **47:27–28**
oncovirus envelope, **25:455**
Paramyxoviridae and, **39:130, 136**
paramyxoviruses, **33:29–30**
pestiviruses, **41:73, 75, 80, 86, 89, 47:61–62**
positive-strand RNA viruses and, **41:180**
retroviral envelope, **44:210–211**
rubella virus, E2 and E1, **44:123–130**
expression, **44:125–126**
maturation, **44:123–127**
pulse-chase radiolabeling, **44:123–124, 126–127**
targeting, **44:127–130**
transport, **44:128–129**
simian hemorrhagic fever virus and, **41:179**

- Sindbis virus mutant, 33:349–351, 353–354, 356–358
- tickborne encephalitis virus
antigenic sites on, 31:124
digestion time course, 31:140
translational suppression by retroviruses and, 41:194, 196
readthrough suppression, 41:197–199, 204, 206
ribosomal frameshifting, 41:212, 217
vaccinia and, 34:47
varicella zoster virus encoded, 38:63–68
viral
functions, 33:1
polarized cells and, 33:32–33
virus infections and, 35:221
- Glycoprotein 70, positive-strand RNA viruses and, 41:133, 164
- Glycoprotein I, varicella zoster virus, 38:64–65
- Glycoprotein II, varicella zoster virus, 38:65–66
- Glycoprotein III, varicella zoster virus, 38:66–67
- Glycoprotein IV, varicella zoster virus, 38:67
- Glycoprotein NS28, rotavirus
biological properties, 38:23–24
carbohydrate in, nature, 38:24–25
orientation in endoplasmic reticulum, 38:24–25
as receptor, 38:26
- Glycoprotein V, varicella zoster virus, 38:67–68
- Glycoprotein VP7
in double-shelled particle of rotavirus, 38:8
in rotavirus, 38:19–23
carbohydrate attached to, nature of, 38:19
as cell attachment protein, 38:23
gene structure, 38:19–20
retention in endoplasmic reticulum, 38:21–23
signal peptide, 38:20–21
rotavirus, 38:19–23
- Glycosylation, 29:115
Bunyaviridae and, 40:236, 246–250, 262
DNA replication and, 34:18
flavivirus-specified proteins, 33:58–61
HEF polypeptide, 40:216–217, 220
hepadnavirus and, 34:66
characterization, 34:90–92
epitopes, 34:128
pre-S sequences, 34:98, 103–104
hepatitis C virus and, 40:71–73, 84
HIV structure and, 39:17, 39–41
influenza virus and, 34:251, 254–256
lentiviruses and, 34:192–194
neurodegenerative diseases caused by prions and, 41:253
Paramyxoviridae and, 39:132
pestiviruses and, 41:79–80
positive-strand RNA viruses and, 41:101, 145–146, 164, 179
vaccinia and, 34:55
- Glycosyl-phosphatidylinositol anchor, 42:206
- Goat
Cruetzfeldt-Jakob disease in, 29:7, 11
kuru in, 29:7
scrapie in, 29:2, 6–8, 21–22
pathogenesis, 29:18
transmission, 29:24
transmissible mink encephalopathy in, 29:7–9
- Golgi complex
Bunyaviridae and, 40:236, 260–262
hepadnavirus and, 34:99, 101
influenza virus and, 34:249, 254, 265
- Gonorrhea, 43:23–24
- Gossypium hirsutum*, facultative resistance, 29:341
- Governmental distribution, plant viruses in developing countries and, 41:383–384
- gp41
HIV structure and, 39:3, 15, 24, 39–41
immunodominant domain, 42:158–159
amino acid sequences, 42:158–159
epitopes, 42:159–161
synthetic peptides, commercial tests based on, 42:161–162
- gp120
HIV structure and, 39:7, 13, 15
gag gene products, 39:23–24
gene products, 39:39–48, 50
interaction with CD4, 42:115–116
- gp160, HIV structure and, 39:39–41, 47–48
- G1 protein, Bunyaviridae and, 40:264

- G1 protein, Bunyaviridae and (*cont.*)
 genome organization, 40:243, 245–251
 morphogenesis, 40:260–262
 structure, 40:238
- G2 protein, Bunyaviridae and, 40:264
 genome organization, 40:243, 245–251
 morphogenesis, 40:260–262
 structure, 40:238
- G proteins
 defective interfering viruses and,
 40:191
 in signal transduction from plasma
 membrane, 37:3–4
- Granulin, 29:202
- Granulocytes, Epstein-Barr virus and,
 40:31
- Granulosis viruses, 28:141–173, 29:195,
 198
 as biological insecticides, 28:143–146
 cellular and molecular biology, 28:150–
 167
 enveloped nucleocapsids, 28:155–156
 hemagglutination by, 28:156
 envelope lipids, 28:160
 envelope proteins, 28:156–160
 genome, 28:165–167
 high-voltage electron microscopy,
 30:71, 73, 77
 nucleocapsids and capsids, 28:160–162
 occluded virus, 28:150–153
 protein matrix proteins, 28:153–155
in vivo replication, 28:146–150
- Grapevine stem pitting-associated virus,
 immunosorbent electron microscopy,
 29:178
- Great Britain, *Plantago* viruses endemic
 in, 27:117–118
- Groundnut, plant viruses in developing
 countries and
 crop improvement, 41:357–358, 360–
 361, 367, 369, 371, 377
 remedial action, 41:381, 394
- Ground squirrel hepatitis B virus, hepad-
 navirus and, 34:66
 characterization, 34:79, 85, 90
 genome organization, 34:69
 pre-S sequences, 34:109
 replication, 34:72
- Ground squirrel hepatitis virus, genomic
 RNA organization, 32:52
- Group 5 virus, insect, 25:315
 serological properties, 25:342
 structural proteins, 25:332–333
- Growth, plants, TMV multiplication and,
 33:215–216
- Growth factor receptors, 37:5–7
- Growth factors
 role in HIV expression inhibition,
 43:119–120
 in signal transduction from plasma
 membrane, 37:4–10
- Growth hormone deficiency syndrome,
 caused by lymphocytic choriomen-
 ingitis virus persistent infection,
 46:324–333
- GSS, *see* Gerstmann-Sträussler syndrome
- GTP (guanosine 5'-triphosphate), picor-
 naviral genomes and, 40:130–131
- Guanidine hydrochloride, antiviral anti-
 body affinity and, 34:302–303
- Guanidium chloride, archaeobacterial vi-
 ruses and, 34:179
- Guanine-cytosine, in bacteriophages nu-
 cleic acids, 27:221–222
- Guanosine, acyclic and carbocyclic ana-
 logs, 42:16–19
- Guinea pig
 Creutzfeldt-Jakob disease in, 29:7–8,
 11, 19
 model, varicella-zoster virus, cell-medi-
 ated immunity, 46:303–306
- Gut-associated lymphoid tissue, oral vac-
 cination and, 41:409–410, 414

H

- Haemophilus influenzae*, 35:233–234
 influenza virus and, 34:268
- Haemophilus somnus*, 35:233
- HAHI test, torovirus, 43:263
- Hairy shaker syndrome, pestiviruses
 and, 41:67
- Halobacterium cutirubrum*, archaeobac-
 terial viruses and, 34:164, 167
- Halobacterium halobium*, 34:146, 164–
 167, 185
 bacteriophage Φ H, 34:185
 genetic variability, 34:150–153
 lysogens, 34:153–157
 properties, 34:147–149
 transcription, 34:157–162

- bacteriophage Φ N, **34:145**, 162–163
Halobacterium salinarum phage Hs1, archaeobacterial viruses and, **34:163–165**
 Halophiles, archaeobacterial viruses and, **34:144–145**, 184
 Hamster, **29:43**
 cannibalism model, **29:14**
 Creutzfeldt-Jakob disease in, **29:7**, 11
 scrapie in, **29:3**, 7–9, 11, 15–18
 pathogenesis, **29:19**
 transmissible mink encephalopathy in, **29:7–9**
 Hamster cells, adenovirus and, **39:90–93**
 oncodna viruses, **39:106–107**, 109–111
 sequence-specific methylation, **39:111–112**, 114–116
 species specificity, **39:95–103**
 Hamster embryo cells, transformation by chickenpox virus, **28:313–314**
 Hand-foot-and-mouth disease, **42:347–348**
 Hantaan viruses, **40:263–264**, **42:229**
 Bunyaviridae, structure, **40:238**
 characterization, **31:34**
 genome organization, **40:244–245**, 248–249, 251, 253–254
 and hemorrhagic fever with renal syndrome, **31:32**
 interactions with host cells, **40:262**
 morphogenesis, **40:260–261**
 proposed serological classification, **31:33**
 replication, **40:255**
 structure, **40:238**, 242
 transmission, **31:34**
 Hantavirus, *see* Hantaan viruses
Hantavirus, **40:235–236**
 genome organization, **40:243**, 248–249, 253
 structure, **40:240–241**
Haplopappus gracilis, protoplast yield, **29:224**
 Haplotypes
 hepadnavirus and, **34:123**, 125, 127
 lactate dehydrogenase-elevating virus and, **41:136–137**, 141, 143–144
 Haptens, antiviral antibody affinity and, **34:288**
 Harvey sarcoma virus
 DNA replication and, **34:24**
 v-ras gene product, MAbs, **29:113**
 HA test, torovirus, **43:263**
 HAV, *see* Hepatitis A virus
 HBV, *see* Hepatitis B virus
 Health, plant viruses in developing countries and, **41:365–372**
 Heart, poliovirus effect, **34:221**
 Heat shock, HIV LTR activation, **43:107**
 Heat shock proteins
 70-kDa (hsp 70) promoter in *trans*-activation of transcription, **37:48–49**
 in mosquito cells, **33:362**
 picornaviral genomes and, **40:146**
 HEF glycoprotein of influenza C virus, **40:213–214**
 functions
 membrane fusion, **40:226–228**
 receptor-binding activity, **40:223–226**
 receptor-destroying enzyme, **40:221–223**
 relationship with coronavirus glycoprotein HE, **40:229–231**
 structure, **40:214–218**
 antigenic epitopes, **40:220–221**
 HEF spike, **40:218–219**
 Helicases, positive-stranded RNA viruses, **47:169–187**
 consensus sequence, **47:174–175**
 2C protein, **47:177–178**
 DEAD box proteins, **47:174–175**
 encoding, **47:162**
 functions, **47:169**
 nsP2 protein, **47:178–179**
 role in RNA replication, **47:181–187**
 superfamilies, **47:174–177**
Helicobacter pylori, **43:39**
Helminthosporium victoriae, **43:343–344**
 Helper virus
 defective interfering viruses and, **40:199**, 202–204, 206
 parvoviruses and, **33:91**
 satellite RNA for biocontrol and, **39:321–322**
 Hemadsorption test, ASF and, **35:266**
 Hemagglutinating encephalomyelitis virus, HEF glycoprotein of influenza C virus and, **40:229**

- Hemagglutination**
 Bunyaviridae and, **40:236**, **245**
 HEF glycoprotein of influenza C virus and, **40:213**
 functions, **40:221**, **223**, **225–226**, **228–229**, **231**
 structure, **40:214**, **216**, **220**
 immune adherence, chickenpox virus antibodies, **28:317**
 parvovirus serotype and, **33:104**
 Sindbis virus encephalitis and, **36:259**
- Hemagglutination inhibition**, **29:99**
- flavivirus**
 epitopes, **31:144–148**
 group reactive antigenic determinants, identification, **31:107**
 rotaviruses and, **36:181**, **185–186**, **191–194**
 neutralization, **36:184**, **186**, **193–194**
 protection, **36:204–205**
 for serological relationships between flaviviruses, **31:107**
 yellow fever E MABs, **31:112**
 yellow fever virus MABs, **31:155**
- Hemagglutinin**
 antiviral antibody affinity and, measurement
 direct, **34:289**, **299–300**
 relative, **34:306**
- HIV structure and**, **39:7–8**, **42**, **45–46**
- influenza virus**, **33:2–4**, **34:248**, **274**
 antibodies to synthetic peptides and, **31:73–74**
 antigenic sites
 changes at low pH, **31:71–73**
 effect of carbohydrate on, **31:73**
 cleavage, **34:268–271**
 components, **34:249–257**
 cytoplasmic domain, **33:7–8**
 ecto domain, **33:4–6**
 epitopes on, structure, **31:69–71**
 fusion, **34:265–268**
 genes, HA1 portion nucleotide sequences, **31:67**
 genetic reassortment, **34:258–259**
 genome constellation, **34:260**
 host cell selection of antigenic variants, **31:68**
 pathogenicity, **34:261–262**, **271–272**
 receptor binding site, **33:6**
 receptor-binding variants, **31:68–69**
 receptor specificity, **34:262–265**
 structure, **31:58–62**
 transmembrane domain, **33:6–7**
 type A, antigenic drift, **31:62**
 type B
 antigenic variation in, **31:64–67**
 HA1 polypeptide sequences, **31:65**
 variants selected with MABs, **31:62–64**
 killed antiviral vaccines and, **39:280**, **284**
 lentiviruses and, **34:205**
 Paramyxoviridae and, **39:131**
 picornaviruses and, **36:173**
 rotaviruses and, **39:166**, **181**, **183**
 vaccinia and
 genome, **34:48**
 vector, **34:53**, **57–58**, **60**
- Hematopoietic transformation**, Ab-MLV and, **35:55–67**
- Hemodialysis**, hepadnavirus and, **34:132**, **134**
- Hemolysin**, oral vaccination and, **41:415**
- Hemolysin inhibition**, **29:99**
- Hemolysis**
 HEF glycoprotein of influenza C virus and, **40:226–227**
 lentiviruses and, **34:205**
- Hemorrhage**
 equine arteritis virus and, **41:156**
 lentiviruses and, **34:203**
 pestiviruses and, **41:57**, **59**, **64**, **90**
- Hemorrhagic fever**
 clinical course, **47:32–33**
 Crimean-Congo, **43:18**
 dengue, **31:152**, **47:365**
 Ebola, **47:3–10**
 new emerging and reemerging, **47:9–10**
 Marburg, **47:2–7**
 with renal syndrome, **43:18–19**
 Reston, **47:10–11**
 simian, *see* Simian hemorrhagic fever virus
- Hepadnaviral polymerase**, **46:180–183**
 experimental approaches, **46:180–181**
 minus strand priming, **46:182–183**
 mutational analyses, **46:181–182**
 sequence similarities, **46:181**

- Hepadnavirus envelope proteins**
 characterization
 DNA sequence data, **34:78–82**
 L protein expression, **34:86–90**
 M protein expression, **34:83–86**
 diagnosis, **34:129–132**
 mRNA transcription, **34:75–78**
 pre-S sequences
 expression, **34:92–95, 102–106**
 glycosylation, **34:90–92**
 hepatitis B vaccines, **34:132–135**
 hepatocytes, **34:95–98**
 immunodominant epitopes, **34:106–108**
 regulation, **34:98–102**
 serological cross-reactivity, **34:108–111**
 T-cell recognition, **34:111–113**
 pre-S-specific epitopes
 antibody response, **34:123–126**
 antigenicity, **34:118–121**
 immunogenicity, **34:121–123**
 peptide synthesis, **34:113–118**
 T-cell recognition, **34:127–129**
- Hepadnaviruses**, **34:65–69, 135, 46:167–192, 47:254**, *see also* Hepatitis B virus; Pararetroviruses
 budding, **44:48**
 characteristics, **44:5**
 C promoter and pregenomic RNA, **44:20–21**
 defective interfering viruses and, **40:188, 197**
 discovery and epidemiology, **32:41–42**
 DNA, covalently closed circular, **46:170–172**
 DNA structure, **32:38, 43**
 genes and gene products, **32:51–56**
 env, **32:54**
 gag, AUG role, **32:53–54**
 pol, **32:54**
 X in mammalian isolates, **32:54–55, 58**
 genome organization, **34:69–71**
 genomic RNA
 organization, **32:38–39, 43, 49–50**
 packaging and repackaging, **32:71–74**
 transcription, **32:79–82**
 control of, **32:81–82**
 hepatocellular tumors and, **32:42–43**
 integration, frequency, **32:75–76**
 life cycle, **46:170–172**
 packaging, hepatitis delta virus, **43:208–209**
 Pol translation, **44:41–42**
 promoters and subgenomic transcripts, **44:21–22**
 protein products, **46:174–176**
 regulatory functions, **44:15–16**
 replication, **34:71–75**
 as retroid viruses, **32:35–37**
 reverse transcription, **46:172, 184–192**
 covalently closed circular DNA formation, **46:191–192**
 minus strand DNA priming and synthesis, **46:184–189**
 plus strand DNA priming and synthesis, **46:189–191**
 pregenomic RNA organization, **46:184**
 RNA packaging, **46:186**
 reverse transcription pathway, **32:43–45**
 DNA synthesis and, **32:63–67**
 RNA, encapsidation
 cis-acting signals on pregenomic RNA, **46:177–180**
 core particle assembly, **46:176–177**
 missense mutations, **46:177**
 RNA packaging, **44:54–55**
 splicing, **44:22**
 study with MAbs, **29:102**
 suppression, **43:220–223**
 surface antigen forms, **46:175–176**
 transcripts, **46:173–174**
 viral absorption, **43:213**
 virion
 assembly in hepatocytes, **32:55–56**
 structure, **46:170–171**
- Heparin**, effect on persistent viruses, **26:54–55**
- Hepatitis**
 infectious
 history, **32:129–130**
 serum pool MS1, **32:130–131**
 symptoms, **32:130–131**
 killed antiviral vaccines and, **39:284**
 lentiviruses and, **34:202**
 rotaviruses and, **39:184**

- Hepatitis (*cont.*)
- serum
 - history, **32:130**
 - serum pool MS2, **32:130–131**
 - Hepatitis A
 - antigen, **39:224–228, 230**
 - diagnosis
 - antibodies to HAV, **32:132–133**
 - clinical symptoms, **32:132**
 - nonspecified antibodies, **32:134**
 - epidemiology
 - age-specific prevalence, **32:136**
 - geographical distribution, **32:135–136**
 - seasonal pattern, **32:136–137**
 - HAV-induced, **32:131–132**
 - immunization with γ -globulin, **32:158–159**
 - transmission
 - among homosexuals, **32:139**
 - children in day-care centers, **32:137**
 - contact with nonhuman primates, **32:139–140**
 - foodborne outbreaks, **32:138–139**
 - shellfish and, **32:138–139**
 - to nonhuman primates, **32:131**
 - person-to-person, fecal/oral route, **32:137–138**
 - waterborne outbreaks, **32:138**
 - Hepatitis A virus, **40:57, 84–85**
 - animal models, **39:215–216**
 - antigen detection technique, **32:134–135**
 - biophysics, three virion structures
 - buoyant density, **32:142**
 - sedimentation coefficient, **32:142–143**
 - cDNA for genome assay
 - hybridization with genomic RNA, **32:157–158**
 - nucleotide sequence, **32:154–157**
 - antigenic peptides, computer-predicted, **32:156–157**
 - cleavage sites, computer-predicted, **32:155–156**
 - restriction map of overlapping clones, HM175 strain, **32:153–154**
 - synthesis and cloning, **32:151–153**
 - characterization, **39:221**
 - antigenic structure, **39:224**
 - buoyant density, **39:222**
 - capsid proteins, **39:223**
 - classification, **39:226**
 - electron microscopy, **39:221–222**
 - nucleic acid, **39:224–225**
 - stability, **39:222**
 - clinical characteristics, **39:212–214**
 - cloning, **40:64**
 - cytopathic strains, **39:227–228, 230–231**
 - defective interfering viruses and, **40:188, 193**
 - epidemiology
 - age distribution, **39:216–217**
 - duration of infectivity, **39:218–219**
 - epidemic waves, **39:216**
 - patterns of infection, **39:217–218**
 - routes of infection, **39:220–221**
 - seasonal patterns, **39:216**
 - in feces, during incubation period and hospitalization, **32:134**
 - genome
 - gene localization, **39:244**
 - molecular cloning, **39:242**
 - nucleotide sequences, **39:244–247**
 - organization, **39:242–243**
 - genomic RNA
 - characteristics, **32:144**
 - hybridization with cDNA, **32:157–158**
 - history, **39:211–212**
 - human studies, **39:214–215**
 - infectious agent, **40:58–61**
 - infective process, **39:209–247**
 - morphology and structure, **32:140–142**
 - electron microscopy, **32:141**
 - oral vaccination and, **41:410, 413**
 - picornaviral genomes and, **40:108–109, 116, 126, 158**
 - picornaviruses and
 - genome, **36:163–165**
 - recombinants, **36:170–171**
 - polypeptides VP1-VP4, **32:143**
 - prevention, **39:236–237**
 - active immunization, **39:238–242**
 - passive immunization, **39:237–238**
 - prolonged shedding, uncommon, **32:140**
 - propagation in cell culture
 - antigen detection and yield, **32:148–149**
 - lytic strains, **32:149**

- monkey cell lines, **32:147–148**
 - persistent infection without cell damage, **32:148–149**
- replication
 - RNA synthesis, **32:150**
 - specific proteins, **32:149–150**
 - induction in infected cells, **32:149**
 - translated from RNA *in vitro*, **32:149**
- replication in cell culture, **39:226–227**
 - cycle, **39:230–236**
 - cytopathic strains, **39:227–229**
 - infectivity assays, **39:228, 230**
- resistance to physical and chemical agents, **32:145–147**
- strain differences, insufficient, **32:140**
- vaccines, animal assays
 - chimeric, prospects, **32:162–163**
 - DNA sequences in heterologous system, **32:162**
 - inactivated, from infected cell cultures, **32:159–160**
 - live, attenuated, **32:160**
 - subunit, purified viral proteins, **32:160–161**
 - synthetic peptides, **32:161–162**
- Hepatitis B, **39:256**
- Hepatitis B surface antigen, **40:58, 60, 78, 83**
 - antiviral antibody affinity and, **34:298**
 - hepadnavirus and, **34:66–69, 135**
 - characterization, **34:83, 86, 88–90, 93, 95**
 - diagnosis, **34:129–130**
 - epitopes, **34:120, 122, 128**
 - mRNA transcription, **34:76**
 - pre-S sequences, **34:95, 97–107, 109–110, 112**
 - vaccine, **34:132, 134–135**
 - vaccinia and, **34:53, 55, 57–58, 60**
- Hepatitis B virus, **40:57, 84–85, 95, 46:167–168, 47:253–292**
 - animal cells and, **36:116**
 - carrier-mediated delivery of drugs for, **35:289–290**
 - cloning, **40:63–64**
 - component vaccine production
 - antigen-coding genome part and, **32:25–26**
 - recombinant DNA technology and, **32:22–23, 25**
 - core particles, oral vaccination and, **41:425–426**
 - core protein, **44:49**
 - and E proteins, **47:267**
 - CTL attachment to antigen-positive hepatocytes, **47:355–356**
 - defective interfering viruses and, **40:187, 197–198**
 - diagnosis, **42:176–177**
 - EnhI, **47:258**
 - EnhII, **47:258–259**
 - epidemiology of infection, **47:254–255**
 - future research, **47:292**
 - genomic organization, **46:173, 47:256–259**
 - hepadnavirus and, **34:66–69, 135**
 - characterization, **34:79, 83, 85–86, 88–91**
 - cross-reactivity, **34:110**
 - diagnosis, **34:129–132**
 - epitopes, **34:113, 115–116, 118–119, 122–123, 126, 128–129**
 - expression, **34:92–95**
 - genome organization, **34:69**
 - hepatocytes, **34:95–98**
 - immunodominant epitopes, **34:106–108**
 - mRNA transcription, **34:77**
 - pre-S sequences, **34:100–102, 105**
 - replication, **34:72**
 - T-cell recognition, **34:111–113**
 - vaccine, **34:132–135**
 - hepatitis delta virus helper, **43:188–190**
 - hepatocellular carcinoma, **47:269–272**
 - historical background, **46:168–170**
 - and HIV expression, **43:112–113**
 - immunogenicity of
 - antigen aggregates, **32:23, 28**
 - preS2 gene product, **32:25–26**
 - synthetic antigen peptides, **32:29**
 - infectious agent, **40:58–61**
 - insertional mutagenesis, **47:270–271**
 - interacting with CD8⁺ T cells, **47:355**
 - MAbs, **29:101**
 - minus strand priming, **46:182–183**
 - morphology, **47:255–256**
 - mutational analyses, **46:181–182**
 - oral vaccination and, **41:411–413**
 - epitope presentation systems, **41:424, 427–428**

- Hepatitis B virus** (*cont.*)
 oral vaccination and (*cont.*)
 nucleocapsid antigen, 41:421–422, 425
 ORFs, 46:174–176
 picornaviral genomes and, 40:143
 polymerase, 47:267–268
 P protein expression, 46:187
 prevention, 40:81, 83–84
 promoters, 47:258
 replication, 40:78, 47:262–263
 interferon-induced inhibitor of, 38:182
 RNA packaging, 44:53–54
 splicing, 44:22
 structural morphogenesis, 43:208
 surface antigens, 35:179–180
 surface proteins, 47:263–267
 trans-activators, oncogenic potential, experimental evidence, 47:289–291
 transcription, 47:259–262
 transcriptional control regions, 44:20
 transfections, 46:186
 transgene model, 47:356
 translational suppression by retroviruses and, 41:211
 transmission, 42:216
 x protein, 47:268–269
 binding to transcription factors, 47:282–283
 essential and dispensable domains for trans-activation, 47:279–281
 functional trans-activator domain, 47:278, 280–281
 interaction with cellular proteins unrelated to basal transcriptional machinery, 47:284, 286
 interaction with protein kinase C signal transduction pathway, 47:283–284
 interaction with ras–raf–mitogen-activated protein kinase pathway, 47:284–285
 mechanisms of trans-activation, 47:282–286
 reactive oxygen intermediate involvement, 47:284
 trans-activation, 47:272–278
- Hepatitis C**, 39:210
Hepatitis C-like viruses, 47:55
Hepatitis C virus, 40:57–58, 94–96
 cloning, 40:62–67, 73–77, 87
 genomic organization, 40:67–73
 infectious agent, 40:58–62, 86
 positive-strand RNA viruses and, 41:100–101
 prevention, 40:79–84
 serological test, 42:177
 viral replication, 40:77–79
- Hepatitis D**, 39:210
Hepatitis delta virus, *see* **Hepatitis D virus**
Hepatitis D virus, 40:60–62, 67, 95, 43:187–226
 attachment and penetration, 43:213–214
 cDNA-transfected cell lines, 43:193–194
 chimpanzees and woodchucks, 43:191–192
 complementary RNA-transfected cell lines, 43:194
 core, 43:197–198
 defective interfering viruses and, 40:197–198
 delta antigens, associated properties, 43:214–215
 delta virus packaging, 43:209–212
 dimerization and oligomerization, 43:216–217
 epidemiology and pathogenesis, 43:188–189
 genome replication, 43:198–208
 autocatalytic processing, 43:203–204
 editing, 43:206–208
 initiation and elongation, 43:199–203
 polymerase, 43:199–201
 replication scheme, 43:205–206
 RNA species, 43:198–199
 small delta antigen requirement, 43:202–203
 transcription initiation sites and putative promoters, 43:201–202
 hepadnavirus packaging, 43:208–209
 hepatitis B virus as helper, 43:188–190
 infection
 chimpanzee and woodchuck, 43:191
 mouse, 43:192–193
 primary hepatocytes, 43:193
 lipid in, 43:197
 nuclear localization, 43:215–216

- packaging into sAg particles, **43:217–218**
- pathogenesis and hepadnavirus suppression, **43:220–223**
- post-translational modifications, **43:219–220**
- potential applications, **43:223–226**
- proteins, **43:196**
- ribozyme, **43:223–225**
- RNA, **43:196–197**
- binding, **43:216**
 - cleavage and ligation, **43:194**
 - editing, **43:195**
- RNA-directed synthesis, **43:195**
- role of amino acids unique to δ Ag-L, **43:218–219**
- self-litigation reaction, **43:204**
- size, **43:195–196**
- structure and replication, **43:189–191**
- studies *in vitro*, **43:194–195**
- suppression of hepadnavirus replication, **43:222–223**
- use as vector, **43:224–225**
- Hepatitis E, **39:210, 221**
- Hepatitis E virus, **40:57–59, 84–85, 94–96**
- cloning, **40:70, 87–91**
 - expression strategy, **40:91–93**
 - infectious agent, **40:63, 85–87**
 - prevention, **40:93–94**
- Hepatitis viruses, diagnosis using synthetic peptides, **42:176–178**
- Hepatocarcinogenesis, HBV trans-activators, **47:272–291**
- carboxy-terminally truncated HBV surface proteins, **47:286–289**
 - cellular regulatory sequences as HBx-mediated trans-activation target, **47:276–277**
 - HBx, **47:272–286**
 - heterologous regulatory sequences as HBx-mediated trans-activation target, **47:274–276**
 - oncogenic potential, experimental evidence, **47:289–291**
 - regulatory sequences as HBx-mediated trans-activation target, **47:274**
 - transcription factor binding sites as HBx-mediated trans-activation target, **47:277–278**
 - trans-hypothesis, **47:291**
- Hepatocellular carcinoma, **47:269–272**
- cis (in)-activation of cellular genes, **47:270–272**
 - epidemiology, HBV-associated, **47:269–270**
 - hepatitis C virus and, **40:81, 83**
 - trans-activation of cellular gene expression, **47:272**
- Hepatocyte nuclear factor 1, binding site, **47:259**
- Hepatocytes
- hepadnavirus and, **34:69**
 - epitopes, **34:120**
 - pre-S sequences, **34:95–98, 108**
 - replication, **34:75**
 - vaccine, **34:134**
 - hepatitis delta virus-infected primary culture, **43:193**
- Hepatoma cells, hepadnavirus and, **34:76, 95, 97**
- HEPT derivatives, **42:31–34**
- Heracleum latent virus, **25:112**
- Herbal remedies, with *Plantago* spp., **27:110–111**
- Herpes simplex virus, **41:1, 5, 12, 17, 20, 47:363**
- animal cells and, **36:113**
 - antiviral compound effect on, **26:54–55**
 - in virus multiplication, **26:55**
 - attachment, inhibition by oxidized *o*-diphenolic compounds, **30:84–85**
 - clinical treatment with
 - acyclovir, **30:126**
 - BVDU, **30:126–127**
 - FIAC, **30:127**
 - trisodium phosphonofornate, **30:127**
 - diagnosis using synthetic peptides, **42:173**
 - helper for AAV replication, **32:252**
 - high-voltage electron microscopy, **30:66–67**
 - and HIV expression, **43:110**
 - HIV structure and, **39:4, 7, 21**
 - immunosorbent electron microscopy, **29:187**
 - infection by skin abrasions, **42:214–216**
 - inhibition by
 - cobra- α -neurotoxin, **30:111**
 - 2-deoxy-D-glucose, **30:113–114**
 - glucosamine, **30:113–114**

- Herpes simplex virus (*cont.*)
 inhibition by (*cont.*)
 hygromycin B, **30:111**
 methyl daunaosamine, **30:114–115**
 phosphonoglycolic acid, **30:108–109**
 pokeweed antiviral protein, **30:112**
 purine nucleosides, **30:92–100**
 pyrimidine nucleosides, **30:100–104**
 succinyl concanavalin A, **30:111–112**
 trisodium phosphonoformate,
30:107–108, 127
 mechanism of transformation by,
27:322–324
 new glycoprotein, **29:114**
 novel polypeptide, **29:114–115**
 protection with MAbs, **29:121**
 protein modification, **29:115**
 structural analysis, **29:111**
 uncoating, inhibition by arildone and
 its derivatives, **30:89–90**
 vaccinia and, **34:48, 50, 57**
 viral demyelination, **42:280–281**
 virus-specific polypeptides, **29:114**
- Herpes simplex virus replication, **37:85–116**
 α gene products in
 combinatorial effects, **37:101**
 properties and functions, **37:92–100**
 interferon-induced inhibition of,
38:179–181
 mechanism of transactivation of β
 genes in, **37:100–101**
 τ or late gene mRNA synthesis in,
37:112–113
 overview of, **37:87–88**
 structural and metabolic changes in
 cell nucleus after infection and,
37:88–90
 synthesis of viral α or immediate early
 mRNAs in, **37:90–92**
 viral DNA replication in, **37:102–112**
 virion assembly in, **37:113–115**
- Herpes simplex virus type 1
 antibodies, **29:101**
 early glycoprotein (GVP-11), maturation,
29:115
 epidemiology, **29:104**
 glycoprotein D, hepatitis and,
34:106
 induced leader binding protein 1,
43:110
 picornaviral genomes and, **40:118, 149**
 purification of glycoproteins, **29:118**
- Herpes simplex virus type 2
 antibodies, **29:101**
 epidemiology, **29:104**
 oncogenicity
 cervical carcinoma induction, **32:285**
 inhibition by AAV in hamster cells,
32:285–286
 papilloma lesion conversion to carcinoma,
32:285–286
 purification of glycoproteins, **29:118**
- Herpesvirus, *see also* Equine herpesviruses 2 and 5
 animal cells and, **36:119, 121, 135–136**
 attachment proteins of, **27:185**
E-5-(2-bromovinyl)-2'-deoxyuridine effects,
42:20–23
 cellular receptors for, **27:185**
 classification, **44:358**
 cyclic and carbocyclic guanosine analog
 effect, **42:16–19**
 cyclopentenylcytosine effects, **42:11–12**
 defective interfering viruses and,
40:196–197
 glycoproteins of, **33:31–32**
 HSV-1 glycoprotein D, vaccinia and,
34:53, 55–57, 60
 immunosorbent electron microscopy,
29:186
 induced apoptosis, **45:18–19**
 infection in AIDS patients, **43:108**
 manifestation in oral cavity, **42:218**
 penetration and uncoating of, **27:185–187**
 rapid enzyme immune filtration test,
29:101
 taxonomic polypeptides, **29:104**
 T-cell tumors and, **27:318–322**
 α TIF-mediated *trans*-activation of
 transcription, **37:54–55**
 tumorigenesis by, **27:299–324**
 viral demyelination, **42:280–281**
 viral oncogenicity, adeno-associated virus and,
25:437–438
- Herpesvirus of turkeys
 in cultured cells
 induction of
 DNA polymerase, **30:251**
 thymidine kinase, **30:251–252**
 nonproductive infection, **30:254**

- productive infection, **30:252–253**
- genomic DNA
 - homology with MDV werotypes, **30:234–237**
 - latent in lymphoblastoid cell lines, **30:260–261**
 - during passages in cultured cells, **30:240–241**
 - physicochemical properties, **30:229, 231**
 - purification, **30:227, 229**
 - ultrastructure, **30:230–231**
- specific antigens and proteins, **30:241–244, 249–251**
 - glycoprotein A, **30:244–248**
 - glycoprotein B, **30:248–249**
 - nuclear antigen, **30:250**
- temperature-sensitive mutants, **30:254–255**
- vaccine against Marek's disease, **30:226, 266–268**
- virion structure, **30:226–229**
- Herpetic stromal keratitis, **47:363–364**
- Heterochromatin, *Drosophila* retrotransposons and, **36:38–39, 92**
- Heteroduplex mapping, Ab-MLV RNA and, **35:47**
- Heteroduplex model, illegitimate recombination, **43:284–287**
- Heterogeneity
 - antiviral antibody affinity and, **34:284, 307**
 - measurement
 - direct, **34:290–292, 295, 301**
 - relative, **34:303–304**
 - human herpesvirus 6, **41:22–24**
 - lentiviruses and, **34:195**
 - viral suspension, **39:265–266**
 - virus population, **39:266–267**
- Heterologous promoters, regulation, **47:327–328**
- Heterologous viruses, and HIV expression, **43:107–115**
- Hexamethylene bis-acetamide, **43:105**
- High-voltage electron microscopy
 - application in virology
 - animal viruses, **30:66–70**
 - bacteriophages, **30:70–71**
 - baculoviruses, **30:71–75**
 - history, **30:43–45**
- microscope
 - availability for research, **30:65–66**
 - construction, **30:58–62**
 - instrumental accessories
 - cryoprotection, **30:63–65**
 - environmental cells, **30:62–63**
- theoretical concepts, **30:45–58**
 - chromatic aberration, **30:50–52**
 - contrast correction, **30:54–56**
 - depths of field and focus, **30:54**
 - electron penetrating power, **30:47–48**
 - heating and ionization effects, **30:52–54**
 - high-energy electrons, **30:46–47**
 - resolving power and resolution, **30:56–58**
 - spherical aberration and differentiation, **30:48–50**
- Histones
 - archaeobacterial viruses and, **34:180**
 - DNA replication and, **34:9–10**
- Hit and run phenomenon, **31:358**
- HI test, torovirus, antibody detection, **43:266**
- HIV, *see* Human immunodeficiency virus
- HM-L medium, **25:207**
- Hodgkin's disease, human herpesvirus 6 and, **41:33–34**
- Hog cholera, contrasted with ASF, **35:263**
- Hog cholera virus, **41:54–55, 83–91**
 - clinical picture, **41:55–57**
 - comparisons to pestiviruses, **41:68, 70**
 - pathology, **41:57–58**
 - properties, **41:72–74, 76–81**
- Homology
 - adenovirus and, **39:102**
 - antiviral antibody affinity and, **34:305–306**
 - archaeobacterial viruses and, **34:184**
 - Halobacterium halobium*, **34:155–157**
 - Sulfolobus* virus like particle SSV1, **34:180, 183–184**
 - cucumber mosaic virus and, **41:287, 322**
 - antigenic properties, **41:292, 296**
 - genome organization, **41:297–298, 301–302, 305, 309, 313**
 - DNA replication and, **34:32**
 - adenovirus, **34:6**

- Homology (*cont.*)
 DNA replication and (*cont.*)
 bovine papilloma virus, **34:23**
 Epstein-Barr virus, **34:30-31**
 hepadnavirus and
 characterization, **34:79, 86**
 epitopes, **34:122, 127**
 pre-S sequences, **34:96, 109-110**
 hepatitis A virus and, **39:224, 226, 243**
 HIV structure and, **39:9, 20, 54**
 influenza virus and, **34:257-258**
 lentiviruses and, **34:195**
 neurodegenerative diseases caused by
 prions and, **41:248, 258, 262, 267**
 oral vaccination and, **41:426, 429-430, 436**
 Paramyxoviridae and, **39:132-134, 137, 148**
 in parvovirus polypeptides, **33:127**
 pestiviruses and, **41:89**
 bovine viral diarrhea virus, **41:61, 65**
 properties, **41:72, 75, 78, 80-81, 83**
pol gene products, **39:24, 29, 31**
 positive-strand RNA viruses and,
 41:148-150, 164, 167, 180, 182
 rotaviruses and, **39:183, 185, 193, 199**
 satellite RNA for biocontrol and,
 39:321
 Theiler's murine encephalomyelitis virus and, **39:293**
 translational suppression by retroviruses and, **41:210**
 vaccinia and, **34:51**
 virus isolates, genetic relationships and, **25:288**
- Honey bee viruses, host range, **31:301-302**
- Hop trefoil cryptic virus
 location in parenchyma, **32:192**
 mixture of three viruses, **32:181**
- Hordeum vulgare*, leaf protoplasts, virus infection, **29:227**
- Hordevirus, **25:63-68**
- Hormones
Drosophila retrotransposons and,
 36:54, 75-77
 effect on mouse mammary tumor virus transcription, **26:81-84**
 and HIV expression, **43:104-106**
 influenza virus and, **34:265**
 pestiviruses and, **41:56, 68**
 symptoms of viral infection and,
 33:239-240
- Host
 age, parvovirus infection and, **33:93-95**
 functions, parvovirus DNA replication and, **33:156**
 immune response, positive-strand RNA viruses and, **41:160-163, 176-178, 181**
 immunocompromised, cytomegalovirus infection, **46:218, 220-223**
 mRNA translation after poliovirus infection, CBP complex and criticism of model, **33:191**
 early studies, **33:184-185**
 inactivation of complex by infection, **33:185-187**
 mechanism of inactivation, **33:187-188**
 poliovirus mediation of p220 cleavage, **33:188-191**
- Host-CBII interactions
 genetics, plant viruses and applications to selected combinations, **33:226-232**
 concept of gene-for-gene relationship, **33:224-226**
 pathogenic determinants, **33:232-234**
 parvovirus, nonproductive, **33:165-169**
 with virus, questions concerning, **33:330-331**
- Host cell
 metabolism, human herpesvirus 6 and, **41:12-14**
 role in virus infection
 CPE(+) and CPE(-) clones of *Aedes albopictus*, **33:333-339**
 response to methionine deprivation, **33:339-343**
- Host defense mechanisms
 bacterial effects, **35:232-234**
 viral effects, **35:227-232**
- Host passage effect
 beet curly top virus and, **25:179-180**
 cucumber mosaic virus and, **25:177-179**
 insect transmitted viruses and, **25:180-181**
 manifestation of, **25:172**

- plant breeding and, **25:185–187**
- with plant viruses, **25:169–172**
- potato X virus, **25:176**
- potato yellow dwarf virus and, **25:180**
- reversibility, **25:182–184**
- tobacco mosaic virus and, **25:172–176**
- tobacco necrosis virus and, **25:177**
- wound tumor virus and, **25:180**
- Host plant
 - alterations in metabolism
 - attempts to influence symptom type with hormones, **33:239–240**
 - common features in symptom type variation, **33:234–239**
 - interference of viral products, **33:241–247**
 - interaction of plant viruses with induction of symptoms, **33:206–208**
 - viral properties specifying symptom type, **33:208–217**
 - virus-coded proteins and possible functions, **33:217–224**
- Host range
 - banana bunchy top virus, **33:309**
 - determinants, alphavirus glycoproteins, **33:11**
 - dianthoviruses
 - experimental studies, **33:277–278**
 - natural isolates, **33:276**
 - flaviviruses, **33:50–51**
- Host spectrum, pestiviruses and, **41:70–71**
- H protein, **29:115, 323**
- HSB-2 cells, human herpesvirus 6, **41:21, 23, 25, 36**
- HSV, *see* Herpes simplex virus
- HTLV, *see* Human T-cell lymphotropic virus
- Human, role in plant-virus transmission, **28:122–123**
- Human B-lymphotropic virus, **41:3**
- Human endogenous retroviruses, **41:144**
- Human foamy virus, **46:100**
- Human growth hormone, neurodegenerative diseases caused by prions and, **41:261**
- Human herpesvirus 6, **41:1–2, 43:25–26**
 - biology
 - diagnostic tools, **41:24–27**
 - disease, **41:30–37**
 - immune response, **41:37–39**
 - latency, **41:29–30**
 - seroepidemiology, **41:27–28**
 - transmission, **41:28–29**
 - diagnosis using synthetic peptides, **42:172**
 - discovery, **41:2–4**
 - future directions, **41:39–40**
 - growth properties, **41:7**
 - animal models, **41:14–15**
 - culture conditions, **41:11–12**
 - host cell metabolism, **41:12–14**
 - susceptible cell lines, **41:8–9**
 - susceptible lymphocytes, **41:9–11**
 - viral DNA, **41:14**
 - and HIV expression, **43:111–112**
 - molecular biology
 - genome, **41:15–19**
 - heterogeneity, **41:22–24**
 - proteins, **41:19–22**
 - susceptibility to antivirals, **41:24–25**
 - structure, **41:4–7**
- Human immunodeficiency virus
 - animal cells and, **36:111–112, 126, 135**
 - antigenic viral products, **42:114**
 - and bacillary epithelioid angiomatosis, **43:41**
 - cellular responses, **42:125–127**
 - CTLs, **42:125–127**
 - defective interfering viruses and, **40:188, 195–196**
 - diagnosis using synthetic peptides, **42:157–166**
 - antigenic structure, **42:158**
 - commercial tests based on synthetic gp41 peptides, **42:161–162**
 - C-terminal part of gp120, **42:162–163**
 - gp41 immunodominant domain, **42:158–161**
 - immunogenic domains as source of peptides, **42:162–164**
 - other test formats, **42:165–166**
 - peptides from other proteins of HIV, **42:165**
 - peptides from V3 loop, **42:164**
 - rate of false-positive results, **42:162–163**
 - sensitivity problem, **42:162**
 - enhancing antibodies, **42:117**
 - entry, CD4 cytoplasmic tail role, **44:219–221**

- Human immunodeficiency virus (*cont.*)
- envelope glycoproteins, 44:234–235
 - env proteins, 43:61
 - expression, 43:58, 44:231–232
 - fusogenic process, 42:116
 - gene expression, 43:61–97
 - activators and inhibitors, 43:97–125
 - cellular stress, 43:106–107
 - chromatin structure role, 43:118–119
 - cytokines, 43:102–104, 119–120
 - differentiating agents, 43:104–106, 119–120
 - DNA methylation role, 43:118–119
 - growth factors, 43:119–120
 - heterologous viral products, 43:120–121
 - heterologous viruses, 43:107–115
 - hormones, 43:104–106, 119–120
 - immune cell activation, 43:99–102
 - lipopolysaccharide activation, 43:101
 - NF- κ B inhibitors, 43:121–123
 - oncogenes, 43:115–117, 119–120
 - proto-oncogenes, 43:115–117
 - Rev inhibitors, 43:124
 - second messenger activating compounds, 43:104–106
 - study methods, 43:97–99
 - surface markers, 43:99–102
 - Tat inhibitors, 43:123–124
 - cellular regulators of transcription, 43:62–75
 - post-transcriptional regulation, 43:84–97
 - dsl kinase, 43:95–97
 - efficiency of initiation of translation, 43:93
 - importance of translational efficiency, 43:94
 - Rev protein, 43:85–92
 - Rev response element, 43:87–91
 - translational regulation, 43:92–97
 - gene products
 - function, 42:111, 113
 - synthesis, 42:113–114
 - virion and infected cell, 42:111–115
 - genomic organization, 43:60–61, 44:230–232
 - comparison with feline immunodeficiency virus, 45:228–229
 - gp41
 - functional domains, 44:241–243
 - membrane permeability, 45:82–85
 - gp120
 - asparagine residues, 44:236–237
 - binding to CD4, 44:224–225
 - functional domains, 44:239–241
 - interaction
 - CD4, 42:115–116
 - D1 and D2 domains of CD4, 44:214–217
 - loop structures, 44:236
 - gp160
 - association with CD4, 44:243–244
 - maturation, 44:233–238
 - proteolytic cleavage, 44:238
 - hepatitis C virus and, 40:73
 - human herpesvirus 6 and, 41:39
 - biology, 41:34–36
 - discovery, 41:2, 4
 - growth properties, 41:11, 15
 - immunopathology, 47:357–358, 361
 - induced apoptosis, 45:19–21
 - infection, 43:53–125
 - and CD4 cell surface depletion, 44:243
 - pathogenesis, 43:54–59
 - AIDS development, 43:57–58
 - clinical latency, 43:55–57
 - initial infection, 43:54–55
 - processes triggering clinical progression, 43:58
 - phases, 42:111
 - isolates, phenotypic changes, 43:57
 - lactate dehydrogenase-elevating virus and, 41:133, 151
 - latency and activation, Rev role, 43:92
 - lentiviruses, 34:189–190, 44:13–15
 - structure, 34:194–195
 - virus-host cell interaction *in vitro*, 34:200
 - life cycle, 43:59–61
 - LTR
 - activation, 43:99–100
 - inhibition, 43:117
 - steroid receptor superfamily, 43:104
 - structure, 43:62
 - transcription, 43:80
 - model, 42:109–110
 - mucosal and systemic immunity, 42:132–133

- myristylated matrix proteins, **44:49**
- natural history, **42:108–111**
- amino acid sequence of HIVmn isolate, **42:119–120**
 - anti-binding site antibodies, **42:123–124**
 - cleavage sites, **42:121**
 - envelope interaction with V3, **42:122**
 - features, **42:122–123**
 - isolate-specific, **42:118**
 - mutational analyses, **42:121**
 - noncontiguous domains, **42:122**
 - principal neutralizing determinants, **42:117–125**
 - V3, **42:118–119**
- Nef, **44:245–246**
- oral vaccination and, **41:422**
- picornaviral genomes and, **40:148**
- poly(A) site regulation, **44:31–32**
- principal neutralizing determinant, **44:240**
- proteins, membrane permeability modification, **45:81–86**
- replication, **43:59–60**
- interferon-mediated inhibition, **43:119**
- RNA genome, **43:60**
- sexual activity in context of, **42:230–232**
- superinfection, **44:211**
- surface interactions with target cells, **42:115–117**
- T-cell apoptosis, **45:45–47**
- time course of immunobiological responses, **42:123–124**
- translational suppression by retroviruses, **41:216–217, 219, 223–224, 228, 230**
- transmission modes, **42:108**
- viral demyelination, **42:284–285**
- virion structure, **44:230**
- virus variation, **42:138**
- Vpu protein, membrane permeability, **45:85–86**
- Human immunodeficiency virus structure, **39:1–2, 56–57, 42:111–112**
- AIDS, **39:3, 8–10**
- antiral design, **39:5–8**
 - drug development, **39:4–5**
- gag* gene products, **39:17–24**
- genome structure, **39:10–11**
- glycoproteins, **39:39–50**
- infectious cycle, **39:14–17**
- morphogenesis, **39:11–14**
- pol* gene products, **39:24**
- integrase, **39:39**
 - protease, **39:24–29**
 - reverse transcriptase, **39:29–38**
- regulatory proteins, **39:50–56**
- Human immunodeficiency virus transcription
- cellular regulators, **43:62–75**
 - Ap1, **43:74**
 - basal transcription, **43:63–65**
 - COUP-TF, **43:74**
 - induced transcription, **43:67–72**
 - intragenic enhancers, **43:74–75**
 - LTR regulatory elements, **43:63**
 - NFAT-1, **43:73–74**
 - Sp1 role, **43:65–67**
 - upstream factors, **43:72–74**
 - USF-1 binding site, **43:72–73**
- models of activation, **43:76–78**
- Nef protein, **43:82–84**
- Tat, **43:75–82**
- Vpr protein, **43:84**
- Human immunodeficiency virus type 1, **46:99–146**
- CD4-independent infection of cells by, **38:139–140**
 - CD4 receptor, expression and tropism, **38:125–142**
- DNA
- double-stranded proviral, **46:101, 104**
 - significance in infectiousness, **46:123–124**
- gaining resistance in inhibitors, **42:34–35**
- gene expression
- auxiliary proteins, **40:12–14**
 - early expression, **40:5–9**
 - organization, **40:1–3**
 - structural expression, **40:9–12**
 - transcription factors, **40:3–5**
- LTR, **46:104**
- proteolytic processing, **46:106**
- replication, **46:101–106**
- initial events, **46:101, 104–105**
- reverse transcription
- first template switch, **46:137–146**
 - efficiency, **46:142**
 - genomic RNA dimerization, **46:143**

- Human immunodeficiency virus
 type 1 (*cont.*)
 reverse transcription (*cont.*)
 first template switch (*cont.*)
 interstrand and intrastand, **46:145**
 mode, **46:145**
 oligoribonucleotide size, **46:141**
 RNA-dependent DNA polymerization, **46:140**
 RNase H digestion, **46:141**
 origin, **46:122–125**
- RNA
 genomic, interaction with tRNA^{Lys3},
46:127–130
 templates, **46:129**
 trans-activation response element,
46:104
 virus assembly and maturation,
46:102–103, 105–106
 virus–host cell membrane fusion,
46:101
- Human immunodeficiency virus type 1
 reverse transcriptase, **46:107–119**
 association constants, DNA primer–
 DNA template, **46:131**
- DNA
 polymerization, RNA- and DNA-de-
 pendent, **46:131–133**
 template–DNA primer duplex,
46:114–115
 torsion-induced bends, **46:115**
 160^{gag-pol} precursor, **46:124**
 heterodimer, **46:108–109**
 hydroxyl-radical footprinting, **46:113–**
114
 inhibitors, **42:31–35**
 interaction with primer and template,
46:113–116
 polymerase active site, **46:113**
 specific binding, **46:115–116**
 nuclease footprinting, **46:114**
 polymerase active site and deoxy-
 nucleoside 5'-triphosphate binding
 site, **46:116–119**
 polymerization by, fidelity, **46:133–134**
 recombinant, **46:108**
 ribonucleases, **46:134–137**
 structure, **46:109–113**
 dimerization sites, **46:112**
 functional domains, **46:110–111**
 p51 and p66 domains, **46:109, 112**
- Human immunodeficiency virus vac-
 cines, **42:103–141**
 cell-to-cell fusion, **42:106**
 chimpanzee trials, **42:127–129**
 delivery systems, **42:134, 136–137**
 development obstacles, **42:105–108**
 effect on virus transmission, **42:139–**
140
 goals, **42:140**
 human trials, **42:129–131**
 mucosal immunity, **42:138**
 obstacles, **42:140–141**
 postexposure, **42:130–131**
 protection against sexual transmission,
42:132
 protective immunity, **42:131–137**
 secretory immunity, **42:132–134**
 SIV model, **42:139**
 systemic immunity, **42:132, 135–136**
 target organ immunity, **42:132**
 variants in the virus, **42:107**
- Human papillomavirus
 in benign lesions and tumors, **37:130,**
132–135
 carcinomas and, **37:125–161**
 DNA fragment integration in cervical
 carcinomas, **44:325–327**
 DNA replication in, **37:140–141**
 early observations on, **37:126**
 E4 gene product in, **37:141–142**
 gene expression regulation, **37:139–**
140
 genital
 gene expression regulation by viral
 gene products, **44:341**
 transcription, **44:328–329**
 negative factors, **44:334–335**
 potential modulators, **44:334**
 restricted host cell specificity de-
 terminants, **44:333**
 genome structure, **37:135–137**
 immune response to, **37:154–158**
 interaction with cells, **37:128–129**
 lesions induced by, **37:128, 130–**
131
 molecular biology of, **37:135–142**
 RNA transcription in, **37:137–138**
 transformation
in vivo, **37:150**
 oncogenes and, **37:149**
 studies on, **37:144–150**

- types, histological classification of, **37:151–152**
 virion properties, **37:127–128**
- Human papillomavirus infection
 diagnosis, **37:159–160**
 epidemiology, **37:150–152**
 evidence from cytology and histology, **37:151**
 interacting factors, **37:152–154**
 prevention, **37:160**
 subclinical, **37:151**
 treatment, **37:160–161**
- Human papillomavirus type 16
 E2
 as repressor, **44:342–343**
 as *trans*-activator, **44:341–342**
 genome structure, **44:309–310**
- Human parainfluenza virus type 3, **39:132–134**
 genome organization, **39:135–138, 140–141**
 transcription, **39:141–142, 144, 147, 149**
- Human reovirus, **29:59–60**
 activation, **29:64**
 defective interfering particles, **29:81–85**
 gene products, **29:69–71**
 subgenomic RNAs, **29:78–79**
 transcription, temperature optimum, **29:64**
- Human rhinovirus 1, **39:293**
- Human rhinovirus 14
 HIV structure and, **39:2, 7**
gag gene products, **39:20–24**
 glycoproteins, **39:44–46, 50**
pol gene products, **39:29**
 mutants, VP1 and VP3 alterations, **32:10**
 Theiler's murine encephalomyelitis virus and, **39:311**
- Human rhinoviruses, animal cells and, **36:113, 121, 137**
- Human T-cell leukemia virus receptor, **44:210**
- Human T-cell leukemia virus types I and II
 demyelination, **42:286**
 diagnosis using synthetic peptides, **42:167**
- Human T-cell lymphotropic viruses, **46:100**
 human herpesvirus 6 and, **41:2, 18**
 translational suppression by retroviruses and, **41:197, 214, 216, 219–221, 228**
- Human T-cell lymphotropic virus type I, **42:250, 47:378–379**
 age-dependent increase in seropositivity, **43:149**
 amino acid sequences of B-cell immunodominant epitopes, **43:159**
 assay reliability, **43:152**
 dissemination, **43:168–171**
env gene sequences, **43:155**
 epidemiology
 characteristics, **47:380–381**
 in Pacific populations, **43:148–155**
 changing patterns, **43:150–151**
 newly recognized focus in Melanesia, **43:151–155**
 future research directions, **43:171–174**
 genetic heterogeneity, **43:155–162**
gag and *env* epitope conservation, **43:152–160**
 geographic-specific genotypes, **43:160–162**
 interfamilial and intrafamilial sequence diversity, **43:156–157**
 genetic structure, **47:382–384**
 geographic molecular subtypes, **47:387–402**
 ancestral lineages in Japan, **47:397–400**
 genotypes, **47:389**
 intrastrain and temporal variations, **47:401–402**
 localization, **47:392**
 Melanesia, **47:391, 394–395**
 Middle East, **47:400–401**
 RFLP techniques, **47:390–391, 397–398**
- Hagahai, **43:152, 154, 171–172**
 and HIV expression, **43:113–114**
 in Japanese Americans, **43:151**
 nucleotide sequences, **43:156**
 phylogenetic analysis and molecular evolution, **43:163–168**
 phylogenetic relationship with STLV-I, **47:403–404**

- Human T-cell lymphotropic virus
 type I (*cont.*)
 phylogenetic trees, 43:165–167,
 47:393–396
 place diseases, 43:147–148
 prevalence in Japanese migrants in
 Hawaii, 43:151
 as privileged markers of migration of
 ancient human populations,
 47:411–412
 sexual transmission, 43:149
 tissue-specific genomic mutations,
 47:387–388
 transfusion-acquired infection, 43:150
- Human T-cell lymphotropic virus type
 II, 43:173–174, 47:379
 Africa, 47:405, 407–409
 epidemiological characteristics, 47:381
 genetic structure, 47:382–384
 molecular subtypes, 47:404–406
 nucleotide sequences, 47:406
 as privileged markers of migration of
 ancient human populations,
 47:411–412
- Human T-cell lymphotropic virus type
 III, lentiviruses and, 34:189
- Husbandry, ASF and, 35:256
- HVT, *see* Herpesvirus of turkeys
- Hybrid dysgenesis, *Drosophila* retro-
 transposons and, 36:35, 42–45
- Hybridization, *see also In situ* hybridiza-
 tion
 adenovirus and, 39:97–98, 100, 102
 archaeobacterial viruses and, 34:145
Halobacterium halobium, 34:162
Sulfolobus virus-like particle SSV1,
 34:179
Thermoproteus tenax, 34:171, 174
 cucumber mosaic virus and, 41:284,
 293, 296, 322
 defective interfering viruses and,
 40:194, 201, 205
- DNA replication and
 adenovirus, 34:3
 bovine papilloma virus, 34:21, 24,
 26, 28
 SV40, 34:18
- equine arteritis virus and, 41:165
- hepadnavirus and
 characterization, 34:90
 mRNA transcription, 34:75
- pre-S sequences, 34:105–106
- hepatitis A virus and, 39:219
- hepatitis E virus and, 40:87–90
- human herpesvirus 6 and, 41:3–4
 discovery, 41:3–4
 molecular biology, 41:16–17, 22–23
 lactate dehydrogenase-elevating virus
 and, 41:126, 130, 136, 141, 146,
 148
- lentiviruses and
 structure, 34:195–197, 200
 virus-host cell interaction *in vivo*,
 34:207
- neurodegenerative diseases caused by
 prions and, 41:248
- Paramyxoviridae and, 39:147
- picornaviral genomes and, 40:108,
 144–145
- plant viruses in developing countries
 and, 41:357, 366–367
- rotaviruses, 39:167, 180, 192–193, 196
 RNA, 46:72–73
- translational suppression by retro-
 viruses and, 41:225
- vaccinia and
 genome, 34:46–47
 vector, 34:55–56
- Hybridization assay, torovirus, 43:264–
 265
- Hybridization studies
 parvovirus DNA, 33:108–109
 prion proteins, 35:105–106
- Hybridoma, 29:132–133
- antibodies
 immunoglobulins, 29:144
 virus-specific, screening, 29:144–145
- cloning, 29:142–144
- conservation, 29:146
- culture, 29:137, 139, 145
- homogeneity, 29:146–147
- positive
 detection, 29:144
 enhanced frequency, 29:139–142
 yields, 29:140–142
- rotaviruses, 36:185
- Hybrids
 animal cells, 36:112
Drosophila retrotransposons, 36:94
 insertional mutagenesis, 36:79, 85,
 89–90
 intracellular cycles, 36:63, 67

organization, **36:47**, **54**
 scattered repetition, **36:36–39**, **41**
 transcription, **36:69–71**, **76**
 picornaviruses and, **36:170**
 rotaviruses and, **36:200**, **205**
 Hydrangea ringspot virus, *Plantago* host
 and occurrence, **27:112**
 Hydrolysis
 DNA replication, **34:18**
 influenza virus, **34:254**
 killed antiviral vaccines and, **39:270**
 Hydrophilicity
 archaeobacterial viruses and, **34:180**
 hepadnavirus and, **34:79**, **82**, **118**
 influenza virus and, **34:273**
 Hydrophobia, **42:396–397**
 Hydrophobicity
 archaeobacterial viruses and, **34:179–**
 182
 Bunyaviridae and, **40:247–248**
 HEF glycoprotein of influenza C virus
 and, **40:214**, **216**, **219**, **227**
 hepadnavirus and, **34:82**
 influenza virus and, **34:251–253**, **255–**
 256
 lentiviruses and, **34:193**
 1[(2-Hydroxyethoxy)methyl]-6-(phenyl-
 thio)thymine derivatives, **42:31–**
 34
 Hydroxylamine, **29:30–32**
 (S)-9-(3-Hydroxy-2-phosphonylmethoxy-
 propyl)adenine, **42:23–25**
 (S)-1-(3-Hydroxy-2-phosphonylmethoxy-
 propyl)cytosine, **42:24**
 Hygromycin B, antiviral activity, **30:111**
 Hypermutation, defective interfering vi-
 ruses and, **40:183**
 Hyperplasia, lentiviruses and, **34:203**
 Hypochlorite solution, dilute, **29:218**
Hypochoeris mosaic virus
 cytopathology, **36:9–10**
 natural occurrence, **36:3**, **8**
 purification, **36:15**
 Hypovirulence
 defective dsRNA role, **43:368–**
 369
 molecular basis, **43:371–373**
 reo-like viruses associated with,
 43:369–371
 Hypovirus, unencapsidated dsRNA, *see*
 Chestnut blight fungus

I

ICAM-1, *see* Intercellular adhesion mole-
 cule 1
 Icosahedral viruses, morphology, **27:4–6**
 ICP0
 and ICP4, combinatorial effects in
 HSV replication, **37:101**
 and ICP27, combinatorial effects in
 HSV replication, **37:101**
 properties and functions, **37:95–97**
 ICP4
 and ICP0, combinatorial effects in
 HSV replication, **37:101**
 and ICP27, combinatorial effects in
 HSV replication, **37:101**
 ICP8, properties, **37:105–106**
 ICP22, properties and functions, **37:99**
 ICP27
 and ICP4 or ICP0, combinatorial ef-
 fects in HSV replication, **37:101**
 properties and functions, **37:97–99**
 ICP47, properties and functions, **37:99–**
 100
 Idoxuridine, **35:272–273**
 IgA protease, bacterial, **35:233**
 Ig gene structure, Ab-MLV and, **35:56–58**
 IL-2, *see* Interleukin 2
 IL-3, *see* Interleukin 3
 Iilarvirus, **25:48–54**
 antibodies, production, **29:134–135**,
 145
 MAb-determined antigenic properties,
 29:150–151
 Plantago hosts and occurrence, **27:114**,
 125–126
 transport function, **38:216–218**
 Immortalizing genes, Epstein-Barr virus,
 40:19–48
 Immune cell, activation, and HIV expres-
 sion, **43:99–102**
 Immune deficiency, in LCMV model,
 45:38–44
 Immune deviation, **47:368–370**
 Immune disorders, human herpesvirus 6
 and, **41:33–34**
 Immune lysis, virions, envelope antigens
 and, **25:462**
 Immune response
 age-dependent poliomyelitis, **41:125**,
 134–141, **144**

- Immune response (*cont.*)
 Bunyaviridae and, **40:253**
 chickenpox virus in humans, **28:314–326**
 defective interfering viruses and, **40:187, 192**
 equine arteritis virus and, **41:160–163**
 host, positive-strand RNA viruses and, **41:160–163, 176–178, 181**
 human herpesvirus 6 and, **41:37–39**
 humoral, Theiler's murine encephalomyelitis virus and, **39:307–308**
 lactate dehydrogenase-elevating virus, **41:112–123, 151**
 MDV and HVT vaccines, chicken cell surface antigens and, **30:269**
 Marek's disease lymphoma cells, **30:267–268**
 MDV-infected cells, **30:266–268**
 MDV virions, **30:266–267**
 oral vaccination and, **41:410–411, 413, 424, 434, 438**
 genetic stabilization, **41:425, 427, 430**
 pestiviruses and, **41:86–87, 90**
 border disease virus, **41:66–67**
 comparisons, **41:69, 71**
 hog cholera virus, **41:57**
 positive-strand RNA viruses and, **41:181**
 rotavirus, **44:165–167**
 infants and children, **44:176–178**
 P- and G-type specificities, **44:177**
 simian hemorrhagic fever virus and, **41:176–178**
- Immune serum globulin, hepatitis A virus and, **39:237–238**
- Immune status, human papillomaviruses and, **37:154–158**
- Immune system
 oral vaccination and, **41:409, 431**
 pestiviruses and, **41:67**
 subacute retroviruses and, **27:294–296**
 and virus-induced pathology, **31:357–358**
- Immunity
 cell-mediated
 human papillomaviruses, **37:157–158**
 role in virus persistence, **26:42–44, 46–47**
 Theiler's murine encephalomyelitis virus and, **39:306–307**
- domain
 torovirus, **43:253–255**
 yeast killer system, **43:356**
- humoral
 human papillomaviruses and, **37:154–157**
 role in virus persistence, **26:42–44, 46**
- oral vaccination and
 bacterial disease, **41:414–417**
 viral disease, **41:411–414**
 paramyxoviridae, **37:227–235**
 parvoviruses, **38:415**
 viral infection-induced
 antibodies and, **32:3–4**
 antigenic changes and, **32:4–5**
 cell-mediated, **32:3–4**
 complications after consecutive infections, **32:14**
- Immunization, *see also* Vaccination
 antipolio, antibody responses in, site specificity of, **37:268–272**
 cucumber mosaic virus and, **41:291**
 lentiviruses and, **34:204**
 poliovirus and, **34:217, 224**
 with recombinant bacteria, **41:409–438**
 rotavirus
 active, **44:172–174, 180–185**
 passive, **44:170–172, 175–176**
 viral, **35:238–239**
- Immunoblot assays, human herpesvirus 6 and, **41:20, 25, 38–39**
- Immunocomplexes, adenovirus–antibody, **29:186**
- Immunocytochemical staining, positive-strand RNA viruses, **41:128, 158**
- Immunocytochemical studies, prions and, **35:115–116**
- Immunodepression
 lymphocytic choriomeningitis virus-type species-induced, **31:9**
 virus-induced, **26:47**
- Immunodiffusion
 cucumber mosaic virus and, **41:291–294, 296**
 pestiviruses and, **41:72–73**
- Immunoelectron microscopy, **29:99, 105**
 ADRV and, **35:194, 195, 216**
 antibody binding site location, **29:112**

- double-shelled rotaviruses and, 35:202–205
- hepatitis A virus and, 39:210, 213, 221, 227
- torovirus, 43:261–262
- in virology, 29:169
- viruses, 27:17–21
- Immunoelectroosmophoresis, ASF and, 35:267
- Immunofluorescence, 29:99, 104, *see also* Cross-immunofluorescence
 - ADRV and, 35:205
 - equine arteritis virus and, 41:159
 - hepatitis A virus and, 39:215, 226–228
 - hepatitis C virus and, 40:77–78
 - hepatitis E virus and, 40:85, 90
 - pestiviruses and, 41:73
 - poliovirus and, 34:222
- Immunogenetics, Theiler's murine encephalomyelitis virus and, 39:304–305, 307
- Immunogenicity
 - cucumber mosaic virus and, 41:290–291
 - killed antiviral vaccines and, 39:257, 261, 273–277, 284
 - specificity, 39:260, 280–281
 - oral vaccination and, 41:413, 415, 430, 438
 - bacteria as carriers, 41:431, 434, 436–437
 - epitope presentation systems, 41:423–428
 - foreign antigens in *Salmonella*, 41:417, 421–422
 - simian hemorrhagic fever virus and, 41:176–178
- Immunoglobulins
 - adenovirus and, 39:124
 - anti-ASF, 35:264
 - antiviral antibody affinity and, 34:298–301
 - DNA replication and, 34:9
 - Epstein-Barr virus and, 40:20–21, 23
 - hepatitis A virus and, 39:213–214, 237
 - hepatitis C virus and, 40:74
 - HIV structure and, 39:2, 7, 47
 - IgA, oral vaccination and, 41:410–411, 422–423
 - IgE, Epstein-Barr virus and, 40:31
- IgG
 - defective interfering viruses and, 40:192
 - equine arteritis virus and, 41:161
 - Fc receptors, induction, 28:319–320
 - human herpesvirus 6 and, 41:31–33, 38, 40
 - lactate dehydrogenase-elevating virus and, 41:112, 114, 118–122
 - oral vaccination and, 41:417, 421–422
- IgM
 - human herpesvirus 6 and, 41:31–33, 38
 - positive-strand RNA viruses and, 41:114, 119–120, 122, 161
 - oral vaccination and, 41:414, 418–421
 - picornaviral genomes and, 40:146
 - rotaviruses and, 36:189
 - rotavirus-specific, 44:180, 183
 - Theiler's murine encephalomyelitis virus and, 39:307
- Immunological reactions, paramyxovirus infection effect, 37:233–234
- Immunology
 - ASF, 35:263–265
 - filoviruses, 47:38–39
- Immunomodulation, persistently infected cells, 31:376–377
- Immunopathology, virus-induced, 47:353–372
 - autoimmunity, 47:365–367
 - cytokines as proinflammatory participants, 47:355
 - delayed-type hypersensitivity reactions, 47:358–360
 - HBV transgene model, 47:356
 - HIV, 47:357–358, 361
 - immune inflammatory disease control, 47:367–370
 - inflammatory responses involving antibody, 47:364–365
 - lesions primarily involving CD8⁺ cells, 47:354–358
 - murine Coxsackie B virus model, 47:356–357
 - reactions primarily involving CD4⁺ T cells, 47:358–364
 - cytolytic virus infections, 47:363–364
 - type 1, 47:359–361

- Immunopathology, virus-induced (*cont.*)
 reactions primarily involving
 CD4⁺ T cells (*cont.*)
 type 2, 47:361–363
 Sin Nombre virus, 47:357
 Th1 cell induction, 47:369
- Immunoprecipitation
 hepadnavirus, 34:104
 lentiviruses, 34:192, 195
 vaccinia, 34:58
- Immunoreactivity
 human herpesvirus 6, 41:20
 neurodegenerative diseases caused by
 prions, 41:248
- Immunosorbent electron microscopy,
 29:188
 advantages, 29:192
 antibody-coated grid technique,
 29:171–177, 190
 effect of virus extract pH, 29:176
 vs. PA-CGT, 29:178–179
 specificity, 29:174–175
 antigen-coated grid technique, 29:171,
 187–188, 191
 antisera, 29:189
 buffers, 29:189
 cryptic virus detection in plants,
 32:186–187
 decoration, 29:190–191
 definition, 29:170
 detection of viruses, 29:169–194
 direct trapping of viruses on grids,
 29:191
 disadvantages, 29:192
 grid coating, 29:189
 incubation temperature, 29:190
 incubation time, 29:189–190
 methods, 29:170–188
 pH effect, 29:190
 plant vs. animal viruses, 29:192–193
 protein A-coated bacteria technique,
 29:171, 182–186, 191–192
 protein A-coated grid technique,
 29:171, 177–182, 186, 190–193
 bovine serum albumin effect,
 29:181–182
 time and temperature effects,
 29:181–183
 techniques, nomenclature, 29:171
- Immunostimulatory complexes, hepad-
 navirus and, 34:134
- Immunosuppression
 age-dependent poliomyelitis and,
 41:128–130, 143
 etiology, 41:124–125
 motor neuron protection, 41:134–
 136, 138–140
 hepatitis E virus and, 40:86
 human herpesvirus 6 and, 41:32
 lactate dehydrogenase-elevating virus
 and, 41:151
 lentiviruses and, 34:204
 Theiler's murine encephalomyelitis vi-
 rus and, 39:305–306
- IMP dehydrogenase inhibitors, 42:13–16
- Inactivated vaccines
 hepatitis A virus, 39:238–239
 poliovirus
 improvement in, potential for,
 37:269–270
 and OPV, responses to, difference
 between, 37:268–269
 whole virion, 32:21
- Inactivation, killed antiviral vaccines
 and, 39:257–260, 283–284
 agents, 39:260–261
 changes in virion immunogenicity,
 39:273–274
 duration of agent action, 39:262–
 263
 efficiency, 39:274–280
 improvement, 39:281–283
 kinetics, 39:264–272
 specificity, 39:280–281
- Incubation
 cucumber mosaic virus, 41:323
 lentiviruses, 34:189
 neurodegenerative diseases caused by
 prions, 41:246, 255
 replication, 41:267, 269
 scrapie, 41:258–259
 transgenic mice, 41:262, 264
- Incubation period
 ADRV and, 35:213
 ASF and, 35:257
 prions, 35:107–109
- Indian meal moth, granulosis virus of,
 28:141–173
- Indirect fluorescent assay
 human herpesvirus 6, 41:3–4, 20, 25–
 26, 28
 torovirus, 43:264

- Indirect immunoperoxidase plaque test, ASF and, 35:267
- Infection
- abortive, with parvoviruses, 33:168
 - from alphaviruses, course of events after, 38:375
 - arenavirus
 - in cell cultures, 31:9–10
 - interspecies transmission, 31:9
 - neonatally acquired, 31:9
 - transuterine transmission, 31:9
 - venereal transmission, 31:9
 - bunyavirus, 31:38–40
 - cells by HIV-1
 - CD4-independent, 38:139–140
 - CD4 role, 38:137–139
 - cryptic, parvovirus and, 33:168
 - cytotoxic
 - lactate dehydrogenase-elevating virus and, 41:126–128, 130, 139, 143–144, 181
 - simian hemorrhagic fever virus and, 41:175, 181
 - enteric, hepatitis A virus and, 39:211, 221
 - latent, insect virus, 31:296–301
 - nonpersistent virus, monitoring field, 31:408
 - use of bait plants, 31:408–409
 - persistent, with flavivirus, 33:79–81
 - viral, *see* Viral infection
- Infectious bronchitis virus, 41:149
- translational suppression by retroviruses, 41:211, 214, 220–221, 223
- Infectious diseases
- global surveillance system, 43:49
 - new, emerging, and reemerging
 - Akabane disease, 43:19
 - animal pathogens, 43:42–46
 - astroviruses, 43:25
 - bacillary epithelioid angiomatosis, 43:41
 - behavioral and societal factors, 43:23–26
 - behavioral prevention strategies, 43:3
 - bovine spongiform encephalopathy, 43:42–45
 - callitrichid arenavirus disease, in tamarins, 43:47
 - canine distemper, in black-footed ferret, 43:47
 - canine parvovirus disease, 43:29–30
 - capacity of microorganisms and viruses to cause, 43:7–9
 - cat scratch disease, 43:40–41
 - Chlamydia pneumoniae*, 43:39
 - cholera, 43:10–11
 - Crimean–Congo hemorrhagic fever, 43:18
 - cyanobacteria disease, 43:40
 - day-care and virus diarrhea, 43:24–25
 - dengue, 43:14–16
 - disease prevention strategies, 43:3
 - Ebola hemorrhagic fever, 43:34–35
 - ecological factors, 43:13–19
 - factors leading to spread of microorganisms and viruses, 43:10–13
 - feline immunodeficiency virus, 43:45–46
 - food-borne, 43:27–28
 - group A streptococcal disease, 43:39–40
 - Helicobacter pylori*, 43:39
 - hemorrhagic fever with renal syndrome, 43:18–19
 - HIV/AIDS, 43:9–10
 - human ehrlichiosis, 43:37
 - human herpesvirus type 6, 43:25–26
 - human parvovirus B19, 43:26
 - important human bacterial, rickettsial, and mycotic pathogens, 43:35–41
 - important human protozoan pathogens, 43:41–42
 - influenza, 43:12–13
 - interaction between microorganisms and viruses and human and animal hosts, 43:28–31
 - legionellosis, 43:38
 - lelystad virus disease, 43:46
 - Lyme disease, 43:36–37
 - malaria, 43:41–42
 - Marburg hemorrhagic fever, 43:34–35
 - modern agriculture, 43:26–28
 - norwalk-like viruses and, 43:25
 - pathogens of endangered species, 43:47
 - prevention and control, 43:48–49

- Infectious diseases (*cont.*)
 global surveillance system (*cont.*)
 public awareness and education,
 43:4–6
 rabies, 43:20–23
 Reston virus, 43:35
 Rift Valley fever, 43:16–17
 rotavirus diarrhea, 43:25
Salmonella enteritidis in eggs, 43:28
 sexually transmitted diseases,
 43:23–24
 simian immunodeficiency virus,
 43:45–46
 tick-borne encephalitis, 43:17–18
 tuberculosis, 43:38–39
 Venezuelan equine encephalitis,
 43:17
 yellow fever, 43:16
 zoonotic factors, 43:19–23
- Infectious mononucleosis, Epstein–Barr
 virus, 44:370–371
 T-cell apoptosis, 45:44–45
- Infectivity
 antibody-dependent enhancement, *see*
 Antibody-dependent enhancement
 bipartite genome of dianthoviruses,
 33:281–283
 killed antiviral vaccines and, 39:257,
 284
 changes in virion immunogenicity,
 39:273, 276, 280
 duration of agent action, 39:262–264
 inactivation
 agents, 39:260–261
 kinetics of, 39:264–272
 step, 39:259–260
 specific, of viruses, 25:217–219
- Inflammation
 lactate dehydrogenase-elevating virus
 and, 41:123, 125
 Theiler's murine encephalomyelitis vi-
 rus and, 39:296, 298–303, 310
- Inflammatory disease
 immune, control, 47:367–370
 lentiviruses and, 34:190, 201–205
- Inflammatory responses, involving anti-
 body, 47:364–365
- Influenza A virus, 29:102
 antigenic drift, 29:103, 32:4
 diagram of, 31:54
 electron micrograph of, 31:54
 genome RNA segment and coding as-
 signments, 31:56
 HEF glycoprotein and, 40:213
 functions, 40:224, 227–228
 structure, 40:214, 216, 220–221
 peplomers
 aggregation, immunogenicity and,
 32:28
 isolation and structure, 32:28
 properties, 31:53–55
 reassortants between virulent and ge-
 netically modified strains, 32:19
 repeated infections, 32:5
- Influenza B virus, 29:102
 antigenic drift, 29:103
 HA1 polypeptide, sequences, 31:65
 HEF glycoprotein and, 40:213–214,
 216, 224, 227–228
 properties, 31:53–55
 variants, 29:104
 positions of amino acid sequence
 changes, 31:66
- Influenza C virus
 antigenic stability, 31:55
 HEF glycoprotein, *see* HEF glycopro-
 tein of influenza C virus
- Influenza virus, 29:96, 34:247–248, 274
 amino acid alterations, 29:111
 animal cells and, 36:119, 133–134
 antibody binding site location, 29:112
 antigenic change, 43:12–13
 antigenic drift, 29:103, 120
 antigenic shift, mechanism, 31:57–58
 antigenic variation, 31:55–94
 antiviral antibody affinity and, mea-
 surement
 direct, 34:288, 294, 296, 301
 relative, 34:306
 apoptosis induced by, 45:21
 attachment, inhibition by protease in-
 hibitors, 30:85
 avian vs. seal strains, 29:107
 Bunyaviridae and, 40:255, 257
 characterization with MAbs, 29:103
 comparison with alphavirus fusion,
 45:143–145
 components, 34:248
 hemagglutinin, 34:249–252
 influenza C virus, 34:256–257
 membrane protein m1, 34:255–256
 neuraminidase, 34:253–255

nonstructural proteins, **34:255–256**
 nucleocapsid protein, **34:252–253**
 polymerase-associated proteins,
 34:249
 defective interfering viruses and,
 40:190, 192–194
 diagnosis with MAbs, **29:101**
 genetic reassortment, **34:257–258**
 genetic resistance, **34:273–274**
 genome constellation, **34:258–260**
 hepadnavirus and, **34:97**
 HIV structure and, **39:7, 40, 42, 44–46**
 human infection, **29:103**
 immunosorbent electron microscopy,
 29:187
 inhibition by poly(C,S⁴,U₁₀), hamster,
 ferret, **30:107**
 interferon-induced antiviral actions,
 42:82
 matrix protein antigen, **31:89–90**
 M2 protein, ionic pore formation in
 membranes, **45:86–89**
 mRNA, **29:66**
 mutation, **34:260–261**
 NA molecule, structural analysis,
 29:111
 nonstructural protein antigens, **31:90–**
 91
 NS1 mRNA, splicing, **35:31–32**
 nucleocapsid proteins, in transcription,
 29:108
 nucleoprotein antigens, **31:88–89**
 oral vaccination and, **41:411, 417, 422**
 origin of new viruses, **31:57–58**
 Paramyxoviridae and, **39:144**
 pathogenicity, **34:261, 271–273**
 penetration, inhibition by synthetic oli-
 gopeptides, **30:86–87**
 picornaviruses and, **36:173–175**
 PMN and, **35:230**
 polymerase protein antigen, **31:87–91**
 potyvirus coat protein and, **36:298**
 protection with MAbs, **29:121**
 protein, functional areas, **29:107**
 replication, interferon-induced inhibi-
 tion, **38:188–191**
 respiratory viral infection, **42:227–228**
 rotaviruses and, **39:166, 169, 199**
 seal, **29:103**
 T lymphocyte recognition sites, **31:92–**
 94

uncoating, **27:175**
 vaccine, **35:238**
 vaccinia and, **34:53, 57–58, 60**
 variant selection and mapping, **29:110**
 Influenza virus hemagglutinin, **28:221–**
 224, 29:117, 33:2–4, 34:261–271
 amino acid substitutions, **29:111**
 animal cells and
 endocytosis, **36:121**
 entry, **36:132, 135**
 membrane fusion, **36:125–129**
 receptors, **36:113, 116**
 antibodies raised against synthetic
 peptides and, **31:73–74**
 antigenic drift, **31:62**
 antigenic sites
 carbohydrate effect on, **31:73**
 changes at low pH, **31:71–73**
 antigenic variants
 host cell selection of, **31:68**
 selected with MAbs, **31:64**
 antigenic variation in type B virus,
 31:64–67
 cytoplasmic domain, **33:7–8**
 ectodomain, **33:4–6**
 epitopes on, structure, **31:69–71**
 fusion protein activity, **29:117**
 genes, nucleotide sequences of HA1
 portions, **31:67**
 HA1 polypeptide sequences of type B
 virus, **31:65**
 polypeptides, diagrammatic representa-
 tion of, **31:60**
 receptor binding site, **33:6**
 receptor-binding variants, **31:68–69**
 structure, **31:58–62**
 study, **29:106**
 transmembrane domain, **33:6–7**
 Influenza virus neuraminidase, **33:28–29**
 antigenic variants, **31:76–79**
 crystals complexed with MAbs, **31:83–**
 87
 genes, deletions in, **31:79–80**
 homology in, **31:80, 83**
 N terminus, sequences, **31:81–82**
 polypeptides, diagrammatic representa-
 tion of, **31:60**
 relationship among subtypes, **31:80–83**
 sequences at N terminus, **31:81–82**
 structure, **31:74–87**
 study, **29:106**

- Influenza virus neuraminidase (*cont.*)
 tetramer, schematic diagram, **31:77**
 variants, amino acid sequence changes,
31:78
- Influenza virus receptor, **42:228**
- Inhibition
 adenovirus and, **39:92, 95**
 sequence-specific methylation,
 39:111–124
 species specificity, **39:103**
 HIV structure and, **39:4, 6–7, 26, 56**
 gag gene products, **39:19, 21**
 glycoproteins, **39:41, 43, 46–47**
 pol gene products, **39:25–32, 34–36**
 regulatory proteins, **39:54**
 Paramyxoviridae and, **39:133–135,**
 150, 152
 satellite RNA for biocontrol and,
39:334, 337
 Theiler's murine encephalomyelitis vi-
 rus and, **39:294**
- Inhibitors
 Bunyaviridae and, **40:245–249, 261,**
 263
 cucumber mosaic virus and, **41:319,**
 328
 defective interfering viruses and,
40:192–194
 HEF glycoprotein of influenza C virus
 and, **40:213, 216, 221, 223, 226**
 HIV-1 and, **40:8, 12, 14**
 human herpesvirus 6 and, **41:35**
 growth properties, **41:11–12**
 molecular biology, **41:21–22, 24–25**
 lactate dehydrogenase-elevating virus
 and, **41:151**
 age-dependent poliomyelitis, **41:119,**
 132, 141
 mice, **41:108**
 neurodegenerative diseases caused by
 prions and, **41:253**
 picornaviral genomes and cis-acting el-
 ements, **40:121, 128–129**
 mRNAs, **40:145–146, 148**
 phenotype, **40:154**
 trans-acting factors, **40:131–132, 134**
 simian hemorrhagic fever virus and,
41:179
 translational suppression by retro-
 viruses, **41:204, 218–219, 221, 223,**
227–228, 232
- Initiation
 Bunyaviridae and, **40:257**
 picornaviral genomes and, **40:159–160**
- Initiation codons, Bunyaviridae and,
40:250, 252
- Initiation correcting factor, picornaviral
 genomes and, **40:135–137**
- Initiation factors
 cross-linking to mRNA, **33:186**
 eukaryotic, **33:176**
 initiation complex formation role,
25:29–32
 picornaviral genomes, **40:114, 129–**
136, 138
 mRNAs, **40:144–146, 148, 156**
 translation initiation, **40:139–140**
- Inoculation
 cucumber mosaic virus and, **41:285,**
 291, 297
 epidemiology, **41:335, 337–338**
 satellite RNAs, **41:322**
 defective interfering viruses and,
40:203
 neurodegenerative diseases caused by
 prions and, **41:246, 258–259, 262,**
264
 in nonpersistent virus transmission,
31:392–393
 plant viruses in developing countries
 and, **41:359, 379**
 poliovirus, **34:239–241**
 neurovirulence, **34:223–225, 229–**
 230, 233, 235–236, 238
- Inoviridae
 basic properties, **27:210**
 morphological variation, **27:251**
- Insect cells, foreign genes expressed by
 baculovirus vectors, **35:178–181**
- Insecticides
 plant viruses in developing countries
 and, **41:360, 373–374, 376**
 in reducing nonpersistent virus spread,
31:409–412
- Insect parvovirus, **25:311–313**
 serological properties, **25:340**
 structural proteins, **25:331**
- Insects
 plant viruses in developing countries
 and, **41:371, 388–389**
 transmission
 dianthovirus, **33:290–291**

- virus, host passage effects, **25:180–181**
- virus infection, pathology, **25:275–278**
- Insect viruses, **25:273–347**
- amino acid analysis, **25:322**
- associated enzymes, **25:319–320**
- biological properties, **25:343–346**
- biology and ecology of, **26:117–143**
- group 5, **25:315**
- latency
- activation of latent infections, **31:296–301**
 - concept, **31:294–296**
 - host range
 - arthropod-borne animal viruses, **31:305–306**
 - arthropod-borne plant viruses, **31:306–307**
 - broad, **31:302–305**
 - cricket paralysis virus, **31:302–304**
 - Drosophila* C virus, **31:304–305**
 - honey bee viruses, **31:301–302**
 - restricted, **31:301–302**
 - vectors, **31:305–307**
 - and virus-like particles, **31:307–313**
 - Drosophila* virus, **31:311–313**
 - Nodamura virus, **31:307–309**
 - wasp viruses, **31:309–311**
- mini, **25:315**
- from mosquito cells, **30:34–35**
- nucleic acids, properties, **25:286–289**
- physical properties, **25:286**
- serological properties, **25:334–335**
- small isometric, **25:285–286**
- structural proteins, **25:318–323**
- unclassified virus, **25:318**
- structural protein, **25:333**
- Insertional mutagenesis, adenovirus and, **39:91, 95**
- DNA persistence, **39:103–110**
- integrative recombination, **39:110–111**
- In situ* hybridization
- human herpesvirus 6 and, **41:28, 35**
 - lactate dehydrogenase-elevating virus and, **41:105, 126, 128, 130, 133, 138**
 - pestiviruses and, **41:85**
 - Theiler's murine encephalomyelitis virus and, **39:298, 301, 309–310**
- Insulin, Epstein-Barr virus and, **40:40**
- Insulin receptor, homology with *ros* gene product, **32:112**
- Int-1* as growth factor, **37:4**
- Int-2* as growth factor, **37:4**
- Integrase
- Drosophila* retrotransposons and, **36:59**
 - feline immunodeficiency virus, **45:235**
 - HIV structure and, **39:11, 13, 16, 39**
 - translational suppression by retroviruses and, **41:194, 197, 205, 231**
- Integration, parvovirus DNA into host DNA, **33:139**
- Intercellular adhesion molecule 1
- coxsackie A viruses, **42:361–362**
 - Epstein-Barr virus and, **40:36**
 - HIV structure and, **39:44–47, 50**
- Interference, flavivirus and, **33:81–82**
- Interference site, *Totivirus*, **43:323–324**
- Interfering viruses, *see* Defective interfering viruses
- Interferon- α
- Epstein-Barr virus and, **40:33**
 - hepatitis C virus and, **40:81**
- Interferon- α/β , **42:62**
- Interferon- γ
- enhancers inducible by, **42:74, 76–77**
 - gene expression, **42:68–71**
 - responsiveness, cis-acting sequence, **42:78–79**
- Interferon- α gene, **42:65, 68**
- Interferon- β gene, regulatory cis element, **42:64**
- Interferon-induced antiviral actions, **42:57–96**
- dsRNA-dependent protein kinase, **42:85–86**
 - inhibition of dsRNA-dependent pathways, **42:93–95**
 - mechanisms, **42:81–83**
 - MHC class I proteins, **42:88–90**
 - Mx proteins, **42:86–88**
 - 2'-5'-oligoadenylate synthetases, **42:83–85**
 - viral defense, **42:90–95**
- Interferon-induced proteins, **42:58**
- antiviral state and, **38:147–194**
 - 2-5A synthetase as, **38:154–156**
 - functions, **38:149–176**
 - guanylate-binding, **38:171–172**
 - human MxA, **38:163–166**
 - human MxB, **38:166–167**

- Interferon-induced proteins (*cont.*)
 indolamine 2,3-dioxygenase as,
 38:175–176
 IP-10 as, 38:174–175
 ISG15 as, 38:173
 17-KDa, 38:172–174
 Mx, 38:158–171
 related genes of mammals and fish
 as, 38:168–169
 Mx2
 mouse, 38:162–163
 rat, 38:168
 Mx1, rat, 38:167–168
 P1 kinase as, 38:156–158
 yeast VPS1 as, 38:169–171
- Interferon-inducible genes
 expression inhibition, 42:91–93
 regulation by interferons, 42:71–72
 transcription, 42:74–75
- Interferon- γ receptors, 42:72–73
- Interferon receptors, regulation, 42:72–73
- Interferon-regulated cellular gene expression, 42:71–81
 cis-acting sequences, 42:78–79
 interferon-inducible genes, 42:71–72
 interferon receptors, 42:72–73
 signal transduction, 42:73–78
 trans-acting factors, 42:79–81
- Interferons, 42:57–63
 as antiviral agent, 35:240–241
 conjugate, 35:305–306
 liposome-mediated delivery, 35:305
 antiviral state, 42:57–58
 biosynthesis, 42:62–71
 transcriptional and posttranscriptional regulation, 42:62–64
 type I, 42:62–68
 type II, 42:68–71
 categories of response, 42:61
 defective interfering viruses and,
 40:184–185, 192
 defective response in virus persistence,
 26:44
 effect on persistent viruses, 26:40
 genes regulated by, 42:58–60
 hepatitis C virus and, 40:61, 81
 human herpesvirus 6 and, 41:38
 immune system response, 31:370–371
 induction by rubella virus, 44:104
 influenza virus and, 34:273
 inhibition of virus replication by,
 38:176–193
 for DNA viruses, 38:177–182
 for RNA viruses, 38:182–193
 killed antiviral vaccines and, 39:256
 lactate dehydrogenase-elevating virus
 and, 41:116–117, 119–121, 137,
 141
 lentiviruses and, 34:205, 208
 lymphocyte function and, 35:228–232
 nomenclature, 42:58
 pathological effects, 31:371–373
 picornaviral genomes and, 40:134, 157
 rabies virus, 42:395–396
 subtypes, 42:58
 in treatment of chickenpox, 28:337–338
 viral-bacterial synergistic action and,
 35:221–222
- Interferon-stimulated gene factors,
 42:79–81
 gene factor 3, activation, 42:73–74
- Interferon-stimulated response elements,
 42:78–80
- Interferon type I, induction by
 10-carboxymethyl-9-acridone, 30:118
 1,5-diaminoanthraquinones, 30:118
 polyribonucleotides, 30:117
 propane diamines, 30:119–120
 pyrimidinones, 30:118–119
 tilorone, 30:117–118
m-xylene diamines, 30:119–120
- Interferon type II, induction by carboxymethyl germanium sesquioxide,
 30:120
- Interleukin 1
 lentiviruses and, 34:206
 transcriptional activation of HIV,
 43:103
- Interleukin 2
 Ab-MLV and, 35:64
 and bovine herpesvirus 1, 35:231
 hepadnavirus and, 34:112
 HIV-1 and, 40:3
 human herpesvirus 6 and, 41:3, 11–12
- Interleukin 3, Ab-MLV and, 35:63–64
- Interleukin 4, Epstein-Barr virus and,
 40:31
- Interleukin 5, Epstein-Barr virus and,
 40:23

- Interleukin 6, Epstein-Barr virus and, **40:23**
- Interleukin 1 β , human herpesvirus 6 and, **41:38**
- Interleukins, lactate dehydrogenase-elevating virus and, **41:120**
- Internalization
and animal cells
early interactions, **36:109**
endocytosis, **36:117–119, 121–122**
enveloped viruses, **36:131–133, 135–136**
nonenveloped viruses, **36:137–138**
receptors, **36:116**
parvovirus, **33:138**
- International Agricultural Research Centres, plant viruses and, **41:350, 397**
crop improvement, **41:361, 363–364**
remedial action, **41:386, 393**
- International Board for Plant Genetic Resources, plant viruses and, **41:350, 364, 393–395**
- International Centre for Agricultural Research in Dry Areas, developing countries and, **41:364, 394**
- International Committee on Taxonomy of Viruses
human herpesvirus 6 and, **41:3, 24**
pestiviruses and, **41:54**
- International Crops Research Institute for the Semi-Arid Tropics, developing countries and, **41:364, 382, 394**
- International Rice Research Institute, plant viruses in developing countries and, **41:357, 365, 375**
- Intestine, poliovirus effect, **34:220–221**
- Intracisternal A-particles, *Drosophila* retrotransposons and
intracellular cycles, **36:60, 64**
organization, **36:50, 55, 60**
transcription, **36:35, 97**
- Intrauterine infection, pestiviruses and, **41:66, 83, 87, 91**
bovine viral diarrhea virus, **41:60–66**
comparisons, **41:69, 71**
hog cholera virus, **41:56–57**
- Introns
adenovirus and, **39:102–103**
removal of from cellular oncogenes, **35:27–28**
RSV RNA and, **35:22–26**
- Iodination
hepadnavirus and, **34:85**
lentiviruses and, **34:194**
- Iododeoxycytidine, vaccinia and, **34:57**
- 5-Iodouridine-deoxyriboside
effect on persistence viruses, **26:51–52, 54–55**
formula, **26:51**
- Ions
bacterial adherence and, **35:223–224**
fluxes in alphaviruses, fusion and, **38:385–386**
intracellular levels, poliovirus infection and, **33:192–193**
- Iridovirus, **46:347–401**, *see also* Frog virus 3
African swine fever classified as, **35:251–253**
base composition, **25:306**
capsid, **46:367–369**
characteristics, **30:1**
classification, **46:350–366**
alternative approaches, **46:360–361**
comparative studies, **46:352–359**
current system, **46:350–352**
invertebrate, **46:362–364**
new nomenclature, **46:359–360**
new scheme, **46:365–366**
suggested changes to current system, **46:362–366**
vertebrate, **46:364–365**
conformation, **25:306–310**
description, **46:348–349**
DNA–DNA dot-blot hybridization values, **46:356–358**
ecology, **46:391–399**
future directions, **46:399–401**
genes, **46:388–390**
homology studies, **25:310**
hybridization complexes, **46:357, 359**
infectious particles per host, **46:392**
invertebrate
classification, **46:362–364**
DNA restriction endonuclease profile, **46:354–357**
iridescence phenomenon, **46:371–372**
lipid membrane, **46:361, 368–370**
models of host–iridovirus population dynamics, **46:391**
molecular biology, **46:386–391**
morphology of, **25:283–285**

- Iridovirus (*cont.*)
 nature and strandedness, **25:306**
 particle core, **46:370–371**
 persistence
 alternative hosts, **46:398–399**
 in host populations, **46:396–397**
 physical, **46:395**
 physicochemical properties, **46:366–367**
 repetitive DNA, **46:390–391**
 restriction endonuclease analysis, **25:310**
 serological properties, **25:339–340**
 structural proteins, **25:330–331**
 transmission, **46:393–395**
 vertebrate, **46:348**
 classification, **46:364–365**
- Iridovirus replication
 cell penetration and uncoating, **46:373**
 cytoskeletal manipulation, **46:383–385**
 DNA methylation, **46:374–375**
 DNA replication, **46:373–374**
 enzymatic activities, **46:385–386**
 host macromolecular synthesis shut-down, **46:373–375**
 methylated DNA transcription, **46:378**
 mRNA stability and methylation, **46:380–381**
 nongenetic reactivation, **46:377–380**
 transcription, **46:377–381**
 translation, **46:381–382**
 virion packaging, **46:382–383**
- Iron
 bacterial adherence and, **35:224**
 lentiviruses and, **34:206**
 picornaviral genomes and, **40:151**
- Irradiation
 archaeobacterial viruses and, **34:175, 177, 182**
 inactivation, scrapie agent resistance, **29:32–33**
 kuru agents resistance, **29:12**
- Irreversibility of inactivation, killed antiviral vaccines and, **39:260**
- Irrigation, plant viruses in developing countries and, **41:358–360, 366, 373, 375–378**
- Isoacceptors, translational suppression by retroviruses and, **41:228–230, 232**
- Isocitrate dehydrogenase, lactate dehydrogenase-elevating virus and, **41:107–109**
- Isocoumarins, HEF glycoprotein of influenza C virus and, **40:223**
- Isolation
 Ab-MLV, **35:41–42**
 cucumber mosaic virus, **41:329–330, 338**
 pestiviruses and, **41:84–85**
- Isometric viruses
 morphology of, **27:6–9**
 plant, **31:323–324**
Plantago hosts and occurrence, **27:116, 129–130**
- Isoprenylation, hepatitis delta virus, **43:211–212**
- J**
- Jamestown Canyon encephalitis, characteristics and occurrence, **28:412–419**
- Japan, HTLV-I occurrence, **47:397–400**
- Japanese encephalitis, **27:71–101**
 cell-mediated immunity, **27:79–80**
 control, **27:95–100**
 inapparent infection and pathogenesis, **27:76–80**
 vaccine, **27:97–98**
 variations, **27:88–95**
 vertebrate and amplifier hosts, **27:85**
- Japanese encephalitis virus, **29:110**
 antigenic relationships, **31:116–117**
 characteristics and occurrence, **28:381–383**
 ecology, **27:80–95**
 geographically related strain variations, **31:118**
 hemolytic properties, **27:75**
 isolation, **27:83–85**
 from mosquito cells, **30:31, 34**
 MAbs, neutralizing activities, **31:136**
 overwintering, **27:85–88**
 pathogenic properties, **27:72–75**
 peripheral multiplication, **27:78–79**
 protection from, with MAbs, **29:122**
 serological subgrouping, **31:108**
 strains, **27:74**
 transmission vector, **27:82–83**
- JC virus, and HIV expression, **43:113**

Johnsongrass mosaic virus, potyvirus
 coat protein and, **36:276**
 genome organization, **36:276–277**
 structure, **36:285**
 subgroups, **36:305**
 taxonomy, **36:294, 298, 301, 303**
Jun oncogene, in signal transduction
 within nucleus, **37:19–20**
Junonia coenia, densovirus vectors,
47:334
 Juvenile hormone, pesticide production
 and, **36:338–339**

K

KB infectivity standard, for WTV,
25:226–228
 Kelp fly virus, **25:315**
 serological properties, **25:341**
 structural proteins, **25:332**
 Keratin 6, Epstein-Barr virus and, **40:35**
 Keratinocyte-responsive factor 1, pa-
 pillomavirus, transcription, **44:331**
 Keratinocytes, **42:211–212**
 Keyhole limpet hemocyanin, hepad-
 navirus and, **34:133**
 Kidney
 ASF, **35:261, 263**
 chronic viral infection, **42:233–234**
 DNA replication, **34:10, 31**
 hepadnavirus, **34:97**
 hepatitis A virus, **39:227, 239**
 human herpesvirus 6, **41:32**
 lentiviruses, **34:203**
 poliovirus, **34:221, 225–227**
 positive-strand RNA viruses, **41:114,**
122, 158, 162, 171–172
 rotaviruses, **39:168–169**
 Killed antiviral vaccines, **39:255–259,**
283–284
 changes in virion immunogenicity,
39:273–274
 efficiency, **39:274–280**
 improvement, **39:281–283**
 specificity, **39:280–281**
 duration of agent action, **39:261–264**
 inactivating agents, **39:260–261**
 inactivation step, **39:259–260**
 kinetics of inactivation, **39:264**
 biology, **39:264–265**

chemistry, **39:265–272**
 Killer particles, evolution, **27:243–245**
 Kinetics, killed antiviral vaccines and
 biology, **39:264–265**
 changes in virion immunogenicity,
39:275–277
 chemistry, **39:265–272**
 duration of agent action, **39:262–263**
 Kinetin, **29:242**
 for callus tissue culture, **29:223**
 Klenow fragment, HIV structure and,
39:36–38
 Kuru, **29:3, 5, 10, 35:83–84**
 agents, resistance to irradiation, **29:12**
 and cannibalism, **29:13–15, 24**
 cause, **29:12**
 distribution, **29:12**
 duration of illness, **29:8**
 epidemiology, **29:13**
 incidence, **29:13**
 incubation periods, **29:7**
 natural host, **29:6**
 plaques, **29:10, 12, 21–22, 45**
 prions and, **41:242–243, 257**
 senile plaques, **29:22**

L

Laboratory animals, virus diagnosis in,
27:45–47
 Laboratory diagnosis, pestiviruses and,
41:83–87
 LaCrosse encephalitis virus
 disease characteristics and occurrence,
28:406–412
 transmission, **28:378**
 La Crosse virus, **40:237, 241, 256–258,**
260
 encephalitis induction
 in humans, **30:287–289**
 in newborn mice, **30:289–290**
 genome organization, **40:244, 248, 252**
 glycoproteins, **30:305–306**
 transmission, host role, **30:306–307,**
309
 β -Lactamase, hepadnavirus and, **34:116**
 Lactate dehydrogenase-elevating virus,
41:100–102, 180–182
 age-dependent poliomyelitis, **41:143–**
144

- Lactate dehydrogenase-elevating virus (*cont.*)
 age-dependent poliomyelitis (*cont.*)
 ecotropic proviral content, 41:141–143
 motor neuron infection, 41:126–129
 motor neuron protection, 41:134–141
 MuLV, 41:128–134
 pathology, 41:124–126
 equine arteritis virus and, 41:163–164, 167
 mice, 41:102, 123–124
 host immune responses, 41:117–123
 immune responses, 41:112–117
 pathology, 41:123
 virology, 41:102–112
 molecular properties
 structure, 41:144–145
 transmission, 41:154–155
 variants, 41:150–153
 virion RNA, 41:146–150
 simian hemorrhagic fever virus and, 41:178–180
- Lactoferrin, lentiviruses, 34:206
- Lactoperoxidase, lentiviruses, 34:194
- Lactuca saligna*, cucumber mosaic virus, 41:292, 314–315
- La France disease, 43:373–378
 dsRNA
 molecular characterization, 43:375–377
 packing, 43:377–378
 etiology, 43:378
- Laminin, 29:42
- Langerhans' cell, 42:212
- Large hepatitis B surface protein, 47:266–267
- Larynx
 carcinomas, human papillomavirus, 37:135
 papillomas, human papillomavirus, 37:134–135
- Latency, human herpesvirus 6 and, 41:29–30
- Latency of insect viruses
 activation of latent infections, 31:296–301
 field, 31:300–301
 laboratory
 chemicals, 31:298
 with foreign viruses, 31:298–300
 physical factors, 31:297
 rearing conditions, 31:297–298
 concept, 31:294–296
 host range, 31:301–307
 arthropod-borne animal viruses, 31:305–306
 arthropod-borne plant viruses, 31:306–307
 broad, 31:302–305
 cricket paralysis virus, 31:302–304
Drosophila C virus, 31:304–305
 honey bee viruses, 31:301–302
 restricted, 31:301–302
 vectors, 31:305–307
 and virus-like particles, 31:307–313
Drosophila virus, 31:311–313
 Nodamura virus, 31:307–309
 wasp viruses, 31:309–311
- Latent membrane protein, Epstein-Barr virus and, 40:34–40, 47
 EBNA-2, 40:29–32
 genome, 40:26
- Late viral genes, cucumber mosaic virus and, 41:328–329
- Latex agglutination test, ADRV, 35:215
- N*-Lauroylsarcosine, archaeobacterial viruses and, 34:180
- LB medium, 25:208
- LCMV, *see* Lymphocytic choriomeningitis virus
- Leader binding protein 1
 HSV-1-induced, 43:110
 role in HIV basal transcription, 43:63–65
- Leafhopper
 BCTV transmission, dicotyledonous plants, 30:144
 bean summer death virus and TobYDV transmission, 30:144
 cell culture
 AC20 cell line, 25:212–215
 established lines, 25:208–212
 media, 25:201–202
 chloris striate mosaic virus transmission, 30:143
 infection by wound tumor virus, 29:72–73, 89
 MSV transmission, 30:143
 tests with cells from, 25:232
- Leaf mold, biocontrol with satellite RNA, 39:336

- Lectins
 and bovine herpesvirus 1, **35:231**
 HEF glycoprotein of influenza C virus
 and, **40:223**
 HIV-1 and, **40:3**
- Legionellosis, **43:38**
- Legumes
 cucumber mosaic virus and, **41:335–336**
 plant viruses in developing countries
 and crop improvement, **41:360–361, 367, 371, 375**
 remedial action, **41:378, 395**
- Leishmania braziliensis*, **43:344–345**
- Lelystad virus disease, **43:46**
- Lens crystallin, **29:42**
- Lentiviruses, **34:189–191, 46:100**
 antigenic instability, **32:4, 29**
 HIV-1, **44:13–15**
 HIV structure and, **39:11, 50**
 structure
 molecular, **34:191–196**
 ultrastructure, **34:191**
 virus-host cell interaction *in vitro*
 biological parameters, **34:196–198**
 viral gene expression, **34:198–200**
 virus-host cell interaction *in vivo*
 clinical disease, **34:200–202**
 pathogenesis, **34:204–208**
 pathology, **34:202–203**
- Lentivirus infections, model system, *see*
 Feline immunodeficiency virus
- Lepidoptera, pesticide production and,
36:322, 325
- Lesions
 counting, improved method for,
25:253–254
 equine arteritis virus and, **41:156–157**
 influenza virus and, **34:268**
 lentiviruses and, **34:189–190**
 virus-host cell interaction *in vivo*,
34:202–206
 poliovirus and, **34:223, 225, 229, 231, 233**
- Lettuce
 cucumber mosaic virus, **41:336**
 plant viruses in developing countries,
41:359, 372–375, 383
- Lettuce big-vein virus, in developing
 countries, **41:359–360, 369**
- Lettuce infectious yellows virus
 genome organization and functions of
 gene products, **47:135–136**
 ribosomal frameshifting, **47:141–142**
- Lettuce mosaic virus, **33:239**
 diagnosis, with RIA, **29:162**
 immunization of mice, **29:133–136**
 MAb-determined antigenic properties,
29:153
 MAbs, **29:134**
- Leucine, influenza virus and, **34:264**
- Leukemia
 Epstein-Barr virus and, **40:33**
 human herpesvirus 6 and, **41:4, 33**
 lactate dehydrogenase-elevating virus
 and, **41:129, 140, 158**
- Leukocyte function, respiratory defense
 mechanisms and, **35:236**
- Leukocyte function-associated antigen 1,
 Epstein-Barr virus and, **40:36**
- Leukocyte function-associated antigen 3,
 Epstein-Barr virus and, **40:36**
- Leukocytes
 lentiviruses and, **34:190, 202**
 pestiviruses and, **41:57, 63–64**
 poliovirus and, **34:221**
- Leukoencephalomyelitis, lentiviruses
 and, **34:189–190, 202–203**
- Leukoencephalopathy, progressive multi-
 focal, **42:283–284**
- Leukopenia, pestiviruses and, **41:63, 66**
- Leviviridae, basic properties, **27:210**
- Life cycle
 bacteriophage $\phi 6$, **35:163–172**
 bacteriophage PRD1, **45:283**
 hepadnaviruses, **46:170–172**
 HIV, **43:59–61**
 parvovirus, early events, **33:137–139**
 parvoviruses
 DNA replication, **33:149–162**
 gene expression, **33:139–149**
 nonproductive virus-host cell interac-
 tion, **33:165–169**
 poliovirus, **46:6–14**
 rous sarcoma virus, **35:3–4**
 Semliki Forest virus, **45:115**
- Ligands
 animal cells and
 enveloped viruses, **36:117–119, 121–122**

- Ligands (*cont.*)
 animal cells and (*cont.*)
 receptors, **36:112**
 antiviral antibody affinity and,
34:283–284
 measurement
 direct, **34:297**
 relative, **34:306**
 Epstein-Barr virus and, **40:39–40**
 HIV structure and, **39:26, 46**
 prions and, **41:269–270**
- Light microscopy
 animal cells and, **36:132**
 furoviruses and, **36:10**
- Lilac chlorotic leafspot virus, **25:114–115**
- Lily symptomless virus, immunosorbent electron microscopy, **29:176**
- Linkage, cucumber mosaic virus and, **41:290**
- Linkage disequilibrium, prions and, **41:256**
- Lipase activity, membrane permeability modification, **45:75–76**
- LIP gene, **29:4**
- Lipid membrane, iridoviruses, **46:361, 368–370**
- Lipids
 animal cells and
 enveloped viruses, **36:132**
 membrane fusion, **36:127, 129**
 nonenveloped viruses, **36:137**
 receptors, **36:112**
 archaeobacterial viruses and, **34:144, 185**
Sulfolobus virus-like particle SSV1, **34:179**
Thermoproteus tenax, **34:173–174**
 Berne virus, **43:241**
 hepatitis A virus and, **39:222**
 hepatitis delta virus, **43:197**
 HIV structure and, **39:13–14, 21**
 influenza virus and, **34:252–253, 255–256**
 killed antiviral vaccines and, **39:260**
 neurodegenerative diseases caused by prions and, **41:243**
 oncovirus envelope, **25:453**
 pestiviruses and, **41:72, 83**
 Sindbis virus encephalitis and, **36:257**
 vaccinia and, **34:43**
- Lipopolysaccharide
 lactate dehydrogenase-elevating virus and, **41:117–118, 120**
 oral vaccination and, **41:415, 432, 435**
- Liposomes
 as antiviral drug carriers, **30:124–125**
 carrier-mediated drug delivery and, **35:295–298**
 immunomodulators, **35:303–305**
 vaccines, **35:300–301**
 prions and, **35:116–117**
 in protoplast inoculation with viral RNA, **29:239–241**
- Lissamine rhodamine B, **29:245**
- Listeria monocytogenes*, oral vaccination and, **41:414–415, 417**
- Little cherry disease, **25:117–118**
- Liver
 ASF, **35:261–262**
 hepadnavirus and, **34:135**
 mRNA transcription, **34:76**
 pre-S sequences, **34:97, 100–101**
 replication, **34:71**
 hepatitis C virus and, **40:60–61, 66**
 hepatitis E virus and, **40:86–87, 89–90**
 human herpesvirus 6 and, **41:31–32**
 lactate dehydrogenase-elevating virus and, **41:106, 108, 111, 121–122**
 lentiviruses and, **34:203**
 picornaviral genomes and, **40:148**
 poliovirus and, **34:221**
- Liver disease, hepatitis C virus and, **40:58–59**
- Liver tissue, virus detection in, **27:38–40**
- Localization
 cucumber mosaic virus and, **41:313–314, 318, 323, 325, 331**
 DNA replication and, **34:17–18**
 hepadnavirus and
 epitopes, **34:115, 118**
 pre-S sequences, **34:95, 97, 99**
 influenza virus and, **34:273**
 lactate dehydrogenase-elevating virus and, **41:106, 111–112**
 poliovirus and, **34:221**
 vaccinia and, **34:44, 58, 60**
- Long terminal repeats
 Ab-MLV, **35:50**
 avian retroviral, *see* Avian retroviral
 LTR
Drosophila retrotransposons, **36:92**

- insertional mutagenesis, **36:78**, 80–82, 84
 intracellular cycles, **36:65–66**
 organization, **36:47–55**
 scattered repetition, **36:39**
 transcription, **36:68**, 70, 74–76
 feline virus and, **35:53**
 HIV-1, **40:3–8**, 10, 13
 HIV structure, **39:51–52**, 54–56
 human herpesvirus 6 and, **41:18**, 35–36
 RSV, transcriptional interference and, **35:13–14**, 33
 Low-density lipoprotein, animal cells and, **36:119**
 L protein, **47:27**
 Bunyaviridae and, **40:236**, 238, 243–244
 RNA segment, Bunyaviridae and, **40:236**, 264
 genome organization, **40:243–244**, 261
 structure, **40:238–239**
 in vesicular stomatitis virus, **38:104–109**
 functional domains of, **38:108–109**
 primary structure, **38:105–108**
 role in transcription, **38:119–122**
 LT-B, oral vaccination and, **41:426–428**, 430
 LTR, *see* Long terminal repeats
 Lucerne transient streak virus, **33:216**
 LuIII
 infectious, generation during transducing virus production, **47:326**
 recombinant genomes, heterologous promoters, **47:328**
 transducing viruses
 titers, **47:323–325**
 transduction range, **47:329–330**
 LuIII–luciferase genome, pseudotyping, **47:330–332**
 LuIII–luciferase transducing virus
 genome encapsidation pattern study, **47:333**
 persistence of expression, **47:332**
 LuIII vectors, **47:321–322**
 Lung
 influenza virus effect, **34:268**
 lentiviruses effect, **34:205**
 poliovirus effect, **34:221**
 Lupinus, cucumber mosaic virus and, **41:335**
 Lupus erythematosus, **29:48**
 Luteovirus, **44:421–422**
 Luteo virus
 antibody production, **29:134–135**, 145
 MAB-determined antigenic properties, **29:151–152**
 Luteoviruses, **46:415–457**
 gene expression, **46:435–444**
 internal initiation of translation, **46:438–440**
 proteolysis and cap-independent translation, **46:443–444**
 readthrough, **46:442–443**
 subgenomic mRNA synthesis, **46:440–442**
 translational frameshifting, **46:435–438**
 gene function determination, **46:424–425**
 genome structure, **46:417–424**
 coding sequence and strain variations, **46:420–423**
 ORF arrangement, **46:417–420**
 putative recombination, **46:424**
 terminal structures and noncoding regions, **46:422–423**
 infection diagnosis, **46:450–452**
 ORFs 5 and 6, **46:431–434**
 P1 and P2 proteins, **46:427–428**
 particle structure, **46:444–448**
 epitope location, **46:445**
 heterologous encapsidation, **46:447–448**
 particle assembly determinants, **46:448**
 readthrough protein, **46:445–447**
 tertiary, **46:444–445**
 Plantago host and occurrence, **27:114**, 126
 P0 protein, **46:426–427**
 P3 protein, **46:428–429**
 P4 protein, **46:429–431**
 P5 protein, **46:431–434**, 445–447
 replication, **46:449–450**
 resistance, **46:452–453**
 subgroup II, replication proteins, **47:199**

- Luteoviruses (*cont.*)
 taxonomy
 barley yellow dwarf virus, satellite RNA, 46:456–457
 pea enation mosaic virus problem, 46:455–456
 speciation, 46:453–454
 ST9-associated satellite-like RNA, 46:456
 structure, 46:454
- Luxury functions
 definition, 31:358
 inhibition, 31:375–376
- Lycopersicon esculentum*, leaf protoplasts, virus infection, 29:227
- Lyme disease, 43:36–37
- Lymphadenopathy, human herpesvirus 6 and, 41:34–35
- Lymphadenopathy/AIDS virus, lentiviruses and, 34:189
- Lymph nodes
 ASF, 35:261–263
 hepadnavirus and, 34:112, 127
 lentiviruses and, 34:203
 poliovirus and, 34:220
- Lymphoblastoid cell lines
 from HVT-infected chicken, 30:257–258
 from MDV-infected chicken, 30:255–258
 antigens, 30:255, 257
 ultrastructure, 30:256
 from MVD-infected turkey, 30:257
- Lymphoblastoid cells
 Epstein-Barr virus and, 40:38, 45
 hepatitis C virus and, 40:60
- Lymphoblasts, Epstein-Barr virus, 40:29, 33, 47
- Lymphocystivirus*, classification, 46:351
- Lymphocyte function, viral infection, 35:230–232
- Lymphocytes, *see also* Cord blood lymphocytes; Peripheral blood lymphocytes
 activation in LCMV infection, 45:39–40
 B, *see* B cells
 cytotoxic
 killing mechanism, 45:23–26
 mediated DNA fragmentation, target susceptibility, 45:26–28
 defective interfering viruses and, 40:196
 DNA replication and, 34:29
 Epstein-Barr virus and, 40:20, 47–48
 EBNA-1, 40:41
 EBNA-2, 40:28, 32
 genome, 40:26
 latent membrane protein, 40:36
 target cell, 40:20–23
 hepadnavirus and, 34:98, 111, 127
 hepatitis C virus and, 40:78
 HIV-1 and, 40:1–2, 4, 9
 human herpesvirus 6 and
 biology, 41:32, 34
 discovery, 41:2–4
 growth properties, 41:7–14
 structure, 41:5, 7
 lactate dehydrogenase-elevating virus and
 age-dependent poliomyelitis, 41:139–141, 144
 mice, 41:115–116, 119–120
 lentiviruses and, 34:203–205, 208
 Moloney leukemia virus expression in, 26:76–77
 pestiviruses and, 41:58, 63, 67, 84–85
 polyclonal, virus-stimulated activation, 31:365–366
 programmed cell death, 45:32–34
 T, *see* T cells
- Lymphocytic choriomeningitis
 persistent infections, 26:38
 antiviral compound effect, 26:57–60
- Lymphocytic choriomeningitis virus,
 41:141, 47:353
 CD8⁺ T-cell-mediated immunopathology, 47:354–358
 model, T cell response, apoptosis, and immune deficiency, 45:38–44
 persistent infection, growth hormone deficiency syndrome, 46:324–333
 in persistently infected cells, 29:113
- Lymphocytic choriomeningitis virus-type species
 G1 and G2 proteins, 31:6
 gene products
 coding, 31:10–14
 comparison with Pichinde virus, 31:11
 GPC primary, 31:6
 infection of rodents, 31:9

- reassortants, genetically diploid, **31:10**
 reassortment, **31:10**
 relationship to other New World arenaviruses, **31:12**
- S RNA species
 ambisense coding arrangement, **31:10–18**
 intergenic region, inverted complementary sequence, **31:15–16**
 origin, **31:16–18**
- Lymphoid cells
 human herpesvirus 6 and, **41:2–3**
in vitro transformation system, Ab-MLV and, **35:44–45**
 lentiviruses and, **34:203**
- Lymphoid differentiation, Ab-MLV, **35:74**
 markers for, **35:58–60**
- Lymphoid tissues, poliovirus and, **34:220**
- Lymphoid transformation, Ab-MLV, **35:69**
- Lymphokines, as immunodilators, **35:241**
- Lymphoma
 human herpesvirus 6 and, **41:33–34**
 lactate dehydrogenase-elevating virus and, **41:129**
 pestiviruses and, **41:77**
- Lymphoprep, **29:222**
- Lymphoproliferative diseases, human herpesvirus 6 and, **41:33–34**
- Lysine, influenza virus and, **34:266, 268**
- Lysis
 archaeobacterial viruses and, **34:185**
Halobacterium phages, **34:167**
Halobacterium salinarium phage Hs1, **34:164**
Thermoproteus tenax, **34:172, 174**
 poliovirus and, **34:219, 226**
 PRD1, **45:314**
 virus-infected cells, by TNF- α , **45:28–30**
- Lysogens, archaeobacterial viruses and, **34:146, 185**
 gene expression, **34:160–162**
Halobacterium halobium, **34:153–158, 162**
Halobacterium phages, **34:166**
Thermoproteus tenax, **34:169, 173**
- Lysogeny, **29:298**
- Lysosomes
 animal cells and
 endocytosis, **36:118, 121–122**
 enveloped viruses, **36:131**
 nonenveloped viruses, **36:138**
 parvovirus virions and, **33:138**
 poliovirus and, **34:219**
 Lysozymes, hepadnavirus and, **34:115**
Lyssavirus, rabies viruses and, **36:240–245, 247–249**
- Lytic infection
 adenovirus and, **25:435**
 simian hemorrhagic fever virus and, **41:173–175**
- M**
- MAB, *see* Monoclonal antibodies
- Macerase, **29:219, 225**
- Macerocyme, **29:219–220, 222, 224**
 R-10, **29:220**
- Machlomovirus*, **44:420**
- Macroglobulin, HEF glycoprotein of influenza C virus and, **40:221**
- Macromolecular carriers, drug delivery and, **35:289–293**
- Macromolecules, co-entry into membranes, promotion by virus particles, **45:64–68**
- Macrophage activation effects, and antibody-dependent enhancement, **31:349–351**
- Macrophages
 ASF, **35:265**
 bacterial effects, **35:232–233**
 Epstein-Barr virus, **40:31**
 equine arteritis virus, **41:156**
 HIV-1, **40:1, 4**
 HIV expression in, **38:126**
 in hybridoma culture, **29:139**
 lactate dehydrogenase-elevating virus, **41:102, 155**
 age-dependent poliomyelitis, **41:125–128, 131, 133, 136–139, 143–144**
 mice, **41:104–113, 115–117, 119–121, 123–124**
 molecular properties, **41:146, 148, 152**
- lentiviruses
 virus-host cell interaction *in vitro*, **34:196–198**

- Macrophages (*cont.*)
 lentiviruses (*cont.*)
 virus-host cell interaction *in vivo*,
 34:202–203, 205–208
 oral vaccination, 41:415, 423–424, 430
 poliovirus, 34:221
 positive-strand RNA viruses, 41:180–
 182
 respiratory defense mechanisms,
 35:225–226
 response to bovine herpesvirus,
 45:210–211
 simian hemorrhagic fever virus,
 41:169–170, 175, 177–178
 Theiler's murine encephalomyelitis vi-
 rus and, 39:297, 299–301, 303
 viral effects, 35:227–230
- Macula adherers, 42:192
- Mad cow disease, *see* Bovine spongiform
 encephalopathy
- Madin–Darby canine kidney cells,
 36:116, 123, 42:195–196
 biochemical and immunoelectron mi-
 croscopic studies, 42:206–207
 influenza virus and, 34:259, 262, 271–
 272
- Maedi virus, lentiviruses and, 34:189–
 191
 structure, 34:191, 194
 virus-host cell interaction *in vitro*,
 34:196–197
 virus-host cell interaction *in vivo*,
 34:200–202, 204–208
- Magnesium
 archaeobacterial viruses and, 34:147,
 163, 165
 cucumber mosaic virus and, 41:288,
 313
 lentiviruses and, 34:194
- Maguari virus, 40:262
- Maize, plant viruses in developing coun-
 tries and, 41:355–356, 366, 368
- Maize chlorotic mottle virus, 44:420
 immunosorbent electron microscopy,
 29:179
- Maize dwarf mosaic virus
 diagnosis with RIA, 29:162
 immunization of mice, 29:133–136
 MAb-determined antigenic properties,
 29:153
 MAbs, 29:134
- Maize rough dwarf virus
 immunosorbent electron microscopy,
 29:187
 sequence, 45:267
- Maize streak virus
 Cicadulina spp. as vector, 30:143
 coat protein, 30:161–162
 genomic DNA
 coding and intergenic regions,
 30:160–163
 nucleotide sequence, 30:160–161,
 163
 small encapsicated fragment,
 30:163–164
 specific properties, 30:172–173
 properties, 30:144
- Major histocompatibility complex
 animal cells and, 36:113, 116, 131
 class II, 47:360–361
 interaction with CD4, 44:212
 D1 and D2 domains, 44:214–217
 class I proteins, interferon-induced an-
 tiviral actions, 42:88–90
 expression, 42:257–259, 294
 lentiviruses and, 34:205
 oral vaccination and, 41:411–412, 415–
 417, 422
 Theiler's murine encephalomyelitis vi-
 rus and, 39:304–305, 307
- Major late promoter
 adenovirus and, 39:90, 100–103
 in *trans*-activation of transcription,
 37:47–48
- Malang Research Institute for Food
 Crops, plant viruses in developing
 countries and, 41:379
- Malaria, 43:41–42
 vaccinia and, 34:61
- Malate dehydrogenase, lactate dehy-
 drogenase-elevating virus and,
 41:107, 109
- Mammalian cell, adenovirus, gene ex-
 pression and, 25:357–360
- Mammalian cells, RSV-infected, 35:26–
 27
- Mammalian type C virus
 cross-reactivity with M-PMV, 25:472
 envelope, antigenic properties, 25:466
- Mammals, virus persistence in, 26:42–
 47
- Mammary gland, lentiviruses, 34:203

- Mannose**
 Bunyaviridae and, **40:261**
 HEF glycoprotein of influenza C virus and, **40:216**
 hepadnavirus and, **34:91**
 human herpesvirus 6 and, **41:21**
- Mapping**
 cucumber mosaic virus, **41:284, 293, 313–315, 328, 338**
 equine arteritis virus, **41:165**
 gene, vaccinia and, **34:45–48**
 hepatitis A virus, **39:223, 242**
 HIV structure, **39:23, 46–48**
 human herpesvirus 6, **41:19**
 rotaviruses, **39:178–180, 184–186, 196**
 Theiler's murine encephalomyelitis virus, **39:313**
 topological, *see* Topological mapping, flavivirus epitopes
- Marburg hemorrhagic fever, 47:2–7**
Marburg virus, characteristics, 47:15
Marek's associated tumor surface antigen, MAbs, 29:101
- Marek's disease, chicken**
 caused by MDV, **30:225–226**
 control by
 HVT vaccine, **30:226**
 MDV serotype vaccines, **30:266–270**
 lymphoblastoid cell lines, **30:255–266**
 lymphoma cells, in MDV vaccinal immunity, **30:267–268**
- Marek's disease herpesvirus, 41:17**
Marek's disease virus, 29:101, 113
 in cultured cells, **30:251–254**
 genomic DNA
 comparison with DNA
 EBV, **30:235–237**
 HVT, **30:234–237**
 latent in lymphoblastoid cell lines
 antigen induction, **30:262, 264–266**
 location in cell chromosomes, **30:261–263**
 structure and properties, **30:260–261**
 transcription, **30:264**
 MDV I serotype, oncogenicity-related fragments
 enzyme-cleavage pattern, **30:237–239**
 nucleotide sequences, **30:239–240**
 physical map, **30:232–233**
 physicochemical properties, **30:229, 231**
 purification, **30:227, 229**
 three serotypes, homology, **30:233–237**
 ultrastructure, **30:230–231**
- Marek's disease induction, chicken, 30:225–226**
 specific antigens and proteins, **30:241–244, 249–251**
 glycoprotein A, **30:244–248**
 glycoprotein B, **30:248–249**
 nuclear antigen, **30:250**
 temperature-sensitive mutants, **30:254–255**
 vaccines, immune reaction induction, **30:266–270**
 virion structure, **30:226–229**
- Mastitis, lentiviruses and, 34:190, 202–203**
- Matrix protein**
 HIV structure and, **39:18, 21–24**
 Paramyxoviridae and, **39:132–133, 140**
- Matrix protein antigen, influenza virus, 31:89–90**
- Maturation**
 flavivirus, **33:77–78**
 parvovirus virions, **33:163, 165**
- Mayvill cellulase, 29:220**
MB medium, 25:202–207
M cells, 42:210, 220–221, 224–225
MDV, *see* Marek's disease virus
- Measles, subacute sclerosing panencephalitis virus and, 26:72–74, 108**
Measles virus, 29:112, 114, 39:133–134, 150
 antibody production, **29:96–97**
 defective interfering viruses and, **40:193**
 detection of structural change, **29:118**
 formalin-inactivated vaccine, immunopathology, **32:7, 14–15**
 genome organization, **39:137–138, 140**
 hemagglutinin, **29:118**
 MAB groups, **29:107, 109**
 H protein, maturation, **29:115**
 matrix protein, **29:113**
 penetration, inhibition by synthetic oligopeptides, **30:86–87**

- Measles virus (*cont.*)
 persistence, leading to SSPE, **29:120–121**
 in persistently infected cells, **29:113**
 transcription, **39:141–142, 144, 146–149**
 unusual composite protein, **29:114**
- Medicago*, protoplast culture, **29:243**
- Medicago polymorpha*, cucumber mosaic virus and, **41:335**
- Meicelase P, **29:219**
- Melanesia, HTLV-I, **47:391, 394–395**
- Melanocytes, **42:212**
- Membrane fusion
 animal cells and, **36:108–109, 130, 139**
 fusion proteins, **36:123–126**
 influenza HA, **36:126–129**
 macromolecule transport, **36:110**
 HEF glycoprotein of influenza C virus and, **40:226–228**
- Membrane permeability, modification by
 animal viruses, **45:61–103**
 enhanced permeability to other compounds, **45:74–75**
 late, mechanism, **45:70–75**
 lytic proteins, from bacteriophages, **45:98–101**
- modification
 divalent cations and pH, **45:73–74**
 lipase activity, **45:75–77**
 monovalent cations and membrane potential, **45:71–73**
 nonviral lytic proteins, from natural sources, **45:101–102**
 vesicular traffic in cells infected with animal viruses, **45:77–78**
- virus entry
 macromolecule co-entry, **45:64–68**
 mechanisms, **45:63–64**
 proton motive model, **45:68–70**
- Membrane potential
 in alphaviruses, fusion and, **38:386**
 monovalent cations and, **45:71–73**
- Membrane protein, **28:180**
- Membranes
 bacteriophage $\phi 6$, **35:144–146, 168–172**
 flavivirus proteins, **33:61–62**
 influenza virus M2 protein ionic pore formation, **45:86–89**
 macromolecular co-entry, **45:64–68**
 mucous, viral-lesion diagnosis, **27:21–23**
 prion infectivity, **35:116, 122–123**
- Memory, oral vaccination and, **41:411–412**
- Memory T-lymphocyte responses, varicella-zoster virus, **46:285–286, 290–300**
 natural infection, **46:291–296**
 varicella vaccine, **46:296–300**
- Mengo virus, **39:293, 311**
- IF phosphorylation, **33:197**
- picornaviral genomes and, **40:106, 133–134, 161**
 replication, interferon-induced inhibition, **38:185–186**
- Meninges, Ab-MLV and, **35:43**
- Meningitis
 lentiviruses and, **34:202–203**
 Oropouche virus infection, **30:296**
- 2-Mercaptoethanol, Ab-MLV and, **35:45**
- Merkel cells, **42:212**
- Messenger RNA
 adenovirus, **39:99–101, 103**
 biogenesis, **26:1–35**
 stability of formation, **31:216–218**
 transcription
 activation of expression of late genes, **31:199–204**
 control signals, **31:179–187**
 E1A protein-mediated activation of, **31:188–195**
 early, repression of, **31:195–199**
 early to late transition, **31:199–204**
 pre-early to early transition, **31:188–195**
 regulation, **31:170–204**
 units, **31:170–179**
 transcript processing regulation, **31:204–211**
 transport from nucleus to cytoplasm, regulation, **31:211–216**
- adenovirus genomic map
 intermediate mRNA, **25:380–382**
 late mRNA, **25:384–388**
- archaeobacterial viruses and, **34:181**
- avian leukosis virus and, **35:24**
- avian retroviral
c-myc, **30:207–209**
 polyadenylation, **30:204–205**

- Bunyaviridae, **40:263**
 genome organization, **40:244, 252**
 replication, **40:255–259**
 structure, **40:239**
 cap structure, **25:23–25**
 and cellular mRNA, translation in virus infected cells, **31:244–265**
 adenovirus-infected cells, **31:262–265**
 competition between early and late viral mRNAs, **31:255–256**
 mechanisms mediating switch from host to viral protein synthesis, **31:251–252**
 by mRNA abundance, **31:253–254**
 poliovirus-infected cells, and p200, **31:256–262**
 cleavage and early inhibition of host protein synthesis, **31:257–259**
 cleavage and eIF-3 inactivation, **31:260–261**
 as essential subunit of cap binding factor, **31:259–260**
 shutoff of host protein synthesis by animal viruses, characteristics, **31:247–249**
 by viral mRNA efficient translation, **31:254–255**
 C-mRNA, hepatitis B virus transcription, **47:259–260**
 codon usage, **31:272**
 coronavirus, **47:231**
 coupling of transcription, transport, and translation, **31:269–271**
 cucumber mosaic virus and, **41:286, 297, 306, 329**
 defective interfering viruses and, **40:188, 198**
 destructive modes of regulation, **31:271–272**
 DNA replication and
 bovine papilloma virus, **34:21–22, 26**
 SV40, **34:17**
 EGFR-specific in A431 cells, **32:119**
 Epstein-Barr virus, **40:24, 26, 31–32, 41**
 eukaryotic
 cap binding proteins of, **33:176**
 CBP complex role, **33:180–182**
 eIF-4A component of CBP complex
 role, **33:182–184**
 identification of CBPs, **33:177–178**
 structural complexity of CBPs, **33:179–180**
 translation initiation signals, **25:25–29**
 flavivirus, **33:52–53**
 FV3, transcription
 host RNA polymerase II and, **30:13–14**
 methylation, **30:14**
 virion proteins and, **30:14–15**
 genomic and subgenomic, hepadnaviral transcripts, **46:173–174**
 hepadnavirus and
 characterization, **34:78**
 pre-S sequences, **34:99–100, 102, 104**
 transcription, **34:75–78**
 HIV-1, **40:2–3, 5–6, 8–11**
 HIV structure, **39:15–16, 53**
 host, CBP complex role in shutoff of translation by poliovirus infection
 criticism of model, **33:191**
 early studies, **33:184–185**
 inactivation of CBP complex by infection, **33:185–187**
 mechanism of inactivation, **33:187–188**
 poliovirus mediation of p220 cleavage, **33:188–191**
 in HSV replication, **37:90–92, 112–113**
 human herpesvirus 6 and, **41:10, 36**
 lentiviruses and, **34:199–200**
 methylated and blocked 5' end of, **25:23–25**
 methylation and stability, **46:380–381**
 N, Bunyaviridae, **40:259**
 neurodegenerative diseases caused by prions and, **41:244, 250, 270**
 Paramyxoviridae, **39:132–135**
 genome organization, **39:135–138, 140–141**
 genome replication, **39:150–151**
 transcription, **39:142, 144–148**
 picornaviral genomes
 cis-acting elements, **40:114–115, 118–119, 126, 128**
 properties, **40:143–151**
 structure, **40:106–107**
 trans-acting factors, **40:129–133, 135**

- Messenger RNA (*cont.*)
- poliovirus, translation, 33:184–185, 46:6
 - polycistronic, continuous translation of, 25:11–12
 - positive-strand RNA viruses and, 41:100–101
 - common properties, 41:180–181
 - equine arteritis virus, 41:164–168
 - lactate dehydrogenase-elevating virus, 41:146
 - prions, 35:109–111
 - reinitiation and related phenomena, 31:265–269
 - secondary structure, translation, 33:180, 182, 184, 191
 - subgenomic synthesis, luteoviruses, 46:440–442
 - terminal sequences, peculiarities of, 25:18–20
 - 3'-terminus, poly(A) sequences at, 25:18–20
 - +RNA-like structures at, 25:20–23
 - Theiler's murine encephalomyelitis virus, 39:293–294, 301–302
 - translational suppression by retroviruses and, 41:194, 196
 - readthrough suppression, 41:197–201, 203–206, 209
 - ribosomal frameshifting, 41:210, 230
 - translation initiation site in, 25:25–29
 - 5' terminal cap and, 25:32–35
 - influence in, 25:32–35
 - translation regulation, 31:230–244
 - frameshifting during elongation, 31:243–244
 - initiation at other-than-AUG codons, 31:239–241
 - leaky scanning, 31:238–239
 - monocistronic nature of, 31:235–237
 - reinitiation, 31:241–243
 - suppression of terminator codon, 31:244
 - synthesis of more than one protein, mechanisms, 31:237–244
- vaccinia and
- genome, 34:46
 - vector, 34:55–57
- viral
- competition with host mRNA, 33:193
 - degradation by 2'-5'A analogs, 30:121
 - X-mRNA, hepatitis B virus transcription, 47:261
- Metal ions, necessary for DNA polymerase activity, PRD1, 45:305
- Metallothionein, Epstein-Barr virus and, 40:34
- Methanobrexibacter smithii*, archaeobacterial viruses and, 34:168
- Methanogens, archaeobacterial viruses and, 34:144–146, 168, 184
- Methionine
- archaeobacterial viruses and, 34:181
 - deprivation, replication of Sindbis virus in mosquito and, 33:339–343, 358, 362
 - hepadnavirus and, 34:86
 - vaccinia and, 34:58
- Methotrexate, hepadnavirus and, 34:103
- Methoxymethyl-2'-deoxyuridine, antiviral activity, 30:103–104
- N*-Methyl-D-aspartate receptor, rabies virus, 42:404–406
- Methylation
- adenovirus, 39:93–95
 - eukaryotic promoters, 39:122–123
 - oncodna viruses, 39:104–110
 - promoter inactivation, 39:123–124
 - reversal of promoter inhibition, 39:117–119
 - sequence specificity, 39:111–114
 - spreading, 39:119–122
 - in vitro* methylation, 39:114–117
 - archaeobacterial viruses, 34:163
 - DNA
 - iridoviruses, 46:376–377
 - role in HIV expression inhibition, 43:118–119
 - transcription, 46:380
 - and DNA replication, 34:24
 - mRNA, 46:380–381
 - Paramyxoviridae, 39:145
 - RSV RNA, 35:14–17
 - vaccinia, 34:44
- Methylation enzymes, positive-stranded RNA viruses, 47:187–190
- Methyl daunosamine, antiviral activity, 30:114–115
- 5-Methyldeoxycytidine, adenovirus and, 39:94, 115, 123

- Methylglyoxal bis(guanylhydrazone), human cytomegalovirus inhibition, **30:110–111**
polyamine biosynthesis and, **30:110**
- MGM-401 medium, **25:207**
- MHC, *see* Major histocompatibility complex
- MHV, GP-1, **29:106**
- Microencapsulation
for drug delivery, **35:301–302**
immunodilators and, **35:301–302**
vaccines and, **35:298–299**
- Microfilaments, cytoskeletal manipulation, iridoviruses, **46:384**
- Microglial cells, **42:255**
perivascular, **42:257–258**
- β_2 -Microglobulin, cytomegalovirus-binding, **36:116**
- Microtubule-associated proteins, Paramyxoviridae and, **39:152**
- Microtubules
cytoskeletal manipulation, **46:383–384**
furoviruses, **36:10–11**
- Microviridae, basic properties, **27:210**
- Middle East, HTLV-I occurrence, **47:400–401**
- Midge, bunyavirus transmission, Australia, **30:284, 286, 307–308**
- Mineralization, lentiviruses and, **34:201**
- Mineral oils, for reducing nonpersistent virus spread, **31:420–421**
- Minichromosomes, DNA replication and, **34:10, 16**
- Mini virus, insect, **25:315**
serological properties, **25:342**
- Mink
kuru, **29:7**
scrapie, **29:7–9**
transmissible mink encephalopathy, **29:6–9**
- Mink enteritis virus, **38:403–441**, *see also* Parvoviruses
antigenic variation, **38:423–424**
historical background, **38:405–406**
- Minute virus of mice vectors, **47:321, 323**
transduction range, **47:329–330**
- Mitigator element, adenovirus and, **39:101–102**
- Mitochondria
Paramyxoviridae, **39:144**
picornaviral genomes, **40:148–149**
- Mitogen
Epstein-Barr virus, **40:21**
lentiviruses, **34:204**
- Mitomycin C, **29:282, 299**
- Mobile dispersed genes, *Drosophila* retrotransposons and, **36:34, 92–93, 95**
insertional mutagenesis, **36:65, 67**
organization, **36:47, 52**
scattered repetition, **36:37–38, 41, 43, 45**
transcription, **36:70–71, 74**
- Model systems, development, **45:225**
- Modernization, agricultural, *see* Plant viruses in developing countries
- Modified Wecker test, picornaviruses and, **36:158–159**
- Molecular cloning
Ab-MLV, **35:50–51**
ADRV, **35:207**
bacteriophage $\phi 6$, **35:153–157**
- Moloney leukemia virus, **35:41–42**
Ab-MLV and, **35:50–51**
protein expression in, **35:46–47**
selective expression in lymphocytes, **26:76–77**
in vitro transformation of lymphoid cells, **35:44–45**
- Moloney murine leukemia virus, **46:333**, *see also* Retroviruses
DNA structure, **32:38–39, 41**
genes and gene products
env, **32:51**
gag, **32:50–51, 71–72**
pol, **32:50–51, 71–72**
genomic RNA organization, **32:38**
protein distribution, **29:115–116**
reverse transcription, **32:37, 39–41**
translational suppression by retroviruses, **41:198, 200–201, 204–205, 208**
- Moloney murine lymphoma virus, *Drosophila* retrotransposons and, **36:56–59**
- Moloney sarcoma virus, hepadnavirus and, **34:102**
- MoMLV, *see* Moloney murine leukemia virus
- Monensin, Bunyaviridae and, **40:261**
- Monkey
Creutzfeldt-Jakob disease, **29:7–8, 11**
kuru, **29:7–8**

- Monkey (*cont.*)**
 scrapie, **29:7-9**
 simian hemorrhagic fever virus and,
 see Simian hemorrhagic fever vi-
 rus
 transmissible mink encephalopathy,
 29:7-9
- Monoclonal antibodies, 29:193**
 ADRV and, **35:207-208**
 in affinity columns, **29:118**
 analysis of epitope find structure,
 29:165
 in tobacco mosaic virus, **29:155-160**
 animal cells and, **36:133**
 antiviral antibody affinity and, **34:285,**
 308
 measurement
 direct, **34:295-298, 301**
 relative, **34:303-306**
 in antiviral drug targeting, **30:125**
 assays, **29:164**
 avidity, determination, **29:109**
 binding, monitoring, **29:104**
 binding group analysis for structure,
 29:110
 bunyaviral glycoprotein neutralization,
 30:305-306
 Bunyaviridae and, **40:245**
 carrier-mediated delivery of antiviral
 agents and, **35:294**
 characterization, **29:146-149**
 in characterization of protein structure
 and function, **29:105-112**
 cocktail, **29:163-164**
 competitive binding, **29:108-109**
 relative interference efficiencies,
 29:109
 steric effects, **29:108-109**
 correlation of binding sites with pro-
 tein structure, **29:108-112**
 cross reactions, **29:122-123, 164-**
 165
 cucumber mosaic virus and, **41:291,**
 293, 295
 cytotoxicity with, **29:122**
 in definition of virus-specific protein,
 29:105-118
 dengue 2 virus
 infection-enhancing titers, **31:156**
 -specific, characteristics, **31:145**
 in diagnostic virology, **29:100-102**
 in differentiation of active areas on
 protein, **29:106-108**
 DNA replication and, **34:18**
 enhancement of virus infection, **29:121**
 epitope, structure-dependent function,
 29:158-159
 flavivirus epitopes
 binding assays, **31:129-134**
 cooperative effects between, **31:128-**
 137
 functional assays, **31:134-137**
 HEF glycoprotein of influenza C virus
 and, **40:220, 229**
 hepadnavirus and
 characterization, **34:89-90**
 diagnosis, **34:129**
 epitopes, **34:120**
 pre-S sequences, **34:110**
 hepatitis A virus and, **39:224, 228,**
 230
 hepatitis C virus and, **40:60, 78**
 heterospecific, screening for, **29:145**
 HIV structure and, **39:23, 34, 48, 66**
 human herpesvirus 6 and, **41:3**
 biology, **41:26-27, 32**
 growth properties, **41:9-12**
 molecular biology, **41:19, 21, 23**
 identification
 functional protein, **29:106**
 virus, **29:99-104**
 limitations, **29:104**
 immunoglobulin isotype, determina-
 tion, **29:148-149**
 immunological techniques applied to,
 29:96-99
 immunoprecipitation, detergent condi-
 tions, **29:97, 99**
 investigation
 protein synthesis in persistently in-
 fected and transformed cells,
 29:112-115
 viral protein processing and matura-
 tion, **29:115-118**
 viruses, **29:95-130**
 virus pathogenesis, **29:119-121**
 Japanese encephalitis virus, neutraliz-
 ing activities, **31:136**
 lactate dehydrogenase-elevating virus
 and, **41:112, 114-115, 119, 138-**
 139
 lentiviruses and, **34:193, 195**

- neutralizing, virus attenuation and, 32:19–20
- nomenclature, 29:149
- Paramyxoviridae and, 39:133–134
- parvoviruses, 33:105–106, 38:419–423
- pestiviruses, 41:84–86, 88, 47:65–66
- bovine viral diarrhea virus, 41:61
 - properties, 41:74–75, 79–80
- picornaviruses and, 36:158, 168, 260
- against plant viruses, 29:131–168
- application to virus diagnosis, 29:161–165
 - production, 29:133–134
 - properties desired, 29:163
- poliovirus and, 34:222, 237, 243
- potyvirus coat protein and, 36:301–303
- as probes for virus protein expression, 29:112–118
- production, 29:96–97
- large scale, 29:145–146
- protective effects, 29:119, 121–122
- purification, 29:146
- rabies viruses, 36:217
- Africa, 36:240–243
 - Asia, 36:250
 - Europe, 36:238–240
 - North America, 36:223–225, 227–229, 232–236
- reaction with novel virus proteins, 29:114–115
- recognition
- HVT-specific antigens, 30:241–251
 - MDV-specific antigens, 30:241–251
 - in lymphoblastoid cell lines, 30:264–265
- rotaviruses and, 39:168, 182–184, 186
- neutralization, 36:183–187, 192–202
 - protection, 36:189–191
 - surface proteins, 36:202–204
- in serology, 29:123
- Sindbis virus encephalitis and, 36:259, 266
- specific for p15E, 29:106
- specificity, 29:97–99, 122–123, 164–165
- assay, 29:164
 - determination of, 29:147–148
- St. Louis encephalitis virus, 31:146
- Theiler's murine encephalomyelitis virus and, 39:308–311
- therapeutic uses, 29:121–122
- in vaccine preparation, 29:122
 - in viral epidemiology, 29:102–104
 - in viral taxonomy, 29:102–104
 - for virus diagnosis, 29:161–164
 - advantages, 29:165
 - yellow fever type-specific, 31:119, 155
- Monocytes
- Epstein-Barr virus and, 40:31–32
 - HIV-1 and, 40:1–2
 - lactate dehydrogenase-elevating virus and, 41:104, 133
- lentiviruses and
- virus-host cell interaction *in vitro*, 34:196–197
 - virus-host cell interaction *in vivo*, 34:207–208
- pestiviruses and, 41:64
- Mononucleosis, infectious, *see* Infectious mononucleosis
- Monopartite virus, 25:10
- Morbidity
- pestiviruses, 41:58
 - positive-strand RNA viruses, 41:156, 170
- Morbilliviruses, 29:102, 39:131
- genome organization, 39:135, 137–138, 140
 - transcription, 39:147, 149
- Morphogenesis
- Bunyaviridae, 40:236, 260–262
 - pestiviruses, 41:72
 - rotaviruses, 39:176
 - vaccinia, 34:47
 - viral infections, 33:238–239
- Morphology
- archaeobacterial viruses, 34:184
 - Halobacterium halobium*, 34:162
 - Halobacterium* phages, 34:164, 167
 - Methanobrexibacter smithii*, 34:168
 - Sulfolobus* virus-like particle SSV1, 34:179
 - Thermoproteus tenax*, 34:171–172, 174
- Bunyaviridae, 40:237–242
- cucumber mosaic virus, 41:284, 288, 323
- hepatitis A virus, 39:227
- lentiviruses, 34:198
- parvoviruses, 33:96–97
- pestiviruses, 41:53, 90

- Morphology** (*cont.*)
 positive-strand RNA viruses, 41:100,
 155, 168, 181
 rotaviruses, 39:164, 192
 vaccinia, 34:55
 viruses, 27:2–14
 variation, 27:14
- Mortality**
 pestiviruses and, 41:58, 68
 positive-strand RNA viruses and,
 41:156, 170
- Mosaics, viral infection and, 33:236–238**
- Mosquito**
 arbovirus transmission, 37:277–279
 bunyavirus transmission, 30:281–285,
 307–309
 EEE virus transmission, 37:287–298
 and encephalitis incidence, 28:357–438
 iridoviruses transmission, 46:393
 malaria transmission, 43:41–42
 spread of diseases
 Akabane disease, 43:19
 dengue, 43:14–16
 Rift Valley fever, 43:16–17
 Venezuelan equine encephalitis,
 43:17
 yellow fever, 43:16
 togavirus-infected cell cultures, *see*
 Togaviruses
 virus multiplication in, 33:329
- Mosquito cells**
 Bunyaviridae and, 40:258, 262–263
 replication of Sindbis virus in, 33:331–
 332
 virus production in, vertebrate and,
 38:370–371
- Motor neurons, lactate dehydrogenase-el-
 evating virus and, 41:102**
 age-dependent poliomyelitis, 41:124–
 143
 molecular properties, 41:151–152
- Mouse**
 AIDS-like symptoms, 41:119, 121–
 122
 Creutzfeldt-Jakob disease, 29:7–8, 11,
 23
 hepatitis delta virus-infected, 43:192–
 193
 immunization, with plant viruses,
 29:133–137
 kuru, 29:7
 lactate dehydrogenase-elevating virus
 and, 41:102–124
 modulation of prion diseases by gene
 in MHC, 29:21
 scrapie, 29:2–3, 7–9, 11, 21–23, 43
 genetic loci controlling, 29:4
 pathogenesis, 29:18–19
 transgenic, neurodegenerative diseases
 caused by prions and, 41:259, 261–
 267, 269–270
 Mouse cells, transformation by chicken-
 pox virus, 28:312–313
 Mouse hepatitis virus, 42:222–223, 261–
 265
 autoimmune T cell reactions, 42:265
 demyelination, 42:263
 equine arteritis virus and, 41:167
 immune response, 42:264
 JHM strain, 42:293
 lactate dehydrogenase-elevating virus
 and, 41:104–105, 111, 117, 149
 MAb-resistant variants, 42:262
 pathogenesis and host genes, 42:263–
 264
 remyelination, 42:264
 sequences required for subgenomic
 RNA synthesis, 47:231–232
 sequencing studies, 42:263
 strains, 42:261–262
 3'-terminal structure, 47:221–222
 transduction range, 47:329–330
 Mouse intracisternal A-particle, transla-
 tional suppression by retroviruses
 and, 41:211, 214
 Mouse mammary tumor virus
 animal cells and, 36:135
Drosophila retrotransposons and
 insertional mutagenesis, 36:80, 86
 intracellular cycles, 36:60
 transcription, 36:67, 69, 75
 furoviruses and, 36:19
 hormonally regulated transcription of,
 26:81–84
 rotaviruses and, 36:195
 translational suppression by retro-
 viruses and, 41:197, 212, 217, 219–
 221, 224, 229–230
 M protein
 Bunyaviridae and, 40:238
 defective interfering viruses and,
 40:191

- flaviviruses, **33:50**
- MSV, *see* Maize streak virus
- Mucosal-associated lymphoid tissue, oral vaccination and, **41:410**
- Mucosal disease, **47:53**, **56–57**
development, **47:96–97**
induction, DI particle role, **47:93–94**
pestiviruses and, **41:82**, **89**
bovine viral diarrhea virus, **41:58**, **60–61**, **65**
comparisons, **41:69**, **71**
- Mucous membranes, viral-lesion diagnosis on, **27:21–23**
- Mucus, in respiratory tract, **35:221**
- Mule deer, chronic wasting disease in, **29:6**, **9**
- Multipartite genome, **25:10**
- Multiple sclerosis, **29:47**, **39:292**, **42:286**, **47:359**, **367**
linked to rubella virus, **44:75–76**
- Multiplicity of infection
lactate dehydrogenase-elevating virus and, **41:104**
rotaviruses and, **39:177**, **186**
- Mumps virus, **39:132–133**
formalin-inactivated vaccine, immunopathology, **32:15**
genome organization, **39:135–136**, **138**, **140**
transcription, **39:142**, **144**, **148**
- Muramyl tripeptide dipalmitoyl-phosphatidylethanolamine, **35:303–304**
- Murine cytomegalovirus, as model system, **46:237–238**
- Murine hepatitis virus, animal cells and, **36:116**
- Murine leukemia virus, **44:208–210**
antiviral antibody affinity and, **34:303**
defective interfering viruses and, **40:196**
gp 70, structural analysis, **29:111**
HIV structure and, **39:18–19**, **28**, **30**
influenza virus and, **34:270**
lactate dehydrogenase-elevating virus and
age-dependent poliomyelitis, **41:125**, **128–135**, **137**, **139**, **141**, **143**
mice, **41:121–122**
translational suppression by retroviruses and, **41:197**, **200–205**, **207–210**
- Murine type C virus, envelope, antigenic properties, **25:466–471**
- Murray Valley encephalitis, disease characteristics and occurrence, **28:383–385**
- Mushroom, La France disease, **43:373–378**
- Mutagenesis, *see also* Insertional mutagenesis
cucumber mosaic virus and, **41:324**
Drosophila retrotransposons and, **36:77–78**
excess function, **36:84–85**
interference, **36:85–86**
loss of function, **36:78–84**
overproduction, **36:85**
phenotype, **36:87**
scattered repetition, **36:38**, **45**
suppression, **36:87–91**
- effects on plant viral properties specifying symptom type, **33:208–211**
- hepatitis A virus and, **39:246–247**
- HIV structure and, **39:31–32**, **40**, **47**, **51**
- oral vaccination and, **41:433**, **436**
- poliovirus and, **34:241**
- rotaviruses and, **39:197**
- translational suppression by retroviruses and, **41:205**, **218–220**, **225**, **231**, **233**
- vaccinia and, **34:49**
- Mutagens, viruses as, **31:363–365**
- Mutants
Ab-MLV and, **35:72–74**
protein tyrosine kinase-conserved region, **35:73–74**
bacteriophage $\phi 6$ and, **35:151–153**
Bunyaviridae and, **40:251**, **260**
defective interfering viruses and, **40:181–183**, **185–188**
animals and humans, **40:191**, **195**, **198**
plants, **40:204**
deletion, recombination among, **43:296–298**
- Epstein-Barr virus and, **40:46–47**
EBNA-2, **40:28**
genome, **40:26**
latent membrane protein, **40:36–39**
target cell, **40:21–22**

Mutants (*cont.*)

- HEF glycoprotein of influenza C virus and, 40:220, 225–226
 - hepatitis E virus and, 40:94
 - HIV-1 and, 40:6, 9, 12
 - nonsense, PRD1, 45:289–290
 - parvovirus
 - frameshift, 33:148
 - host-range, 33:167–168
 - picornaviral genomes and, 40:107
 - cis-acting elements, 40:117, 120, 122–124, 127
 - mRNAs, 40:150
 - phenotype, 40:154–158
 - RNA replication, 40:152–153
 - structure, 40:107, 110, 113
 - trans-acting factors, 40:132–133, 135–138
 - translation initiation, 40:141, 143
 - poliovirus, protease and, 33:189–190
 - temperature-sensitive
 - flavivirus, 33:80–81
 - HVT, 30:254–255
 - MDV, 30:254–255
- Mutations
- adenovirus and, 39:92, 103
 - animal cells and, 36:116, 125, 133
 - archaeobacterial viruses and, 34:154–155
 - cucumber mosaic virus and, 41:337
 - deletion, plant viruses, 25:219
 - DNA replication and
 - adenovirus, 34:5, 8
 - bovine papilloma virus, 34:24–29
 - SV40, 34:12–13, 16, 18–19
 - Drosophila* retrotransposons and, 36:34, 91–93, 96
 - intracellular cycles, 36:60, 62
 - scattered repetition, 36:36, 39–40, 42–44, 47
 - frame-shift, *see* Frame-shift mutations
 - frequencies, flavivirus genomes, 31:117
 - furoviruses and, 36:24
 - hepadnavirus and, 34:79, 86
 - hepatitis A virus and, 39:242, 245–247
 - HIV structure and
 - gag* gene products, 39:19, 22
 - glycoproteins, 39:47
 - pol* gene products, 39:25, 30, 32, 35
 - regulatory proteins, 39:52, 54–56
 - human herpesvirus 6 and, 41:36
 - influenza virus and, 34:274
 - components, 34:257
 - genome constellation, 34:258
 - pathogenicity, 34:260–261, 264, 266, 268, 272
 - killed antiviral vaccines and, 39:260
 - lentiviruses and, 34:192–193, 206
 - neurodegenerative diseases caused by
 - prions and, 41:259, 261, 269–270
 - oral vaccination and
 - bacteria as carriers, 41:432–436
 - foreign antigens in *Salmonella*, 41:418–420
 - genetic stabilization, 41:429
 - Paramyxoviridae and, 39:141, 144–145
 - pestiviruses and, 41:56, 65, 89, 91
 - comparisons, 41:71
 - properties, 41:75–76, 81
 - picornaviruses and, 36:154
 - biological tests, 36:155–158
 - genome, 36:165
 - protein analysis, 36:160
 - revertants, 36:166–168
 - RNA, 36:174
 - vaccine development, 36:175–176
 - plant viruses in developing countries and, 41:353, 382
 - poliovirus and, 34:218, 239–243
 - neurovirulence, 34:226–239
 - positive-strand RNA viruses and, 41:116, 175, 182
 - potyvirus coat protein and, 36:307
 - in RNA viruses, 31:359
 - rotaviruses and, 36:183, 192–195, 198, 200–202, 39:180, 195
 - comparison to other reoviruses 190191, 39:194–195
 - temperature sensitivity, 39:172–181
 - satellite RNA for biocontrol and, 39:335
 - Sindbis virus encephalitis and, 36:260, 265–266
 - Theiler's murine encephalomyelitis virus and, 39:309
 - translational suppression by retroviruses and, 41:196
 - readthrough suppression, 41:199–200, 203–205, 209
 - ribosomal frameshifting, 41:221, 224, 230

vaccinia and, **34:46**, 49, 53
 MVT-101, HIV structure and, **39:26–27**
 Mx proteins, interferon-induced antiviral actions, **42:86–88**
myc gene, picornaviral genomes and, **40:148**
Mycobacterium, oral vaccination and, **41:437**
Mycobacterium tuberculosis, **35:233**
 Mycoplasma-like organisms, *Plantago* hosts and occurrence, **27:116**
 Mycotic pathogens, new, emerging, and reemerging, **43:35–41**
 Mycoviruses, groups A-F with dsRNA genome, characteristics, **32:207–208**
 Myelin, Theiler's murine encephalomyelitis virus and, **39:301–303**, 305–306, 308, 313
 Myelin basic protein, Theiler's murine encephalomyelitis virus and, **39:302**, 306–307
 Myeloencephalitis, equine abortion virus, **45:158**
 Myeloma cells
 conservation, **29:146**
 culture, **29:137**
 fusion with spleen cells, **29:138–142**
 in production of MAbs against plant viruses, **29:137**
 Myocarditis, canine parvovirus and, **38:414–415**
 Myositis, Sindbis virus encephalitis and, **36:156**, 160
 Myristylation, poliovirus capsid proteins, **46:18–19**
 functional significance, **46:37–38**
 Myxoviruses
 animal cells and, **36:121**
 cellular receptors for, **27:145–147**
 HEF glycoprotein of influenza C virus and, **40:213–214**, 228
Myzus persicae, **29:255**
 cucumber mosaic virus and, **41:333–334**, 336

N

Nairovirus, **40:235**, 237, 263
 genome organization, **40:244**, 249
 structure, **40:240–241**
Nairoviruses, **40:235–236**
 genome organization, **40:244**, 249, 251, 254
 isolation, **31:26**
 major proteins, **31:26**
 proposed serological classification, **31:27**
 RNA species, **31:26**
 characteristics, **31:19**
 coding assignments, **31:26**
 structure, **40:238**
 NANBH (non-A, non-B hepatitis agents), **40:94–95**
 cloning, **40:64**, 66, 74–75
 infectious agent, **40:59–61**, 84–85
 parenterally transmitted, **40:57**, 84, 95
 cloning, **40:64**, 67, 70, 74–75
 infectious agent, **40:59–62**
 prevention, **40:79**, 81, 83
 prevention, **40:93**
 replication, **40:78**
 Nasal cavity, **42:226**
 Nascent chain analysis, adenovirus RNA, **26:3–4**
 Nasopharyngeal carcinoma, Epstein-Barr virus, **27:300–304**
 Nasopharyngeal secretions, virus detection in, **27:23–24**
 Natural killer cells
 response to bovine herpesvirus infection, **45:211–212**
 Theiler's murine encephalomyelitis virus, **39:306**
 Nebraska calf diarrhea virus, **44:180**, 183
 Necrogenesis, by plant viruses, **26:205–208**
 Necrosis
 cucumber mosaic virus, **41:319**, 321, 323–324
 defective interfering viruses, **40:203**
 lentiviruses, **34:203**
 pestiviruses, **41:58**, 67
 plant viruses in developing countries, **41:377**
 viral infection, **33:234–235**
Necrovirus, **44:420**
nef, in HIV gene expression control, **38:134–135**
 Nef protein, **43:82–84**; **44:245–246**
 HIV-1, **40:8–9**, 13

- Nef protein (*cont.*)
 HIV structure, **39:50, 54**
- Negative regulatory element
 adenovirus, **39:103, 111**
 Epstein-Barr virus, **40:30**
 HIV structure, **39:54–55**
- Negative regulatory factor, HIV-1, **40:5**
- Negative staining of viruses, **27:15–16**
 artifacts in, **27:46–47**
 immunoelectron microscopy, **27:17–19**
- Nematodes
 plant viruses in developing countries, **41:355, 368–369, 374**
 transmission of dianthoviruses, **33:289–292**
- Neomycin
 DNA replication, **34:22**
 vaccinia, **34:55, 58**
- Neonate
 parvovirus diseases in, **38:412, 414–415**
 rodent, tacaribe virus experimental infection, **31:9**
- Neoplasias, parvoviruses, **33:94**
- Neoplastic cells
 human herpesvirus 6, **41:33–34**
 translational suppression by retroviruses, **41:194**
- Neoplastic disorders, **29:48**
- Neotopes, **29:147, 154, 157**
- Nephropathia epidemica, Hantaan viruses, **31:32**
- Nepoviruses, **25:60–61**
 MAb-determined antigenic properties, **29:152–153**
Plantago hosts and occurrence, **27:114–115, 126–128**
 transport function, **38:214**
- Nerve growth factor, prions, **35:111**
- Nesoclutha pallida*, *see* Leafhopper
- neu* oncogene
 Epstein-Barr virus, **40:40**
 identity with *c-erbB-2*, human, rat, **32:120–122**
 in signal transduction, **37:7**
- Neuraminic acid, influenza virus, **34:274**
 components, **34:251, 254**
 pathogenicity, **34:261–262, 264**
- Neuraminidase
 antiviral antibody affinity, **34:299**
 HEF glycoprotein of influenza C virus, **40:214, 224, 228**
 influenza virus, **33:28–29**
 antigenic variants, **31:76–79**
 components, **34:253–257**
 crystals complexed with MAbs, **31:83–87**
 deletions in, **31:79–80**
 homology, **31:80, 83**
 molecules, electron micrograph and diagram, **31:75**
 pathogenicity, **34:271–272**
 relationships among subtypes, **31:80**
 sequences at N terminus, **31:81**
 structure, **31:74–87**
 Paramyxoviridae, **39:131**
- Neuroblastoma cells, influenza virus, **34:271**
- Neurodegenerative diseases caused by prions, *see* Prions, neurodegenerative diseases caused by
- Neuroendocrine dysfunctions, virus-induced, in absence of cytolysis and inflammation, **46:333–337**
- Neuroendocrine responses, defective interfering viruses, **40:187**
- Neurological disease, lentiviruses, **34:201–202**
- Neuronal cells, viral infection, **42:232–233**
- Neuronal vacuolation, prion diseases, **35:89–93**
- Neuron subpopulations, virus specificity, **42:252–253**
- Neurotransmitter antagonists, antiviral properties, **42:404–406**
- Neurovirulence
 Bunyaviridae, **40:245**
 hepatitis A virus, **39:245**
 lactate dehydrogenase-elevating virus, **41:150–151**
 picornaviral genomes, **36:163–164; 40:104, 155–157**
 picornaviruses
 biological tests, **36:157–158**
 protein analysis, **36:160**
 recombinants, **36:168, 170**
 revertants, **36:165–168**
 vaccine development, **36:175–176**
 Theiler's murine encephalomyelitis virus, **39:292**

- Neutralization, **29:99**
 equine arteritis virus, **41:160–162**
 hepatitis A virus, **39:224**
 prevention, **39:238, 241**
 replication, **39:227–228, 230**
 HIV structure, **39:23–24, 44, 46–48**
 human herpesvirus 6, **41:25–26, 31, 38**
 killed antiviral vaccines, **39:260, 273**
 lactate dehydrogenase-elevating virus
 age-dependent poliomyelitis, **41:138–139**
 mice, **41:111, 113, 115, 124**
 molecular properties, **41:150, 152–153**
 oral vaccination, **41:410–412, 423, 426, 437–438**
 pestiviruses, **41:67, 74–75, 80, 85**
 rotaviruses, **36:207; 39:167, 171, 197**
 domains, **36:191–202**
 protection, **36:190–191**
 protein, **36:183–187**
 studies, **39:181–184, 186**
 surface proteins, **36:202–204, 206–207**
 vaccination, **39:187–190**
 simian hemorrhagic fever virus, **41:177–178**
 Theiler's murine encephalomyelitis virus, **39:307–310**
- Neutralization reaction, envelope antigens, **25:461–462**
- Neutralization test, chickenpox antigens, **28:315–316**
- Neutralization titers
 anti-yellow fever E MAbs with flavivirus group/subgroup reactivity, **31:112**
 and degree of serological relationships among flaviviruses, **31:107**
 flavivirus epitopes, **31:144–148**
 yellow fever virus type-specific and cross-reactive MAbs, **31:155**
- Neutrophils
 lentiviruses, **34:206**
 pestiviruses, **41:57, 64, 66**
 polymorphonuclear, in bovine herpesvirus infection, **45:206, 212–213**
- Newcastle disease virus
 Paramyxoviridae, **39:132–134, 151**
 genome organization, **39:136–138, 140**
 transcription, **39:141–144, 147–149**
 pestiviruses, **41:64**
 rotaviruses, **39:182–183, 187**
- NF- κ B
 HIV-1, **40:3–5, 10**
 HIV expression in, **38:127–128**
 inhibitors, **43:121–123**
 potent activators, **43:105**
 role in HIV transcription, **43:67–72**
 in *trans*-activation of transcription, **37:69–70**
 transcription factors, **43:102**
- NF-IL6, human papillomavirus transcription, **44:335–336**
- Nicking, parvoviral DNA, **33:160–162**
- Nicotiana benthamiana*
 cassava latent virus infection, **30:141–142, 166–170**
 leaf protoplasts, virus infection, **29:227**
 TGMV infection, **30:166–167, 169**
- Nicotiana clelandii*
 cucumber mosaic virus, **41:285, 321–322**
 defective interfering viruses, **40:202–203**
- Nicotiana glauca*, cucumber mosaic virus, **41:321**
- Nicotiana glutinosa*, **29:319**
- Nicotiana rustica*, leaf protoplasts, virus infection, **29:227**
- Nicotiana sylvestris*, protoplast isolation, **29:224–225**
- Nicotiana tabacum*
 protoplasts
 auxin requirement, **29:224**
 isolation, **29:217–219, 255**
 resistance to viruses, **29:251–252, 339**
 suspension cultures, tobacco mosaic virus infection, **29:249–250**
 virus infection
 cell culture protoplasts, **29:229**
 leaf protoplasts, **29:227, 240**
- Nicotiana velutina* mosaic virus, furoviruses, **36:1, 8–9, 16**
- Nicotinic acetylcholine coreceptor, rabies virus, **42:384–387**
- Nodamura virus, and virus-like particles, **31:307–309**

- Noncytopathogenic viruses, pestiviruses, **41:54, 84, 89, 91**
 bovine viral diarrhea virus, **41:59, 61, 64–66**
 comparisons, **41:71**
 properties, **41:79–82**
- Nongenetic reactivation, iridoviruses, **46:377–380**
- Non-Hodgkin's lymphoma, human, herpesvirus 6, **41:33–34**
- Nonpersistent viruses
 control, **31:417–421**
 antiviral factors, **31:418**
 application of aphid alarm pheromones, **31:419**
 breeding for resistance, **31:417**
 chemical applications
 insecticides, **31:419–420**
 interference with vector behavior, **31:418–419**
 mineral oil, **31:420–421**
 pyrethroids, **31:420**
 reduction of landing sites, **31:418–419**
 economic importance, **31:387–388**
 host range, **31:390**
 incidence of virus infection, monitoring, **31:408–409**
 field, **31:408**
 use of bait plants, **31:408–409**
 sources, **31:388–392**
 alfalfa mosaic virus, **31:389**
 carlaviruses, **31:389**
 caulimoviruses, **31:389**
 cucumoviruses, **31:389**
 potyviruses, **31:389–390**
 whitefly-transmitted, **31:390**
 spread
 dependence on aphid number, **31:415–416**
 environmental effect, **31:398–400**
 external sources, **31:391**
 forms, **31:409–417**
 internal sources, **31:390–391**
 models, **31:413–417**
 role of sources in, **31:390–392**
 in soybeans, **31:416–417**
 in space, **31:410–413**
 suitability of sources for, **31:391–392**
 with time, **31:410–412**
 vectors, **31:392–398**
 biology and epidemiology, **31:394–398**
 aphids, **31:394–395**
 migration and flight, **31:395–398**
 whiteflies, **31:394**
 characteristics of transmission, **31:392–394**
 acquisition and inoculation, **31:392–393**
 retention, **31:393**
 specificity, **31:393–394**
 importance, live trapping and evaluation, **31:405–407**
 monitoring methods, **31:400–405**
- Nonstructural proteins
 alphavirus, **47:195**
 filoviruses, **47:27–28**
 influenza virus, **31:90–91**
 pestiviruses, **47:63–64**
 rotavirus
 NS26, **38:32**
 NS28, *see* Glycoprotein NS28
 NS34, **38:31**
 NS35, **38:31**
 NS53, **38:31–32**
- Nonvector, infectivity, **25:233**
- Nonviral systems
 antisense RNA effect, **44:291–292**
 hammerhead ribozyme effect, **44:281–282**
 oligodeoxynucleotide effect, **44:290**
- 2'-Nordeoxyguanosine, HSV inhibition, **30:98–99**
- Northern blotting, prions, **35:109**
- Norwalk-like viruses, **43:25**
- Norwalk virus, **42:223**
- Novaviridae, RNAs, 3'-cis-acting sequences, **47:222**
- NP protein, **47:20–22**
- N protein
 Berne virus, **43:244–245**
 Bunyaviridae, **40:238, 253–255, 260, 263–264**
 coronaviruses, **28:71**
- NS gene, defective interfering viruses, **40:190**
- NS1 gene, hepatitis C virus, **40:72**
- NS_M protein, Bunyaviridae
 genome organization, **40:243, 245–246, 248–249, 251**
 replication, **40:258**

- structure, **40:238**
- NS2 protein, defective interfering viruses, **40:190**
- NS protein, phosphorylated, in vesicular stomatitis virus, **38:109–117**
 - functional domains, **38:112–117**
 - primary structure, **38:111–112**
 - role in transcription, **38:119–122**
 - similar to eukaryotic transcription activators, **38:117–118**
- NS_S protein, Bunyaviridae, **40:264**
 - genome organization, **40:243, 251–254**
 - replication, **40:258–259**
 - structure, **40:238**
- Nuclear factor I, DNA replication, **34:8–9**
- Nuclear factor of activated T cells, NFAT-1, **43:73–74**
- HIV-1, **40:4**
- Nuclear magnetic resonance, HIV structure, **39:9–10**
 - gene products, **39:18, 34**
 - regulatory proteins, **39:52–53**
- Nuclear membrane, budding in HSV replication, **37:114–115**
- Nuclear polyhedrosis virus
 - high-voltage electron microscopy, **30:71–76**
 - induced apoptosis, **45:16–17**
 - pesticide production, **36:315–317**
 - considerations, **36:317–319, 321**
 - prevention of contamination, **36:322–323**
 - process assurance, **36:323–326**
 - process description, **36:326–333**
 - virus replication, **36:332, 334–340**
- Nuclear stock, plant viruses in developing countries, **41:352–353, 382–384**
- Nucleic acids
 - archaeobacterial viruses, **34:145**
 - Halobacterium halobium*, **34:151**
 - Sulfolobus* virus-like particle SSV1, **34:177–178, 180**
 - Thermoproteus tenax*, **34:172**
 - bacteriophages, comparative anatomy, **27:219–223**
 - cucumber mosaic virus, **41:286, 298, 321, 324**
 - neurodegenerative diseases caused by prions, **41:243, 246, 259, 264**
 - DNA replication, **34:32**
 - hepadnavirus, **34:98**
 - hepatitis A virus, **39:224–225, 231**
 - insect viruses, **25:286–289**
 - killed antiviral vaccines, **39:257–258, 260, 263–264**
 - lentiviruses, **34:191**
 - poliovirus, **34:222**
 - potyvirus coat protein, **36:275, 279, 291**
 - prions, **35:85–87, 117–119**
 - rotaviruses, **36:194, 200**
 - Totivirus*, **43:308–309**
 - viral, in electrotransfection of plant protoplasts, **37:329–341**
 - virion, **25:150–152**
- Nucleic acid synthesis, TMV multiplication, **33:215**
- Nucleocapsid antigen, oral vaccination, **41:417, 421–422, 425**
- Nucleocapsid protein
 - influenza virus, **34:252–253**
 - Paramyxoviridae, **39:129, 132–134**
 - genome organization, **39:138–139, 141**
 - replication, **39:150–152**
 - transcription, **39:141, 144–146, 148**
- Nucleocapsids
 - assembly in HSV replication, **37:113–114**
 - bacteriophage $\phi 6$, **35:146–151, 164–165**
 - Bunyaviridae, **40:238, 241–242, 259–260**
 - defective interfering viruses, **40:191**
 - hepatitis C virus, **40:71**
 - human herpesvirus 6, **41:5, 7, 16, 20**
 - oral vaccination, **41:424, 428**
 - positive-strand RNA viruses, **41:100–101**
 - common properties, **41:180–181**
 - equine arteritis virus, **41:158, 163**
 - lactate dehydrogenase-elevating virus, **41:144–145, 148**
 - simian hemorrhagic fever virus, **41:179**
- Nucleoprotein
 - archaeobacterial viruses, **34:180**
 - cucumber mosaic virus, **41:288, 329**
 - VP30, **47:26–27**
- Nucleoprotein antigen, influenza virus, **31:88–89**

- Nucleoside triphosphate, DNA replication, **34:18**
- Nucleotide phosphohydrolase, *Totivirus*, **43:327**
- Nucleotides
- adenovirus, **39:90–91**
 - oncodna viruses, **39:105–106**
 - sequence-specific methylation, **39:116, 119, 123**
 - species specificity, **39:101–103**
 - archaeobacterial viruses, **34:151, 177, 183**
 - Bunyaviridae, **40:243, 250**
 - cucumber mosaic virus, **41:283, 285–287**
 - defective interfering viruses, **40:195, 199–202, 204–206**
 - DNA replication, **34:32**
 - adenovirus, **34:2, 4, 6–7, 9**
 - bovine papillomavirus, **34:23**
 - Epstein-Barr virus, **34:29–30**
 - SV40, **34:11–12, 20**
 - Drosophila* retrotransposons, **36:87**
 - organization, **36:47, 50–51, 53–54**
 - scattered repetition, **36:39–40**
 - transcription, **36:68**
 - furoviruses
 - beet necrotic yellow vein virus, **36:18, 20–22**
 - soil-borne wheat mosaic virus, **36:23–26**
 - genome organization, **39:135–140; 41:297–313, 316**
 - HEF glycoprotein of influenza C virus, **40:214**
 - hepadnavirus
 - characterization, **34:78–79, 81**
 - genome organization, **34:70**
 - hepatitis A virus, **39:210, 226, 242, 244, 246**
 - hepatitis C virus, **40:66–67, 69–71, 73, 75**
 - HIV-1, **40:6**
 - HIV structure, **39:3, 31, 51**
 - human herpesvirus 6, **41:15, 17–20, 23**
 - influenza virus
 - components, **34:249, 253, 255**
 - genetic resistance, **34:273**
 - pathogenicity, **34:262**
 - killed antiviral vaccines, **39:263**
 - lentiviruses
 - structure, **34:192–196**
 - virus-host cell interaction *in vitro*, **34:198–199**
 - neurodegenerative diseases caused by prions, **41:256**
 - Paramyxoviridae, **39:132–133**
 - parvovirus DNA, changes, **33:113–115**
 - pestiviruses, **41:77–78, 81–82, 86, 90**
 - picornaviral genomes, **40:104**
 - cis-acting elements, **40:120–128**
 - evolution, **40:158, 161**
 - mRNAs, **40:143, 147, 149**
 - phenotype, **40:157–158**
 - RNA replication, **40:152–154**
 - structure, **40:104–110, 113**
 - trans-acting factors, **40:137–138**
 - translation initiation, **40:141–142**
 - picornaviruses
 - genome, **36:162–165**
 - recombinants, **36:170–171**
 - revertants, **36:165–168**
 - poliovirus, **34:239, 242**
 - neurovirulence, **34:228, 231, 233–235, 239**
 - structure, **34:218**
 - positive-strand RNA viruses, **41:100, 146, 148–149, 153, 179**
 - potyvirus coat protein, **36:276–277**
 - ribosomal frameshifting, **41:211–213, 220, 225, 231**
 - rotaviruses, **36:195**
 - satellite RNAs, **41:317, 319, 322**
 - Sindbis virus encephalitis, **36:256–257, 262**
 - Theiler's murine encephalomyelitis virus, **39:293, 296, 309, 311**
 - transcription, **39:145, 147–149**
 - translational suppression by retroviruses and readthrough suppression, **41:201, 203–205, 207**
 - vaccinia, **34:49**
 - virus-host plant relationships, **41:324, 327**
- Nucleotide sequence
- AAV type 2, **32:246–247**
 - internal terminal repeat, **32:248–249**
 - BMV RNA3
 - 3'-end, **32:234–235**
 - 5'-terminal, **32:230–231**
 - cDNA for HAV RNA, **32:154–157**

- leafhopper-transmitted MSV, **30**:160–164
- LTR, avian retroviral
 analogies with transposons, **30**:191–192
 endogenous, **30**:188–191
 exogenous, **30**:187–191
- MDV I, oncogenicity-related DNA, **30**:239–240
- oncogenes *yes* and *src*, homology, **32**:102–104
- whitefly-transmitted geminiviruses, **30**:151–156
- Nucleus
 adenovirus mRNA transport to cytoplasm from, **31**:211–216
 flavivirus proteins, **33**:64
 HSV infection-associated changes, **37**:88–89
 parvovirus virions, **33**:138–139
 signal transduction within, **37**:18–22
- Nudaurelia B group, **25**:314–315
 serological properties, **25**:341
- O**
- Oat golden stripe virus, **36**:28
 cytopathology, **36**:9–10
 natural occurrence, **36**:4
 vectors, **36**:12
- Oat sterile dwarf virus, immunosorbent electron microscopy, **29**:187–188
- Oct-1, human papillomavirus transcription, **44**:335–336
- Olfactory epithelium, **42**:226
 (2'-5')A *n*-Oligoadenylate, **35**:291–292
 2'-5'-Oligoadenylate analogs, *see* 2'-5'A analogs
 2'-5'-Oligoadenylate synthetases, interferon-induced antiviral actions, **42**:83–85
- Oligodendrocytes, **42**:253–255, 292–293
 Theiler's murine encephalomyelitis virus, **39**:297, 300–303, 313
 demyelination, **39**:305–306, 308–309
- Oligodeoxynucleotides
 antiviral effects, **44**:288–290
 effects in nonviral systems, **44**:290
 in living organisms, **44**:293–294
 stability and chemical modification, **44**:285–286
 target selection and mode of action, **44**:286–288
 uptake into cells and toxicity, **44**:288
- Oligodeoxyribonucleotide, adenovirus, **39**:122–123
- Oligomerization
 hepatitis delta virus, **43**:216–217
 HIV structure, **39**:40, 42
- Oligonucleotides
 cucumber mosaic virus, **41**:322
 DNA replication, **34**:18
 hepatitis C virus, **40**:69
 insect viruses, **25**:288
 lentiviruses, **34**:194
 neurodegenerative diseases caused by prions, **41**:244
 pestiviruses, **41**:77
 picornaviruses, **36**:162–163
 poliovirus, **34**:228–229, 239
 positive-strand RNA viruses, **41**:130, 148, 152, 158
 translational suppression by retroviruses, **41**:205, 223, 231
- Oligopeptides, synthetic, penetration inhibition of
 influenza viruses, **30**:87–88
 measles virus, **30**:86–87
- Oligoribonucleotides, hepadnavirus, **34**:72
- Oligosaccharides
 Bunyaviridae, **40**:248, 261
 HEF glycoprotein of influenza C virus, **40**:216, 221
 influenza virus, **34**:274
 components, **34**:249, 251
 pathogenicity, **34**:262, 268
- Oligosaccharide sites
 rabies virus, **33**:14–16
 vesicular stomatitis virus, **33**:14–16
- Olipidium brassicae*, plant viruses in developing countries, **41**:359–360, 369
- OMP decarboxylase/CTP synthetase inhibitors, **42**:10–13
- Oncodna viruses, **39**:95
 DNA persistence, **39**:104–110
 integrative recombination, **39**:110–111
- Oncogenes
 and adenovirus, **39**:91–92, 95, 104–105, 110

Oncogenes (*cont.*)

- c-erbB-1*
 - in adenocarcinomas, **32:122**
 - identity with EGFR gene, **32:119–120**
 - location on chromosome, **32:7, 119**
- c-erbB-2*
 - identity with *neu* gene, **32:120–122**
 - in squamous cell carcinoma, **32:122**
- Epstein-Barr virus, **40:32, 40**
- HIV-1, **40:1**
- HIV expression, **43:115–117**
- in HPV transformation, **37:149**
- human herpesvirus 6, **41:34**
- lactate dehydrogenase-elevating virus, **41:105, 129**
- neurodegenerative diseases caused by prions, **41:249**
- picornaviral genomes, **40:147–149**
- in signal transduction, **37:1–24**
- neu*, **37:7**
- v-erbA*, **37:19–20**
- v-rel*, **37:17–18**
- v-erbB* of AEV, **32:104–109**
 - nucleotide sequence, **32:107**
- v-src* family, **32:109–114**
 - classification, four groups, **32:111**
 - kinase domains in products, **32:110–114**
- v-src* of RSV
 - cellular oncogene activation, **32:98**
 - discovery, **32:98–99**
- v-yes*, avian sarcoma virus Y73
 - discovery, **32:102**
 - nucleotide sequence, **32:102–104**
- Oncogenesis, avian retrovirus-induced
 - LTR role, **30:205–214**
 - mechanisms, **30:205–211**
- Oncogenicity, MDV I, **30:233–234**
 - specific DNA fragments, **30:237–240**
- Oncoretroviruses, **47:377–412**
 - epidemiological characteristics, **47:380–382**
 - HTLV-I, **47:380–381**
 - HTLV-II, **47:381**
 - PTLV-L, **47:382**
 - STLV-I, **47:381–382**
 - STLV-PP, **47:382**
 - historical background, **47:377–379**
 - HTLV-I, **47:378–379**
 - HTLV-II, **47:379**
 - PTLV-L and STLV-PP, **47:379**
 - STLV-I and STLV-II, **47:379**
- Oncovirus
 - bovine leukemia virus, characteristics, **25:476–477**
 - envelope antigens, **25:451–482**
 - assays, **25:460–461**
 - carcinogenesis, **25:481**
 - cell differentiation, **25:480–481**
 - chemical composition, **25:453–454**
 - classification, **25:477–480**
 - evolution, **25:477–480**
 - immunologic response, **25:481–482**
 - in intact virions, **25:461–463**
 - methods of studying, **25:458**
 - scheme, **25:453**
 - structure, **25:452–453**
 - envelope proteins, precursors, **25:456–458**
 - purification, **25:458–459**
 - lentiviruses
 - structure, **34:191–192, 194, 196**
 - virus-host cell interaction *in vitro*, **34:199**
- Onozuka cellulase, **29:219**
- Onozuka R-10, **29:220, 224–225**
- Onozuka SS, **29:224–225**
- Oocytes
 - amphibian, protein synthesis in, **25:8–9**
- Xenopus*
 - alfalfa mosaic virus RNA translation, **25:50**
 - membrane permeability, modification, **45:87**
- Open reading frames
 - Bunyaviridae, **40:250**
 - genome organization, **40:244, 246–250, 252–254**
 - structure, **40:239**
 - CaMV, **32:56–67**
 - cucumber mosaic virus, **41:298, 302, 308–309**
 - defective interfering viruses, **40:182, 197–199**
 - DNA replication, **34:21–22, 24–29**
 - Drosophila* retrotransposons
 - insertional mutagenesis, **36:63, 85**
 - organization, **36:53, 55–60**
 - transcription, **36:68**
 - Epstein-Barr virus, **40:26, 33, 37**

- equine arteritis virus, **41:165–167**
 HEF glycoprotein of influenza C virus, **40:229**
 hepadnavirus, **32:51–55; 34:66–68**
 characterization, **34:82, 88**
 genome organization, **34:69**
 hepatitis A virus, **39:242**
 hepatitis C virus, **40:67, 69–70**
 hepatitis E virus, **40:89, 91, 93**
 HIV structure, **39:56**
 human herpesvirus 6, **41:18, 36**
 lactate dehydrogenase-elevating virus, **41:146, 148, 153**
 neurodegenerative diseases caused by prions, **41:249–250**
 Paramyxoviridae, **39:147, 149–150**
 parvovirus
 DNA, **33:112–114**
 nonstructural polypeptides, **33:128, 133**
 pestiviruses, **41:78–79, 82, 90**
 picornaviral genomes, **40:104**
 cis-acting elements, **40:115–116**
 mRNAs, **40:143–144**
 structure, **40:107–108**
 translation initiation, **40:141**
 retroviruses, **32:50–51**
 Theiler's murine encephalomyelitis virus, **39:294, 296**
 vaccinia, **34:48–49**
 Oral carcinomas, human papillomaviruses, **37:135**
 Oral cavity, epithelial lining, **42:217**
 Oral poliovirus vaccine, OPV and IPV, differential responses, **37:268–269**
 Oral vaccination with recombinant bacteria, **41:409–411**
 bacteria as carriers, **41:430–437**
 epitope presentation systems, **41:423–428**
 foreign antigens in *Salmonella*, **41:417–421**
 bacterial antigens, **41:422–423**
 viral antigens, **41:417, 421–422**
 genetic stabilization, **41:428–430**
 immunity to bacterial disease, **41:414–417**
 immunity to viral disease, **41:411–414**
 outlook, **41:438**
 Orbiviruses, rotaviruses, **39:164, 193, 195**
 ORFs, *see* Open reading frames
 Organ transplantation, human herpes virus 6, **41:29, 31–32, 37**
 OriP, Epstein-Barr virus, **40:41–48**
Ornithodoros, ASF, **35:254**
 Oropouche virus, human infection febrile illness, **30:296**
 meningitis, **30:296**
Orosius argentatus, *see* Leafhopper
 Orthomyxoviridae, negative-stranded RNA, **31:1–2**
 Orthomyxoviruses
 animal cells, **36:113**
 endocytosis, **36:119**
 entry, **36:134**
 membrane fusion, **36:125**
 receptors, **36:112, 117**
 attachment proteins, **27:167–168**
 cellular receptors, **27:168–170**
 HEF glycoprotein of influenza C virus, **40:229**
 Paramyxoviridae, **39:144**
 penetration by, **27:170–173**
 picornaviruses, **36:173**
 uncoating, **27:173–174**
 Orthopoxviruses, **29:205, 209**
 Oryzavirus, **45:260–261**
 Osteoporosis, lentiviruses, **34:201**
 Ovine progressive pneumonia, lentiviruses, **34:190**
 Oxidative stress, activator of HIV LTR function, **43:107**
- P**
- p52, picornaviral genomes, **40:137, 156**
 p53
 human papillomavirus transcription, **44:336**
 role in apoptosis, **45:11–12, 49**
 p56^{lck}
 association with CD4, **44:217–219**
 intermolecular associations involving, **44:223–224**
 T cell activation role, **44:221–223**
 thymic development role, **44:212–214**
 p80, pestiviruses, **41:81–82, 85**
 p125, pestiviruses, **41:80–82, 85**
 P160, MLV *vs.* P120, **35:70–71**
 p220, cleavage, poliovirus mediated, **33:188–191**

- PAGE, *see* Polyacrylamide gel electrophoresis
- Palindromes, DNA replication, **34:13, 32**
- Palindromic inserts, rearrangements at, **43:298–300**
- Palindromic sequences, in parvovirus DNA, **33:109–110, 155–156**
- Pancreas, hepadnavirus, **34:97**
- Panencephalitis, subacute sclerosing, **42:282–283**
- Papaya, plant viruses in developing countries, **41:358**
- Papillomas, laryngeal, human papillomaviruses, **37:134–135**
- Papillomavirus, **44:305–348**, *see also* Bovine papillomavirus
- animal, transformation studies, **37:142–144**
- association with benign lesions, **44:306**
- diagnosis using synthetic peptides, **42:173–175**
- gene expression regulation by cellular transcription factors, **44:327–337**
- BPV-1 transcription, **44:327–328**
- DNA-binding factors, **44:331–333**
- KRF-1, **44:331**
- Oct-1 and NF-IL6, **44:335–336**
- p53, **44:336**
- retinoic acid receptors, **44:336**
- TEF-1, **44:329–331**
- YY1, **44:336–337**
- gene expression regulation by viral gene products, **44:337–343**
- genital papillomavirus, **44:341**
- human papillomavirus type 16 E2 as repressor, **44:342–343**
- as *trans*-activator, **44:341–342**
- gene regulation
- active infection, **44:344–346**
- cervical cancer, **44:347**
- viral latency, **44:346–347**
- genome structure, **44:309–311**
- history, **44:307–309**
- human, carcinomas, **37:125–161**
- infection by epidermal trauma, **42:212–213**
- replication
- E1 protein as factor, **44:312–313**
- E2 protein as factor, **44:313–315**
- transient, **44:311–312**
- transforming genes
- acting on E2F, **44:324–325**
- E5, **44:316–317**
- E6, **44:317–318, 321–324**
- E7, **44:317–321**
- Papovaviruses
- animal cells, **36:113, 121**
- attachment proteins, **27:192**
- cellular receptors, **27:193**
- gene expression, **26:77–81**
- immunosorbent electron microscopy, **29:192**
- induced apoptosis, **45:21**
- penetration by, **27:194**
- picornaviral genomes, **40:149**
- uncoating, **27:194–195**
- vaccinia, **34:45**
- Parainfluenza virus, high-voltage electron microscopy, **30:69**
- Paralysis
- lactate dehydrogenase-elevating virus age-dependent poliomyelitis, **41:125–127, 129, 134–139, 143–144**
- molecular properties, **41:150–151**
- picornaviruses, **36:163, 168, 170**
- Theiler's murine encephalomyelitis virus, **39:292, 296, 299**
- Paramyxoviridae, **37:211–235; 39:129–135**
- antibody response, **37:229–231**
- antigenicity, **37:227–229**
- effect on immunological reactions, **37:233–234**
- genome
- organization, **39:135–141**
- replication, **39:150–152**
- structure, **37:217–220**
- immunity, aspects, **37:227–235**
- induction of autoimmunity by, **37:234–235**
- introduction to, **37:211–213**
- molecular structure, **37:213–222**
- pathogenesis, molecular aspects, **37:222–227**
- persistent infections from, **37:224–227**
- replication, **37:220–222**
- single entry of complex, **39:144–145**
- single species RNA, **31:2**
- T-cell response to, **37:231–232**
- transcription, **39:141–143, 146–149**
- multiple entry of complex, **39:145–150**

- RNA processing by cleavage, 39:142–144
- virion structure, 37:213–217
- Paramyxoviruses, 29:32; 42:280
- animal cells
- endocytosis, 36:119
 - enveloped viruses, 36:134
 - membrane fusion, 36:125
 - receptors, 36:112–113
- attachment proteins, 27:175–176
- cellular receptors, 27:145–174, 176–178
- glycoproteins, 33:29–30
- HEF glycoprotein of influenza C virus, 40:228–229
- HN protein, functional areas, 29:107
- influenza virus, 34:251, 254, 270
- peplomers, 32:22–23
- component vaccine production, 32:23
- pestiviruses, 41:64
- uncoating, 27:178
- Paraparesis, tropical spastic, 43:149–150
- Pararetroviruses, 44:1–56
- adaptations, 44:3
- classification, 44:4–6
- gag-pol* core, 44:10–11
- genome organization, 44:6–8
- RNA 3'-end formation, 44:26–32
- structure and assembly, 44:45–47
- capsid structures, 44:48–50
 - envelope, 44:47–48
 - packaging strategies, comparison, 44:54–55
- RNA packaging, 44:52–54
- virus-like particle formation, 44:51–52
- viral transmission and cell-to-cell spread, 44:11–13
- Parasites
- animal cells, 36:107
 - Drosophila* retrotransposons, 36:94
 - oral vaccination, 41:410–411, 417, 423
- Paratopes, antiviral antibody affinity, 34:287, 298, 303
- Parenchyma, lentiviruses, 34:203
- Parenchymal cells, influenza virus, 34:272
- Parkinson's disease, 29:47
- Parsnip yellow fleck virus, aphid transmission, 28:118
- Parvovirus B19
- diagnosis using synthetic peptides, 42:176
 - human, 43:23
- Parvoviruses, 29:33; 38:403–441; 47:304–338, *see also* Densoviruses
- adeno-associated virus, 47:306–311
 - antigenic relationships, 38:418–423
 - antigenic variation, 38:423–429
 - autonomous, 47:308, 311–312
 - comparison with AAV, 32:291–292
 - list, 33:92
 - mediated gene delivery, 47:335–337
- autonomous vectors, 47:320–333
- generation of infectious virus, 47:325–326
 - heterologous promoter regulation, 47:327–328
- LuIII–luciferase transducing virus
- role, 47:333
- LuIII vector, 47:321–322
- minute virus of mice vectors, 47:321, 323
- packaging cell lines, 47:326–327
- titers of transducing virus, 47:323–325
- transduction range of MVM and LuIII transducing viruses, 47:329–330
- diseases from, 38:407–418
- in fetus/neonate, 38:412, 414–415
 - immunity to, 38:415
 - natural host ranges, 38:415–418
 - in older animals, 38:408–413
- experimental host range properties, 38:433–434
- genetic analysis, 38:434–436
- gene vectors, 47:317–335
- adeno-associated virus, 47:317–320
 - autonomous, 47:320–333
 - densoviruses, 47:333–335
- genome organization, 38:430–432
- genome structure
- coding strategy, 33:117–137
 - DNA structure and sequence, 33:106–111
 - organization of genome, 33:111–117
- hemagglutination dependence on pH, 38:432–433
- historical background, 38:405–407
- induced apoptosis, 45:22

- Parvoviruses (*cont.*)
 infectious cycle, 47:314
 life cycle
 DNA replication, 33:149–162
 early events, 33:137–139
 gene expression, 33:139–149
 nonproductive virus-host cell interaction, 33:165–169
 virion assembly and maturation, 33:162–165
 NS1 gene, 47:312
 oncolytic effects, 47:315–316
 pathogenicity, 33:91–93
 phylogenetic relationships, 38:439–440
 picornaviral genomes, 40:149
 as potential gene delivery vehicles, 47:304–305
 pseudotyping of LuIII–luciferase genome, 47:330–332
 replication, 42:222; 47:305–307
 serotype, pathogenic potential, 33:95
 strategy for producing recombinant, 47:317–319
 study with MAbs, 29:103
 susceptibility to, factors affecting, 33:93
 transcriptional activators, 47:314–315
 variation among, 38:434–436
 virion structure
 antigenic, 33:104–106
 biochemical, 33:97–104
 morphology, 33:96–97
 virus sequence variation in, 38:439–440
 Passage trials, ADRV, 35:206
 Passionfruit woodiness virus, potyvirus
 coat protein, 36:275
 structure, 36:281, 283, 285
 taxonomy, 36:292
 Passive immunization, lactate dehydrogenase-elevating virus, 41:138–139
Pasteurella hemolytica, 35:233
 pestiviruses, 41:59
 Pathogenesis
 cucumber mosaic virus, 41:283, 317, 323–324, 337–338
 cytomegalovirus, 46:234–236
 equine arteritis virus, 41:155–158
 hepatitis A virus, 39:215
 human herpesvirus 6, 41:32, 40
 killed antiviral vaccines, 39:256
 neurodegenerative diseases caused by prions, 41:257–258, 271
 new perspective, 46:314
 pestiviruses, 41:54, 91
 bovine viral diarrhoea virus, 41:59, 61, 64–65
 comparisons, 41:68
 simian hemorrhagic fever virus, 41:168–171, 173
 Pathogenic determinants, action, 33:232–233
 Pathogens
 Bunyaviridae, 40:264
 defective interfering viruses, 40:194–204, 206
 hepatitis C virus, 40:69, 73–75, 95
 hepatitis E virus, 40:86, 94–95
 HIV-1, 40:14
 oral vaccination, 41:410, 414, 423, 426
 picornaviral genomes, 40:154, 157
 plant viruses in developing countries, 41:397–398
 crop improvement, 41:359, 365, 367, 371, 375
 remedial action, 41:383, 393
 rotaviruses, 39:164–165, 189, 196–197
 satellite RNA for biocontrol, 39:323, 332
 Theiler's murine encephalomyelitis virus, 39:309–313
 Pathology
 autoimmunity, 31:365–369
 modification of cellular antigens, 31:366–368
 molecular mimicry, 31:368–369
 polyclonal lymphocyte activation, 31:365–366
 cell fusion, 25:239–241
 chromosome alteration mechanisms, 31:361–363
 concept of, 31:357–358
 cucumber mosaic virus, 41:323
 cytogenic changes, virus-induced, 31:360–361
 disruption of differentiated cell function, 31:373–379
 cell receptor function, 31:374–375
 cured cells, 31:377–379
 immunomodulation of persistently infected cells, 31:376–377

- inhibition of luxury functions, 31:375–376
- endocrine disorders, 31:359
- hit and run phenomenon, 31:358
- immunological system role, 31:358
- insect, infection in, 25:275–278
- interferons, 31:370–373
- lactate dehydrogenase-elevating virus, 41:123, 125
- luxury functions, 31:358
- mutations, 31:359
- neurodegenerative diseases caused by prions, 41:246, 259, 264
- oral vaccination, 41:416
- pestiviruses, 41:57–58, 63–68
- simian hemorrhagic fever virus, 41:169
- vector cell monolayers, 25:234–241
- viruses as mutagens, 31:363–365
- PBLs, *see* Peripheral blood lymphocytes
- Pea, plant viruses in developing countries, 41:361, 370–372
- Pea enation mosaic virus, 33:246
 - genome organization, 46:453
 - protoplast infection, 29:226, 228
 - replication, 46:447
 - inhibition, 29:254
 - taxonomy, 46:453–454
- Peanut clump virus, 36:1, 3, 27
 - cytopathology, 36:9
 - molecular biology, 36:26–27
 - natural occurrence, 36:5–6
 - particle dimensions, 36:17–18
 - purification, 36:15
 - vectors, 36:14
- Peanut green mosaic virus, 33:236–237
- Peanut stripe virus, in developing countries, 41:371–372, 381–382, 394
- Peanut stunt cucumovirus
 - antigenic properties, 41:296
 - taxonomy, 41:284
 - virus particle, 41:288
- Peanut stunt virus, in developing countries, 41:361
- PEA virus, teratogenic to cattle, 30:295–296
- Pectinase, 29:219, 225
- Pectolyase-Y 23, 29:219, 225
- Penciclovir, 42:17, 19
- Penetration, hosts by viruses, 27:141–204
- Penicillium chrysogenum*, virus-like particles, 29:256–257
- Pentamer, 46:22–24
 - poliovirus, 46:55
- Pentosan polysulfate, 42:2–3
- Pentoxifylene, HIV inhibition, 43:122–123
- Pepper, satellite RNA for biocontrol, 39:323–324, 326, 328–331, 333
- Pepper mottle virus, potyvirus coat protein, 36:275
 - structure, 36:282–283, 285
 - taxonomy, 36:298
- Pepsan technique, 42:151
- Pepsin, hepadnavirus, 34:95
- Peptide carriers, carrier-mediated drug delivery, 35:289–293
- Peptides
 - animal cells, 36:110, 128, 133
 - Bunyaviridae, 40:246, 248
 - cucumber mosaic virus, 41:284, 293
 - furoviruses, 36:20, 25
 - hepadnavirus, 34:69
 - antibody response, 34:123–126
 - antigenicity, 34:118–121
 - characterization, 34:82, 85–86, 89–90
 - immunogenicity, 34:121–123
 - lentiviruses, 34:193–194
 - pre-S sequences, 34:95–97, 102, 109–110, 113
 - synthesis, 34:113–118
 - T-cell recognition, 34:127–129
 - vaccine, 34:133–135
 - hepatitis A virus, 39:223–224, 241, 246
 - HIV structure, 39:5, 7, 18
 - glycoproteins, 39:42, 44, 47–49
 - pol* gene products, 39:25, 27
 - regulatory proteins, 39:51–52
 - neurodegenerative diseases caused by prions, 41:270
 - oral vaccination, 41:412–413, 416, 423–424, 438
- Paramyxoviridae, 39:148
- picornaviruses, 36:161
 - potyvirus coat protein, 36:307
 - genome organization, 36:279
 - structure, 36:280, 282
 - subgroups, 36:305
 - taxonomy, 36:291–293, 304
- Sindbis virus encephalitis, 36:258

- Peptides (*cont.*)
 synthetic, *see* Synthetic peptides
 Theiler's murine encephalomyelitis virus, **39:296, 309**
 translational suppression by retroviruses, **41:196, 211, 214–218, 224–225, 231**
- Peptidyltransferase, **29:42**
- Perchloric acid, archaeobacterial viruses, **34:179**
- Perennial crops, plant viruses in developing countries, **41:360–361**
- Peripheral blood lymphocytes
 human herpesvirus 6, **41:4, 25**
 biology, **41:27, 30–32, 38**
 growth properties, **41:8–10, 13**
 pestiviruses, **41:84–85**
- Peripheral blood mononuclear cells, human herpesvirus 6, **41:29**
- Peripheral blood mononuclear leukocytes, pestiviruses, **41:64**
- Peripheral nervous system, rabies virus transport, **42:387–391**
- Peritoneal macrophages, equine arteritis virus, **41:173–175**
- Peritoneum
 lactate dehydrogenase-elevating virus, **41:104–105, 109, 117, 121, 137**
 simian hemorrhagic fever virus, **41:173–175**
- Peronospora tabacina*, **29:255**
- Persistent Infection Cell Culture (PICC) test, **26:49–51**
- Pest control, plant viruses in developing countries, **41:396**
 crop improvement, **41:372–373**
 remedial action, **41:379, 385–388, 391–393, 395**
- Pesticide production, **36:315–317**
 economics, **36:317–318**
Heliothis NPV, **36:322**
 prevention of contamination, **36:322–323**
 process assurance, **36:323–326**
 process description, **36:326–333**
 virus replication, **36:332, 334–340**
 importation, **36:320–322**
 quality control, **36:340–342**
 shelf stability, **36:319**
 tissue culture, **36:318–319**
- Pesticides, plant viruses in developing countries, **41:372–373, 376**
- Pestiviruses, **41:53–54, 90–91; 47:53–113**
 border disease, **47:53, 57**
 border disease virus, **41:66–68**
 bovine viral diarrhea, **47:53, 56–57**
 BVDV, **41:58–66**
 difference from others, **47:101–102**
 classical swine fever, **47:53, 58**
 comparisons, **41:68–71**
 cytopathogenicity, NS3 role, **47:111–112**
 diseases, **47:55–56**
 genome organization, **47:59–60**
 glycoproteins, **47:61–62**
 hepatitis C virus, **40:70–73, 84, 95**
 hog cholera virus, **41:54–58**
 laboratory diagnosis, **41:83–86**
 MAbs, **47:65–66**
 mucosal disease, **47:53, 56–57**
 development, **47:96–97**
 nonstructural proteins, **47:63–64**
 nucleocapsid protein, **47:59**
 nucleotide sequence, **47:66–68**
 ORF, **47:58–59**
 polyprotein, **47:58–64**
 positive-strand RNA viruses, **41:100–101, 180**
 properties, **47:55**
 antigens, **41:72–76**
 cloning, **41:76–78**
 structure, **41:71–73**
 viral proteins, **41:78–83**
 putative cleavage sites, **47:59, 61**
 relationships among, **47:65–68**
 significance, **47:54**
 taxonomy, **47:54–55**
 vaccination, **41:86–90**
 viral evolution, **47:111–113**
 virion properties, **47:64–65**
- Pestivirus RNA recombinations, **47:68–111**
 analysis of BVDV pair #1, **47:71–72**
 BVDV cellular insertions, biological significance, **47:70–71**
 cellular sequences in BVDV genome, **47:68–70**
 cIns, **47:83–85**
 copy-choice model, **47:102–103**
 double duplication, **47:107**

- during negative-strand synthesis, 47:103
 nonhomologous, 47:103–105
 sequences at 3'-crossing-over site, 47:107, 110
 single template switch, 47:103, 105–106
 site specificity, 47:106–107, 110–111
 three-step process, 47:105–111
 ubiquitin-coding sequences, 47:73–83
 viral gene autarky, 47:85–96
- Petunia* sp., leaf protoplasts, virus infection, 29:228
- Peyer's patches
 epithelial surface, 42:220
 oral vaccination, 41:409, 414
 poliovirus, 34:220
- pH
 animal cells
 early interactions, 36:109
 endocytosis, 36:118, 121–123
 enveloped viruses, 36:131–136
 membrane fusion, 36:126–129
 nonenveloped viruses, 36:136–138
 receptors, 36:111, 117
 antiviral antibody affinity, 34:302
 Bunyaviridae, 40:245–246
 cucumber mosaic virus, 41:290, 294
 divalent cations, 45:73–74
 effect on virus inoculation of vector cell monolayers, 45:271–273
 HEF glycoprotein of influenza C virus, 40:227
 influenza virus, 34:252, 265
 lentiviruses, 34:194
 low, changes in influenza antigenic hemagglutinin sites at, 31:71–73
 lowering by alphaviruses, course of events after, 38:375–376
 pesticide production, 36:339, 341
 potyvirus coat protein, 36:287
 Sindbis virus encephalitis, 36:259–260, 268
- Phage DNA, unusual bases, 27:222–223
- Phage MS2, killed antiviral vaccines, 39:270–271
- Phagocytosis, oral vaccination, 41:415–416, 422, 436
- Pharynx, regions, 42:218
- Phaseolus*, plant viruses in developing countries, 41:358, 371–372
- Phaseolus vulgaris*
 bean golden mosaic virus infection, 30:141–142, 164, 166
 leaf protoplasts, virus infection, 29:228
- Phenolization, archaeobacterial viruses, 34:172
- Phenotype
 adenovirus, 39:92, 105, 109–110
 defective interfering viruses, 40:196
 DNA replication, 34:27
Drosophila retrotransposons
 insertional mutagenesis, 36:77–78, 80–85, 87–90
 scattered repetition, 36:43
 Epstein-Barr virus, 40:19–20, 24, 48
 EBNA-2, 40:29
 HIV-1, 40:12
 latent membrane protein, 40:35–37, 39
 hepatitis A virus, 39:242, 246
 HIV structure, 39:40, 44
 human herpesvirus 6, 41:7, 9–11
 influenza virus
 genetic reassortment, 34:257–258, 260
 genetic resistance, 34:273
 pathogenicity, 34:264
 neurodegenerative diseases caused by prions, 41:267
 oral vaccination, 41:429, 432–433
 picornaviral genomes
 cis-acting elements, 40:117, 120, 122–123
 evolution, 40:160
 mutation, 40:154–158
 RNA replication, 40:152–153
 structure, 40:107
 trans-acting factors, 40:137
 picornaviruses, 36:154
 biological tests, 36:155
 genome, 36:165
 protein analysis, 36:160–161
 RNA, 36:174
 vaccine development, 36:175–176
 poliovirus, 34:239, 242–243
 neurovirulence, 34:227–228, 230, 233, 235
 pathogenesis, 34:224

- Phenotype (*cont.*)
 rotaviruses, **39**:171, 174–176, 178, 180, 184–186, 195–197
 Theiler's murine encephalomyelitis virus, **39**:310
 vaccinia, **34**:46
- Phenotypic variation of bacteria, adherence, **35**:223
- Pheromones, alarm, from aphids, **31**:419
- Philadelphia chromosome, **35**:65–67
- Phlebovirus*, **40**:235–237
 genome organization, **40**:249–251, 254
 structure, **40**:240–241
- Phleboviruses, **40**:235, 262–264
 coding assignments, **31**:32
 coding strategy, **31**:40–41
 genome organization, **40**:244–245, 249, 251–252, 254
 glycoprotein precursor, **31**:32
 L RNA, **31**:31–32
 morphogenesis, **40**:255–256, 259–260
 mRNA transcription processes, **31**:32
 proposed serological classification, **31**:30–31
 RNA species characteristic of, **31**:19
 S RNA transcription processes, **31**:32
 structure, **40**:238, 242
 transmission, **31**:30
- Phloem-limited plant viruses, transport genes in, **38**:225–226
- Phloem tissue, luteovirus tissue, **46**:449–450
- phoP* gene, oral vaccination, **41**:434–436
- Phorbol esters, induced endocytosis, **44**:226, 229
- Phosphate, influenza virus, **34**:253
- Phosphatidylinositol, secondary messengers derived from, **37**:2–3
- Phospholipase C, stimulation by viruses, **45**:75–76
- Phospholipids
 in FV3 virion, **30**:2
 neurodegenerative diseases caused by prions, **41**:244, 253
- Phosphonoacetic acid, **42**:23
 formula, **26**:51
 human herpesvirus 6, **41**:21, 24–25
- Phosphonoformic acid, **42**:23
 human herpesvirus 6, **41**:21, 24–25
- Phosphonoglycolic acid, antiviral activity, **30**:108–109
- 9-(2-Phosphonylmethoxyethyl)adenine, **42**:24–26
- 9-(2-Phosphonylmethoxyethyl)guanine, **42**:25
- Phosphoprotein
 influenza virus, **34**:253
 Paramyxoviridae, **39**:132–134, 138
 genome replication, **39**:152
 transcription, **39**:141, 143, 147–149
- Phosphorylation
 Bunyaviridae, **40**:260
 defective interfering viruses, **40**:195
 DNA replication, **34**:17–18
 Epstein-Barr virus, **40**:29, 37–38
 HIV-1, **40**:12
 HIV structure, **39**:17–18, 52, 54
 influenza virus, **34**:253, 256, 272
 initiation factors, poliovirus infection, **33**:190, 192
 neurodegenerative diseases caused by prions, **41**:269
 parvovirus proteins, **33**:147
 picornaviral genomes, **40**:131, 133–134
 serine, by protein kinase C, **44**:219
 tyrosine, during T cell activation, **44**:221–222
 vaccinia, **34**:57
- Photoinactivation, killed antiviral vaccines, **39**:267–268, 270
- Photosynthesis, mosaics, **33**:236–237
- P3HR1, Epstein-Barr virus, **40**:28, 30–31, 33
- Phytohemagglutinin
 human herpesvirus 6, **41**:3, 8, 27, 32
 lactate dehydrogenase-elevating virus, **41**:140
 pestiviruses, **41**:67
- Phytophthora parasitica*, **29**:225
- Phytoreovirus*, **38**:254–256; **45**:253–259
 characteristics, **38**:251–252
 genome organization for, **38**:260–291
- Phytosanitary problems, plant viruses in
 developing countries, **41**:378, 397
 agricultural modernization, **41**:352
 crop improvement, **41**:363
 remedial action, **41**:380, 383, 386–387, 389, 393–394
- Pichinde virus
 G1 and G2 proteins, **31**:6
 gene products
 coding, **31**:10–14

- comparison with lymphocytic choriomeningitis virus-type species, **31:11**
 - GPC primary, **31:6**
 - L RNA species, **31:8**
 - nucleocapsids, **31:7**
 - reassortment, **31:19**
 - S RNA species, **31:8**, 10–14
 - intergenic region, inverted complementary sequence, **31:15–16**
 - subgenomic, **31:13–14**
- Picorna-like virus supergroup
 - replication proteins, **47:199–203**
 - 3'-terminal structures, **47:218–220**
- Picornaviral genomes, 5'-untranslated region, **40:103–162**
- cis-acting elements, **40:114–116**
- initiator codon, **40:116–117**
- negative control element, **40:127–129**
- positive control element, **40:117–126**
- evolution, **40:158–162**
- mRNAs, **40:143**
- cap independence, **40:145–147**
- negative control elements, **40:147–149**
- potentials, **40:149–151**
- ribosome binding, **40:143–145**
- phenotypic expression, **40:154–158**
- primary structure, **40:107–108**
- region of, **40:103–104**, 162
- RNA replication, **40:151–154**
- secondary and tertiary structures, **40:108–114**
- size, **40:104–107**
- trans-acting factors
 - interactions, **40:135–138**
 - mRNAs, **40:129–131**
 - RNAs, **40:131–135**
- translation initiation, **40:139–143**
- Picornaviridae, **46:2**
- poliovirus, **34:218**
- Picornavirus 3A protein, **45:79–81**
- Picornaviruses, *see also* Coxsackie A virus
 - attachment proteins, **27:187**
 - cellular receptors, **27:187–188**
 - cucumber mosaic virus, **41:305**
 - diagnosis with
 - MAbs, **29:101**
 - synthetic peptides, **42:168–169**
 - early replication inhibition by
 - 2-(3,4-dichlorophenoxy)-5-nitrobenzonitril, **30:91**
 - 4'5-dihydroxy-3,3',7-trimethoxyflavone, **30:90**
 - hepadnavirus, **34:97**
 - hepatitis A virus, **39:222–223**, 225–227, 232, 243
 - HIV structure, **39:21–22**, 24, 29
 - inhibition of translation by, **33:194–195**
 - competition model, **33:195–196**
 - other models for cardioviruses, **33:196–198**
 - interferon-induced antiviral actions, **42:82**
 - penetration and uncoating, **27:188–189**
 - receptors, **44:204**, 207
 - recombination, **44:146**
 - replication complexes, binding to
 - 3'-terminal sequences, **47:219**
 - Theiler's murine encephalomyelitis virus, **39:291–294**, 311; **42:266–270**
- PID gene, **29:23–24**
- PID-1 gene, **29:4**
- Pig, ASF in, *see* African swine fever
- Pipets, in plant virus research, **29:222**
- Pisum sativum*, plant viruses in developing countries, **41:370**, 372
- Placenta, Akabane virus replication, sheep, **30:293**, 300
- Plantago mottle virus, *Plantago* host and occurrence, **27:116**, 129
- Plantago severe mottle virus, *Plantago* host and occurrence, **27:112**, 120
- Plantago* spp.
 - agricultural aspects, **27:108–111**
 - in bird seed, **27:111**
 - commercial uses, **27:110–111**
 - in forage mixtures, **27:110**
 - in herbal remedies, **27:110–111**
 - occurrence and ecology, **27:105–108**
 - as problems in seed cleaning, **27:109–110**
 - viruses affecting, **27:103–140**
 - in Great Britain, **27:117–118**
 - importance, **27:119–131**
 - list, **27:112–116**
 - transmission, **27:117**
 - as weeds within crops, **27:108–109**

- Plantago yellows disease, *Plantago* host and occurrence, 27:116
- Plantain virus 4, *Plantago* host and occurrence, 27:114, 124
- Plantain virus 5, *Plantago* host and occurrence, 27:115, 128
- Plantain virus 6, *Plantago* host and occurrence, 27:115, 129
- Plantain virus 7, *Plantago* host and occurrence, 27:113, 122
- Plantain virus 8, species affected and occurrence, 27:112, 119
- Plantain viruses A and B, *Plantago* host and occurrence, 27:116, 130
- Plantain virus X, *Plantago* host and occurrence, 27:112, 120
- Plant breeding, host passage effects, 25:185–187
- Plant cell
 - auxin requirements, 29:223–224
 - from callus tissue, infection, 29:248–251
 - suspension culture, 29:216
 - isolation of protoplasts from, 29:223–225
 - viroid-infected, 29:250–251
 - virus particle-infected, 29:248–250
- Plant disease, biocontrol, *see* Satellite RNA, biocontrol of plant disease
- Plant introduction, plant viruses in developing countries, 41:353
- Plant material
 - decaying, release of viruses, 31:326–327
 - roots or seeds, uptake of viruses, 31:328–329
 - undisturbed roots, release of viruses, 31:326–327
- Plant propagation material, plant viruses in developing countries and agricultural modernization, 41:351–354
- certification, 41:386–387
- health improvement, 41:379–380, 391–396
- quarantine, 41:385–386
- rehabilitation, 41:384
- risk analysis, 41:387–391
- virus-free material, 41:380–384
- Plant protoplasts, electrotransfection with viral nucleic acids, 37:329–341
- Plant reoviruses, 45:249–277, *see also*
 - Rice dwarf virus
 - biological properties, 38:258–260
 - characters of taxonomic importance in, 38:250–253
 - classification, 38:250–253; 45:250–251
 - fijivirus, 45:258, 260
 - genome organization, 38:260–291
 - genomes, structural and functional properties, 38:249–302
 - genome segment characteristics, 45:264
 - inter- and intraviral sequence relationships, 45:261–267
 - nucleic acid in, 38:256
 - oryzavirus, 45:260–261
 - particle morphology, 38:253
 - physical properties, 38:253–256
 - phytoreovirus, 45:253–259
 - plants transformed by cDNAs, studies using, 45:268
 - protein, 38:254–256
 - segment-specific inverted repeats, 45:252–254
 - terminal oligonucleotide sequence, 45:251–253
 - vector cell monolayer studies, 45:269–275
 - adsorption and penetration of virus particles, 45:273
 - cell line establishment, 45:269–271
 - pH effect on virus inoculation, 45:271–273
 - virus growth curves, 45:273–275
- Plants
 - antiviral substances, 29:251–255
 - caulimovirus infection
 - plasmodesmata role, 32:45
 - protoplast use in studies of, 32:46
 - cell differentiation, regulation, 29:87
 - cell growth, regulation, 29:87
 - cryptic viruses
 - in cells and organs, 32:191–194
 - distribution in cultivars, 32:194–195
 - culture, for protoplast isolation, 29:217–218
 - defense reactions, 29:344–345
 - dicotyledonous, geminiviruses
 - leafhopper-transmitted, 30:144–145
 - whitefly-transmitted, 30:141–143
 - healthy, dsRNA particles, 32:208–209

- leaves, pretreatment, for protoplast isolation, **29:218–219**
- male-sterile lines, dsRNA, **32:208**
- monocotyledonous, leafhopper-transmitted geminiviruses, **30:143–144**
- resistance against viral infections, **29:251–255, 314, 337–348**
 - extreme, **29:337–341**
 - facultative, **29:337–341, 343, 346**
- tissue culture, **29:216**
- transmission, **32:172, 179, 189–190**
- viral infection sequence, **29:338**
- virus disease, MAbs, **29:102**
- virus-infected
 - chimeric protein, **29:323**
 - differential temperature treatment, **29:349–356**
 - pathogenesis-related proteins, **29:322**
- virus interactions with, **26:201–237**
 - antiviral substances, **26:213–217**
 - localization, **26:202–205, 208–210**
 - necrogenesis, **26:205–208**
 - resistance, **26:214–217**
 - virus multiplication, **26:210–217**
- wound-inducible hormone in tumorigenesis, **29:85–87**
- Plant virology, electrotransfection in, applications and prospects, **37:339–341**
- Plant virus-coded transport function
 - cAMP in, **38:227–228**
 - compartmentalization, **38:239**
 - compatibility with hypothetical host factors, **38:240–241**
 - complementation between related and unrelated viruses, **38:231–238**
 - energy dependence, **38:241–242**
 - expression
 - and plant virus genome organization, **38:203–226**
 - by viral genomes, **38:201–242**
 - virus-host compatibility needed for, **38:226**
 - host dependence, **38:226–231**
 - knowledge advances, **38:202–203**
 - phenomenological nonspecificity, on complementation, **38:231–238**
 - threshold concentration, **38:239**
 - ts, host-dependent suppression, **38:227**
 - viral coat protein gene in, **38:230–231**
 - virus-specific factors in, **38:229–231**
 - vRNP as possible additional element, **38:241**
- Plant viruses, *see also specific viruses*
 - acquired resistance, **29:320**
 - Aleyrodidae as vectors, **28:135–137**
 - antisera, **29:132**
 - aphids as vectors, **28:114–133**
 - cell-to-cell movement, **29:251–252, 313–314**
 - means, **29:344–345**
 - deletion mutation, **25:219**
 - diagnosis, **29:161**
 - division into tentative transport groups, **38:206–226**
 - DNA, infection of protoplasts, **29:241**
 - DNA-containing, **25:16–17**
 - dsDNA, **28:5–12**
 - dsRNA, **25:16**
 - elements, **38:203–205**
 - epitopes, **29:132**
 - in first transport group, **38:206–216**
 - formation and expression in infected cell, **25:9–14**
 - genetic engineering with, **28:1–33**
 - genome organization, and transplant function expression, **38:203–226**
 - genome transport
 - from infected to healthy cells, **29:315–317**
 - phenomenon, **29:315–319**
 - role of plasmodesmata, **29:314–319**
 - highly purified, for hyperimmunization of mice, **29:136–137**
 - host range control, role of transport function, **29:341–344**
 - immunosorbent electron microscopy, **29:186, 192–193**
 - infection
 - effect on antibiotic production in fungi, **29:256–257**
 - subliminal symptomless, **29:345–348**
 - systemic, **29:313**
 - transport from, **29:348–359**
 - interaction between, leading to transport function complementation, **29:336–337**
 - interactions with host
 - induction of symptoms, **33:206–208**
 - viral properties specifying symptom type, **33:208–217**

- Plant viruses (*cont.*)
- interactions with host (*cont.*)
 - virus-coded proteins and possible functions, **33:217–224**
 - MAbs, **29:132–168**
 - mosaic group, **29:317–318**
 - mRNA translation, factors controlling, **25:72–75**
 - peculiarities, **25:35–72**
 - structural and functional aspects, **25:17–18**
 - mutants, complementation between, **29:332–336**
 - nucleic acid type in, **28:1–33**
 - origin in environmental waters, **31:326–329**
 - release from roots and plant material, **31:326–327**
 - sewage, **31:327–328**
 - uptake through roots or seeds, **31:328–329**
 - phloem-limited, **29:318**
 - complementation with helper virus, **29:343–344**
 - transport genes in, **38:225–226**
 - precipitin test, **29:132**
 - propagation, **25:196–197**
 - in protoplasts
 - dot molecular hybridization, **29:247**
 - electron microscopy, **29:247**
 - sucrose gradient assay, **29:247**
 - pseudococcidae as vectors, **28:133–135**
 - recovery from water samples, methods, **31:321–322**
 - replication
 - bioassay, **29:243–244**
 - determination, **29:243–247**
 - inhibition by plants, **29:253–254**
 - research, use of protoplasts and separated cells, **29:215–262**
 - in rivers and lakes
 - elongated viruses, **31:322–323**
 - isometric viruses, **31:323–324**
 - RNA
 - detection, in protoplasts, **29:247**
 - infection of protoplasts, **29:235–241**
 - replication, virus-coded products in, **29:328**
 - in subliminal infection, **29:347**
 - satellite systems in, **25:68–72**
 - in second transport group, **38:216–219**
 - serological detection, **29:244–247**
 - fluorescent antibody staining, **29:244–245**
 - peroxidase staining, **29:245–246**
 - quantitation of virus antigens in protoplasts, **29:246–247**
 - staining methods, **29:244–246**
 - ssDNA, **28:13**
 - ssRNA, **28:15–18**
 - state of occurrence in waters, **31:324–326**
 - sternorrhyncous vectors, **28:113–140**
 - in third transport group, **38:219–223**
 - transport
 - efficiency, determination, **29:319–322**
 - function, **29:313–364**
 - in vascular bundles, **29:253**
 - transport function, interviral phenomenological exchangeability, **38:226–228**
 - tropism to cell types, in facultative resistance, **29:343**
 - unrelated vector, infection, **25:232**
 - vector cell monolayers, **25:192–266**
 - as vehicle for genetic information, **29:256**
 - virion minus-strand RNA containing, **25:14–16**
 - virion plus-strand RNA containing, **25:9–10**
- Plant viruses in developing countries, **41:349–350**
- agricultural modernization, **41:351**
 - crop improvement, **41:351**
 - plant propagation material, **41:351–354**
 - crop improvement, **41:354**
 - cropping, **41:354–361**
 - intensification, **41:375–377**
 - crop protection, **41:372–375**
 - genetic crop upgrading, **41:361–372**
 - plant propagation material
 - certification, **41:386–387**
 - health improvement, **41:379–380, 391–396**
 - quarantine, **41:385–386**
 - rehabilitation, **41:384**
 - risk analysis, **41:387–391**
 - virus-free material, **41:380–384**
 - remedial action, **41:377–379**

- risks, **41:396–398**
 zucchini yellow mosaic virus, **41:371, 377**
- Plaque assays
 hepatitis A virus, **39:228, 230**
 rotaviruses, **39:192**
 studies, **39:174, 176, 178–179, 184–185**
 in vitro reassortment, **39:168–169**
- Plaque-forming units, poliovirus, **34:238**
- Plasma
 hepatitis A virus, **39:210**
 hepatitis C virus, **40:60, 64, 74, 78**
- Plasma cells, lentiviruses, **34:203**
- Plasma membrane
 animal cells, **36:107–108**
 early interactions, **36:109**
 endocytosis, **36:117, 123**
 enveloped viruses, **36:133, 136**
 macromolecule transport, **36:111**
- Bunyaviridae, **40:236, 260, 262**
 defective interfering viruses, **40:191–195**
- Epstein-Barr virus, **40:26, 37–40, 47**
 furoviruses, **36:10–11**
- HEF glycoprotein of influenza C virus, **40:224**
- influenza virus
 components, **34:249, 252, 254–255**
 pathogenicity, **34:265**
 lentiviruses, **34:191**
 signal transduction from, **37:2–16**
- Plasmaviridae, basic properties, **27:210**
- Plasmids
 archaeobacterial viruses, **34:185**
 Halobacterium halobium, **34:154–157**
 Sulfolobus virus-like particle SSV1, **34:177–179**
 bacteriophages, **27:263–265**
 defective interfering viruses, **40:205**
- DNA replication, **34:2, 33**
 adenovirus, **34:4–5**
 bovine papillomavirus, **34:21–28**
 Epstein-Barr virus, **34:29–32**
 SV40, **34:11**
- Epstein-Barr virus, **40:41, 43–44, 46–48**
 hepadnavirus, **34:99–100, 103–106**
 HIV structure, **39:33**
 oral vaccination, **41:428–430, 433, 437**
- P, encoded receptor, PRD1, **45:299–301**
- picornaviral genomes, **40:118, 136**
- poliovirus, **34:230**
 vaccinia, **34:45**
 genome, **34:48**
 vector, **34:51, 53**
- Plasmin, influenza virus, **34:265**
- Plasmodesmata
 diameter, **29:315**
 role in virus transport function, **29:315, 344–345**
 structure, **29:315**
 tropism of transport proteins for, **38:239–240**
- Plasmodium berghei*, oral vaccination, **41:419, 423**
- Plasmodium yoelii*, oral vaccination, **41:419, 423, 430**
- Platelet-derived growth factor, in signal transduction, **37:4–9**
- Platelets, pestiviruses, **41:64**
- Pleomorphic bacteriophages, distribution, **27:217–219**
- Plum pox virus
 immunosorbent electron microscopy, **29:175**
 potyvirus coat protein, **36:276, 307**
 structure, **36:281, 283, 285–287**
- PMN, *see* Polymorphonuclear neutrophils
- Pneumocystis carinii* pneumonia, AZT for, **35:274**
- Pneumonia
Chlamydia, **43:39**
 influenza virus, **34:268, 274**
 Legionellosis, **43:38**
 lentiviruses, **34:189–190**
 structure, **34:193, 195**
 virus-host cell interaction *in vitro*, **34:196–197**
 virus-host cell interaction *in vivo*, **34:202**
- Pneumoviruses, Paramyxoviridae, **39:131–132, 136–138, 140, 144, 149**
- Poinsettia cryptic virus, not identified as cryptic virus, **32:181**
- Pokeweed antiviral protein, antiviral activity, **30:112**
- Polarity
 influenza virus, **34:248**
 vaccinia, **34:46**
- Polarized epithelial cells, **42:187–235**

- Polarity (*cont.*)
- alimentary canal, 42:217–225
 - basal membrane, 42:188–190
 - in culture, 42:195–198
 - domains, 42:188–189
 - established cell lines, 42:195–198
 - genitourinary tract, 42:230–232
 - macula adherens, 42:192
 - neuronal cells, 42:232–233
 - properties, 42:188–193
 - protein sorting mechanisms, 42:205–207
 - respiratory system, 42:225–230
 - role in establishment of local or systemic viral infections, 42:209–211
 - significance of polarity to viral pathogenesis, 42:207–209
 - skin, 42:211–217
 - surfaces, 42:192–193
 - viral glycoproteins, 33:32–33
 - viral persistence, 42:233
 - virus entry, 42:198–201
 - virus release, 42:199–205
 - zonula adherens, 42:191–192
 - zonula occludens, 42:190–191
- pol* gene
- HIV-1, 40:2
 - HIV structure, 39:10–11, 16, 19
 - integrase, 39:39
 - protease, 39:24–29
 - reverse transcriptase, 39:29–38
 - for polyprotein
 - hepadnaviruses, 32:54
 - MoMLV, 32:50–51, 71–72
 - translational suppression by retroviruses, 41:194, 196–197
 - readthrough suppression, 41:197–203, 205, 207–209
 - ribosomal frameshifting, 41:211–212, 214, 219–223, 229–231
- Polioencephalomyelitis, 39:295–296
- Poliomyelitis
- age-dependent, *see* Age-dependent poliomyelitis
 - Finnish
 - contributing factors, 37:253–254
 - elimination, 37:244–246
 - no poliovirus circulation, 37:247–248
 - outbreak, 37:243–273
 - control, 37:252–253
 - salient features, 37:251–252
 - strains causing, 37:254–259
 - viral antigenic sites, 37:259–268
 - return to vaccinated population, 37:249–254
 - immunizations for, antibody responses
 - in, site specificity of, 37:268–272
- Poliomyelitis virus, 39:292, 299
- Poliovirus, 29:31; 34:217–218, 239–244; 46:1–56
- animal cells, 36:117, 136
 - antigenic drift, 37:261–263
 - arginine residues, 46:50–51
 - assembly, 29:116–117
 - pathways, 46:20–21
 - phenotypes, 46:53–54
 - process, 46:34–38, 53–56
 - β -barrel, 46:16–17
 - capsid, 29:116
 - cavity associated with, 46:50
 - empty, 46:25–29, 55–56
 - protein–RNA binding, 46:51
 - capsid proteins, alpha carbon models, 32:11–13
 - cascade of polyprotein processing, 46:3–4
 - chimeric vaccine, 32:162
 - coding portion, 46:5
 - endocytosis
 - by M cells, 42:221
 - receptor-mediated, 34:219
 - enterovirus infections, 42:224–225
 - genomic organization, 46:3–6
 - hepatitis A virus, 39:222, 231–232, 241–243, 245
 - HIV structure, 39:23–24, 29, 49
 - host protein synthesis inhibition
 - alteration of intracellular ion levels, 33:192–193
 - competition between viral and host mRNAs, 33:193
 - dsRNA, 33:191–192
 - mRNA, 33:193–194
 - infection of cells, 47:211–212
 - interserotype recombinants, 32:18–19
 - life cycle, 46:6–14
 - events, 46:8
 - protease 2A^{PRO} release, 46:11–12
 - protease 3C^{PRO} release, 46:12–13
 - RNA
 - replication, 46:13–14
 - translation, 46:10–11

- virus entry and uncoding, **46:7**, 9–10
- membrane permeability, **45:79–81**
- morphogenesis, **46:19–30**
 - empty capsid, **46:25–29**
 - 55 protomer, **46:20–22**
 - provirion, **46:29–30**
 - 14S protomer, **46:22–24**
- mRNA translation, **33:184–185**
- neurovirulence
 - definitions, **34:222–223**
 - mice, **34:235–239**
 - molecular basis, **34:228–235**
 - Sabin attenuated strains, **34:227–228**
 - variants, **34:223–226**
- no circulation in Finnish population, **37:247–248**
- 5′-NTR, **46:4–5**
- oral vaccination, **41:413**, 428
- pathogenesis
 - entry, **34:220–221**
 - host range, **34:222**
 - tissue tropism, **34:221–222**
- phenotypic variation, significance, **37:265–268**
- picornaviral genomes, **40:155–160**
 - cis-acting elements, **40:117–125**, 127–128
 - mRNAs, **40:145–146**, 148–149
 - structure, **40:104–105**, 107–111, 113
 - trans-acting factors, **40:132–137**
 - translation initiation, **40:139**, 141–142
- picornaviruses, **36:153–154**
 - biological tests, **36:155–158**
 - genome, **36:162–165**
 - protein analysis, **36:158–161**
 - recombinants, **36:168**, 170–171
 - revertants, **36:165–168**
 - vaccine development, **36:176**
- potyvirus coat protein, **36:289**
- protein cleavage inhibition, **30:113**
- proteolytic cleavages, **46:5–6**
- reappearance in Finnish population, **37:249–251**
- recombinant vaccinia virus
 - assembly process studies, **46:34–35**
 - vectors, P1 and 3CD expression, **46:35–37**
- recombination, **46:85**
- replicative intermediates, **47:184**
- RNA
 - replication, **47:161–162**, 177, 201, 207–208
 - 5′-terminal strands, **47:222**
- RNA encapsidation, **46:30–34**
 - defective interfering particles, **46:31–32**
 - RNA requirements, **46:31**
 - signals, **46:32–33**
 - studies, complementation system, **46:39–53**
 - subcellular location, **46:33–34**
- RNA–protein interactions, **46:49–50**
- 3′-RNA terminal, **47:219**
- serological types, **46:2**
- 14S pentamers, **46:55**
- strains
 - comparison, MAb role, **29:102**
 - type 3, from outbreak in Finl, **37:254**
 - uncommon antigenic structure, outbreak in Finl, **37:253**
- β strands, **46:16–17**
- structure, **34:218–219**
- subgenomic replicon, **46:52**
- Theiler's murine encephalomyelitis virus, **39:291**, 293–294, 311
- type 3, neutralization, **29:112**
- uncoating inhibition by
 - arildone, **30:88–89**
 - arildone derivatives, **30:89**
- variants, **37:259–261**
- virion, **46:14–19**
 - capsid protein myristylation, **46:18–19**
 - properties, **46:15–16**
 - structure, **46:16–18**
- VP1
 - amino-terminal portion, **46:47–49**
 - detection, **29:106**
- Poliovirus-infected cells
 - cap binding factor, p200 as subunit, **31:259–260**
 - early inhibition of host protein synthesis, p200 cleavage, **31:257–259**
 - eIF-3 inactivation, p200 cleavage, **31:260/261**
- Poliovirus infection, CBP complex role in shutoff of host mRNA translation complex inactivation by infection, **33:185–187**
- criticism of model, **33:191**

- Poliovirus infection, CBP complex role in shutoff of host mRNA translation (*cont.*)
 early studies, **33:184–185**
 mechanism of inactivation, **33:187–188**
 mediation of p220 cleavage, **33:188–191**
- Poliovirus type3/Finland/84 strains, **37:254–259**
 antigenic properties, **37:255–257**
 difference from vaccine strains, **37:254–255**
 further fate, **37:258–259**
 host-dependent modification of antigenic site 1, **37:263–265**
 origin, **37:258–259**
 and P3/Saukett-NPHI, antigenic differences in recognition of, **37:270–272**
 variation, **37:257**
- Poliovirus type 3 mutants
 attenuation-induced, **32:16–18**
 VP1, immunogenic site, **32:10–11**
- Poliovirus vaccine, inactivated
 improvement in, potential for, **37:269–270**
 and oral, differential responses, **37:268–269**
 whole virion, **32:21**
- Pol protein
 badnaviruses, **44:43–44**
 caulimoviruses, **44:43**
 feline immunodeficiency virus, **45:231–235**
 hepadnaviruses, **44:41–42**
 HIV-1, **40:2**
 retroviruses and retrotransposons, **44:40–41**
 translation, **44:40–41**
 Gag:Pol ratio regulation, **44:44–45**
- Poly(A), addition to adenovirus mRNA, **26:18–23**
- Poly(A) site, **44:26–32**
 absence of complete signal at 5' end, **44:28–29**
 occlusion by promoter proximity, **44:29**
 regulation, **44:26–28**
 HIV-1, **44:31–32**
 use efficiency modulation by sequences in U3, **44:29–31**
- Polyacrylamide gel electrophoresis
 ADRV, **35:194–195, 197–198, 200–202**
 cucumber mosaic virus, **41:286, 288**
 picornaviruses, **36:160–161**
- Polyadenylation
Drosophila retrotransposons, **36:53, 70**
 Paramyxoviridae, **39:142–143, 145–146**
 parvovirus DNA, **33:117**
 potyvirus coat protein, **36:276**
 regulation during adenovirus transcript processing, **31:205–207**
 RSV RNA, **35:17–18**
 Sindbis virus encephalitis, **36:257**
 Theiler's murine encephalomyelitis virus, **39:293**
- Polyamines, archaeobacterial viruses, **34:180**
- Polycistronic mRNA
 expression, peculiarities, **25:10–14**
 independent gene translation, **25:11**
- Poly(C,S⁴,U₁₀), single-stranded, antiviral activity, **30:107**
- Polyethylene glycol
 furoviruses, **36:15–16**
 picornaviruses, **36:157**
- Polyhedrin, **29:202**
 baculovirus vectors for foreign gene expression, **35:178**
- Polyhedrosis virus
 cytoplasmic, *see* Cytoplasmic polyhedrosis virus
 nuclear, **29:195–198, 210**
- Poly(L-lysine) conjugates, **35:292**
- Polymerase
 Berne virus, **43:247**
 Bunyaviridae, **40:244, 257, 263**
 defective interfering viruses, **40:182–183, 194**
 hepatitis B virus, **47:267–268**
 hepatitis delta virus, genome replication, **43:199–201**
 influenza virus, **34:259, 261**
 picornaviral genomes, **40:143–144, 152, 154, 161**
 plant virus symptoms, **33:221–222**
 Theiler's murine encephalomyelitis virus, **39:294**
 viral HSV DNA, properties, **37:104–106**

- Polymerase-associated proteins, influenza virus, **34:249**
- Polymerase chain reaction
 amplification of torovirus reverse transcriptase, **43:265**
 assays, coxsackie A viruses, **42:345–346**
 defective interfering viruses, **40:185, 189, 194, 196**
 hepatitis C virus
 cloning, **40:67, 69–70, 75**
 infectious agent, **40:62**
 prevention, **40:80–81**
 replication, **40:77**
 hepatitis E virus, **40:89**
 human herpesvirus 6, **41:23, 26, 28–29**
 killed antiviral vaccines, **39:284**
 pestiviruses, **41:85**
 positive-strand RNA viruses, **41:148, 158**
 technique in HPV diagnosis, **37:160**
- Polymerase gene, full-length, transformation with, tombusviridae, **44:418–419**
- Polymeric carriers of antiviral agents, **35:293**
- Polymerization
 cucumber mosaic virus, **41:316**
 DNA, RNA- and DNA-dependent, **46:131–133**
 by HIV-1 reverse transcriptase, fidelity, **46:133–134**
 HIV structure, **39:4, 11, 21, 56**
pol gene products, **39:29–38**
 neurodegenerative diseases caused by prions, **41:248, 270**
 oral vaccination, **41:424–425**
- Polymethyl methacrylate microcapsules, delivery of antiviral agents, **35:298–299**
- Polymorphism, neurodegenerative diseases caused by prions, **41:256, 261**
- Polymorphonuclear granulocytes, respiratory defense mechanisms, **35:229–230**
- Polymorphonuclear neutrophils, in bovine herpesvirus infection, **45:206, 212–213**
- Polymyxin B, **29:282**
- Polynucleotide kinase, archaeobacterial viruses, **34:172**
- Polynucleotides, killed antiviral vaccines, **39:261, 267, 281–282**
- Polyomavirus, **42:233–234**
 animal cells, **36:136**
 cellular receptors, **27:147**
 dsDNA, resistance to radiation, **29:33**
 T antigen, **29:97**
- Polypeptides
 adenovirus
 early, **25:373–375**
 intermediate, **25:382–384**
 late, **25:390–391**
 animal cells, **36:125, 129, 135, 138**
 archaeobacterial viruses, **34:180**
- Bunyaviridae
 genome organization, **40:243–246, 248–253**
 morphogenesis, **40:260–261**
 structure, **40:238–239**
- cucumber mosaic virus, **41:287**
 data base searches, **38:291–292**
 defective interfering viruses, **40:201**
 DNA replication, **34:9**
- Drosophila* retrotransposons
 insertional mutagenesis, **36:81**
 intracellular cycles, **36:63**
 organization, **36:56**
 transcription, **36:69–70**
- expression of cloned genomic segments, **38:299–302**
- furoviruses, **36:27**
 beet necrotic yellow vein virus, **36:18–21**
 particle dimensions, **36:17**
 peanut clump virus, **36:27**
 soil-borne wheat mosaic virus, **36:24–26**
- HEF glycoprotein of influenza C virus, **40:214, 216–217, 225–226, 229**
- hepadnavirus, **34:67, 135**
 characterization, **34:86, 89–91**
 pre-S sequences, **34:99, 101–103, 112**
- hepatitis A virus, **39:223, 225, 243**
 hepatitis C virus, **40:64, 66**
 HIV structure, **39:25, 32, 47**
 human herpesvirus 6, **41:19–21, 38–39**
- HVT-specific
 immunoprecipitation, **30:241–242, 250**
 two-dimensional gel electrophoresis, **30:246–247**

- Polypeptides (cont.)**
 influenza virus, **34:251, 273**
 lentiviruses, **34:192–194**
 MDV-specific
 immunoprecipitation, **30:241–242, 250**
 two-dimensional gel electrophoresis, **30:246–247**
 nonstructural, parvoviruses, **33:127–137, 143**
 oral vaccination, **41:413, 426**
 Paramyxoviridae, **39:131–132, 147–148**
 parvovirus capsids, **33:98–104, 143**
 pestiviruses, **41:78–79**
 Phytoreovirus, **38:254–256**
 picornaviral genomes
 cis-acting elements, **40:114–116, 118, 120, 125**
 mRNAs, **40:144**
 RNA replication, **40:153–154**
 structure, **40:107**
 trans-acting factors, **40:129, 138**
 plant reovirus sequence information, comparison, **38:292–299**
 poliovirus, **34:218–219, 237**
 potyvirus coat protein
 genome organization, **36:277, 279**
 structure, **36:280, 288–289**
 Sindbis virus encephalitis, **36:257**
 structural, parvoviruses, **33:122–127**
 vaccinia, **34:44**
 genome, **34:46–47, 49**
 vector, **34:58**
 viral, inhibition of host mRNA synthesis, **33:193–194**
 virally encoded, for plant reoviruses, **38:291–302**
 virus-induced, **25:364–368**
 VP1-VP4 of HAV, **32:143**
 use for animal vaccination, **32:160–161**
- Polyprotein**
 hepatitis A virus, **39:232, 242–243, 246**
 HIV structure, **39:22, 24, 27–29, 33, 39**
 lentiviruses, **34:194, 200**
 pestiviruses, **47:58–64**
 poliovirus, **34:219**
 precursor Pr p175, pestiviruses, **41:82**
 Theiler's murine encephalomyelitis virus, **39:294**
- Polyribonucleotides, interferon type I, **30:117**
- Polysaccharides**
 archaeobacterial viruses, **34:144**
 sulfated, **42:2–5**
- Polysomes, influenza virus, **34:249**
- Polyvinyl sulfate, influenza virus, **34:252**
- Polyviruses, cytopathic structures, **47:212**
- Population dynamics, host-iridovirus, models, **46:391**
- Populations**
 ancient human, HTLV-1 and -2 as privileged markers of migration, **47:411–412**
 Finnish, and poliomyelitis vaccination, **37:247–254**
 host, iridovirus persistence, **46:396–397**
 killed antiviral vaccines, **39:266–267**
 Pacific, HTLV-I epidemiology, **43:148–155**
- Pork products, ASF, **35:254–255**
- Positive-stranded RNA viruses, **31:1–2; 41:99–102, 180–182; 47:159–236**
 adaptations, **47:160–161**
 assembled replication complexes, **47:214**
 capping and methylation enzymes, **47:187–190**
 control of asymmetric positive- and negative-strand synthesis, **47:233–235**
 evolutionary pathways, **47:159–160**
 genome-linked virus proteins, **47:190–191**
 genome replication, **47:161**
 helicases, *see* Helicases, positive-stranded RNA viruses
 host proteins, RNA replication, **47:205–209**
 infection of cells, **47:211–212**
 lacking NTP-binding motifs, **47:180**
 nsP1 mutants, mapping, **47:189**
 ORFs, **47:169**
 properties, **47:168, 170–173**
 replication complexes and virus movement in plants, **47:205**
 replication proteins, **47:191–203**
 alpha-like virus supergroup, **47:191–197**
 carmo-like virus supergroup, **47:197–199**

- corona-like virus supergroup, **47:203**
 picorna-like virus supergroup,
 47:199–203
 sobemo-like virus supergroup, **47:199**
 RNA-dependent RNA polymerase,
 47:161–173
 RNA replication, *see* RNA replication
 subgenomic RNAs, **47:162**
 Postinfectious encephalomyelitis,
 42:281–282
 Postnatal infections, pestiviruses, **41:66,**
 68–69, 90–91
 Posttranscriptional processing, HIV-1,
 40:3
 Posttranslational modifications
 Epstein-Barr virus, **40:29**
 HIV-1, **40:3, 12**
 HIV structure, **39:12, 17**
 prion proteins, **35:102–104**
 Potato, plant viruses in developing coun-
 tries, **41:368–369, 372, 384**
 Potato leafroll virus, **33:302**
 complementation with helper virus,
 29:343–344
 immunization of mice, **29:136**
 immunosorbent electron microscopy,
 29:173
 infection diagnosis, **46:451**
 MAb-determined antigenic properties,
 29:152
 MAbs, **29:135**
 particle assembly determinants, **46:448**
 P4 protein, **46:430–431**
 replication, **46:449–450**
 resistance to, **46:452**
 RNA translation, **46:439–440**
 subgenomic mRNA synthesis, **46:440–**
 442
 yield of positive hybridomas, **29:140–**
 142
 Potato mop-top virus
 cytopathology, **36:9–10**
 immunosorbent electron microscopy,
 29:173–174
 natural occurrence, **36:3, 7–8**
 particle dimensions, **36:18**
 purification, **36:16**
 vectors, **36:12–15**
 Potato spindle tuber viroid, **33:223**
 infection of plant cell culture, **29:250–**
 251
 protoplast, **29:241–242**
 Potato virus, satellite RNA for bio-
 control, **39:324**
 Potato virus A, MAbs, **29:135**
 Potato virus T, **25:115–116**
 Potato virus X, **33:221**
 complementation with phloem-limited
 virus, **29:343–344**
 furoviruses, **36:21**
 as helper for tobacco mosaic virus mu-
 tants in cell-to-cell movement,
 29:334–336
 as helper virus, **29:342**
 host passage effects, **25:176**
 Plantago host and occurrence, **27:112,**
 120–121
 potyvirus coat protein, **36:286, 289**
 protoplast infection, **29:228**
 replication
 inhibition, **29:254**
 stimulation, in double infection,
 29:336–337
 RNA, in subliminal infection, **29:347–**
 348
 virus-specific informosome-like
 ribonucleoprotein, **29:350–352**
 Potato virus Y
 in double infection with potato virus
 X, **29:336**
 immunosorbent electron microscopy,
 29:172, 176
 MAb-determined antigenic properties,
 29:153
 MAbs, **29:135**
 diagnosis with, **29:162–163**
 Plantago host and occurrence, **27:112,**
 120–121
 positive hybridomas, **29:140–143**
 potyvirus coat protein, **36:275**
 structure, **36:280–283, 285–287, 290**
 taxonomy, **36:292, 298**
 strains, **29:153**
 Potato yellow dwarf virus, **25:221–**
 223
 host passage effects, **25:180**
 membrane, **25:265–266**
 protoplast infection, **29:227**
 vector cell monolayer, growth curve in,
 25:244–246
 Potexviruses, **25:44–45**
 identification, **31:323**

- Potexviruses (*cont.*)
Plantago hosts and occurrence, **27:112**,
 120
 transport function, **38:219–221**
- Potyvirus coat protein, **36:273–376**
 genome organization, **36:276–279**
 structure
 molecular weight, **36:280–281**
 primary, **36:281–285**
 secondary, **36:285–287**
 tertiary, **36:287–290**
 subgroups, **36:304–306**
 taxonomy, **36:290–291**
 amino acids, **36:291**, 293
 antigenic properties, **36:299–304**
 peptide mapping, **36:291–295**
 sequence homology, **36:293**, 296–
 299
- Potyvirus
 aphid transmission, **28:116–117**
 description, **31:389–390**
 MAb-determined antigenic properties,
29:153–154
Plantago hosts and occurrence, **27:112–**
 113, 120–122
 transport function, **38:215–216**
- Poxviridae, **29:195**
- Poxviruses
 ASF, **35:252**
 high-voltage electron microscopy, **30:67**
 infection by epidermal trauma,
42:213–214
 morphology, **27:4**
 vaccinia, **34:43**
- P protein
 Berne virus, **43:245–246**
 picornaviral genomes, **40:144**, 146
- P120 protein, **35:48–49**
 MLV, *vs.* P160, **35:70–71**
- P210 protein, Ab-MLV, **35:65–66**
- PR, *see* Aspartyl protease PR
- Pre-B cells, Epstein-Barr virus, **40:21**, 23
- Precipitin, cucumber mosaic virus,
41:294
- Pregenome RNA, hepadnavirus, **34:72**,
 75, 77
- Preglycoprotein, Bunyaviridae, **40:250**,
 260
- Pregnancy, pestiviruses, **41:60**, 88
- Preproenkephalin, vaccinia, **34:50**
- Preprosomatostatin, expression, **43:352**
- Prereplicative sites, in HSV replication,
37:109–110
- Primates, STLV-I seroepidemiological
 surveys, **43:163–164**
- Primate T lymphotropic virus
 PTLV-I/II
 molecular epidemiological methods,
47:385–386
 STLV-PP and PTLV-L independence,
47:409–411
- PTLV-L, **47:379**
 epidemiological characteristics,
47:382
 independence from PTLV-I/II,
47:409–411
- Primate type C virus, envelope, antigenic
 properties, **25:471–473**
- Priming
 DNA replication, **34:20**, 33
 hepadnavirus, **34:112**, 127–129
- Prion protein
 amyloid, **35:112–116**
 human, **35:105–106**
 isoforms, **35:96–98**
 MAbs, **35:92–93**
 mRNA expression, **35:109–111**
 neurodegenerative diseases caused by
 prions, **41:242**, 244–245, 259, 262,
 270
 posttranslational modifications,
35:102–104
 protease-resistant, and neurodegenera-
 tive diseases, **41:244**, 256, 271
 amyloid, **41:248–249**, 252, 261, 264–
 265, 270
 familial diseases, **41:259–261**
 infectious prions, **41:246–247**
 PrP genes, **41:248–250**
 replication, **41:267**, 269–270
 scrapie, **41:256**, 258–259
 synthesis, **41:250–253**
 transgenic mice, **41:262**, 264
- PrP 27–30, **35:87**, 93–99
 molecules, **35:93–96**
 scrapie infectivity, **35:116–117**
- PrP^C, prion diseases, **35:87**, 97–98
 structure, **35:98–100**
- Prions, **29:1–56**
 adaptation upon passage, **29:25**
 cell cultures, **35:111–112**
 in CNS, **29:19**

- definition, 29:4
- diseases, 29:6–12
- amyloid plaques, 29:21–22
 - characteristics, 29:7
 - common features, 29:6–8
 - duration of illnesses, 29:8
 - epidemiology, 29:12–13
 - experimental transmission, 29:24
 - incubation periods, 29:6–7
 - host genes controlling, 29:22–24
 - pathogenesis, 29:18–22
- diseases associated with, 35:83–84
- Alzheimer's disease, 35:124–126
 - incubation time, 35:107–109
 - pathogenic mechanisms, 35:88
 - pathology, 35:89–93
 - perspective, 35:126–128
 - PrP 27–30 molecules, 35:93–96
 - scrapie agent strains, 35:119–120
 - transmissible dementias, 35:124–126
- expression of PrP mRNA in, 35:109–111
- gene chromosomal localizations in, 35:106–107
- general considerations for, 35:85–86
- incubation time, 35:107–109
- host genes controlling, 29:22–24
- isolates, 29:24–25
- liposomes, 35:116–117
- molecular models, 29:45–47
- multiple physical forms, 35:122–124
- neurodegenerative diseases caused by, 41:241–243, 271
- bovine spongiform encephalopathy epidemic, 41:257–258
 - familial diseases, 41:259–261
 - infectious prions, 41:246–248
 - prion protein genes, 41:248–251
 - prion proteins, 41:244–245
 - PrP amyloid, 41:248–249
 - replication, 41:264, 267–271
 - scrapie
 - experimental, of sheep and goats, 41:255–257
 - in mice, 41:258–259
 - natural, of sheep and goats, 41:253–255
 - synthesis of PrP, 41:250–253
 - transgenic mice, 41:262–266
- nomenclature, 35:87–88
- nucleic acid, 35:117–119
- reproduction, 35:120–122
 - scrapie agent strains, 35:119–120
 - strains, 29:24–25
 - structures, 29:24
 - as subviral pathogens, 29:47
 - transmission, 29:24–25
 - and viroids, 29:47
 - and viruses, 35:85–86
- Prion theory, 43:43–44
- Pro-B cells, Epstein-Barr virus, 40:20–21, 23
- Procapsids
- φ6, 35:147–151
 - poliovirus, 46:25–29
- Prodrugs, antiviral agents, carrier-mediated delivery, 35:275–286
- Progastrin, influenza virus, 34:265
- Progeny viral DNA, in HSV replication, metabolism, 37:111–112
- Progesterone receptor, genital human papillomavirus transcription, 44:334
- Progressive multifocal leukoencephalopathy, 42:283–284
- Proinsulin, influenza virus, 34:265
- Prokaryotes
- adenovirus, 39:100, 111, 114–115
 - properties, 27:255
- Prokaryotic cells, foreign gene expression, 35:177
- Promoter insertion, *Drosophila* retrotransposons, 36:94
- Promoters
- adenovirus, 39:90, 94–95
 - sequence-specific methylation, 39:111–124
 - species specificity, 39:95–103
 - badnaviruses, 44:25
 - caulimoviruses, 44:22–23
 - neurodegenerative diseases caused by prions, 41:250
 - oral vaccination, 41:430
 - preS2/S*, 44:21
 - proximity, poly(A) site occlusion, 44:29
 - retroviral, 44:17–20
 - splicing, 44:19–20
 - transcriptional regulation, 44:18–19
 - 19S, 44:23
 - 35S, 44:22–23
- Promoters in *trans*-activation of transcription, 37:41–51
- E1B, 37:42–43

- Promoters in *trans*-activation of transcription (*cont.*)
 E2, 37:43–45
 E3, 37:45–46
 E4, 37:46–47
 hsp, 37:48–49, 70
 major late, 37:47–48
 regulated, factors interacting with, 37:55–63
 ATF factor as, 37:61–63
 E2F factor as, 37:55–59
 E4FF factor as, 37:59–60
 TAATGARAT binding protein as, 37:63
 TATAA binding factor as, 37:60–61
 TFIIC as, 37:61
- Proiomelanocortin, influenza virus, 34:265
- Propagule, plant viruses in developing countries, 41:396
 agricultural modernization, 41:352–353
 crop improvement, 41:357, 367–372
 remedial action, 41:380–383, 385, 387
- Propane diamines, interferon type I, induction, 30:119–120
- β -Propiolactone, killed antiviral vaccines, 39:258, 270, 272
- Prospect Hill virus, genome organization, 40:253
- Protease
 animal cells, 36:138
 apoptosis role, 45:49–50
 2A^{pro}, release, poliovirus, 46:11–12
 bacterial adherence, 35:224
 3CD, P1 precursor cleavage, 46:35–36
 3C^{pro}, release, poliovirus, 46:12–13
Drosophila retrotransposons, 36:58–59
 equine arteritis virus, 41:167
 feline immunodeficiency virus, 45:233
 HEF glycoprotein of influenza C virus, 40:219, 222, 227
 hepadnavirus, 34:85
 HIV structure, 39:9–11, 17
 glycoproteins, 39:39, 41
 morphogenesis, 39:19, 21
pol gene products, 39:24–29
 influenza virus, 34:274
 components, 34:253–254
 pathogenicity, 34:265–266, 268–270, 272
 lentiviruses, 34:194
 neurodegenerative diseases caused by prions, 41:244, 252–253, 259
 Paramyxoviridae, 39:131
 pestiviruses, 41:64
 poliovirus, 33:189
 potyvirus coat protein, 36:279
 rotaviruses, 39:183–185
 Sindbis virus encephalitis, 36:258
 Theiler's murine encephalomyelitis virus, 39:294
 translational suppression by retroviruses, 41:194, 197, 231
- Protease inhibitors, influenza virus, attachment, 30:85
- Protection, rotaviruses, 36:187–191
- Protective efficiency, killed antiviral vaccines, 39:256, 259
 changes in virion immunogenicity, 39:273–275, 277–282, 284
 inactivation, 39:259–260
 kinetics, 39:270
- Protein A, 29:191, *see also* Immunosorbent electron microscopy
- Proteinase
 papain-like, closteroviruses, 47:139–140
 poliovirus, 34:219, 228
 Theiler's murine encephalomyelitis virus, 39:294
- Protein C, flaviviruses, 33:50
- Protein content, bacteriophage ϕ 6, 35:142–144
- Protein E, flaviviruses, 33:49–50
- Protein 7K, picornaviral genomes, 40:144
- Protein kinase
 activity, 35:48–49
 dsl, 43:95–97
 dsRNA-dependent inhibition, 42:94
 interferon-induced antiviral actions, 42:85–86
 in FV3 virion, 30:3
 induced by varicella zoster virus, 38:73–74
 picornaviral genomes, 40:131
- Protein kinase C
 in cell transformation by virus, 32:116
 serine phosphorylation by, 44:219
 in signal transduction from plasma membrane, 37:2–3

- signal transduction pathway, interaction of HBx, 47:283–284
- Protein p12, 35:30
- Protein p19, 35:30–31
- Protein product pRb, complex with E2F, 45:13
- Proteins
- Ab-MLV, expression, 35:46–50
- adeno-associated viruses, 25:416–418
- adenovirus, 39:90, 92, 94–95
- early, 25:360–364
- induced polypeptides, 25:364–368
- intermediate, 25:379–380
- oncodna viruses, 39:104, 111
- quasi-late, 25:379–380
- sequence-specific methylation, 39:114–116, 122–123
- species specificity, 39:99–100, 103
- animal cells, 36:107
- early interactions, 36:109–110
- enveloped viruses, 36:131–136
- macromolecule transport, 36:111
- membrane fusion, 36:123–126, 128–129
- nonenveloped viruses, 36:137–138
- receptors, 36:111–113, 116
- antiviral antibody affinity
- direct measurement, 34:286, 292, 295–296
- relative measurement, 34:303–304, 307
- archaeobacterial viruses, 34:144–146
- Halobacterium halobium*, 34:147, 161
- Sulfolobus* virus-like particle SSV1, 34:175, 179–182
- Thermoproteus tenax*, 34:172, 174
- attachment of viruses, 27:148–150
- bovine herpesvirus-encoded, 45:193–194
- Bunyaviridae, 40:262–264
- genome organization, 40:246–249, 251–252, 254
- replication, 40:257–258
- structure, 40:238, 241
- capsid, *see* Capsid protein
- cell
- infected, human herpesvirus 6, 41:21
- role in rubella virus RNA synthesis, 44:115–118
- coat, *see* Coat protein
- conformational changes in, 28:179
- core and E, hepatitis B virus, 47:267
- cucumber mosaic virus, 41:283, 285, 293, 321, 337–338
- gene function, 41:313–314, 316
- genome organization, 41:297–298, 301–302, 305–306, 308–309, 312
- virus-host plant relationships, 41:324–325, 327–330
- virus particle, 41:285–288, 290
- defective interfering viruses, 40:182–184, 187
- animals and humans, 40:190–192, 195–196, 198
- plants, 40:198–199, 201
- DNA-binding, 37:105–106
- DNA replication, 34:32–33
- adenovirus, 34:2–5, 8–9
- bovine papillomavirus, 34:27–28
- Epstein-Barr virus, 34:31
- SV40, 34:10, 13–14, 16–19
- Drosophila* retrotransposons
- insertional mutagenesis, 36:81, 85–86
- intracellular cycles, 36:63
- organization, 36:50, 56–60
- scattered repetition, 36:40–41
- transcription, 36:68, 70, 75
- Epstein-Barr virus, 40:48
- EBNA-1, 40:41, 43–47
- EBNA-2, 40:28–29, 34
- genome, 40:26
- latent membrane protein, 40:35, 37, 39–40
- equine arteritis virus, 41:159, 161, 164, 166
- equine herpesviruses 2 and 5, 44:363–364
- flavivirus-specified, 33:48–49
- glycosylation, 33:58–61
- identification, 33:53–58
- intracellular location and possible functions, 33:61–65
- folded, domains, 28:177–178
- furoviruses, 36:27
- beet necrotic yellow vein virus, 36:18, 20–21
- particle dimensions, 36:17
- peanut clump virus, 36:27
- purification, 36:16
- soil-borne wheat mosaic virus, 36:24–26

Proteins (*cont.*)

- HEF glycoprotein of influenza C virus, 40:216, 219–220, 228–230
- hepadnavirus, *see* Hepadnavirus envelope proteins
- hepatitis A virus
- characterization, 39:223–224
 - genome, 39:243, 246
 - prevention, 39:237, 239–241
 - replication in cell culture, 39:230, 232
- hepatitis C virus, 40:63–64, 66, 71–72, 74
- hepatitis delta virus, 43:196
- hepatitis E virus, 40:93
- HIV-1, 40:2–3, 5–14
- HIV structure, 39:2
- AIDS, 39:5–11
 - gag* gene products, 39:17–24
 - glycoproteins, 39:40, 43, 46–47, 49
 - infectious cycle, 39:15, 17
 - morphogenesis, 39:8–11
 - pol* gene products, 39:24–39
 - regulatory proteins, 39:50–56
- host
- RNA replication, positive-stranded RNA viruses, 47:205–209
 - synthesis, 33:191–194
- human herpesvirus 6, 41:2, 5, 13–14
- biology, 41:26–28, 39
 - molecular biology, 41:17–22
- IFN-induced, 38:147–194
- influenza virus
- components, 34:248–249, 252–253, 255–256
 - genetic reassortment, 34:258
 - genetic resistance, 34:273
 - mutation, 34:261
 - pathogenicity, 34:270–273
- 8K, carmovirus, 44:401
- 9K, carmovirus, 44:401
- 19K, tombusviridae, 44:395–396
- 22K, tombusviridae, 44:395–396
- 28K, carmovirus, 44:400
- 30K
- altered production, effect on tobamovirus phenotype, 38:334–335
 - subgenomic RNA synthesis, 38:329–330
- 33K, tombusviridae, 44:391–392
- 41K, tombusviridae, 44:392–395
- 88K, carmovirus, 44:400
- 92K, tombusviridae, 44:392
- killed antiviral vaccines, 39:258
- changes in virion immunogenicity, 39:273, 277–278, 280–281
 - inactivating agents, 39:260–261
- lactate dehydrogenase-elevating virus
- age-dependent poliomyelitis, 41:131, 145–146, 148–149
 - mice, 41:104, 113, 116, 120, 122, 124
 - large, Paramyxoviridae, 39:132, 134, 152
- late
- adenovirus mRNAs, 25:384–388
 - primary and tertiary structure, 25:391–393
 - mRNAs, mechanism for control, 25:388–390
- lentiviruses
- structure, 34:192–195
 - virus-host cell interaction *in vitro*, 34:199
 - virus-host cell interaction *in vivo*, 34:200, 208
- lytic
- from bacteriophages, 45:98–101
 - nonviral, natural sources, 45:101–102
- oncovirus envelope, 25:454–456
- oral vaccination, 41:412, 434
- epitope presentation systems, 41:424–426, 428
 - foreign antigens in *Salmonella*, 41:419, 422–424
- parvovirus virion assembly, 33:163–164
- and pesticide production, 36:324
- pestiviruses, 41:85, 90
- properties, 41:72, 74, 77–83
- picornaviral genomes, 40:104, 152, 155, 162
- cis-acting elements, 40:125, 127
 - mRNAs, 40:143–151
 - structure, 40:106, 114–115
 - trans-acting factors, 40:132, 134–138
 - translation initiation, 40:139, 141–142
- picornaviruses, 36:154
- analysis, 36:158–161
 - genome, 36:163–165

- recombinants, **36:168, 171**
- revertants, **36:167–168**
- RNA, **36:171, 173**
- poliovirus, **34:218, 236, 243**
 - cleavage inhibition by synthetic amino acid, **30:112–113**
- polymerase, influenza virus, **31:91**
- pore-forming *vs.* ion channel-forming, **45:96–98**
- positive-strand RNA viruses, **41:100–101, 180–182**
- potyvirus coat, *see* Potyvirus coat protein
- purification, **25:376–379**
- rabies viruses, **36:223, 240**
- rotaviruses, **36:181–183, 207; 39:166, 198**
 - function, **36:204–207**
 - neutralization, **36:183–187, 191–192, 198–199**
 - protection, **36:187–191**
 - reassortment, **39:167, 169, 171–172**
 - studies, **39:177–178, 180, 183–186**
 - surface, **36:202–204**
 - vaccination, **39:187–190**
- in RSV-transformed cells, **32:114–116**
- scrapie, **35:95–96**
- simian hemorrhagic fever virus, **41:179–180**
- sorting mechanisms, polarized epithelial cells, **42:205–207**
- structural biochemical properties, **25:318–322**
- surface, *see* Surface proteins
- tobamovirus
 - synthesis regulation, **38:318–320**
 - translation after heat shock, **38:321**
- translational suppression by retroviruses, **41:194, 196, 233**
 - cis-acting sequences, **41:219, 223**
 - frameshift site, **41:216–217**
 - readthrough suppression, **41:198–200, 204–207, 210**
 - ribosomal frameshifting, **41:210–212, 230–231, 233**
- vaccinia, **34:44, 61**
 - genome, **34:47–49**
 - vector, **34:50, 57–58**
- varicella zoster virus-induced, **38:61–75**
- viral, *see* Viral proteins
 - as viral receptors, **44:204–206**
 - viral transport
 - action, tissue specificity, **38:228–229**
 - tropism, for plasmodesmata, **38:239–240**
 - virus-coded, **33:217–219**
 - absence of symptom-producing proteins, **33:222–224**
 - polymerase, **33:221–222**
 - transport, **33:219–221**
- Protein synthesis
 - alphavirus RNA, **45:126–128**
 - in infected cells, bacteriophage $\phi 6$, **35:167–168**
 - inhibitors, flavivirus, **33:70**
 - plant, TMV multiplication, **33:215**
- Protein synthesis in virus-infected animal cells
 - host, shutoff by animal viruses, **31:246–251**
 - switch from host to virus, mechanisms mediating, **31:251–252**
- viral mRNAs
 - and cellular mRNAs, interplay and translation in infected cells, **31:244–265**
 - monocistronic nature, **31:235–237**
 - synthesis mechanism of more than one protein, **31:237–244**
 - translation, **31:230–244**
- Proteolipid protein, Theiler's murine encephalomyelitis virus, **39:302, 306**
- Proteolysis
 - archaeobacterial viruses, **34:181**
 - Bunyaviridae, **40:246**
 - cap-independent translation, luteoviruses, **46:443–444**
 - CBP complex, **33:186–188**
 - cucumber mosaic virus, **41:287**
 - flavivirus polyproteins, **33:67–68**
 - HEF glycoprotein of influenza C virus, **40:217–218, 226–228**
 - hepadnavirus, **34:85, 88, 103**
 - hepatitis A virus, **39:231**
 - HIV structure, **39:7, 17–18**
 - glycoproteins, **39:39, 41–42**
 - pol* gene products, **39:24, 26, 28, 31–33**
 - influenza virus, **34:274**
 - components, **34:253, 257**
 - pathogenicity, **34:265–268, 270–271**

- Proteolysis (*cont.*)
 neurodegenerative diseases caused by prions, 41:244, 248, 270
 oral vaccination, 41:424
 Paramyxoviridae, 39:130–131, 134
 parvovirus capsid polypeptides, 33:100–101, 103–104, 122–124
 pestiviruses, 41:64, 78–80
 picornaviral genomes, 40:144
 poliovirus, 34:219
 Proteolytic processing, HIV-1, 46:106
 Protomer 5S, poliovirus, 46:20–22
 Proton motive model, virus entry and early membrane permeabilization, 45:68–70
 Proto-oncogenes, 37:1
 adenovirus, 39:110
c-myb, 43:116–117
c-myc, in apoptosis, 45:10
 HIV expression, 43:115–117
 Protoplast infection
 addition of poly-L-ornithine, 29:226–230, 232–234
 direct and indirect methods, 29:226
 multiplicity, 29:257
 viral DNA, 29:241
 viral nucleic acids, 29:235–241
 viral RNA, 29:235–241
 buffers, 29:238
 calcium chloride in, 29:237
 cycloheximide in, 29:238
 liposome-mediated, 29:239–241
 osmotic stabilizer, 29:236–237
 polycations in, 29:237–238
 polyethylene glycol in, 29:239
 temperature, 29:238–239
 zinc salts, 29:237–238
 viroids, 29:241–242
 virus particles, 29:226–235
 buffers, 29:231
 calcium chloride in, 29:235
 inocula concentration for, 29:233–234
 osmotic stabilizer, 29:234
 pH, 29:232
 polyethylene glycol in, 29:232–233
 protoplast concentration for, 29:233
 temperature, 29:234–235
 Protoplasts
 cucumber mosaic virus, 41:287, 294, 313, 328
 extreme resistance in, 29:339
 infected, culture, 29:242–243
 inoculation, 29:226–242
 isolation
 from cell suspension cultures, 29:223–225
 enzyme solutions for, 29:219–221
 from leaves, 29:217–223
 osmotic stabilizers, 29:220
 plant, electrotransfection with viral nucleic acids, 37:329–341
 in plant virus research, 29:215–216
 source, 29:256
 technology, applications, 29:256–257
 virus antigen in
 dilution end point, 29:246–247
 ELISA, 29:246
 quantitative determination, 29:246–247
 radioimmunoassay, 29:246
 viruses, 33:147, 217
 Protozoa
 abortion of cattle, 43:46
Totivir, 43:344–346
 Provirion, poliovirus, 46:29–30
 Provirus
Drosophila retrotransposons, 36:92
 insertional mutagenesis, 36:78, 82
 intracellular cycles, 36:60
 organization, 36:51
 scattered repetition, 36:38
 transcription, 36:68
 HIV structure, 39:36–38
 human herpesvirus 6, 41:18
 lactate dehydrogenase-elevating virus, 41:123, 129, 132, 135, 141–144
 translational suppression by retroviruses, 41:198
 PrP, *see* Prion protein
 PrP genes, 35:100–102; 41:248–250
 Prune dwarf virus, 29:151
Plantago host and occurrence, 27:114
 Prunus necrotic ringspot virus
 immunization of mice, 29:136
 MAb-determined antigenic properties, 29:150–151
 MAbs, 29:135
 diagnosis with, 29:161
 Pseudococcidae, as plant-virus vectors, 28:133–135

- Pseudoknots
 cucumber mosaic virus, **41:313**
 translational suppression by retroviruses, **41:204, 221, 223**
- Pseudomonas*, **29:294**
 bacteriophage $\phi 6$, **35:138, 140**
- Pseudomonas acidovorans*, **29:267**
- Pseudomonas aeruginosa*, **29:301, 304**
 phage 7V, **29:267**
- Pseudomonas fluorescense*, **29:301**
- Pseudomonas tabaci*, **29:255**
- Pseudorecombinants
 cucumber mosaic virus, **41:314–316, 318, 323, 331**
 plant viruses, symptom type, **33:211–213, 219**
- Psoralens, **29:31, 33**
 killed antiviral vaccines, **39:261**
- Pteridium aquilinum*, protoplast culture, **29:243**
- PTLV, *see* Primate T lymphotropic virus
- Public awareness, new, emerging, and reemerging infectious diseases, **43:4–6**
- Pulmonary defense mechanisms, **35:224–227**
- Pulse generator, in electrotransfection, **37:333**
- Punta Toro virus
 genome organization, **40:249, 251, 254**
 replication, **40:255–256, 259–260**
- Purification
 adenovirus early proteins, **25:376–379**
 antiviral factor, **26:219–220**
 beet necrotic yellow vein virus, **36:16–17**
 broad bean necrosis virus, **36:15**
 chickenpox virus, **28:291–296**
 coronaviruses, **28:41–43**
 cryptic viruses, plants, **32:195–197**
 cucumber mosaic virus, **41:285, 329–330**
 dianthoviruses, **33:260**
 carnation ringspot virus, **33:261**
 red clover necrotic mosaic virus, **33:261–262**
 sweet clover necrotic mosaic virus, **33:263**
 envelope antigen, **25:458–459**
 furovirus proteins, **36:16**
- HSV-1 and HSV-2 glycoproteins, **29:118**
 human herpesvirus 6, **41:19–20**
 HVT genomic DNA, **30:227, 229**
Hypochoeris mosaic virus, **36:15**
 MAbs, **29:146**
 Marek's disease virus genomic DNA, **30:227, 229**
 oncovirus envelope protein precursors, **25:458–459**
 peanut clump virus, **36:15**
 pestiviruses, **41:54, 78**
 potato mop-top virus, **36:16**
 proteins, **25:376–379**
 rice stripe necrosis virus, **36:15**
 scrapie agent, **29:25–29**
 scrapie PrP, **29:41**
 soil-borne wheat mosaic virus, **36:15**
 viral protein, **29:118**
 virion, **25:138–142**
 viroids, **28:252**
 viruses, **25:223–224**
- Purine, lentiviruses, **34:199**
- Puromycin, archaeobacterial viruses, **34:162**
- Pyocin, **29:301, 304–305**
- Pyrazofurin, **42:10–12**
 antiviral activity, **30:106**
- Pyrethroids, for reducing nonpersistent virus spread, **31:420**
- Pyrimidine biosynthetic pathway, **42:11–12**
- Pyrimidinones, interferon type I induction, **30:118–119**
- Pyrococcus woesci*, archaeobacterial viruses, **34:145, 184**
- Q**
- Quarantine, plant viruses in developing countries, **41:380–383, 385–388, 391–392, 394–396**
 intermediate, **41:386, 396**
 post-entry, **41:385–386**
- R**
- Rabies, **43:20–23**
- Rabies virus, **29:122; 42:375–406; 46:333, 335**

- Rabies virus (*cont.*)
 acute neurological phase, **42:396**
 animal cells, **36:133**
 attenuation, neutralizing MAb effect,
32:19–20
 brain functional alterations, **42:398–**
403
 CNS, **42:391–393, 397**
 compartmentalized cell culture system,
42:388–389
 diagnosis with MAbs, **29:101**
 EEG activity, **42:399–401**
 glycoproteins, **33:13–14**
 cytoplasmic domain, **33:19–22**
 ectodomain, **33:14–17**
 transmembrane domain, **33:17–19**
 5-HT1D-binding sites, **42:400, 403**
 immune response, **42:393–396**
 immunopathology, **42:394–395**
 infection of cells, **42:378–383**
 binding to host cells, **42:380**
 entry into host cells, **42:382–383**
 ganglioside role, **42:380–382**
 kinetics in embryonic neuronal cul-
 ture, **42:379**
 infection of hosts, **42:378**
 interferon in, **42:395–396**
 neuritic extension, **42:388–389**
 neurotransmitter antagonist antiviral
 properties, **42:404–406**
 nicotinic acetylcholine coreceptor,
42:384–387
 Paramyxoviridae, **39:134**
 pathogenesis and pathophysiology,
42:396–403
 pathogenicity study, MAbs in, **29:102**
 peripheral sites of infection, **42:383–**
387
 sensory and motor nerve pathways,
42:387–388
 sequential retrograde and anterograde
 transport, **42:389–390**
 serotonin binding decrease, **42:400,**
402–403
 structure and properties, **42:376–**
377
 transport in peripheral nervous sys-
 tem, **42:387–391**
 variants, selection, **29:119**
 Rabies viruses, epitopic variation,
36:215–217, 250
 Africa, **36:240–242, 246–249**
 Asia, **36:250**
 Caribbean, **36:237–238**
 epizootiology, **36:217–218**
 bat, **36:222–223**
 interspecies transmission, **36:219,**
221
 species-defined enzootics, **36:218–**
220
 Europe, **36:238–245**
 Latin America, **36:237–238**
 North America, **36:223–224**
 bat, **36:228–229**
 rat, **36:230–231**
 terrestrial species, **36:224–228**
 transmission, **36:232–236**
 Radiation
 ionizing, scrapie agent sensitivity in
 presence of oxygen, **29:32**
 killed antiviral vaccines, **39:258**
 changes in immunogenicity, **39:273,**
278
 duration of actions, **39:263**
 inactivation, **39:260–261**
 kinetics of infectivity, **39:267–268**
 Radiation resistance
 Creutzfeldt-Jakob disease agent, **29:12**
 polyomavirus dsDNA, **29:33**
 Radioactivity, vaccinia, **34:57**
 Radioimmunoassay, **29:97–99, 108, 118**
 antiviral antibody affinity, **34:306**
 chickenpox virus antibodies, **28:318**
 competition, **29:162**
 envelope antigens, **25:460**
 hepadnavirus, **34:104, 120**
 hepatitis A virus, **39:219, 227**
 lentiviruses, **34:194–195**
 virus antigen in protoplasts, **29:245**
 Radioimmunofocus assay, hepatitis A vi-
 rus, **39:228, 230, 232, 239**
 Radioimmunoprecipitation
 human herpesvirus 6, **41:25, 38–39**
 intact virions, envelope antigens,
25:463
 pestiviruses, **41:79, 81**
 Radish yellow edge virus
 cellular location in plants, **32:191, 193**
 as cryptic virus, **32:181**
 cytopathology, **32:193**
 Raman difference spectroscopy, PRD1,
45:287–289

- Ranavirus*, classification, **46:351, 364–365**
- Raphanus sativus*, leaf protoplasts, virus infection, **29:228**
- Rapid agglutination test, HIV sensitivity and specificity, **42:165–166**
- Rapid-transit model, spliced and unspliced RNA accumulation, **35:28–30**
- ras* oncogene
Epstein-Barr virus, **40:35**
family, in signal transduction from plasma membrane, **37:13–16**
- Raspberry leaf curl virus, *Plantago* hosts and occurrence, **27:115**
- Raspberry ringspot virus, **33:212**
Plantago hosts and occurrence, **27:115**
protoplast infection, **29:227–229, 231**
- Raspberry yellow dwarf virus, *Plantago* hosts and occurrence, **27:115**
- Ras protein, **43:116**
- ras–raf–mitogen-activated protein kinase pathway, interaction of HBx, **47:284–285**
- Rat, rabies viruses, **36:230–231**
- Rauscher virus, gp 70, structural analysis, **29:110–111**
- RD114/BEV group, envelope antigenic properties, **25:473–474**
- RDRP domain, *Totivirus*, **43:325–327**
- Reactivation, human herpesvirus 6, **41:29–30**
- Readthrough, protein presence, luteoviruses, **46:445–447**
- Readthrough suppression by retroviruses, **41:197–199, 210, 233**
alternate stop codons, **41:204–207**
context, **41:199–204**
tRNAs, **41:207–209**
- Reassortant RNA viruses, picornaviruses, **36:171–174**
- Reassortment in rotaviruses, *see* Rotaviruses, genomic segment reassortment
- Receptor binding
HEF glycoprotein of influenza C virus, **40:223–226, 231**
vesicular stomatitis virus, **33:16–17**
- Receptor binding site, influenza virus hemagglutinin, **33:6**
- Receptor-destroying enzymes, HEF glycoprotein of influenza C virus, **40:221–223, 228–229**
- Receptors
animal cells, **36:111–117, 139**
enveloped viruses, **36:134, 136**
Epstein-Barr virus, **40:31, 39–40, 46–47**
HEF glycoprotein of influenza C virus, **40:214, 220**
lactate dehydrogenase-elevating virus, **41:104, 110–111, 120–121**
oral vaccination, **41:434**
parvoviruses, **33:137, 165**
- Receptor specificity, determining virus host range, **44:203–204**
- Recombinant bacteria, use in oral vaccination, *see* Oral vaccination with recombinant bacteria
- Recombinant DNA technology, virus vaccines, **35:239**
- Recombinants
animal RNA viruses, **32:233–234, 237**
between deletion mutant m4 BMV3 and BMV1 or 2, **32:234–237**
construction, **32:234**
3'-end sequences, **32:235–236**
observations in barley cells, **32:237**
rearrangement mechanism, **32:237–238**
- Recombination, *see also* RNA–RNA recombination
adenovirus, **39:91–92**
oncodna viruses, **39:106, 109–110**
sequence-specific methylation, **39:112–113**
species specificity, **39:98–99**
animal RNA viruses, **43:276–277**
Bunyaviridae, **40:243, 250, 253**
cucumber mosaic virus, **41:324, 334**
defective interfering viruses, **40:183–188, 197, 201, 205**
HEF glycoprotein of influenza C virus, **40:231**
hepatitis A virus, **39:210, 224, 241, 246**
HIV structure, **39:9, 40, 43**
human herpesvirus 6, **41:18**
killed antiviral vaccines, **39:263, 265**
lactate dehydrogenase-elevating virus, **41:129, 133, 141–143**
Paramyxoviridae, **39:137, 151**
pestiviruses, *see* Pestivirus RNA recombinations
plant RNA viruses, **43:277**

- Recombination (*cont.*)
 rotaviruses
 comparison with other reoviruses,
 39:190–195
 future studies, **39:198–199**
 studies, **39:173–174, 176**
 Theiler's murine encephalomyelitis virus,
 39:311, 313
- Red clover cryptic virus, mixture of two
 viruses, **32:181**
- Red clover necrotic mosaic virus, **33:212**
 distribution, **33:258**
 purification, **33:261–262**
 translational suppression by retro-
 viruses, **41:214, 220, 229**
- Red clover necrotic virus, **44:421**
- Regulatory genes, oral vaccination,
41:434–437
- Reinitiation
 implications, **31:265–269**
 and viral mRNA translation, **31:241–**
243
- Remedial action, plant viruses in devel-
 oping countries, **41:377–379**
 certification, **41:386–387**
 health improvement, **41:379–380, 391–**
396
 quarantine, **41:385–386**
 rehabilitation, **41:384**
 risk analysis, **41:387–391**
 virus-free material, **41:380–384**
- Remyelination, Theiler's murine enceph-
 alomyelitis virus, **39:301**
- Reo-like viruses, association with hypo-
 virulence, **43:369–371**
- Reoviridae, **29:57–58; 37:173–206**
 dsRNA genome, characteristics, **32:207**
 genome rearrangements, **46:92**
 replication, **29:64**
 rotaviruses, **39:164–166, 198**
 comparisons, **39:190–195**
 reassortment, **39:168**
 transcriptases, **29:64**
 transcription, **29:63–64**
- Reoviruses, **42:325–338, see also Plant**
 reoviruses
 animal cells, **36:113, 122, 136, 138**
 attachment proteins, **27:189–190**
 binding affinity to murine cell lines,
 42:331
 biochemical studies, **42:334–336**
 cellular receptors, **27:191**
 functional studies, **42:336–338**
 immune response, **42:332–333**
 infectious route, **42:223–224**
 mammalian, **42:326–329**
 genetics, **42:326–327**
 structure, **42:327–328**
 tropism, **42:328–329**
 penetration and uncoating, **27:152,**
190–191
 picornaviruses, **36:171, 173**
 proteins, functional areas, **29:107**
 replication, interferon-induced inhibi-
 tion, **38:186–188**
 variants, selection, **29:119–120**
- Reovirus type 3 receptor, **42:331–338**
- Replicase
 brome mosaic virus, **43:278**
 cucumber mosaic virus, **41:327–331,**
338
 viral, possible for TMV, **26:189–193**
- Replicate intermediates, pestiviruses,
41:77
- Replication
 adenovirus, **39:90, 92–93**
 sequence-specific methylation,
 39:111, 114–115, 117, 123
 species specificity, **39:95, 97–103**
 age-dependent poliomyelitis, **41:125–**
126, 128, 144
 motor neuron protection, **41:136, 141**
 MuLV, **41:129, 131, 133**
 animal cells, **36:108**
 early interactions, **36:109–110**
 endocytosis, **36:123**
 enveloped viruses, **36:131**
 receptors, **36:112**
 archaeobacterial viruses, **34:144, 146**
 Halobacterium halobium, **34:155**
 Sulfolobus virus-like particle SSV1,
 34:177, 183
 bacteriophage $\phi 6$, **35:165–167**
 Bunyaviridae, **40:236, 254–255, 263–**
264
 mRNA molecules, **40:255–256**
 transcription, **40:256–260**
cis-acting sites required for, *Totivirus*,
 43:318–319
 common properties of positive-strand
 RNA viruses, **41:180–181**
 cucumber mosaic virus, **41:283, 338**

- genome organization, **41:302, 306, 313, 315–316**
 satellite RNAs, **41:316–319, 321–322**
 virus-host plant relationships, **41:325–331**
- defective interfering viruses, **40:182–186, 188**
 animals and humans, **40:189–191, 193–197**
 plants, **40:198–199, 202, 205–206**
- dengue 2 virus in U-937 human monocytes, **31:153**
- dianthoviruses, **33:278–281**
- DNA, initiation, *see* DNA replication, initiation of
- Drosophila* retrotransposons, **36:50, 60, 66–67**
- Epstein-Barr virus, **40:47–48**
 EBNA-1, **40:40–47**
 EBNA-2, **40:28**
 genome, **40:26**
- equine arteritis virus, **41:155–160, 167**
- equine herpesvirus 2, **44:367**
- hepadnavirus, **34:66, 135**
 genome organization, **34:70–75**
 pre-S sequences, **34:98**
- hepatitis A virus, **39:216, 224, 226–227**
 cycle, **39:230–236**
 cytoplasmic stains, **39:227–229**
 genome, **39:243**
 infectivity assays, **39:228, 230**
- hepatitis B virus, **47:262–263**
- hepatitis C virus, **40:77–79, 81**
- HIV-1, **40:3–6, 8–9, 13**
- HIV-2
 initial events, **46:101, 104–105**
 virus assembly and maturation, **46:102–103, 105–106**
- HIV structure, **39:14**
gag gene products, **39:19, 21–22, 24**
pol gene products, **39:28–29, 34–35, 37, 39**
 regulatory proteins, **39:52, 54–55**
- human herpesvirus 6, **41:2, 35**
 growth properties, **41:8, 10–12, 14**
 molecular biology, **41:18, 24**
- influenza virus, **34:248**
 components, **34:253–254**
 genetic resistance, **34:273**
 genome constellation, **34:260–261**
 pathogenicity, **34:268, 272**
- killed antiviral vaccines, **39:259–260, 263–264, 267**
- lactate dehydrogenase-elevating virus mice, **41:104–105, 110–111, 113, 115–117, 119–120**
 molecular properties, **41:148, 151**
- lentiviruses
 virus-host cell interaction *in vitro*, **34:196–197, 199–200**
 virus-host cell interaction *in vivo*, **34:200, 202, 207**
- luteoviruses, **46:449–450**
- model of adeno-associated viruses, **25:425–427**
- neurodegenerative diseases caused by prions, **41:243, 264, 267–271**
- nonlytic strategy, viral persistence, **46:321–322**
- oral vaccination, **41:410, 412, 415, 429–430**
- papillomavirus, **44:311–315**
- Paramyxoviridae, **39:129, 131, 135**
 genome, **39:137–139, 150–152**
 transcription, **39:141, 144, 146, 149**
- parvoviruses, **47:305–307**
- pesticide production, **36:316**
 considerations, **36:318**
Heliothis NPV, **36:322, 324, 332, 334–340**
 quality control, **36:340**
- pestiviruses, **41:54, 58, 90**
 BVDV, **41:60, 63, 66**
 comparisons, **41:70–71**
 properties, **41:76–77, 80, 82–83**
- picornaviral genomes, **40:143, 154, 160–161**
 RNA, **40:151–154**
 structure, **40:108–109**
- picornaviruses
 biological tests, **36:155**
 recombinants, **36:171**
 revertants, **36:167–168**
 RNA, **36:171, 174**
- poliovirus, **34:218, 242–243**
 neurovirulence, **34:222, 235**
 pathogenesis, **34:220–222**
- positive-strand RNA viruses, **41:100**
- potyvirus coat protein, **36:278–279**
 by reverse transcription, **44:2–3**

- Replication (*cont.*)
 RNA, poliovirus, **46:7**, 13–14
 rotaviruses, **36:182**; **39:164–165**, 171
 comparison to other reoviruses,
 39:191–192, 194
 studies, **39:175**, 184
 vaccination, **39:187–189**
 RSV RNA, **35:1–4**
 satellite RNA for biocontrol, **39:322**,
 333–334, 337
 simian hemorrhagic fever virus,
 41:175, 177–179
 Sindbis virus encephalitis, **36:255–256**,
 261–262, 269
 S RNA
 bunyaviruses, **31:40–41**
 phleboviruses, **31:40–42**
 Theiler's murine encephalomyelitis vi-
 rus, **39:304**, 310
 tombusviridae, **44:414–416**
 translational suppression by retro-
 viruses, **41:230**
 vaccinia, **34:53**, 61
 viral, and antibody-dependent en-
 hancement, **31:347–349**
 Replication compartments, in HSV repli-
 cation, nature and organization,
 37:110–111
 Rep proteins, adeno-associated virus,
 43:121
 Reproduction, prions, **35:120–122**
 Reproductive capacity, picornaviruses,
 36:155, 159, 166
 Reproductive capacity at supraoptimal
 temperature marker, poliovirus,
 34:227, 233, 235, 243
 Resistance
 antibiotic
 bacteriophage, **27:236**
 oral vaccination, **41:428–429**
 genetic, cucumber mosaic virus, **41:337**
 oral vaccination, **41:415**
 plant viruses in developing countries,
 41:397
 crop improvement, **41:355**, 363, 365–
 367
 crop protection, **41:374–375**
 intensification, **41:376**
 remedial action, **41:378–379**, 392
 Resistance genes, action, **33:232**, 234
 Respiratory disease, *see also* Viral-bacte-
 rial synergistic interaction in respi-
 ratory disease
 equine rhinopneumonitis virus, **45:156**
 Respiratory syncytial virus, **47:359**, 362–
 363
 antibody production, **29:97**
 diagnosis with synthetic peptides,
 42:167–168
 formalin-inactivated, immunopathol-
 ogy, **32:7**, 15
 glycoproteins, properties, **32:15**
 Paramyxoviridae, **39:133–134**
 genome organization, **39:136–138**,
 140
 transcription, **39:141**, 144, 149
 penetration, inhibition by BABIM,
 30:87–88
 two subtypes, **32:5**
 Respiratory system, polarized epithelial
 cells, **42:225–230**
 Respiratory tract, influenza virus,
 34:247–248
 components, **34:254**
 pathogenicity, **34:268**
 Reston hemorrhagic fever, **47:10–11**
 Reston virus, **43:35**
 Restriction endonuclease
 baculoviruses, **25:288**, 297–299
 densovirus, **25:313**
 iridovirus, **25:310**
 Restriction enzymes, archaeobacterial vi-
 ruses, **34:145**
 Halobacterium halobium, **34:152**, 154
 Methanobrexibacter smithii, **34:168**
 Restrictive infection, parvovirus, **33:166–**
 167
 Retention, in nonpersistent virus trans-
 mission, **31:393**
 Retention time, cucumber mosaic virus,
 41:331
 Reticulocyte lysates
 Bunyaviridae, **40:251**, 257–258
 picornaviral genomes, **40:128**
 Reticulocytes, picornaviral genomes,
 40:133
 Reticuloendotheliosis virus, intron se-
 quences, **35:25**
 Retinoic acid, **43:105**
 HIV expression inhibition, **43:120**

- Retinoic acid receptors, human papillomavirus transcription, **44:336**
- Retroelement, in relation to reverse transcription, **44:1–2**
- Retroid viruses
 DNA synthesis pathways, **32:62–71**
 genomic RNA structure, **32:38–39, 49–57**
 coding region homology, **32:59–62**
 gene organization comparison, **32:57–59**
 reverse transcriptase domains, **32:60**
 reverse transcription pathways, **32:35–49**
- RNA
 packaging inside particle, **32:71–74**
 transcription from DNA, **32:76–84**
 translation, **32:84–85**
- Retrotranscription, *Drosophila* retrotransposons, **36:75**
 intracellular cycles, **36:66–67**
 organization, **36:50–51, 54–55**
- Retrotransposons
 copia elements, *Drosophila*, **32:85**
 intracisternal A particles, mouse, **32:85–86**
 Pol translation, **44:40–41**
 translational suppression by retroviruses, **41:194, 196, 210**
 Ty elements, yeast, **32:85**
- Retroviral insertion, into germline apoptosis gene, **45:23**
- Retroviruses, **44:1–56**
 adaptations, **44:3**
 animal cells
 endocytosis, **36:119**
 entry, **36:134–135**
 membrane fusion, **36:125**
 receptors, **36:113, 117**
 attachment proteins, **27:182–183**
 avian
 endogenous
 LTR, nucleotide sequences, **30:188–191**
 properties, **30:183**
 exogenous
 LTR, nucleotide sequences, **30:187–191**
 properties, **30:183**
 genomic RNA
 replication cycle, **30:180–182**
 reverse transcription-replication, **30:193–195**
 oncogenic, mechanisms of action, **30:205–211**
 properties, **30:179–180**
 transcripts, polyadenylation, LTR role, **30:204–205**
 use for heterologous gene expression, **30:216–217**
- cellular receptors, **27:183–184**
 characteristics, **44:4**
 classification, **44:208–209**
 defective interfering viruses, **40:188, 194–196**
Drosophila retrotransposons, **36:35, 92, 97**
 insertional mutagenesis, **36:78, 82**
 internal sequences, **36:55–60**
 intracellular cycles, **36:60–67**
 LTRs, **36:50–55**
 organization, **36:47–50**
 scattered repetition, **36:38, 40**
 transcription, **36:76**
- Gag and Gag–Pol precursors, **44:48–49**
gag–pol core, **44:8–9**
 Gag protein expression, **44:51**
 genes and gene products, **32:50–57**
 comparison with CaMV genes, **32:58–59**
 genome organization, **44:6–8**
 genomic RNA, organization, **32:38, 49–50**
 glycoproteins, **33:22–23**
 cytoplasmic domain, **33:24–25**
 ectodomains, **33:23–24**
 envelope, **44:210–211**
 hepadnavirus, **34:75**
 HIV-1, **40:1, 10**
 HIV structure, **39:2, 5, 11, 51**
gag gene products, **39:19–22**
pol gene products, **39:24–39**
 influenza virus, **34:270**
 integration, obligatory, **32:74–75**
 lactate dehydrogenase-elevating virus, **41:105, 132–133, 144**
 lentiviruses, **34:189**
 structure, **34:191, 194**

- Retroviruses (*cont.*)
 lentiviruses (*cont.*)
 virus-host cell interaction *in vitro*,
 34:198, 200
 neurodegenerative diseases caused by
 prions, **41:248**
 packaging and repackaging, **32:71–74**
 penetration and uncoating, **27:184–**
 185
 picornaviruses, **36:171, 173**
 Pol translation, **44:40–41**
 promoters and transcripts, **44:17–20**
 proviral form, **44:2**
 regulatory functions, **44:13–15**
 replication, interferon-induced inhibi-
 tion, **38:191–193**
 as retroid viruses, **32:35–37**
 reverse transcription pathway, **32:37,**
 39–41; 46:119–122
 RNA 3'-end formation, **44:26–32**
 RNA transcription
 from integrated DNA, **32:76–79**
 enhancer elements, **32:77–78**
 genome splicing, **32:77–79**
 from unintegrated DNA, **32:79**
 species, **46:100**
 structure and assembly, **44:45–47**
 capsid structures, **44:48–50**
 comparison of packaging strategies,
 44:54–55
 envelope, **44:47–48**
 RNA packaging, **44:52–54**
 virus-like particle formation, **44:51–**
 52
 superinfection immunity, **44:207–211**
 translation, features of leader affect-
 ing, **44:33–36**
 from non-AUG codon, **44:35–36**
 secondary structures, **44:34–35**
 upstream ORFs, **44:35**
 translational suppression by, *see*
 Translational suppression by retro-
 viruses
 as tumor viruses, **27:285–289**
 subacute type, **27:294–296**
 type D, HIV type, **46:105–106**
 as vectors for DNA cloning, **32:287–**
 288
 viral transmission and cell-to-cell
 spread, **44:11–13**
 visna virus, **42:275**
- Retrovirus-like elements, in animals,
 32:86
- Retrovirus RNA, *see* Rous sarcoma virus
 RNA
- Reverse gyrase, archaeobacterial viruses,
 34:178
- Reverse transcriptase, **46:100**
 animal cells, **36:134**
 defective interfering viruses, **40:194**
 Drosophila retrotransposons
 intracellular cycles, **36:60, 62–64**
 organization, **36:58–59**
 feline immunodeficiency virus,
 45:233–234
 hepatitis C virus, **40:62, 64**
 HIV-1, *see* Human immunodeficiency
 virus type 1 reverse transcriptase
 HIV structure, **39:4, 11, 13**
 gag gene products, **39:18–19**
 glycoproteins, **39:29–39**
 infectious cycle, **39:15–16**
 human herpesvirus 6, **41:4, 35**
 lentiviruses, **34:192, 194, 198**
 torovirus, polymerase chain reaction
 amplification, **43:265**
 translational suppression by retro-
 viruses, **41:194, 197, 205, 211, 231**
 in viral replicative cycle, **44:2**
- Reverse transcription
 CaMV, pathway, **32:47–49, 68–71**
 hepadnaviruses, pathway, **32:43–45,**
 63–67
 HIV-1, **40:2**
 first template switch, **46:137–146**
 host tRNA^{Lys3} primer, **46:125–131**
 origin, **46:122–125**
 sites of hypermutability and paus-
 ing, **46:134**
 lactate dehydrogenase-elevating virus,
 41:146, 148
 retroid virus replication, **32:35–37, 86–**
 87
 retroviruses, pathway, **32:37, 39–41**
 scheme, retroviruses, **46:119–122**
- Revertants, of host range mutants of
 Sindbis virus, **33:353–354**
- rev* gene, **43:87**
 in HIV gene expression control,
 38:133–134
 HIV structure, **39:51**
 Rev protein, **43:85–92**

- feline immunodeficiency virus,
45:240–242
HIV-1, 40:9–12
inhibitors, 43:124
rev protein, HIV structure, 39:11, 16, 50,
52–54
Rev-responsive element
HIV-1, 40:11–12
HIV structure, 39:6, 16, 53–54
Rhabdoviridae, single species genomic
RNA, 31:2
Rhabdoviruses, 39:129
animal cells
endocytosis, 36:119, 121
entry, 36:134–135
membrane fusion, 36:126
receptors, 36:113, 117
attachment proteins, 27:178–179
defective interfering viruses, 40:206
genome, 39:134, 136, 150
penetration and uncoating, 27:179–
180
Plantago hosts and occurrence, 27:116,
130
rabies viruses, 36:248–249
transcription, 39:141–142
viral demyelination, 42:281
Rhapidosomes, 29:302
Rhesus rotavirus
reassortment, 39:170–171
strain MU18006, 44:180, 183–184
studies, 39:172, 179, 183
vaccination, 39:187–189
Rheumatoid arthritis, 29:47
Rhinovirus
picornaviral genomes, 40:104–105
provirion, 46:29
Rhinoviruses
direct inactivation by
4',6-dichloroflavan, 30:91
4'-ethoxy-2'-hydroxy-4,6'-dimeth-
oxychalcone, 30:90–91
inhibition by enviroxime, 30:109–110
picornaviral genomes, 40:132, 154, 159
cis-acting elements, 40:117, 126, 128
structure, 40:105, 108–111
3'-proximal element of capsid-coding
region, 47:227
replication, 42:229–230
Rhizomania, furoviruses, 36:6–7
Rhizopus, pectinase, 29:219
Rhodanine, as virus uncoating inhibitor,
27:166
Rhododendron, protoplasts, 29:221
Rhozyme HP, 29:150, 219–220
Ribavirin, 42:13–16
analogs and derivatives, antiviral ac-
tivities, 30:105–107
carrier-mediated drug delivery,
35:273–274, 286–287
liposome-encapsulation, 35:295–298
prodrugs, 35:284–296
side effects, 35:274
Ribavirin 2',3',5'-triacetate, antiviral ac-
tivity, 30:105
Ribgrass mosaic virus, 33:226
Plantago hosts and occurrence, 27:113,
122
Ribonuclease, 29:282
Bunyaviridae, 40:239
defective interfering viruses, 40:193,
201
hepatitis A virus, 39:224–225
HIV-1 reverse transcriptase, 46:134–
137
influenza virus, 34:252
picornaviruses, 36:161–162
Theiler's murine encephalomyelitis vi-
rus, 39:293
Ribonuclease H
Drosophila retrotransposons, 36:58–
59
HIV structure, 39:31–32, 35–37
Paramyxoviridae, 39:143
Ribonuclease L, activation, 42:93–94
Ribonucleoprotein
Bunyaviridae, 40:236, 238–239, 260
HIV structure, 39:11, 13–14
influenza virus, 34:252, 255
particles, *in vitro* splicing systems,
35:19–20
Ribonucleoprotein complexes
formation, 43:202
hepatitis delta virus, core, 43:197–198
roles, 43:210, 212
Ribonucleotide reductase
in bovine herpesvirus, 45:199
varicella zoster virus-induced, 38:72–
73
Ribonucleotides, hepadnavirus, 34:75
Ribosomal frameshifting
closteroviruses, 47:140–144

- Ribosomal frameshifting (*cont.*)
 translational suppression by retroviruses, **41:196–197, 202, 210–233**
- Ribosomes
 archaeobacterial viruses, **34:181**
 in arenaviruses, **31:8–9**
 Bunyaviridae, **40:257–258**
 cucumber mosaic virus, **41:288, 320, 327**
Drosophila retrotransposons, **36:63–64, 68**
 equine arteritis virus, **41:167**
 furoviruses, **36:10**
 hepatitis C virus, **40:69**
 picornaviral genomes, **40:104, 108**
 cis-acting element, **40:114–115, 117–119, 121, 123, 125–128**
 evolution, **40:160**
 mRNAs, **40:143–147, 150–151**
 trans-acting factors, **40:129–133, 138**
 translation initiation, **40:140–141**
 readthrough suppression, **41:202, 204, 206–207**
 Theiler's murine encephalomyelitis virus, **39:294**
 translational suppression by retroviruses, **41:196, 233**
- Ribosome shunt, caulimoviruses, **44:36–37**
- Ribozymes, **44:273–285**
 hairpin, **44:283–284**
 hammerhead, **44:274–282**
 antiviral effects, **44:279–281**
 chemical modifications, **44:275–276**
 complementary flanking region length, **44:276**
 delivery molecule design, **44:278–279**
 delivery to target cells, **44:278**
 effects in nonviral systems, **44:281–282**
 structure and sequence requirements, **44:274–275**
 target site selection, **44:276–277**
 hepatitis delta virus, **43:223–225**
 as potential gene regulators, **44:273**
 self-replication, **44:285**
 that cleave DNA, **44:284**
- Rice, plant viruses in developing countries
 agricultural modernization, **41:356–357**
 crop improvement, **41:359–360, 365–366, 376**
- Rice black-streaked dwarf virus, sequence, **45:267**
- Rice dwarf virus, **45:253–358**
 genomic organization, **38:288–291**
 genomic reassortment of variants, **45:267–268**
 sequence conservation, **45:264–267**
 sequence relationships, **45:262–265**
- Rice gall dwarf virus, **45:254, 259**
 sequence relationships, **45:262–265**
- Rice ragged stunt virus, **45:260–261**
 characteristics, **38:252–253**
 plants transformed by, **45:268**
- Rice stripe necrosis virus, **36:27–28**
 natural occurrence, **36:4–5**
 particle dimensions, **36:17**
 purification, **36:15**
 vectors, **36:12**
- Rice tungro virus, **33:239**
- Rice yellow mottle virus, plant viruses in developing countries, **41:356, 359, 365**
- Ricketts pathogens, new, emerging, and reemerging, **43:35–41**
- Rifampicin, vaccinia sensitivity, **34:46**
- Rift Valley fever, **43:16–17**
- Rift Valley fever virus, **40:264**
 genome organization, **40:244, 249–251, 254**
 morphogenesis, **40:260**
 replication, **40:256**
 study with MAbs, **29:103**
- Rimantadine, as virus uncoating inhibitor, **27:163–165**
- Risk, plant viruses in developing countries, **41:387–391, 395–398**
- RNA
 AAV transcripts in DNA genome, **32:249–250, 255–258**
 function regulation
 by helper viruses, **32:258**
 mutation effects, **32:259–260**
 adenovirus, **39:90, 100, 102, 110, 117**
 ADRV, **35:194–202**
 animal cells, **36:131, 134, 137**
 antisense, **44:290–292**
 expression in transgenic mice, **44:293**
 archaeobacterial viruses, **34:146**

- Halobacterium halobium*, **34:158–160**
- Sulfolobus* virus-like particle SSV1, **34:181–183**
- avian retroviral
 polypurine tract, **30:193–195**
 primer binding site, **30:193–195**
 reverse transcription-replication, **30:193–195**
 LTR formation during, **30:194–195**
- binding domain, *Totivirus*, **43:327**
- Bunyaviridae, **40:236**
 interactions with host cells, **40:262–263**
 replication, **40:255–259**
 structure, **40:238–251**
- Bunyaviridae M segment, **40:236**
 genome organization, **40:243–251**
 replication, **40:259**
 structure, **40:238–239**
- bunyaviruses
 gene products, **30:302–304**
 structure, **30:302**
- caulimoviruses, **44:23–24**
- closterovirus, properties, **25:151**
- complementary, hepatitis delta virus, **43:194**
- coxsackie A viruses in tissues, **42:351**
- cucumber mosaic virus, **41:283–284**
 antigenic properties, **41:293, 296**
 genome organization, **41:296–314, 316**
 virus-host plant relationships, **41:323–325, 327–331**
 virus particle, **41:285–288, 290**
- defective interfering, **44:401–409**
 CNV, **44:404–405**
 CyRSV, **44:402–404, 407–408**
 origin, replication, and encapsidation, **44:406–409**
 TBSV-Ch, **44:401–402, 407**
 TCV, **44:405–408**
 transformation with, tombusviridae, **44:417–418**
 use as RNA vectors, **44:409**
- defective interfering viruses, **40:181–183, 185–187, 189**
 animal and human, **40:189–194, 197–198**
 plant, **40:198–206**
- dianthoviruses, properties, **33:266–268**
- DNA replication, **34:11**
 double-stranded, *see* Double-stranded RNA
- Drosophila* retrotransposons, **36:35, 77–86, 88–90, 92**
 insertional mutagenesis, **36:77–86, 88–90**
 intracellular cycles, **36:60, 62–64, 66–67**
 organization, **36:50–51, 53–54, 56, 58**
 transcription, **36:67–71, 74, 76**
- encapsidation, **46:30–34**
 capsid mutations affecting, poliovirus, **46:47–52**
 hepadnaviruses, **46:176–180**
 requirements, poliovirus, **46:31**
 signals, **46:32–33**
 subcellular location, **46:33–34**
- 3'-end formation and poly(A) site, **44:26–32**
 absence of complete signal at 5'-end, **44:28–29**
 occlusion by promoter proximity, **44:29**
 regulation, **44:26–28**
 HIV-1, **44:31–32**
 use efficiency modulation by sequences in U3, **44:29–31**
- Epstein-Barr virus, **40:35, 45, 47**
 EBNA-2, **40:29–30, 32, 34**
 genome, **40:24, 26**
 target cell, **40:23**
- flaviviruses, **33:47–48**
- frameshift, luteoviruses, **46:436–437**
- furoviruses, **36:27–28**
 beet necrotic yellow vein virus, **36:18–23**
 natural occurrence, **36:6**
 particle dimensions, **36:17–18**
 peanut clump virus, **36:26–27**
 soil-borne wheat mosaic virus, **36:23–26**
- genomic, **25:12**
 to antigenomic, hepatitis delta virus, **43:212**
 coxsackie A viruses, **42:354–356**
 evolution, closteroviruses, **47:147–150**
- HEF glycoprotein of influenza C virus, **40:214**

- RNA (*cont.*)
- hepadnavirus, **34:71–72, 76**
 - hepatitis A virus
 - characterization, **39:224–225**
 - genome, **39:244–245**
 - replication in cell culture, **39:231–236**
 - hepatitis C virus, **40:58, 95**
 - cloning, **40:64, 66, 69–70, 74–75**
 - infectious agent, **40:60**
 - replication, **40:77**
 - hepatitis delta virus, **43:189–190, 196–197**
 - binding, **43:216**
 - cleavage and ligation, **43:194**
 - directed synthesis, **43:195**
 - editing, **43:195, 206–207**
 - species, **43:198–199**
 - hepatitis E virus, **40:58, 87, 89–90, 93, 95**
 - HIV
 - cis*-acting repressive sequences, **43:91**
 - genome, **43:60**
 - structure, **39:6, 8, 10, 13**
 - gag* gene products, **39:18–23**
 - infectious cycle, **39:16–17**
 - pol* gene products, **39:29–31, 35–37**
 - regulatory proteins, **39:51–54**
 - HIV-1, **40:2, 6–8, 10, 12, 14**
 - human papillomaviruses, transcription, **37:137–138**
 - hybridization, rotaviruses, **46:72–73**
 - influenza virus
 - components, **34:248–249, 252–253, 255–256**
 - genetic reassortment, **34:257**
 - pathogenicity, **34:264**
 - killed antiviral vaccines, **39:265, 282**
 - lentiviruses
 - structure, **34:191–192, 194–195**
 - virus-host cell interaction *in vitro*, **34:198**
 - virus-host cell interaction *in vivo*, **34:204**
 - luteovirus, putative recombination, **46:424**
 - messenger, *see* Messenger RNA
 - MuLV, intron sequences, **35:26**
 - neurodegenerative diseases caused by prions, **41:250**
 - noncoding regions, tombusviridae, **44:396–399**
 - as oligodeoxynucleotide target, **44:287–288**
 - oral vaccination, **41:413, 425**
 - packaging, retroviruses and pararetroviruses, **44:52–54**
 - Paramyxoviridae, **39:129–130, 134–135**
 - cleavage, **39:142–144**
 - genome organization, **39:136–137**
 - genome replication, **39:150–152**
 - transcription, **39:141, 144–146, 150**
 - parvoviruses, **33:118–119, 144**
 - conformation, **33:145–147**
 - translation, **33:119–122**
 - and pesticide production, **36:341**
 - pestiviruses, **41:53, 56, 68, 90**
 - picornaviral genomes, **40:103–104**
 - cis*-acting elements, **40:115–118, 121–125, 127–128**
 - evolution, **40:160–161**
 - phenotype, **40:154–156**
 - replication, **40:151–154**
 - structure, **40:104, 106–110, 114**
 - trans-acting factors, **40:129, 131–138**
 - translation initiation, **40:139, 141–142**
 - picornaviruses, **36:154**
 - comparison, **36:171–174**
 - genome, **36:161, 164–165**
 - revertants, **36:167–168**
 - vaccine development, **36:175**
 - poliovirus, **34:242**
 - interaction with capsid proteins, **46:51–52**
 - neurovirulence, **34:228, 230, 233, 235, 239**
 - pathogenesis, **34:221**
 - structure, **34:218–219**
 - polymerase, virus-coded, **25:9–10**
 - potyvirus coat protein, **36:275**
 - genome organization, **36:276–279**
 - structure, **36:287–288, 290**
 - pregenomic, **44:20–21**
 - cis*-acting signals, hepadnaviruses, **46:177–180**
 - organization, hepadnaviruses, **46:184**
 - properties, **41:76–78, 80, 82**
 - retroid viruses
 - packaging and unpackaging, **32:71–74**

- transcription, **32:76–84**
translation, **32:84–85**
Rev role in inhibiting splicing, **43:90**
ribosomal
 archaeobacterial viruses, **34:143–146**,
 184
 lentiviruses, **34:192**
rotaviruses, **36:182**, **198**; **39:165–167**,
 197–199
 profiles, **46:72–74**
RRE, **43:87–91**
rubella virus, genome, **44:95–102**
 5'-terminal, **44:107–110**
satellite, *see* Satellite RNA
Semliki Forest virus
 genome, **45:122–123**
 synthesis, **38:356–358**
Sindbis virus encephalitis, **36:256**,
 257, 263
single-stranded, *see* Single-stranded
 RNA
splice sites in, avian leukosis virus,
 35:20, **22**
splicing of, **35:18–26**
ST9-associated satellite-like, lu-
 teoviruses, **46:456**
subgenomic, **25:12–14**
symptom production, **33:223–**
 224
TAR, **42:94**; **43:76–79**
target, selection, hammerhead
 ribozymes, **44:277**
Theiler's murine encephalomyelitis vi-
 rus
 demyelination, **39:309**
 pathogenicity, **39:310–311**
 pathology, **39:298**, **301–302**
 virology, **39:292–294**, **296**
torovirus, **43:241–242**
transfer, *see* Transfer RNA
translation, poliovirus, **46:10–11**
translational suppression by retro-
 viruses, **41:194**, **233**
 readthrough suppression, **41:198**,
 200, **202**, **204**, **207**
 ribosomal frameshifting, **41:212**,
 218–224
VA1, **42:94**
vaccinia, **34:44**, **60–61**
 genome, **34:45–49**
 vector, **34:50**, **55–57**
- RNA ambisense
 arenaviruses
 L and S species, **31:8**
 S species, ambisense coding, **31:10–**
 18
 Bunyaviridae
 L and M mutants, **31:34**
 species, **31:19–21**
 bunyaviruses
 La Crosse virus, S species, **31:24**
 snowshoe hare virus
 L and M species, **31:25**
 species of, **31:24**
 species characteristic of, **31:19**
 S species replication, **31:40–41**
 flaviviruses
 genomic, **31:103–104**
 lipid envelope, **31:104**
 molecular weight, **31:103**
 nucleocapsid, **31:104**
 influenza virus type A, genome seg-
 ment and coding assignments,
 31:56
 lymphocytic choriomeningitis virus-
 type species, S species, **31:10–18**
 nairoviruses
 coding assignments, **31:26**
 species, **31:19**
 phleboviruses
 L species, **31:40–42**
 species characteristic of, **31:19**
 S species, **31:40–42**
 Pichinde virus
 L species, **31:8**
 S species, **31:8**, **10–14**
 uukuviruses
 coding, **31:30**
 L and M species, **31:26**, **39**
RNA-dependent RNA polymerase, **44:115**
 conservation of aspartic acid residues,
 47:165–167
 conserved motifs, **47:163–165**
 negative-stranded RNA, **47:185**
 poliovirus, **46:5**
 supergroups, **47:168**
RNA-directed RNA polymerase
 hepatitis C virus, **40:63**, **67**
 hepatitis E virus, **40:89**, **91**
RNA gel electrophoresis, for ADRV,
 35:216
RNA interactions, poliovirus, **46:49–50**

- RNA polymerase
 archaeobacterial viruses, **34:144–145**
 in arenavirus preparations, **31:7–8**
 cucumber mosaic virus, **41:329**
 eubacterial, **44:436**
 flavivirus, **33:65, 76**
 hepadnavirus, **34:75**
 HIV structure, **39:35, 37**
 influenza virus, **34:248**
 Paramyxoviridae, **39:132, 134**
 pestiviruses, **41:82**
 poliovirus, **34:219, 228**
 potyvirus coat protein, **36:278**
 Theiler's murine encephalomyelitis virus, **39:293**
 vaccinia, **34:44, 48, 53**
 vesicular stomatitis virus, **38:99–122**
- RNA polymerase II, host, role in FV3 transcription, **30:13–14**
- RNA recombinations, *see* Pestivirus RNA recombinations
- RNA replicases
 evolution, closteroviruses, **47:147–150**
 Q β , **47:183, 225**
- RNA replication
 cis-acting nucleotide sequences required for, **47:214–233**
 effect of capsid proteins, **47:203–205**
 host proteins, positive-stranded RNA viruses, **47:205–209**
 internal sequences, **47:225–227**
 membrane role, **47:209–214**
 models, helicase role, **47:181–187**
 poliovirus, **46:7, 13–14**
 rotaviruses, double-stranded, **38:15–16**
 sequences required for subgenomic RNA synthesis
 alpha-like viruses, **47:227–229**
 carmo-like and sobemo-like virus, **47:229–230**
 coronaviruses, **47:230–233**
- 3'-terminal sequences, **47:215–222**
 alpha-like viruses, **47:215–218**
 carmo-like viruses, **47:220–221**
 coronavirus RNAs, **47:221–222**
 negative strands, **47:222–225**
 Novaviridae RNAs, **47:222**
 other 3' structural elements, **47:217–218**
 picorna-like viruses, **47:218–220**
 tRNA-like sequences, **47:215–217**
- 5'-terminal sequences, positive strands, **47:222–225**
- RNA–RNA recombination, brome mosaic virus, **43:275–300**
 in 3'-noncoding region of RNA3, **43:280–293**
 illegitimate recombination models, **43:283–292**
 mechanism of illegitimate recombination, **43:292–293**
 selection effect on crossover sites, **43:281–283**
 systems used, **43:280–282**
 in other regions of RNA3, **43:293–299**
 complementation, **43:293–295**
 conversion to wt sequences, **43:295**
 rearrangements at palindromic inserts, **43:298–300**
 recombination among deletion mutants, **43:296–298**
 sequence repetitions and additions, **43:295–296**
 systems used, **43:293**
- RNase, *see* Ribonuclease
- RNA synthesis
 in Sindbis virus-infected mosquito cells, **33:334–335, 337**
 temperature-sensitive viral mutants, **33:345–346**
- RNA 3'-terminal phosphate cyclase, **29:42**
- RNA tumor virus, **29:110**
 transformation mechanisms, **27:282–299**
 acute type, **27:285–291**
 subacute, **27:291–296**
- RNA vectors, use of defective interfering RNAs as, **44:409**
- RNA virus capsid protein, HIV structure, **39:20–21**
- RNA viruses
 alphavirus, protein synthesis, **45:126–128**
 ambisense coding
 arenaviruses and phleboviruses, **31:10–18**
 bunyaviruses, **31:40**
 mutations in, **31:359**
 negative-stranded, families, **31:1**
 positive-stranded, *see* Positive-stranded RNA viruses

- reassortant, picornaviruses, **36:171–174**
 recombination, **43:276–277**
 replication, interferon-induced inhibition, **38:182–183**
 small, **25:313–314**
 small insect types, **26:117–143**
 as vector for foreign genes, **32:224–227**
 sequence heterogeneity, **32:226–227**
 Rocio encephalitis, disease characteristics and occurrence, **28:419–421**
 Rolling hairpin model, parvoviral DNA replication, **33:156–159**
 Roseola, *see* Exanthem subitum
 Rosette, plant viruses in developing countries, **41:357–358**
 Ross River virus, **42:274**
 Rotaviruses, **29:188, 193; 36:181–183, 207; 44:161–189**
 activation, **29:64**
 active immunization, **44:172–174, 180–185**
 adult diarrhea, *see* Adult diarrhea rotavirus
 antiviral antibody affinity, **34:303**
 B cell response, **44:165–167**
 serotype and structural specificities, **44:168–169**
 biophysical data, **46:86–87**
 diarrhea in children, **43:25**
 dsRNA replication, **38:15–16**
 ELISA, **29:180**
 entry of, **38:12–13**
 future research directions, **38:33–34; 44:187–189**
 gene coding assignments in, **38:8–11**
 genome rearrangements
 discovery, **46:71–74**
 duplication, **46:83**
 evolution, **46:91–92**
 extent, **46:75**
 mechanisms, **46:82–86**
 other genera of *Reoviridae*, **46:92**
 RNA, segments 5 and 6, **46:89–90**
 sequence data, **46:75–79**
 in vitro in cultured cells, **46:79–82**
 genomic segment reassortment, **39:164–165**
 comparison to other reoviruses, **39:190–195**
 evolution, **39:166–167**
 reassortment
 definition, **39:165–166**
 in vitro, **39:167–170**
 in vivo, **39:170–172**
 studies
 future, **39:196–199**
 identification of gene function, **39:180–184**
 mapping gene function, **39:184–186**
 temperature-sensitive mutants, **39:172–180**
 vaccination, **39:189–190**
 genetics, **39:187–188**
 passively acquired immunity, **39:187**
 glycoprotein NS28, **38:23–26**
 glycoprotein VP7, **38:19–23**
 groups, **46:71**
 immunosorbent electron microscopy, **29:176–177, 179–180**
 infections, **44:161–162, 174–175**
 animal models, **44:163–165**
 protection against disease by, **44:178–179**
 influenza virus, **34:270**
 live vaccine, field trials, **32:16, 19**
 maturation in endoplasmic reticulum, **38:17–18**
 molecular biology, **38:11–34**
 neutralization
 domains, **36:191–202**
 proteins, **36:183–187**
 NS26, **38:32**
 NS34, **38:31**
 NS35, **38:31**
 NS53, **38:31–32**
 particles
 double-shelled, **38:8**
 single-shelled, **38:4–8**
 budding, **38:17–18**
 structure and composition, **38:3–8**
 subviral, formation, **38:16–17**
 passive immunization, **44:170–172**
 by breast-feeding, **44:175–176**
 protection, **36:187–191**
 protein coding assignments in, **38:11–12**
 proteins
 location in cell, **38:13–15**
 in morphogenesis, **38:19–26**

- Rotaviruses (*cont.*)
 rearranged genes, function, **46:86–91**
 reassortants between bovine and human strains, **32:19**
 response to natural infection, **44:176–178**
 rhesus, *see* Rhesus rotavirus
 RNA
 hybridization, **46:72–73**
 profiles, **46:72–74**
 plaque-purified, **46:79–80**
 second generation genome rearrangements, **46:82–83**
 segment 5, normal and rearranged forms, **46:77–78**
 standard gene 5, **46:77–78**
 structure, **44:162–163**
 study with MAbs, **29:103**
 surface proteins, **36:202–204**
 functions, **36:204–207**
 T-cell response, **44:167–168**
 serotype and structural specificities, **44:168**
 transcription, **38:15–16**
 uncoating, **38:12–13**
 3' UTR, **46:75, 83**
 variants, **46:77**
in vitro growth properties, **46:89**
 VP1, **38:30**
 VP2, **38:30**
 VP3, **38:30–31**
 VP4, **38:27–29**
 VP6, **38:31**
- Rough endoplasmic reticulum
 alphaviruses, protein import into, **38:359–361**
 Bunyaviridae, **40:261**
- Rous-associated virus 0
 endogenous, chicken, **30:183**
 LTR
 enhancer sequences, **30:203–204**
 structure, **30:188–190**
 transcriptional activity, **30:200–203**
 molecular cloning, **30:184**
 nontransforming, **30:206**
 LTR role, **30:209–210**
- Rous sarcoma virus
Drosophila retrotransposons, **36:57–58**
 ectodomain, **33:23–24**
 glycoprotein cytoplasmic domain, **33:24–25**
 HIV structure, **39:19, 22, 25–26, 40**
 life cycle, **35:3–4**
 LTR
 transcriptional activity, **30:202–203**
 in avian and mammalian cells, **30:197**
 transcription control region, **30:196**
 mammalian cells, **35:26–27**
 nontransforming mutants, tyrosine kinase activity, **32:117**
 P120 protein, **35:48**
 rapidly oncogenic, **30:205**
 translational suppression by, **41:212, 215, 217–219, 221**
v-src
 discovery and function, **32:98–100**
 effects on cell proteins during transformation, **32:114–116**
- Rous sarcoma virus RNA
 capping and methylation, **35:14–17**
 polyadenylation, **35:17–18**
 replication, **35:1–4**
 splicing, **35:18–26**
 cellular introns, **35:27–28**
 models for spliced and unspliced RNA accumulation, **35:28–30**
 rapid transport model, **35:28–30**
 splicing suppression models, **35:30–33**
 species specificity, **35:26–27**
 structure, **35:20, 22**
 transcription, **35:4–14**
 cis-acting elements in *gag* gene, **35:9–12**
 cis-acting elements within LTR region, **35:4–9**
 transcriptional interference, **35:13–14**
 viral-coded trans-activator, **35:12–13**
- RSV, *see* Rous sarcoma virus
 Rubella syndrome, congenital, *see* Congenital rubella syndrome
 Rubella virus, **44:69–150**
 amino acid sequences, **44:140–141**
 antiviral antibody affinity, **34:289, 303–304**
 budding, **44:131–134**
 defective interfering viruses, **40:193**
 dsRNA synthesis, **44:110**
 effect on cell division, **44:138–139**
 epitopes, **44:94–95**

- future directions, **44:148–149**
 infection effect on mitosis, **44:138–139**
 interstrain sequence diversity, **44:142–143**
 linked to multiple sclerosis, **44:75–76**
 macroevolution, **44:144–148**
 macromolecular synthesis, time course, **44:134–135**
 medical significance, **44:70–76**
 membrane biosynthesis stimulation, **44:136–137**
 microevolution, **44:140–144**
 mutability, **44:140–141**
 nonstructural protein, **47:179**
 persistence, and chronic disease, **44:75**
 phylogenetic tree of replicases, **44:146–147**
 posttranslational maturation and transport, **44:122–130**
 C protein, **44:122–123**
 E2 and E1, **44:123–130**
 replication, effect on host cell, **44:135–139**
 replication cycle, **44:102–139**
 attachment and penetration, **44:105–107**
 effect on host cell, **44:135–139**
 macromolecular synthesis time course, **44:134–135**
 permissive cell lines, **44:102–105**
 posttranslational maturation and transport, **44:122–130**
 5'-proximal ORF translation, **44:107–110**
 translation and processing of structural proteins, **44:119–121**
 virion morphogenesis, **44:131–134**
 stability, **44:81–82**
 structural proteins, translation and processing, **44:119–121**
 taxonomy, **44:76–78**
 vaccination, complications, **44:71–73**
 Rubella virus RNA, **47:207**
 genomic, **44:95–102**
 coding strategies, **44:144–145**
 codon usage, **44:98–100**
 nucleotide frequency, **44:102**
 ORFs, **44:97–101**
 positive-polarity orientation, **44:97–98**
 potential stem-and-loop structures, **44:111–112, 116–117**
 sequence alignment, **44:113–114**
 sequence determination, **44:96–97**
 5'-terminal, **44:107–110**
 synthesis, **44:110–119**
 cell protein involvement, **44:115–118**
 defective-interfering, generation, **44:118–119**
 potential regulatory sequences, **44:110–115**
 Rubella virus virion, **44:82–88**
 conformation and function of E1 and E2, **44:88–91**
 immunological determinants, **44:91–95**
 morphogenesis, **44:131–134**
 morphology and physicochemical characteristics, **44:78–81**
 proteins, **44:82–88**
 amino acid sequence, **44:85–86**
 extent of glycan processing, **44:86–87**
 immunological determinants, **44:91–95**
 ORFs, **44:83–84**
 transmembrane sequence, **44:87**
 Rubivirus, positive-strand RNA viruses, **41:101, 112, 146, 180**
 Ryegrass cryptic virus
 cellular location in plants, **32:191, 193**
 immunosorbent electron microscopy, **29:178**
- S**
- Sabin attenuated strain, poliovirus, **34:227–235, 239, 241–243**
 Sabin poliovirus, picornaviruses
 genome, **36:162–163**
 protein analysis, **36:160–161**
 recombinants, **36:168, 170**
 revertants, **36:165–168**
 vaccine development, **36:175**
 Sabin vaccine, picornaviral genomes, **40:155**
Saccharomyces cerevisiae, **43:347–356**
 DNA replication, **34:26**
 GCN4 protein, **40:149–151**
Saccharomyces cerevisiae virus, sub-genomic RNAs, **29:79**

- Safety, killed antiviral vaccines, **39:256**, 259, 284
 changes in virion immunogenicity, **39:273**
 kinetics of inactivation, **39:268**, 270, 272
- Safety test, for biological control agents, **39:324–325**
- sAg particles, hepatitis delta virus, packaging, **43:217–218**
- Sagunis*, hepatitis A virus passage, **39:226**
- Saintpaulia ionantha*, protoplast isolation, **29:225**
- Salivary glands, **42:217–218**
- Salmonella*, **29:266–294**
 archaeobacterial viruses, **34:147**
 hepadnavirus, **34:99**
 oral vaccination, **41:409–410**, **414–416**
 bacteria as carriers, **41:431–437**
 epitope presentation systems, **41:424–427**
 foreign antigens, **41:417–423**
 genetic stabilization, **41:429–430**
- Salmonella dublin*, oral vaccination, **41:418**, **420–421**, **425–427**, **434**
- Salmonella enteritidis*, in eggs, **43:28**
- Salmonella typhi*, oral vaccination, **41:427**, **431–433**, **438**
- Salmonella typhimurium*, oral vaccination, **41:410**, **414–415**, **417**, **438**
 bacteria as carriers, **41:431–434**, **436**
 epitope presentation systems, **41:426–427**
 foreign antigens, **41:417–423**
- Sam68, binding to poliovirus, **47:208**
- Sanitation, plant viruses in developing countries, **41:353**
- Saponin, hepadnavirus, **34:134**
- Satellite RNA
 barley yellow dwarf virus, **46:456–457**
 biocontrol of plant disease, **39:321–322**, **337–338**
 agents, **39:323–325**
 cucumber mosaic virus, **39:322–323**
 field applications, **39:325–326**
 fungal disease, **39:330**, **332**
 plant growth, **39:330–331**
 protective effects in crops, **39:326–330**
 transgenic plants, **39:332–333**, **335–336**
 tobacco, **39:333–335**
 tomato, **39:334–335**
 cucumber mosaic virus, **41:286**, **314**, **316–317**, **338**
 distribution, **41:320–323**
 replication, **41:317–319**
 symptom modification, **41:319–320**
- Cymbidium* ringspot virus, **44:412–414**
- defective interfering viruses, **40:198–204**
 transformation with, tombusviridae, **44:416–417**
 turnip crinkle virus, **44:410–412**
- Satellite system, in plant viruses, **25:68–72**
- Satellite viruses
 defective interfering viruses, **40:197**
 of plants, **28:18–19**
- Schwann cells, Theiler's murine encephalomyelitis virus, **39:301**, **303**
- Scrapie, **29:2**, **8–9**; **35:83–87**, see also Prions
 adaptation process, **29:25**
 antibodies, **29:20**
 and Creutzfeldt-Jakob disease, **29:11**
 digestion
 by proteinase K, **29:41–42**
 by trypsin, **29:41–42**
 distribution, **29:12**
 duration of illness, **29:8**
 endpoint titration, **29:15**
 comparison to incubation time interval assay, **29:17**
 epidemiology, **29:12–13**
 fibrils found with, **29:43**
 incubation period, **29:7**, **15**, **21**
 host genes controlling, **29:4**, **22–24**
 incubation time interval assay, **29:3–4**, **15–18**
 infectivity, dependent on protein, **29:38–39**
 natural host, **29:6**
 nomenclature, **29:4**
 pathogenesis, **29:18–19**
 lack of immune response in, **29:19–21**
 plaques, **29:21**, **45**
 prions, **29:15–18**; **41:242–244**, **246**, **248**

- bovine spongiform encephalopathy epidemic, **41:257–258**
- experimental scrapie in sheep and goats, **41:255–257**
- familial diseases, **41:259, 261**
- mice, **41:258–259**
- natural scrapie in sheep and goats, **41:253–255**
- replication, **41:264, 267, 269–270**
- synthesis of PrP, **41:250–251, 253**
- transgenic mice, **41:262, 264**
- Scrapie agent
- assay, **29:2, 15–18, 27**
 - compared to
 - plasmids, **29:46**
 - potato spindle tuber viroid, **29:32**
 - viruses and viroids, **29:32, 46**
 - current molecular models, **29:46–47**
 - denaturation, effect on prion protein, **29:42**
 - differential sensitivity to proteases, **29:41–42**
 - distribution, **29:26**
 - electron microscopy, **29:43–44**
 - heterogeneity, **29:27**
 - hydrophobicity, **29:27, 29**
 - hypothesis on chemical structure, **29:45–46**
 - inactivation by, **29:39**
 - carboxymethylation, **29:32**
 - DEP, **29:36–38**
 - KSCN, **29:38**
 - proteinase, **29:35–36, 38**
 - trypsin, **29:35–36, 38**
 - urea, **29:37–38**
 - membrane hypothesis, **29:26**
 - molecular size, **29:32–35**
 - molecular weight, **29:33–34**
 - nucleic acid, search for, **29:29–32**
 - nucleic acid core, **29:46–47**
 - oligonucleotides, **29:34–35**
 - peaks of infectivity, **29:26**
 - properties, **29:25–45**
 - unusual, **29:3, 45–46**
 - purification, **29:25–29**
 - purified fractions, rod-like structures, **29:43–45**
 - reaction to chemical modification, **29:30–32**
 - resistance
 - inactivation by irradiation, **29:32–33**
 - procedures that attack nucleic acids, **29:29–31**
 - psoralen photoreaction, **29:30–31**
 - ultraviolet inactivation, **29:30**
 - zinc-catalyzed hydrolysis, **29:31**
 - sedimentation properties, **29:26–27, 34**
 - sensitivity to ionizing radiation in presence of oxygen, **29:32**
 - size, **29:47**
 - spread, **29:18–19**
 - strains, **29:24–25; 35:119–120, 122**
 - in susceptibility to nuclease digestion, **29:29–30**
- Scrapie-associated fibril protein, **35:100, 113**
- Scrapie prion protein, **29:3, 5, 35–43, 47; 35:95–96**
- apparent molecular weight, **29:46**
 - correlation with infectious prion, **29:41–42, 46**
 - lack of immunogenicity, **29:21**
 - microheterogeneity, **29:39**
 - molecular weight, **29:20**
 - nomenclature, **29:4**
 - purification, **29:41**
 - radiolabeling, **29:18, 39–40, 42**
 - resistance to protease digestion, **29:39–40, 42**
 - as structural component of prion, **29:39–42**
- SDS, cucumber mosaic virus, **41:290**
- SDS-PAGE
- cucumber mosaic virus, **41:286**
 - HEF glycoprotein of influenza C virus, **40:216–217**
 - simian hemorrhagic fever virus, **41:179**
- Seal influenza virus, **29:103**
- Seasonal patterns, hepatitis A virus, **39:216**
- Secondary transcription, Bunyaviridae, **40:258–260**
- Second messengers
- activating compounds, HIV expression, **43:104–106**
 - in signal transduction from plasma membrane, **37:2–4**
- Sedimentation coefficient, poliovirus virion, **46:15–16**
- Seed banks, plant viruses in developing countries, **41:371**

- Seed-borne viruses, in developing countries
 crop improvement, **41:368–372**
 remedial action, **41:390–392, 394**
- Seed transmission
 cucumber mosaic virus, **41:331–332**
 plant viruses in developing countries, **41:368, 381**
- Selection
 plant viruses in developing countries, **41:353, 355, 367**
 rotaviruses, **39:171, 191**
in vitro reassortment, **39:168–170**
 studies, **39:176, 179, 181**
- Selectivity, killed antiviral vaccines, **39:283–284**
 changes in virion immunogenicity, **39:273, 278, 281–283**
 inactivating agents, **39:260–261**
- Semiautomated fluorometric assay, ASF, **35:267**
- Semliki Forest virus, **33:331; 42:270–275; 47:359, 361**
 animal cells, **36:108**
 endocytosis, **36:119, 121–123**
 enveloped viruses, **36:130–133**
 membrane fusion, **36:125–126**
 receptors, **36:113, 116**
- Bunyaviridae, **40:262**
- C6/36 cells infected by, fusion at low pH, **38:376–377**
- components, synthesis, **38:356–359**
 demyelination mechanisms, **42:274**
 disturbance of blood-brain barrier, **42:272**
- endocytic uptake, **45:118**
- fusion, **45:119, 133**
 inhibition, sodium/potassium alteration, **45:121**
 pH dependence, **45:132**
- fusogenic protein, identification, **38:380–381**
- humoral and cellular immunity, **42:273**
- inflammatory neuropathology, **42:273–274**
- intraperitoneal infection, **42:272**
- 6K protein role in replication, **45:89–90**
- lactate dehydrogenase-elevating virus, **41:144–145**
- life cycle, **45:115**
- nsP1 protein, **47:189**
- nsP2 protein, **47:178–179**
- outcome of infection, **42:271–272**
- passage histories, **42:271**
- replication in mosquito cells, **33:335–336**
- RNA capping, **47:188**
- RNA genome, **45:122–123**
- rotaviruses, **36:199**
- Sindbis virus encephalitis, **36:256**
- spike protein, protomer diagram, **45:116–117**
- structure, **28:224–230**
- synthesis, **38:358–359**
- Sendai virus, **29:112; 39:132–134**
 animal cells, **36:116, 119, 126, 134**
 defective interfering viruses, **40:191, 205**
- genome
 organization, **39:135–137, 140–141**
 replication, **39:151–152**
- HN protein, hemagglutination and neuraminidase activity, **29:96**
- influenza virus, **34:270**
- in persistently infected cells, **29:113**
- protein, functional areas, **29:107**
- transcription, **39:141–142, 144, 147–149**
- Sensitivity, plant viruses in developing countries, **41:390–391**
- Sequence homology, potyvirus coat protein, **36:308**
 genome organization, **36:277–278**
 structure, **36:283**
 taxonomy, **36:293, 296–299, 303**
- Sequence-independent single-primer amplification
 hepatitis C virus, **40:80**
 hepatitis E virus, **40:88–90, 93**
- Sequences
 adenovirus, **39:92–93, 101**
 Bunyaviridae, **40:255, 263**
 genome organization, **40:243–244, 246, 248–254**
 structure, **40:238–242**
 cucumber mosaic virus, **41:283–285, 287, 296, 338**
 genome organization, **41:297–314, 316**
 satellite RNAs, **41:317, 319, 322**

- virus-host plant relationships, 41:323–324, 327–328
- virus-vector relationships, 41:333–334
- defective interfering viruses, 40:182, 184, 188
 - animals and humans, 40:196–197
 - plants, 40:199–202, 204–205
- Epstein-Barr virus, 40:28, 30, 37–38, 43
- HEF glycoprotein of influenza C virus, 40:214, 216–217, 225, 229–231
- hepatitis A virus, 39:210
 - characterization, 39:223–224, 226
 - genome, 39:244–246
- hepatitis C virus
 - cloning, 40:63, 66–67, 69–71, 73–75
 - infectious agent, 40:62
 - prevention, 40:80–82
- hepatitis E virus, 40:88–91
- HIV-1, 40:2–3, 6–7, 11–12
- HIV structure
 - gag* gene products, 39:19–20, 22
 - glycoproteins, 39:40, 42–43, 47, 49
 - pol* gene products, 39:24, 29, 31–32, 38
 - regulatory proteins, 39:51, 53–55
- human herpesvirus 6
 - biology, 41:26, 34
 - growth properties, 41:14
 - molecular biology, 41:15, 17–20, 23
- neurodegenerative diseases caused by prions, 41:244–245, 248, 250, 258
- replication, 41:267, 269
- transgenic mice, 41:262
- oncodna viruses, 39:104, 106, 109–111
- oral vaccination, 41:412–413, 425, 428, 430
- Paramyxoviridae, 39:132–134, 151
 - genome organization, 39:135–141
 - transcription, 39:142, 145–146, 148–150
- pestiviruses, 41:90
 - properties, 41:75, 77–79, 81–82
- picornaviral genomes, 40:158–161
- positive-strand RNA viruses, 41:100, 182
 - common properties, 41:181
 - equine arteritis virus, 41:164–168
 - lactate dehydrogenase-elevating virus, 41:129, 144, 146, 148–150, 153
 - simian hemorrhagic fever virus, 41:178–179
- rotaviruses, 39:193, 199
- satellite RNA for biocontrol, 39:321
- Theiler's murine encephalomyelitis virus, 39:296, 309, 311
- translational suppression by retroviruses, 41:194, 196–197
- readthrough suppression, 41:198–207, 210
- ribosomal frameshifting, 41:214–224, 231, 233
- Sequence-specific methylation, adenovirus, 39:94–95, 111–114
- eukaryotic promoters, 39:122–123
- in vitro* methylation, 39:114–117
- promoter inactivation, 39:123–124
- reversal of inhibition, 39:117–119
- spreading, 39:119–122
- Serine
 - DNA replication, 34:3–4, 17
 - phosphorylation, by protein kinase C, 44:219
- Seroconversion
 - human herpesvirus 6, 41:29, 31, 37
 - lentiviruses, 34:200
 - pestiviruses, 41:59
- Serodiagnosis
 - human herpesvirus 6, 41:25–26
 - pestiviruses, 41:85–86
- Seroepidemiology
 - ADRV, 35:210, 212–213
 - human herpesvirus 6, 41:27–28
 - pestiviruses, 41:59
- Seroidentification, viruses, 27:51
- Serological classification
 - bunyaviridae
 - Bunyavirus* genus, 31:22–23
 - Nairovirus* genus, 31:27
 - Phlebovirus* genus, 31:30–31
 - unassigned viruses, 31:33
 - Uukvirus* genus, 31:29
 - flaviviruses, subgroups, 31:107–108
- Serological differentiation indices, cucumber mosaic virus, 41:292, 294, 296
- Serological specificity, bipartite genome of dianthoviruses, 33:283, 285
- Serological studies, dianthoviruses
 - MAbs, 33:272–276
 - polyclonal antibodies, 33:269–272

- Serology, **29:99**
 closterovirus, **25:152–157**
 cucumber mosaic virus, **41:284, 291–296, 335**
 equine arteritis virus, **41:100, 156, 164**
 human herpesvirus 6, **41:30, 33, 35, 39–40**
 insect viruses, **25:335–342**
 pestiviruses, **41:68, 70**
 plant viruses in developing countries, **41:385**
 simian hemorrhagic fever virus, **41:174**
- Serotype, oral vaccination, **41:413, 433**
- Serum, virus detection in, **27:24–26**
- Severe combined immunodeficiency (SCID), and rotavirus infections, **46:71**
- Sewage, and plant virus origins, **31:327–328**
- Sexually transmitted diseases, **43:23–24**
- Sheep
 border disease, **47:53, 57**
 breeds, susceptibility to scrapie, **29:23**
 scrapie in, **29:2, 6–8, 12–13, 22–23, 43**
 elevated immunoglobulin G, **29:21**
 genetic loci controlling, **29:4**
 pathogenesis, **29:18**
 transmission, **29:24**
 transmissible mink encephalopathy in, **29:7–8**
- Shigella*, **29:226**
 oral vaccination, **41:414–415, 431**
- Shigella flexneri*, **29:301, 305**
- Shigella sonnei*, **29:301, 304–305**
- Shipping fever, bovine herpesvirus role, **45:204–206**
- Sialic acid
 animal cells, **36:112–113, 116, 127**
 HEF glycoprotein of influenza C virus, **40:216, 221, 224, 226**
 influenza virus receptor, **42:228**
 rotaviruses, **36:206**
- $\sigma 1$ protein, **42:328–329**
- Signals, induction of, **37:7–10**
- Signal transduction, **37:1**
 across cytosol, **37:16–18**
 Epstein-Barr virus, **40:40**
 HIV-1, **40:8**
 within nucleus, **37:18–22**
 from plasma membrane, **37:2–16**
 growth factors in, **37:4–10**
 ras oncogene family in, **37:13–16**
 secondary messengers in, **37:2–4**
 src oncogene family in, **37:10–13**
 regulation by interferons, **42:73–78**
- Simian agent 12 virus, taxonomic polypeptides, **29:104**
- Simian hemorrhagic fever virus, **41:100–101, 168, 180–182**
 cell culture, **41:171–176**
 epizootics, **41:168–169**
 host immune response, **41:176–178**
 molecular properties, **41:178–180**
 pathogenesis, **41:169–171**
- Simian immunodeficiency virus, **43:45–46; 45:225–226**
 HIV structure, **39:5, 43, 51, 55**
- Simian retrovirus-1, translational suppression by, **41:228**
- Simian rotavirus, **39:187**
 mutants, **39:172, 174, 177–179**
 reassortment, **39:170–171**
 studies, **39:182–183, 185–186**
- Simian T lymphotropic virus
 STLV-I, **47:379**
 phylogenetic relationship with HTLV-I, **47:403–404**
 STLV-II, **47:379**
 epidemiological characteristics, **47:381–382**
 STLV-PP, **47:379**
 epidemiological characteristics, **47:382**
 independence from PTLV-I/II, **47:409–411**
- Simian viruses, **42:138–139**
- Simian virus 5, Paramyxoviridae, **39:135, 138, 147–148**
- Simian virus 40
 cotransfection with AAV DNA, **32:272**
 integration into cellular DNA, **32:273–274**
 recombinant structure, **32:272–273**
 defective interfering viruses, **40:184**
 DNA replication, **34:1, 10–12, 32–33**
 bovine papillomavirus, **34:28**
 Epstein-Barr virus, **34:33**
 mechanism, **34:16–20**
 origin, **34:12–16**
- Epstein-Barr virus, **40:21, 34, 38, 42, 44**

- gene expression in cells, **26:77–81**
 gene organization, **26:101**
 replication inhibition
 by AAV, **32:279–280**
 by interferon, **38:177–179**
 T antigen, **29:106**
 ATPase active site, **29:111**
 ATPase activity, function inhibition
 assay, **29:108**
 cross reactions, **29:123**
 Simultaneous-shippage model, translational suppression by retroviruses, **41:224–227**
Sinc, prion diseases, **35:107–108**
 SINC gene, **29:4, 22–24**
 Sindbis virus, **29:121**
 antibody binding site location, **29:112**
 DI particles, **29:83**
 glycoprotein E1, **29:116**
 host and tissue range, **45:117**
 host range mutants restricted in *Aedes albopictus* cells, **33:343–347**
 immunosorbent electron microscopy, **29:181–185, 190, 192**
 impaired budding, **45:130–131**
 induced apoptosis, **45:22**
 in mosquito cells
 cytoplasmic effects, **30:27–28**
 defective-interfering particles, **30:25–26**
 mutant isolation, **30:32–34**
 persistent infection, **30:24–25**
 mutant restricted in vertebrate cells, **33:348–358**
 ORFs, **44:98–101**
 protection, MAb role, **29:121**
 protein, functional areas, **29:107**
 replication in mosquito
 CPE(+) and CPE(-) clones of *Aedes albopictus* cells, **33:343–347**
 methionine deprivation, **33:339–343**
 replication in vertebrate and mosquito cells, **33:331–332**
 rotaviruses, **36:199**
 structure, **28:224–230**
 translational suppression by retroviruses, **41:210**
 Sindbis virus encephalitis, **36:255–256, 268–269**
 structure, **36:256–260**
 virulence, **36:260–261, 267**
 suckling mice, **36:266–268**
 weanling mice, **36:261–266**
 Single-stranded RNA
 BMV
 CAT gene insertion and expression, **32:227–233**
 deletion analysis, **32:223–224**
 m4 mutant in 3'-region, **32:234–237**
 structure, **32:216–218, 220**
 transcript infectivity, **32:220–223**
 linear in HAV, **32:144**
 hybridization with cDNA, **32:157–158**
 poly(A) sequences, **32:144**
 replication in cell culture, **32:150**
 translation *in vitro*, **32:149**
 Single-stranded RNA viruses of plants, **28:15–18**
 Sin Nombre virus, **47:357**
 SIP gene, **29:4**
 SIP/LIP gene, **29:22**
 Skin
 layers, **42:211–212**
 lesions
 diagnosis, **27:21–23**
 pestiviruses, **41:57, 60**
 polarized epithelial cells, **42:211–217**
 Skunk, rabies viruses, **36:216**
 epizootiology, **36:219, 221**
 North America, **36:224, 226–228, 236**
 Slow viruses, tissue tropisms of, **26:72–74**
 Small isometric virus, insect, morphology, **25:285–286**
 RNA properties, **25:316–317**
 serological properties, **25:340–341**
 structural proteins, **25:316–317, 331–333**
 Smallpox, vaccinia, **34:43, 45, 61**
 Smut killer system, **43:356–360**
 Sobemo-like virus supergroup
 replication proteins, **47:199**
 sequences required for subgenomic RNA synthesis, **47:229–230**
 Sobemo viruses
 antibodies, production, **29:134–135, 145**
 MAb-determined antigenic properties, **29:154**

- Societal factors, in regard to new, emerging, and reemerging diseases, **43:23–26**
- Sodium butyrate, **43:104–105**
- Sodium chloride, archaeobacterial viruses, **34:164–165, 167**
- Sodium deoxycholate, **29:282**
- Sodium ions, viral infections, **33:192–193**
- Soil, transmission of dianthoviruses, **33:292–293**
- Soil-borne viruses, plant viruses in developing countries, **41:390–391**
- Soil-borne wheat mosaic virus, **36:1–3, 27**
 cytopathology, **36:10**
 molecular biology, **36:23–26**
 natural occurrence, **36:3–4**
 particle dimensions, **36:17–18**
 purification, **36:15**
 vectors, **36:12–15**
- Solanum, plant viruses in developing countries, **41:368–369, 384**
- Solid-phase immunoassays, synthetic peptides, **42:156–157**
 advantages and disadvantages, **42:150–151**
- Solid-phase radioimmunoassay, **29:170, 188, 193**
 diagnosis of SMV, **29:161–162**
- Somatic cell hybridization, **29:132**
- Sorrel, wound tumor virus-infected, root tumors, **29:87**
- Southern bean mosaic virus, **29:154, 318**
 MABs, **29:135**
 protoplast infection, **29:229, 231–232, 235**
 structure, **28:209–211**
- Southern blotting, with PrP, **35:97**
- Soybean
 model for nonpersistent virus spread in, **31:416–417**
 plant viruses in developing countries, **41:358, 361, 367–368, 372**
 protoplast culture, **29:243**
- Soybean mosaic virus
 diagnosis, with MAB, **29:161**
 immunization of mice, **29:133–136**
 MAB-determined antigenic properties, **29:153**
 MABs, **29:135**
 potyvirus coat protein, **36:275**
 genome organization, **36:277**
 structure, **36:281, 285**
 taxonomy, **36:298, 301**
- Sp1, role in HIV transcription, **43:65–67**
- Species barrier, neurodegenerative diseases caused by prions, **41:258, 262–266**
- Species specificity
 adenovirus, **39:90, 95**
 DNA replication, **39:97–99**
 hamster cells, **39:95–100**
 major late promoter, **39:100–102**
 partial complementation, **39:102–103**
 RSV RNA, **35:26–27**
- Specificity
 in nonpersistent virus transmission, **31:393–394**
 viral, of antibody-dependent enhancement, **31:343–344**
- Spheroidin, **29:202–203**
- Spingomyelin, role in alphavirus virus fusion and infection, **45:135–136**
- Spikoside, hepadnavirus, **34:134**
- Spinal cord
 lactate dehydrogenase-elevating virus age-dependent poliomyelitis, **41:125–128, 130–135, 137–139**
 mice, **41:106, 123**
 lentiviruses, **34:202**
 poliovirus, **34:241**
 neurovirulence, **34:223, 235**
 pathogenesis, **34:220–222**
- Theiler's murine encephalomyelitis virus, **39:310**
 demyelination, **39:304, 306, 308**
 pathology, **39:296, 298–302**
- Spiroplasma citri*
 in host chromosomal DNA, **44:450–453**
 technique for detection, **44:453**
- Spiroplasma virus*, **44:383–384, 429–458**
- SpV1, **44:443–456**
 gene organization, **44:446, 449**
 gene transfer, **44:453–455**
 nucleotide sequence, **44:444, 446–449**
 properties, **44:443–445**
 restriction modification, **44:455–456**
Spiroplasma citri detection, **44:453**
 viral sequences in host chromosomal DNA, **44:450–453**
- SpV4, **44:432–443**

- codon usage, 44:440–443
- gene organization, 44:437–438
- nucleotide sequence, 44:434–436
- properties, 44:432–434
- transcription, 44:436–440
- transfection, 44:434
- translation, 44:440–441
- types, 44:430–431
- Spleen
 - ASF, 35:261–262
 - equine arteritis virus, 41:173
 - lactate dehydrogenase-elevating virus
 - age-dependent poliomyelitis, 41:126, 140–141
 - mice, 41:105–106, 108–109, 114, 118–119, 122
 - lentiviruses, 34:203
 - oral vaccination, 41:409, 414, 417, 427
 - pestiviruses, 41:57
 - Theiler's murine encephalomyelitis virus, 39:306–307
- Spleen cells
 - fusion with myeloma cells, 29:138–142
 - isolation, 29:137–138
 - nonfused, longevity, 29:142–143
- Spleen focus-forming virus
 - glycoprotein, domains of, 33:25–28
 - RNA intron sequences, 35:25
- Spleen necrosis virus
 - cellular introns, 35:27–28
- LTR
 - integration into host DNA, 30:195
 - structure, 30:189–190
 - translational suppression by retroviruses, 41:201–202
- Spliceosome, 35:20
- Spliceosome complexes, splicing suppression, 35:32–33
- Splicing
 - Ab-MLV, 35:51–53
 - adenovirus mRNA, 26:24–28
 - badnaviruses, 44:25–26
 - hepatitis B virus, 44:22
 - parvovirus polypeptides, 33:124–127, 133–136
 - regulation during adenovirus transcript processing, 31:207–211
 - retroviral RNA, 44:19–20
 - RSV RNA, 35:18–26
 - sites, 35:20–22
 - Splicing machinery, antiquity, 27:258–259
 - Splicing suppression models, 35:30–33
 - Spodoptera frugiperda*, baculovirus vectors, 35:178–181
 - Spongiform encephalopathy
 - bovine, 43:42–45
 - deer and elk, 43:45
 - induced apoptosis, 45:22–23
 - Spread
 - cell-to-cell, pararetroviruses and retroviruses, 44:11–13
 - nonpersistent viruses
 - control by
 - antiviral factors, 31:418
 - application of aphid alarm pheromones, 31:419
 - breeding for resistance, 31:417
 - chemical applications, 31:419–421
 - reduction of landing sites, 31:418–419
 - environmental effect, 31:398–400
 - forms of, 31:409–417
 - spatial, 31:410–413
 - temporal, 31:410–412
 - models for description of, 31:413–417
 - dependent on number of aphids, 31:415–416
 - in soybeans, 31:416–417
 - role of sources in, 31:390–392
 - external, 31:391
 - internal, 31:390–391
 - suitability of sources for, 31:391–392
 - vectors
 - biology and epidemiology, 31:394–398
 - characteristics, 31:392–394
 - importance, livetrapping and evaluation of, 31:405–407
 - methods for monitoring, 31:400–405
 - virus infection, monitoring methods, 31:408–409
- Spumavirus, and HIV expression, 43:114–115
- Squamous cell carcinoma cell line, Epstein-Barr virus, 40:35
- Squash leaf curl virus, ultrastructure, 30:146

- Squirrel monkey
 chronic wasting disease, **29:9**
 kuru, **29:14**
- Src* gene
 cis-acting elements, **35:12**
 retrovirus replication, **35:3–4**
 RSV, spliced mRNAs, **35:20–22, 24, 26**
src oncogene family, in signal transduction from plasma membrane, **37:10–13**
- S RNA segments, Bunyaviridae, **40:263, 266**
 genome organization, **40:243–244, 251–254**
 replication, **40:255–256, 259**
 structure, **40:238–239**
- St. Louis encephalitis, disease characteristics and occurrence, **28:400–406**
- St. Louis encephalitis virus
 anti-E glycoprotein epitope MAbs, **31:146**
 antigenic relationships, **31:116–117**
 geographically defined variations, **31:118**
 serological subgrouping, **31:108**
 type-specific epitopes, antigenic variation, **31:120**
 vectors, **33:329**
- Staphylococcal enterotoxin B, T-cell apoptosis, **45:36**
- Staphylococcus*, **29:294**
 influenza virus, **34:268**
- Staphylococcus aureus*, influenza virus, **34:268–269**
- Stellaria media*, cucumber mosaic virus, **41:331**
- Stem cells, virus effects, **26:85–88**
- Steric hindrance, antiviral antibody affinity, **34:299, 302, 305**
- Sternorrhyncous vectors, plant viruses, **28:113–140**
- Steroids
Drosophila retrotransposons, **36:54, 76**
 Paramyxoviridae, **39:148**
- STLV, *see* Simian T lymphotropic virus
- Stomach lining, types of glands, **42:219**
- Stool samples, ADRV, **35:206–207**
- Strawberry green petal, *Plantago* hosts and occurrence, **27:116**
- Streptococcal disease, group A, **43:39–40**
Streptococcus mutans, oral vaccination, **41:429**
Streptococcus pyogenes M protein, oral vaccination, **41:422–423**
Streptomyces, antibiotic production, **29:257**
 Streptomycin, sensitivity to vibriocin, **29:301**
- Stress
 oral vaccination, **41:424**
 pneumonia, **35:234–235**
- Structural proteins
 Berne virus, **43:243–247**
 and nonstructural, densoviruses, **47:313**
 pestiviruses, **41:79–80, 83, 90**
 positive-strand RNA viruses, **41:100–101, 164, 179–180**
 rotavirus
 VP1, **38:30**
 VP2, **38:30**
 VP3, **38:30–31**
 VP6, **38:31**
 translational suppression by retroviruses, **41:194**
 translation and processing, **44:119–121**
 varicella zoster virus, **38:74–75**
- Subacute sclerosing panencephalitis, **29:112–113, 120; 42:250, 282–283, 287–288**
 measles, **26:72–74, 108**
- Subclones, archaeobacterial viruses, **34:173–174**
- Subterranean clover red leaf virus, MAbs, **29:135**
- Subviral pathogens, **29:47–48**
- Succinyl concanavalin A, antiviral activity, **30:111–112**
- Sucrose density gradient
Drosophila retrotransposons, **36:63, 68**
 furoviruses, **36:15–16**
- Sugar, influenza virus, **34:254**
- Sugarcane mosaic virus
 immunosorbent electron microscopy, **29:177**
 potyvirus coat protein, **36:276**
 structure, **36:281, 284–285**
 subgroups, **36:305**
 taxonomy, **36:292, 296, 298, 301**
- Sulfolobus*, **34:144–145, 184–185**

- virus-like particle SSV1
 - components, **34:179–181**
 - DNA, **34:177–179**
 - features, **34:174–177**
 - transcription, **34:181–184**
- Sulfur, archaeobacterial viruses, **34:144–146, 184–185**
- Thermoproteus tenax*, **34:168, 171, 174**
- Superinfection immunity, retrovirus, **44:207–211**
- Suppression, translational, by retroviruses, *see* Translational suppression by retroviruses
- Suppressor cells, viral infection, **35:231**
- Surface immunoglobulin, Epstein-Barr virus, **40:20–21, 23**
- Surface markers, and HIV expression, **43:99–102**
- Surface projections, on viruses, **27:9–11**
- Surface proteins
 - carboxy-terminally truncated hepatitis B virus, **47:286–289**
 - functional trans-activator domain, **47:286–287**
 - mechanisms of trans-activation, **47:289**
 - structural characterization, **47:287**
 - target sequence of trans-activation, **47:287–289**
 - hepatitis B virus, **47:263–267**
- Surfactant, **35:225–227**
- Surveillance mechanisms, in respiratory defense mechanisms, **35:224–227**
- Susceptibility
 - to antivirals, human herpesvirus 6, **41:24**
 - cucumber mosaic virus, **41:288, 292, 331, 334, 336**
 - equine arteritis virus, **41:156, 162**
 - lactate dehydrogenase-elevating virus, **41:128–134, 136, 139, 141–143, 151**
 - neurodegenerative diseases caused by prions, **41:261**
 - oral vaccination, **41:410, 415**
 - pestiviruses, **41:66**
 - plant viruses in developing countries
 - crop improvement, **41:355, 357, 365–366, 375**
 - remedial action, **41:378, 390**
 - simian hemorrhagic fever virus, **41:170**
 - varietal, to banana bunchy top virus, **33:309**
 - vector cell monolayer, **25:233**
 - vector cells, **25:230–231**
- Susceptible cells, human herpesvirus 6, **41:8–11**
- SV40, *see* Simian virus 40
- Sweet clover, tumors, induced by wound tumor virus, **29:86–87**
- Sweet clover necrotic mosaic virus, **33:212**
 - isolation, **33:258**
 - purification, **33:263**
- Sweet potato
 - cucumber mosaic virus, **41:335**
 - plant viruses in developing countries, **41:358, 395–396**
- Swine, Japanese encephalitis infections, **27:100**
- Swine fever, classical, *see* Classical swine fever virus
- Swine virus, **29:96**
- Symbionts, *Drosophila* retrotransposons, **36:94**
- Symptomatology
 - cucumber mosaic virus, **41:323**
 - dianthoviruses, **33:277**
 - reassortants, **33:285–286**
- Symptom modification, cucumber mosaic virus, **41:319–320**
- Symptoms
 - banana bunchy top virus infection, **33:306–309**
 - induction by plant viruses, **33:206–208**
 - plant virus multiplication, **33:213–217**
 - type
 - common features in variations
 - chlorosis and necrosis, **33:234–236**
 - morphogenetic disturbances, **33:238–239**
 - mosaics, **33:236–238**
 - plant viral properties specifying
 - effects of mutagenesis, **33:208–211**
 - pseudorecombinants, **33:211–213**
 - viral multiplication, **33:213–217**
- Synovial fluid, lentiviruses, **34:203–204**
- Synthetic peptides, **42:149–179**
 - advantages and disadvantages in diagnostic tests, **42:150–151**

- Synthetic peptides (*cont.*)
 amino acid sequences, 42:156–157
 antibody reaction with influenza virus hemagglutinin, 31:73–74
 antigen detection, 42:178
 antigenic epitopes, 42:152–153
 commercial tests based on gp41, 42:161–162
 cytomegalovirus diagnosis, 42:172
 Epstein-Barr virus diagnosis, 42:169–172
 false-positive reactivity, 42:156–157
 future prospects, 42:178–179
 hepatitis virus diagnosis, 42:176–178
 HIV diagnosis, *see* Human immunodeficiency virus, diagnosis using synthetic peptides
 HSV diagnosis, 42:173
 human herpesvirus 6 diagnosis, 42:172
 human papillomavirus diagnosis, 42:173–175
 human parvovirus B19 diagnosis, 42:176
 human T-cell leukemia virus diagnosis, 42:167
 mapping of epitopes by overlapping peptides, 42:155–156
 picornavirus diagnosis, 42:168–169
 prediction of continuous epitopes, 42:154–155
 respiratory syncytial virus diagnosis, 42:167–168
 solid-phase immunoassays, 42:156–157
 synthesis, 42:151–152
- T**
- TAATGARAT binding protein, regulated promoters in *trans*-activation of transcription, 37:63
 Tacaribe virus
 experimental infection in rodent neonate, 31:9
 nucleocapsids, 31:7
 Tailed bacteriophages
 distribution, 27:212–216
 evolution, 27:252–254
 morphological variation in, 27:248–249
 properties, 27:210
 Tamarin, callitrichid arenavirus disease, 43:47
 T antigens, from SV40 infections, 26:77, 90–93
 TAR element, HIV-1, 40:6–8
 TAR region
 inhibitory effects on translation, 43:94–95
 Tat, 43:76–79
 TAR RNA, 42:94
 TATA-binding, cytomegalovirus, 46:205
 TATA-binding factor TFIID, in *trans*-activation of transcription, 37:60–61, 67
 TATA box, role in HIV basal transcription, 43:63–65
 TATA element, as promoter target in *trans*-activation of transcription, 37:50–51
tat gene
 defective interfering viruses, 40:195
 HIV-1, 40:6
 in HIV gene expression control, 38:131–133
 Tat protein, 43:75–82
 binding to nascent HIV RNAs, 43:78
 domain structure, 43:75–76
 encoding, 43:75
 enhancing elongation of RNA transcripts, 43:81
 HIV-1, 40:6–9
 inhibitors, 43:123–124
 TAR region, 43:76–79
trans-activation, 43:79–80, 82
 Taxonomy
 cucumber mosaic virus, 41:284–285
 pestiviruses, 41:54, 83
 T-cell leukemia, 43:150
 T-cell receptor, cross-linking with CD4, 44:221–222
 T cells
 activation
 HIV expression, 43:100–101
 role of CD4-p56^{lck}, 44:221–223
 antibody-mediated depletion, 45:39, 41
 apoptosis
 EBV-induced infectious mononucleosis, 45:44–45
 HIV infection, 45:45–47
 CD8⁺, immunopathological lesions involving, 47:354–358

- CD4⁺, immunopathological reactions involving, **47:358–364**
 cytotoxic, *see* Cytotoxic T cells
 Epstein-Barr virus, **40:21, 36**
 functions, viral infection, **35:231–232**
 helper, rotavirus-specific, **44:177**
 hepadnavirus
 epitopes, **34:114, 127–129**
 pre-S sequences, **34:111–113**
 HIV-1, **40:1, 3–5, 9**
 HIV expression, **38:126**
 HIV structure, **39:44, 48**
 tat proteins, HIV structure, **39:11, 16, 50–52**
 Theiler's murine encephalomyelitis virus, **39:304–307**
 human herpesvirus 6, **41:3**
 biology, **41:33–34, 36**
 growth properties, **41:8–10, 12**
 inappropriately stimulated, **43:56**
 influenza virus, **34:253**
 lactate dehydrogenase-elevating virus
 age-dependent poliomyelitis, **41:129, 140**
 mice, **41:112, 115, 117–121**
 lentiviruses, **34:204**
 mature, activation-induced death, **45:35–38**
 MBP-specific, **42:295**
 oral vaccination, **41:411–412, 415–416**
 epitope presentation systems, **41:423, 425–428**
 foreign antigens in *Salmonella*, **41:417–420, 422**
 proliferation
 antigen-specific, varicella-zoster virus, **46:281**
 assay tests, varicella-zoster virus, **46:282**
 recognition sites on influenza antigens, **31:92–94**
 response
 bovine herpesvirus infection, **45:207–209**
 LCMV model, **45:38–44**
 to paramyxoviridae, **37:231–232**
 rotavirus, **44:167–168**
 serotype and structural specificities, **44:168–169**
 varicella-zoster virus tropism, SCID *hu* mouse, **46:276–280**
 viral infection, **35:231–232**
 virus-induced immunopathologies, **47:368**
 T-cell-specific transcription factor, TCF-1, **43:72**
 T-cell tumors, herpesviruses, **27:318–322**
 TC 199-MK medium, **25:207–208**
 Tectiviridae, basic properties, **27:210**
 Tegument, human herpesvirus 6, **41:5, 7**
 Temperature
 archaeobacterial viruses, **34:145, 178**
 DNA replication, **34:16**
 influenza virus, **34:257, 260–261**
 lentiviruses, **34:194**
 poliovirus, **34:242–243**
 neurovirulence, **34:227, 230, 234–235**
 vaccinia, **34:46, 49**
 Temperature-gradient gel electrophoresis, biocontrol, **39:324–325**
 Temperature-sensitive mutants
 persistent viruses, **26:40**
 rotaviruses, **39:172–181, 195**
 Temperature sensitivity, Sindbis virus, host range mutants, **33:343–345**
 Template switching model, illegitimate recombination, **43:292–293**
 Teratogenicity, rubella virus, **44:70–71**
 Terminal protein A, DNA replication, **34:3–5, 8**
 Termination codon, translational suppression by retroviruses, **41:210**
 Testis, *abl* genome, **35:51–52**
 Tetrahydroimidazo[4,5,1-*jk*][1,4]benzodiazepin-2(1*H*)-one derivatives, *see* TIBO
 TFIIC transcription factor, in *trans*-activation of transcription, **37:61, 67**
 Theiler's murine encephalomyelitis virus, **47:359–361**
 autoimmune responses, **42:270, 295**
 cDNA, **39:311, 313**
 chronic demyelination, **42:268–269**
 demyelinating and nondemyelinating, **42:287**
 demyelination, **39:304, 308**
 cellular immunity, **39:306–307**
 humoral immune response, **39:307–308**
 immunogenetics, **39:304–305**
 immunosuppression, **39:305–306**

- Theiler's murine encephalomyelitis virus (*cont.*)
 demyelination (*cont.*)
 infection of nude mice, **39:308–309**
 immune response role, **42:269–270**
 neutralizing antibodies, **42:269**
 5'-noncoding region and neurovirulence, **42:267**
 nucleotide sequences, **42:267**
 pathogenicity, **39:309–312**
 pathology, **42:268**
 acute disease, **39:296–298**
 chronic disease, **39:298–303**
 picornaviral genomes, **40:104, 106, 109, 126, 157, 161**
 tissue culture passage of avirulent TO-like strains, **42:290–291**
 virology, **39:294–296**
 differences between strains, **39:295–296**
 structure, **39:292–295**
- Theiler's viruses, picornaviruses, **36:164–165**
- Thermolysin, tick-borne encephalitis virus time course of digestion with, **31:140**
- Thermoproteus tenax*, **34:146, 184–185**
 properties, **34:168–171**
 virus TTV1, **34:145–146, 171–173**
 virus TTV2, **34:173–174**
 virus TTV3, **34:173–174**
 virus TTV4, **34:174**
- Thin sectioning of viruses, **27:19–20**
 artifacts in, **27:47–49**
 immunoelectron microscopy, **27:20–21**
- Threonine, DNA replication, **34:17**
- Thrips, plant viruses in developing countries, **41:374, 376–377, 391**
- Throat, poliovirus, **34:220**
- Thrombocytopenia
 lentiviruses, **34:202**
 pestiviruses, **41:57, 59**
- Thy-1, Ab-MLV, **35:59–60, 62**
- Thymic tumors, Ab-MLV, **35:40, 62, 67**
- Thymidine
 analogs, **42:20–23**
 hepadnavirus, **34:112, 127**
- Thymidine kinase
 in bovine herpesvirus, **45:198–199**
 gene promoter, analysis, **37:100–101**
 induction in infected cells by
 HVT, **30:251–252**
 MDV, **30:252**
 picornaviral genomes, **40:118–119**
 vaccinia, **34:44**
 genome, **34:48–49**
 vector, **34:50, 53, 55, 57**
- Thymidylate synthetase, varicella zoster virus, **38:73**
- Thymus
 development, role of CD4 and p56^{lck}, **44:212–214**
 lentiviruses, **34:190**
 leukemia, **35:40–41**
- Tiazofurin, antiviral activity, **30:106–107**
- TIBO compounds, HIV structure, **39:23–24, 30**
- TIBO derivatives, **42:31–35**
- Tick-borne encephalitis virus, **29:103**
 geographically defined variations, **31:118**
 glycoprotein digestion, time course, **31:140**
 serological subgrouping, **31:107**
 structural glycoprotein, antigenic sites on, **31:124**
- Ticks, spread of disease
 Crimean–Congo hemorrhagic fever, **43:18**
 encephalitis, **43:17–18**
 human ehrlichiosis, **43:37**
 Lyme disease, **43:36–37**
- Tick virus, ASF, **35:254**
- Tilorone, interferon type I induction, **30:117–118**
- Ti-plasmids, **29:88**
- Tipula oleracae*, iridoviruses transmission, **46:394**
- Tissues, virus detection in, **27:33–42**
- Tissue specificity
 HIV-1, **40:3**
 picornaviral genomes, **40:155–156**
- Tobacco
 biocontrol, **39:323–325, 328–330, 332**
 transgenic plants, **39:333–335**
 cucumber mosaic virus, **41:287, 319–320, 322–325**
 induced resistance in, **29:255**
 interactions with tobacco mosaic virus, **33:226–229**

- leaf, protoplast culture, **29:243**
- Tobacco etch virus
 in double infection with potato virus X, **29:336**
- Plantago* host and occurrence, **27:113**
- potyvirus coat protein, **36:276**
 genome organization, **36:276–277, 279**
 structure, **36:280–281, 283, 285**
 subgroups, **36:305**
 taxonomy, **36:298, 300**
- replication proteins, **47:202**
- Tobacco mosaic virus, **26:145–199;**
29:102, 115, 169, 215–216, 256, 317–319; 33:209–210, 213, 215, 235, 238–240, 243–244, 246
- antiviral antibody affinity, **34:290, 298–302**
- assembly, **28:191–196; 29:117**
- biocontrol, **39:324**
- coat protein, **26:147–154**
 A-protein, **26:148–150**
 multiple polymeric forms, **26:147–148**
- complementation with phloem-limited virus, **29:344**
- as dependent virus, **29:335–336**
- disassembly, **26:159–160**
- disk, **26:156–157**
- in double infection with potato virus X, **29:336**
- ELISA, **29:246**
- facultative resistance to, **29:340–341**
- fine structure, **26:154–159**
- furoviruses, **36:9, 20–21, 24**
- gene expression, **26:182–183**
- genetic map, **26:181–182**
- genome organization, **29:322–325; 41:302, 305–306, 313**
- genome structure and replication cycle, **25:42–44**
- helix formation by, **26:151–154**
- helper virus promoting transport over nonhosts, **29:341–342**
- host passage effects, **25:172–176**
- immunization of mice, **29:136**
- immunosorbent electron microscopy, **29:172, 175, 177, 183, 187**
 AB-CGT, specificity, **29:174–175**
- infection
 detection, **29:245**
 plant cell cultures, **29:248–250**
 infectivity, neutralization with monoclonal and polyclonal antibodies, **29:159–160**
 intersubunit contacts in, **26:157**
 MAb-determined antigenic properties, **29:153–160**
 MAbs, **29:135**
 mosaics, **33:236–237**
 mutants, **29:325–332**
 coat protein, **29:325–327, 349**
 complementation of *ts* transport function by *tr* or helper virus, **29:333–334**
 non-coat-protein, **29:327–332**
 role in synthesis of genomic or sub-genomic RNAs, **29:327–330**
 symptoms, **33:209–210, 218**
 temperature-sensitive, **29:326–327, 330**
 in transport gene, **29:330–332**
- Plantago* hosts and occurrence, **27:113, 122**
- plant resistance to, **29:251–252**
- positive hybridomas, **29:139–142, 144**
- potyvirus coat protein, **36:278, 286–287, 289**
- protein disk, **28:187–189**
- protein molecule, folding, **29:157**
- protoplast infection, **29:227–229, 231–232, 234–235**
 by culture, **29:242**
 stimulation by polyethyleneimine, **29:230**
- replication, **29:252–253**
 complexes, **47:213**
 inhibition, **29:254**
 proteins, **47:192, 196**
- resistance to, **29:339**
- RNA polymerase, **29:328**
- RNA replicase, **29:328**
- RNA replication, **47:209, 226**
- RNA translation, **25:41–42**
- satellite RNAs, **41:322**
- self-assembly, **26:160–175**
 disks and nucleation, **26:160–162**
 elongation, **26:172–175**
 mechanism, **26:166–171**
 nucleation sequence, **26:162–166**
 alternate, **26:171–172**

- Tobacco mosaic virus (*cont.*)
 sequences required for subgenomic RNA synthesis, 47:229
 specific intermediate-length RNAs, 25:39–41
 strains, 29:175
 common epitope, 29:158
 structure, 28:185–196; 29:160
 subliminal symptomless infection, 29:345
 translational suppression by retroviruses, 41:207–209
 translocation protein, 29:251–252
 transport form, 29:349
 transport protein, 33:220–221
 3'-tRNA-like terminal, 47:216–217
 virion
 composition, 26:146–147
 fine structure, 26:154–156
 virus-host plant relationships, 41:329
 virus multiplication, 33:215
 virus particle, 28:189–191; 41:290
 virus-specific informosome-like ribonucleoprotein, 29:350–353
 polypeptides, 29:350–351
- Tobacco mosaic virus RNA, 29:322–323
 cell suspension inoculation with, 29:239
 low-molecular-weight component, 29:322–324
 messenger properties, 26:175–183
 mutants influencing synthesis, 29:327–330
 nucleotide sequences, 29:323–325
 protoplast infection with, 29:236–240
 structure and function, 26:183–189
 subgenomic, 26:178–180
 in subliminal infection, 29:347–348
 translation, 26:180–181
- Tobacco necrosis virus, 25:47; 44:420
 host passage effects, 25:177
 identification, 31:323
Plantago hosts and occurrence, 27:115, 128
 satellite, 25:69
 structure, 28:211
- Tobacco necrotic dwarf virus, 29:253, 343
 protoplast infection, 29:228
- Tobacco rattle virus, 33:212
 immunosorbent electron microscopy, 29:187
- Plantago* hosts and occurrence, 27:114, 123–124
 protoplast infection, 29:227–229, 231
 RNA, 29:330
- Tobacco ringspot virus, 33:22, 223
 MAb-determined antigenic properties, 29:152
Plantago hosts and occurrence, 27:115, 127–128
 satellite RNA, 25:69–70
- Tobacco streak virus, 33:212
 immunization of mice, 29:136
 MAb-determined antigenic properties, 29:150–151
 MAbs, 29:135
Plantago host and occurrence, 27:114, 125–126
- Tobacco stunt virus, in developing countries, 41:369
- Tobacco yellow dwarf virus
Orosius argentatus as vector, 30:144
 properties, 30:144–145
- Tobamoviruses, 47:147–149
 antibody production, 29:134–135, 145
 coat protein gene
 expression, 25:36–37
 location within genomic RNA, 25:37–39
 furoviruses, 36:17
 gene expression regulation, 38:318–334
 gene functions, 38:315–318
 genes, *see* Genes, tobamovirus
 genomes
 ability to manipulate, 38:312–313
 organization, 38:308–312
 identification, 31:322–323
 MAb-determined antigenic properties, 29:154–160
 phenotype, effects of altered 30K protein production on, 38:334–335
Plantago hosts and occurrence, 27:113, 122–124
 potyvirus coat protein, 36:287–288, 299
 proteins, translation after heat shock, 38:321
 protein synthesis, regulation, 38:318–320
 replication, 38:313–315
 transport function, 38:206–211

- Tobraviruses, **25:61–63**
 transport function, **38:211–212**
- TobYDV, *see* Tobacco yellow dwarf virus
- Togaviruses, **41:146, 179–181**
 attachment proteins, **27:180–181**
 cellular receptors for, **27:181**
 6K protein, membrane permeability
 modification, **45:89–91**
 macroevolution, **44:144–148**
 microevolution, **44:140–144**
 in mosquito cell cultures
 cytoplasmic effects, **30:27–28**
 defective-interfering particles,
30:25–26
 in drug-resistant cell mutants,
30:28–29
 growth and morphogenesis, **30:22–23**
 high yield in certain cell lines,
30:26–27
 isolation and identification, **30:29–**
34
 persistent infection
 attenuation during, **30:35–36**
 defective interfering particles,
30:25
 establishment, **30:23**
 superinfection resistance, **30:24–**
25
 virus production, **30:23–24**
 penetration by, **27:181–182**
 taxonomy, **44:76–78**
- Tolerance, plant viruses in developing
 countries, **41:355, 365, 380, 387**
- Toluene, **29:283**
- Tomato
 biocontrol, **39:322–328, 332, 337–338**
 transgenic plants, **39:333–335**
 cucumber mosaic virus, **41:319, 321,**
324
 facultative resistance, **29:340, 346**
 interactions with tobacco mosaic virus,
33:229–230
 plant viruses in developing countries
 crop improvement, **41:358–359, 373,**
375–377
 remedial action, **41:381, 385, 391**
 protoplasts, **29:217, 219**
 resistance to viruses, **29:339**
 virus complementation in, **29:342**
- Tomato aspermy virus
 antigenic properties, **41:296**
 genome organization, **41:314, 316**
 satellite RNAs, **41:319, 322**
 taxonomy, **41:284**
 virus-host plant relationships, **41:324,**
331
 virus particle, **41:287–288, 290**
 virus-vector relationships, **41:333**
- Tomato black ring virus
 immunosorbent electron microscopy,
29:174–175, 183, 186–187
Plantago hosts and occurrence, **27:115**
 satellite RNA, **25:70**
- Tomato bushy stunt virus, **33:216;**
40:198–199, 201–203
 compact (native) virus, **28:196–205**
 defective interfering RNA, **44:401–**
402, 407
Plantago host and occurrence, **27:115,**
128–129
 structure, **28:196–207**
 expanded, **28:205–207**
- Tomato golden mosaic virus
 genomic DNA, nucleotide sequence,
30:151–156
Nicotiana benthamiana infection
 defective particles, **30:169**
 replication cycle, **30:166–167**
 transport function, **38:223–224**
- Tomato ringspot virus
 MAb-determined antigenic properties,
29:152
 MAbs, **29:135**
Plantago hosts and occurrence, **27:115,**
128
- Tomato spotted wilt virus, **40:241, 254,**
260
 in developing countries, **41:374, 376,**
391
Plantago host and occurrence, **27:115**
 transport function complementation,
29:337
- Tomato yellow leafcurl virus, in develop-
 ing countries, **41:358–359**
- Tombusviridae, **44:381–423**
 defective interfering RNA, **44:401–**
409, 417–418
 CNV, **44:404–405**
 CyRSV, **44:402–404**
 origin, replication, and encapsida-
 tion, **44:406–409**
 TBSV-Ch, **44:401–402**

- Tombusviridae (*cont.*)
 defective interfering RNA (*cont.*)
 TCV, 44:405–406
 use as RNA vectors, 44:409
 genome
 expression, 44:389–390
 organization, 44:385–386, 419
 22K and 19K proteins, functions, 44:395–396
 33K and 92K proteins, functions, 44:391–392
 41K protein, function, 44:392–395
 noncoding regions, 44:396–399
 3'-end, 44:397–399
 5'-terminal regions, 44:396–397
 particle structure, 44:383, 385
 related genera, 44:419–422
 replication, 44:414–416
 sequence similarities with carmoviruses, 44:388–389
 taxonomic structure, 44:382–384, 431
 transgenic plants, 44:416–419
 Cymbidium ringspot virus coat protein gene, 44:418
 defective interfering RNA, 44:417–418
 full-length polymerase gene, 44:418–419
 satellite RNA, 44:416–417
- Tombusviruses
 identification, 31:323
Plantago hosts and occurrence, 27:115, 128–129
- Tonoplasts, furoviruses, 36:11
- Tonsils, ASF, 35:261, 263
- Topoisomerase
 archaeobacterial viruses, 34:178
 DNA replication, 34:11, 19
 model of parvoviral DNA replication, 33:159
 role in CTL-induced apoptosis, 45:25
- Topoisomers, archaeobacterial viruses, 34:177
- Topological mapping, flavivirus epitopes, 31:123–137
 cooperative effects between antibodies, 31:128–137
 binding assays, 31:129–134
 functional assays, 31:134–137
 epitope models, 31:123–128
- Torovirus, 43:233–269
 antibody detection, 43:266
 antigenic relationships among, 43:252–253
 detection, 43:261–265
 cell culture isolation, 43:261–263
 ELISA, 43:263–264
 HA test and HI confirmation, 43:263
 hybridization assay, 43:264–265
 indirect fluorescent assay, 43:264
 reverse transcriptase, polymerase chain reaction amplification, 43:265
 disease association, 43:257–258
 electron and solid phase immunoelectron microscopy, 43:261–262
 experimental infection, 43:248–249
 future research, 43:268–269
 genome organization and replication, 43:241–242
 host and host cell range, 43:238
 immune response in infected host, 43:253–255
 infection routes, 43:258
 isolation and growth in culture, 43:237
 morphology and morphogenesis, 43:238–241
 natural infection, 43:249–250
 pathology and pathogenesis, 43:250–252
 persistence of infection in herd, 43:259–260
 physical and chemical properties, 43:241
 positive-strand RNA viruses, 41:146, 149, 166–168, 181
 protein composition and antigenic determinants, 43:243–247
 seroepidemiology, 43:255–256
 susceptibility to environmental influences, 43:258–259
 taxonomic relationship with coronavirus, 43:234–235
 taxonomy, 43:266–268
- Torovirus-like particles, 43:234–236
- Tospovirus*, 40:236
- Totivirus*, 43:304–346
 functional domains, 43:324–332
 genome organization, 43:309–311
 helper viruses, 43:305
 host range, 43:334–335
 interaction with host, 43:335–344

- capsid protein as target of host defense, 43:342–343
- Helminthosporium victoriae*, 43:343–344
- helper and exclusion activities, 43:340–342
- required host genes, 43:336–339
- yeast antiviral system, 43:339–340
- yeast natural variants, 43:340–342
- in vitro* systems
- frame-shifting site, 43:320–323
- identifying *cis*-acting sites, 43:314–324
- signals required for transcription, 43:319–320
- sites required for replication, 43:318–319
- viral interference site, 43:323–324
- virus binding site, 43:315–317
- in vivo* encapsidation signal, 43:316, 318
- morphology and physicochemical properties, 43:307–308
- nucleic acid, 43:308–309
- proteins, functional domains
- capsid protein heterogeneity, 43:328–329
- capsid protein phosphorylation, 43:329–332
- nucleotide phosphohydrolase, 43:327
- RDRP domain, 43:325–327
- RNA binding domain, 43:327
- protozoal, 43:344–346
- replication strategy and virion assembly, 43:311–314
- satellite dsRNAs encoding killer toxins
- smut killer system, 43:356–360
- yeast killer system, 43:347–356
- satellite viruses, 43:305
- taxonomy, 43:306–307
- transmission, 43:332–334
- viral proteins, 43:309
- Toxicity
- oligodeoxynucleotides, 44:288
- potential, antisense treatment, 44:271
- Toxins
- killer, *Totivirus* satellite dsRNA-encoded
- smut killer system, 43:356–360
- yeast killer system, 43:347–356
- translocation through membranes, 45:64–65
- Tracheobronchial epithelium, 42:226
- Trans-acting factors
- adenovirus, 39:94, 117, 123
- picornaviral genomes, 40:135–139, 150, 162
- mRNA, 40:131–135
- RNA, 40:129–131
- regulation by interferons, 42:78–81
- translational suppression by retroviruses, 41:227–230
- Trans*-activation, translational, caulimoviruses, 44:38–39
- Trans*-activation of transcription, 37:35–76
- biochemical mechanisms, 37:63–70
- E1A-dependent
- characteristics, 37:38–41
- promoter targets, 37:41–51
- transcription factor role, 37:51–63
- mechanisms, 37:51–53
- viral, 37:70–74
- Trans*-activation region, HIV structure, 39:6, 16, 51–52
- Trans*-activation response element, HIV-1, 46:104
- Transcription
- adenovirus, 39:91–93
- control signals, 31:179–187
- enhancer elements, 31:183–187
- promoter sites, 31:179–183
- E1A protein-mediated activation, 31:188–195
- early, repression, 31:195–199
- early to late transition, 31:199–204
- late genes, activation of expression, 31:199–204
- mRNA
- stability, 31:216–218
- transport from nucleus to cytoplasm, 31:211–216
- oncodna viruses, 39:107–109
- pre-early to early transition, 31:188–195
- sequence-specific methylation, 39:111, 114–117, 122
- species specificity, 39:99–102
- transcript processing, regulation during, 31:204–211
- polyadenylation, 31:205–207

- Transcription (*cont.*)
 adenovirus (*cont.*)
 transcript processing, regulation during (*cont.*)
 splicing, **31:207–211**
 units, expression during infection, **31:170–179**
- archaeobacterial viruses, **34:146**
Halobacterium halobium, **34:157–162**
Sulfolobus virus-like particle SSV1, **34:181–184**
- bacteriophage $\phi 6$, **35:165–167**
- bovine papillomavirus type 1, **44:327–328**
- Bunyaviridae, **40:252, 255–260, 264**
 bunyavirus S RNA, **31:40–41**
cis-acting signals required for, *Totivirus*, **43:319–320**
- cucumber mosaic virus, **41:309, 323–324**
- defective interfering viruses, **40:184, 200, 204–206**
- DNA replication, **34:33**
 adenovirus, **34:9**
 bovine papillomavirus, **34:22, 24**
 Epstein-Barr virus, **34:31**
 SV40, **34:14–15**
- Drosophila* retrotransposons, **36:35, 91–93, 96**
 insertional mutagenesis, **36:77–87, 89–91**
 intracellular cycles, **36:60, 63, 67**
 organization, **36:50–54**
 scattered repetition, **36:41–44, 46**
- Epstein-Barr virus, **40:48**
 EBNA-1, **40:41–42, 44–47**
 EBNA-2, **40:28–30, 32–34**
 genome, **40:24, 26**
- equine arteritis virus, **41:158, 165–166**
- genital papillomavirus, **44:328–329**
- hepadnavirus, **34:66**
 genome organization, **34:69**
 mRNA, **34:75–78**
 pre-S sequences, **34:98–104**
 replication, **34:71, 75**
- hepatitis B virus, **47:259–262**
- hepatitis C virus, **40:58, 72**
- hepatitis E virus, **40:58, 89–90, 93**
- HIV-1, **40:2, 7–8, 10**
- HIV structure, **39:7, 16, 35, 37, 51, 53–54**
- human herpesvirus 6, **41:19**
- influenza virus, **34:248–249, 253, 255–256**
- initiation site, definition, **26:3**
- iridoviruses, **46:377–381**
 methylated DNA, **46:380**
- lactate dehydrogenase-elevating virus, **41:146, 148**
- lentiviruses
 structural proteins, **34:192–194**
 virus-host cell interaction *in vivo*, **34:207–208**
 virus-host cell interactions *in vitro*, **34:200**
- neurodegenerative diseases caused by prions, **41:250**
- oral vaccination, **41:425, 434, 436–437**
- Paramyxoviridae, **39:129, 133–135, 141–142**
 genome organization, **39:137–141**
 multiple entry of complex, **39:145–150**
 RNA processing, **39:142–144**
 single entry of complex, **39:144–145**
- parvovirus genome, **33:117–119**
- pestiviruses, **41:77**
- phlebovirus S RNA, **31:40–42**
- picornaviral genomes, **40:146–149**
- picornaviruses, **36:170**
- poliovirus, **34:219**
- rotaviruses, **38:15–16; 39:199**
- RSV RNA, **35:4–14**
- Sindbis virus encephalitis, **36:263**
- spiroplasma virus, SpV4, **44:436–440**
- Theiler's murine encephalomyelitis virus, **39:293, 311**
- vaccinia, **34:44–45, 60–61**
 genome, **34:45–49**
 vector, **34:50, 53, 55**
- Transcriptional enhancer factor, papillomavirus, transcription, **44:329–331**
- Transcriptional interference
 in ALV-induced B-cell lymphoma, **30:212–214**
 in eukaryotes, between HSV-TK and mouse α -globin genes, **30:215**
 gene expression control, scheme, **30:216**

- in prokaryotes, **30:214–215**
 RSV LTR, **35:13–14, 33**
- Transcriptional intermediary factor, papillomavirus, transcription, **44:329–331**
- Transcription complexes
 parvovirus, products, **33:144–145**
 vesicular stomatitis virus, polypeptide composition, **38:100–101**
- Transcription control regions, in parvovirus DNA, **33:115–117**
- Transcription factor binding sites, as targets of HBx-mediated trans-activation, **47:277–278**
- Transcription factors
 HIV-1, **40:3–5**
 human herpesvirus 6, **41:18, 36**
- Transducing unit, definition, **47:323**
- Transfection
 adenovirus, **39:102–103, 106, 114, 116**
 DNA replication, **34:27**
 hepadnavirus
 characterization, **34:86**
 expression, **34:102–106**
 pre-S sequences, **34:99**
 replication, **34:75**
 influenza virus, **34:273**
 poliovirus, **34:221, 230**
 spiroplasma virus, SpV4, **44:434**
- Transfer factor, in treatment of chickenpox, **28:338**
- Transferrin, **35:225–227**
 Epstein-Barr virus, **40:36**
 lentiviruses, **34:2'06**
- Transfer RNA
 cucumber mosaic virus, **41:302, 309, 313, 328**
 HIV structure, **39:15–16, 18–19, 35–38**
 isoacceptor species, **46:125–127, 129**
 picornaviral genomes, **40:129**
 primer, retroviruses, **46:121**
 translational suppression by retroviruses
 readthrough suppression, **41:198–201, 204, 206–209**
 ribosomal frameshifting, **41:212, 216–217, 220, 224–233**
 tRNA^{Lys3} primer, HIV-1 reverse transcription, **46:125–131**
- Transformation
 Ab-MLV, **35:55–67**
 lymphoid, **35:69**
 transformant and target cell, **35:50–62**
 equine herpesvirus 2, **44:367–368**
 membrane glycoprotein sensitive to, **29:42**
 MoMLV lymphoid cells, **35:44–45**
 oncogenic, parvovirus, **33:95–96**
 parvovirus infection, **33:168**
 viral, effect on cells, **26:97–100**
- Transforming growth factor β , HIV expression inhibition, **43:119–120**
- Transforming growth factor β 1, **42:363–364**
- Transforming growth factors, Ab-MLV, **35:64**
- Transfusion, hepatitis C virus, **40:58, 83**
- Transgenes, cucumber mosaic virus, **41:337–338**
- Transgenic mice, neurodegenerative diseases caused by prions, **41:259, 261–267, 269–270**
- Transgenic plants, satellite RNA for biocontrol, **39:322, 335–336**
 tobacco, **39:333–335**
 tomato, **39:334–335**
- Trans-hypothesis of hepatocarcinogenesis, **47:291**
- Translation
 adenovirus, **39:99–100, 103, 115, 117**
 archaeobacterial viruses, **34:181–182**
 badnaviruses, **44:39–40**
 Bunyaviridae, **40:263**
 genome organization, **40:243, 247, 251–252**
 replication, **40:255, 257–258**
 bunyavirus S RNA, **31:40–41**
 caulimoviruses, **44:36–39**
 continuous, viruses using strategy of, **38:205**
 cucumber mosaic virus, **41:286, 297, 308, 327**
Drosophila retrotransposons, **36:69–70, 88**
 Epstein-Barr virus, **40:33, 45**
 equine arteritis virus, **41:164–165, 167**
 furoviruses
 beet necrotic yellow vein virus, **36:19–22**
 peanut clump virus, **36:27**

- Translation (*cont.*)
 furoviruses (*cont.*)
 soil-borne wheat mosaic virus, **36:24**,
 26
 hepatitis C virus, **40:69–70**, **72**
 hepatitis E virus, **40:89**
 HIV-1, **40:2**
 HIV structure, **39:16**, **40**, **51**
 influenza virus, **34:248**, **255**, **257**
 inhibition by picornaviruses, **33:194–**
 195
 competition model, **33:195–196**
 other models for cardiocviruses,
 33:196–198
 iridoviruses, **46:381–382**
 lentiviruses, **34:208**
 luteoviruses
 cap-independent, proteolysis, **46:443–**
 444
 internal initiation, **46:438–440**
 leaky termination, **46:442–443**
 neurodegenerative diseases caused by
 prions, **41:245–246**
 oral vaccination, **41:423**, **427**, **430**
 Paramyxoviridae, **39:138**, **147–149**
 parvovirus genome, **33:119–122**
 pestiviruses, **41:76**, **79**, **81–82**
 phlebovirus S RNA, **31:40–42**
 picornaviral genomes
 cis-acting elements, **40:114–129**
 evolution, **40:158**, **160**, **162**
 initiation, **40:139–143**
 mRNAs, **40:143**, **146–151**
 phenotype, **40:154**, **156**
 structure, **40:107–108**
 trans-acting factors, **40:129–138**
 plant virus mRNA *in vitro* systems,
 25:4–8
 in vivo systems, **25:2–4**
 Pol
 badnaviruses, **44:43–44**
 caulimoviruses, **44:43**
 Gag:Pol ratio regulation, **44:44–45**
 hepadnaviruses, **44:41–42**
 retroviruses and retrotransposons,
 44:40–41
 poliovirus, **34:219**, **242**
 mRNA, **46:6**
 RNA, **46:10–11**
 5'-proximal
 ORF, rubella virus, **44:107–110**
 viruses using strategy of, **38:204–**
 205
 retroviruses, leader features affecting,
 44:33–36
 rotaviruses, **39:183**
 Sindbis virus encephalitis, **36:257**
 spiroplasma virus, SpV4, **44:440–441**
 Theiler's murine encephalomyelitis vi-
 rus, **39:293–294**
 tobamovirus, 126K leader role, **38:320–**
 321
 viral mRNA
 in infected cells, **31:24–265**
 competition as regulatory mecha-
 nism of, **31:252–265**
 shutoff of host protein synthesis in
 animal cells, **31:247–249**
 switch between host and viral pro-
 tein synthesis, **31:251–252**
 intrinsic regulating features,
 31:230–244
 mechanism of synthesis of more
 than one protein, **31:237–244**
 frameshifting during elongation,
 31:243–244
 initiation at other-than-AUG co-
 dons, **31:239–241**
 leaky scanning, **31:238–239**
 reinitiation, **31:241–243**
 suppression of terminator codon,
 31:244
 monocistronic nature, **31:235–237**
 in poliovirus-infected cells, and
 p220, **31:256**, **264**
 cleavage and eIF-3 inactivation,
 31:260–261
 specific early inhibition of host
 protein synthesis, **31:257–259**
 as subunit of cap binding factor,
 31:259–260
 Translational suppression by retro-
 viruses, **41:193–197**, **233**
 readthrough, **41:197–199**, **210**
 alternate stop codons, **41:204–207**
 context, **41:199–204**
 tRNAs, **41:207–209**
 ribosomal frameshifting, **41:210–213**
 +1 direction, **41:230–233**
 -1 direction, **41:212**, **214–230**
 Translation initiation site, in mRNA
 molecule, **25:25–29**

- Translation strategy, of flavivirus, 33:65–74
- Translocation
 animal cells, 36:139
 enveloped viruses, 36:122
 macromolecule transport, 36:110
 nonenveloped viruses, 36:137
 receptors, 36:113
Drosophila retrotransposons, 36:34
 hepatitis A virus, 39:232
 HIV structure, 39:40
 picornaviral genomes, 40:148
 Sindbis virus encephalitis, 36:256
 translational suppression by retroviruses, 41:225
 vaccinia, 34:53
- Transmembrane domain
 alphavirus glycoproteins, 33:11–12
 influenza virus hemagglutinin, 33:6–7
 rabies virus, 33:17–19
 vesicular stomatitis virus, 33:17–19
- Transmissible dementias, prions, 35:124–126
- Transmissible mink encephalopathy, 29:9, 24; 35:84
 adaptation process, 29:25
 duration of illness, 29:8
 incubation periods, 29:7
 natural host, 29:6
 prions, 41:242, 258
- Transmission
 ASF, 35:255–256
 cucumber mosaic virus, 41:284, 331, 333–335, 337–338
 filoviruses, 47:6, 14–15
 human herpesvirus 6, 41:28–29
 iridoviruses, 46:393–395
 lactate dehydrogenase-elevating virus, 41:154–155, 157
 neurodegenerative diseases caused by prions, 41:254–258, 262
 plant viruses in developing countries
 crop improvement, 41:357, 367–368, 372, 376
 remedial action, 41:381, 389
 simian hemorrhagic fever virus, 41:170–171
- Transmission ecology, plant viruses, 28:113–114
- Transplantation, organ, and human herpesvirus 6, 41:29, 31–32, 37
- Transport function, *see also* Plant virus-coded transport function
 BNYVV, 38:222–223
 BSMV, 38:221–222
 caulimoviruses, 38:212–214
 comoviruses, 38:214–215
 geminiviruses, 38:223–225
 nepoviruses, 38:214
 potexviruses, 38:219
 potyviruses, 38:215–216
 tobamoviruses, 38:206–211
 tobraviruses, 38:211–212
 tricornaviruses, 38:216–219
- Transport gene of plant viruses, host resistance-breaking mutations in, 38:226–227
- Transport protein
 plant virus symptoms, 33:219–221
 viral, tissue specificity, 38:228–229
- Transposons, analogy with avian retroviral LTR, 30:191–192
- Trehalose dimycolate, 35:302–303
- Trichloroacetic acid, archaeobacterial virus, 34:179
- Trichoderma viride*, pectinase, 29:219
- Tricornaviruses
 cucumber mosaic virus, 41:302, 305, 313, 328
 transport function, 38:216–219
- Trifluorothymidine, 35:272–273
 formula, 26:51
 macromolecular carriers, 35:290
 side effects, 35:274
- Trifolium*
 cucumber mosaic virus, 41:335
 plant viruses in developing countries, 41:361, 375
- Trimolecular hybridization model, illegitimate recombination, 43:287–292
- Trisodium phosphonofornate
 antiviral activity, 30:107–108
 clinical trial against HSV 1, 30:127
 viral DNA polymerase, 30:108
- Tristeza, plant viruses in developing countries, 41:369, 376
- Triticum aestivum*, leaf protoplasts, virus infection, 29:228
- Triton X-100, bacteriophage $\phi 6$, 35:144–145
- Trophoblast interferon, 42:61
- Tropical spastic paraparesis, 43:149–150

- Tropism, poliovirus, **34:221–222**
- Tropomyosin, *Drosophila* retrotransposons, **36:85–86**
- Trypsin
 hepadnavirus, **34:85**
 influenza virus, **34:265, 270**
 potyvirus coat protein, **36:288, 293, 307**
 rotaviruses, **36:181**
 neutralization, **36:184, 186–187, 194, 198**
 surface proteins, **36:204–207**
 tick-borne encephalitis virus time course of digestion with, **31:140**
- Tryptophan, translational suppression by retroviruses, **41:209**
- T-suppressor cells, viral infection, **35:231**
- Tuberculosis, **43:38–39**
- Tubules, furoviruses, **36:10**
- Tubulin, Paramyxoviridae, **39:152**
- Tulip, plant viruses in developing countries, **41:368–369**
- Tulip breaking virus, MABs, **29:135**
- Tumor antigen, adenovirus, **25:375–376**
- Tumor necrosis factor, HIV expression induction, **43:102**
- Tumor necrosis factor α , virus-infected cell lysis, **45:28–30**
- Tumor necrosis factor receptor, Fas/Apo-1, **45:34–35**
- Tumor regressor sera, Ab-MLV genome, **35:47–48**
- Tumors
 adenovirus, **39:89, 91–93**
 oncodna viruses, **39:105–106, 109–110**
 sequence-specific methylation, **39:111, 124**
 species specificity, **39:95, 99**
 animal cells, **36:134**
 DNA replication
 adenovirus, **34:2**
 bovine papillomavirus, **34:20**
 Epstein-Barr virus, **34:29**
 SV40, **34:10**
 Drosophila retrotransposons, **36:61**
 Epstein-Barr virus, **40:20, 24, 34–36, 41**
 human herpesvirus 6, **41:14, 34**
 initiation, wound tumor virus concentration, **25:265**
 lactate dehydrogenase-elevating virus, **41:102, 117, 154–155**
 age-dependent poliomyelitis, **41:124**
 molecular properties, **41:150, 152–153**
 translational suppression by retroviruses, **41:228**
 virus detection in, **27:40–42**
- Tumor viruses, **27:281–334**
 cellular transforming genes, **27:296–299**
 herpesviruses as, **27:299–324**
 mechanisms of tumor production by, **27:281–331**
 promoter insertion model, **27:291–294**
- Tunicamycin
 Bunyaviridae, **40:247, 261**
 HEF glycoprotein of influenza C virus, **40:216–217**
 hepadnavirus, **34:98**
 Sindbis virus encephalitis, **36:260**
- Turnip crinkle virus, **33:216; 40:199–206; 44:385**
 defective interfering RNA, **44:405–408**
 replication proteins, **47:198**
 satellite RNA, **44:410–412**
 structure, **28:207–209**
 3'-terminal, **47:221**
- Turnip mosaic virus
 Plantago host and occurrence, **27:113, 121**
 plant viruses in developing countries, **41:367, 375**
- Turnip rosette virus, **29:154**
 protoplast infection, **29:227, 232, 234–235**
 replication, inhibition, **29:254**
 RNA, protoplast infection, **29:240**
- Turnip yellow mosaic tymovirus
 virus-host plant relationships, **41:328, 330**
 virus particle, **41:290**
- Turnip yellow mosaic virus, **29:318; 33:207, 236–237**
 furoviruses, **36:21**
 immunosorbent electron microscopy, **29:174–175, 183, 186**
 protoplast infection, **29:227**
 replication, inhibition, **29:524**
 replication proteins, **47:195–196**
 RNA, in subliminal infection, **29:347**

3'-tRNA-like structure, 47:216
 Tymovirus, 25:45-47
Plantago host and occurrence, 27:116, 129
 Type B virus, characteristics, 25:474-475
 Type D oncovirus, characteristics, 25:475-476
 Tyrosine
 Ab-MLV, 35:49
 phosphorylation, during T cell activation, 44:221-222
 Tyrosine kinase
abl genome, 35:51
 Ab-MLV, 35:63-66
 cellular protein phosphorylation during transformation, 32:114-116
 Epstein-Barr virus, 40:31-32, 40
 in gene products of src family, 32:109-114

U

Ubiquitin
 pestiviruses, 41:81
 role in BVDV, 47:73-83
 Ultraviolet cross-linking, picornaviral genomes, 40:136
 Ultraviolet radiation
 as cofactor for AIDS progression, 43:106-107
 cucumber mosaic virus, 41:290
 effect on BMV replication, 29:339
 flavivirus translation, 33:70-72
 killed antiviral vaccines, 39:258, 260-261, 267-268
 parvovirus DNA replication, 33:152-153
 Ultraviolet transcription, equine arteritis virus, 41:165
 Uncoating, viral, in cell penetration, 27:159-167, 173-174, 178-182, 184-189, 192, 194-195, 197-198
 inhibitors of, 27:163-167
 intermediates of, 27:161-163
 sites for, 27:160-161
 United States Department of Agriculture (USDA), plant viruses in developing countries, 41:364, 367, 371
 U protein, virion, 44:244-245

Upstream reading frames, picornaviral genomes, 40:107-108, 149-151
 Uridine, equine arteritis virus, 41:156, 158, 164
 Urine, virus detection in, 27:26-27
 USF-1 binding site, 43:72-73
Ustilago maydis, 43:356-360
 Uukuniemivirus, 40:251, 255-256, 260-262
Uukuvirus, 40:235-237
 genome organization, 40:245, 251
 replication, 40:259
 structure, 40:241
 Uukuviruses, 31:26-30; 40:235-236, 263-264
 genome organization, 40:244, 251-252, 254
 proposed serological classification, 31:29
 replication, 40:255-256, 259-260
 RNA species, 31:19, 29
 coding, 31:30
 L and M, 31:26, 29
 structural polypeptides, 31:29
 structure, 40:238, 242

V

v-*Abl*, Ab-MLV, 35:63-67
 Vaccination, *see also* Immunization
 chicken, by MDV serotypes and HTV, 30:266-270
 immune mechanism induction, 30:266-268
 equine arteritis virus, 41:160-163
 hepatitis A virus, 39:214
 active immunization, 39:238-242
 characterization, 39:222, 224
 passive immunization, 39:237-238
 replication in cell culture, 39:227
 HIV structure, 39:3-5, 7, 56
gag gene products, 39:19, 21, 24
 glycoproteins, 39:40, 48-49
 leukemic children, 28:343-344
 oral, with recombinant bacteria, *see*
 Oral vaccination with recombinant bacteria
 pestiviruses, 41:56, 65, 69, 83, 86-90
 principles, 42:103-105
 rotaviruses, 39:189-190

- Vaccination (*cont.*)
 rotaviruses (*cont.*)
 genetics, **39:187–188**
 passively acquired immunity, **39:187**
 studies, **39:182–183**
- Vaccines, *see also* Killed antiviral vaccines
 adjuvants, **35:298–299**
 bovine herpesvirus 1, **35:239**
 Bunyaviridae, **40:249, 264**
 carrier-mediated delivery, **35:298–301**
 defective interfering viruses, **40:193**
 equine herpesvirus, **45:177–180**
 flavivirus strains, assessment, **31:121–123**
 formal, **39:258**
 hepatitis C virus, **40:73, 83–84**
 history and perspectives, **32:1–3**
 immune-stimulating complex, herpesvirus, **45:179**
 inactivated
 component (subunit)
 form of presentation, **32:27–28**
 HAV proteins, **32:160–161**
 recombinant DNA technology, **32:21–25**
 formalin-treated, immunopathology, **32:7, 14–15**
 HAV, **32:159–160**
 synthetic peptides, **32:25–27**
 synthetic peptides form of presentation, **32:28–29**
 from HAV polypeptides, **32:161–162**
 in vitro propagation, **32:6–7**
 whole virion, tumorigenicity of used cells, **32:21**
 influenza, **35:238**
 live
 reassortants, **32:19**
 recombinant viruses
 intraserotype, **32:19–20**
 vaccinia virus as vector for, **32:20–21**
 virus attenuation, **32:5–6**
 HAV, **32:160**
 mutation induction, **32:16–18**
 neutralizing MAb effects, **32:19–20**
 live-attenuated, hepatitis A virus, **39:239–240**
 picornaviral genomes, **40:110, 155, 157**
 picornaviruses, **36:153–154**
 biological tests, **36:155, 158**
 development, **36:175–176**
 genome, **36:162–163, 165**
 protein analysis, **36:158–160**
 recombinants, **36:168**
 revertants, **36:165–168**
 RNA, **36:174**
 poliovirus, inactivated
 improvement, **37:269–270**
 and oral, differential responses, **37:268–269**
 rabies viruses, **36:215, 217**
 Africa, **36:248–249**
 Europe, **36:239–240**
 North America, **36:232, 234**
 recombinant DNA technology, **35:239**
 rotaviruses, **36:182, 204**
 viral, **42:105**
 and antibody-dependent enhancement, **31:352**
 viral-bacterial synergistic interaction in respiratory disease, **35:238–239**
- Vaccinia, **34:43–45, 60–62**
 as expression vector, **34:50**
 foreign genes, **34:50–54**
 recombinants, **34:55–60**
 genome
 DNA sequences, **34:48–49**
 gene mapping, **34:45–48**
 hepadnavirus, **34:98, 103**
- Vaccinia virus
 Bunyaviridae, **40:260, 264**
 hepatitis C virus, **40:84**
 HIV structure, **39:5, 19, 29**
 IUdR effect, **26:51–52**
 recombinant, poliovirus
 assembly process studies, **46:34–35**
 vectors, P1 and 3CD expression, **46:35–37**
 replication, interferon-induced inhibitor, **38:181**
 as vector for recombinants, live vaccine production, **32:20–21**
- Vacuolar proton-ATPase, inhibitors, **45:67–68**
- Vacuoles, furoviruses, **36:10–11**
- VAI RNA, **42:94**
- Valency, antiviral antibody affinity, **34:284, 307**

- measurement, direct, **34:287, 290, 292–293, 297–302**
- Variant surface glycoprotein, prion proteins, **35:104**
- Varicella, *see* Chickenpox
- Varicella vaccine
 maintaining cell-mediated immunity, **46:302–303**
 memory T-cell responses, **46:296–300**
 primary cell-mediated immune response, **46:285–290**
- Varicella-zoster virus, **46:265–306**
 animal models, **38:49–51**
 biology, **38:47–51**
 cell-mediated immune response, **46:280–306**
 assessment methods, **46:281–283**
 guinea pig model, **46:303–306**
 long-term immunity, **46:293**
 maintenance mechanisms, **46:300–303**
 memory T cells, **46:285–286, 290–298**
 primary, **46:283–290**
 clinical treatment
 acyclovir, **30:126**
 BVDU, **30:126–127**
 disease correlations with cell-mediated immunity, **46:272–273**
 DNA, **38:52–53**
 enzymes induced by, **38:68–74**
 gene expression, **38:75–86**
 gene sequences, **46:268–269**
 genomic organization, **38:54–57**
 glycoproteins induced by, **38:63–68**
 and HIV expression, **43:111–112**
 human herpesvirus 6, **41:17**
 infection
 drug delivery for, **35:305**
 peripheral blood cells *in vitro*, **46:273–275**
 primary, viremia, **46:267–271**
 latency, **38:86–91**
 MAbs, **29:101**
 medical significance of related disease, **46:266**
 molecular biology, **38:45–91**
 and other herpesviruses, genetic relationships, **38:81–86**
 pathogenesis, **46:271**
- proteins
 putative functions, **46:267**
 recognized by T lymphocytes, **46:291–292**
 proteins induced by, **38:61–75**
 putative functions, **46:267**
 reactivation
 maintaining cell-mediated immunity, **46:300–302**
 viremia, **46:271–273**
 reexposure, maintaining cell-mediated immunity, **46:300**
 restriction endonuclease maps, **38:57–60**
 structural proteins, **38:74–75**
 structure, **38:51–52**
 subclinical viremia, relationship between episodes, **46:305**
 tropism, T lymphocytes, severe combined immunodeficient *hu* mouse, **46:276–280**
- Vector cell, susceptibility, **25:230–231**
- Vector cell lines
 establishment, plant viruses, **45:269–271**
 viruses, **25:229–230**
- Vector cell monolayer
 definition, **25:195–196**
 dilution curve, **25:248–249**
 efficiency, **25:197–198**
 established and primary cultures, **25:196**
 field studies, **25:264**
 mechanical transfer of SYDV from, **25:224–225**
 neutralization of viruses, **25:259–262**
 passage in, infectivity for plants, **25:220–221**
 pathology, **25:234–241**
 potato yellow dwarf virus, growth curve in, **25:244–246**
 membrane, **25:265–266**
 susceptibilities, **25:233**
 viruses amenable to, **25:198–200**
 wound tumor virus, **25:243–244**
 recovery from field, **25:264–265**
- Vectors
 arthropod, transmission of viral diseases, **33:327–328**
 ASF, **35:253–254**
 baculovirus, **35:177–191**

- Vectors (*cont.*)
- cucumber mosaic virus, **41:331, 333–334**
 - furoviruses
 - disease control, **36:13–15**
 - natural occurrence, **36:11–12**
 - relationships, **36:12–13**
 - of nonpersistent viruses
 - acquisition and inoculation, **31:392–393**
 - arthropod-borne viruses
 - animals, **31:305–306**
 - plants, **31:306–307**
 - biology and epidemiology, **31:394–398**
 - environment effect on spread, **31:398–400**
 - forms of virus spread, **31:409–417**
 - spatial, **31:410–415**
 - temporal, **31:410–412**
 - importance, livetrapping, **31:405–407**
 - incidence, monitoring methods, **31:400–405**
 - landing traps, **31:404–405**
 - sampling insects on vegetation, **31:402**
 - sticky traps, **31:402–403**
 - suction traps, **31:403**
 - vertical traps, **31:403**
 - yellow water traps, **31:402**
 - infection incidence, monitoring field, **31:408**
 - use of bait plants for, **31:408–409**
 - retention, **31:393**
 - specificity, **31:393–394**
 - plant viruses in developing countries
 - crop improvement, **41:355, 357–359, 369, 374**
 - intensification, **41:376–377**
 - remedial action, **41:378, 383, 386, 389–390**
 - specificity, **33:328**
 - research goals, **33:328–330**
 - transmission of dianthoviruses, **33:289–291**
- Vegetative propagation, plant viruses in developing countries, 41:367, 372, 381–382, 385**
- Velvet tobacco mottle virus, 33:216**
- Venezuelan encephalitis virus, 46:334**
- Venezuelan equine encephalitis, 29:117; 43:17**
- Venezuelan equine encephalitis virus, 42:274**
- Venezuelan equine encephalomyelitis, characteristics and occurrence, 28:395–400**
- V-*erbA* oncogene, in nuclear signal transduction, 37:20–22**
- Verruca plana, papillomavirus, 37:128, 130**
- Verruca vulgaris, papillomavirus, 37:128, 130**
- Vertebrate cells, replication of Sindbis virus in, 33:331–332**
- Vertebrates**
- bunyavirus transmission, **30:306–307**
 - FV3 infection in cell culture, **30:8–9**
 - virus production in mosquito cells, **38:370–371**
- Vesicles**
- cucumber mosaic virus, **41:320, 325**
 - flavivirus RNA synthesis, **33:76**
 - lactate dehydrogenase-elevating virus, **41:111–112, 122**
 - neurodegenerative diseases caused by prions, **41:253**
- Vesicular stomatitis virus**
- animal cells
 - endocytosis, **36:119, 123**
 - entry, **36:133, 135**
 - membrane fusion, **36:125–126**
 - receptors, **36:113, 116**
 - antiviral antibody affinity, **34:304**
 - Bunyaviridae, **40:261**
 - defective interfering viruses, **40:184, 186, 190–192**
 - DI particles, **29:83**
 - glycoproteins, **33:13–14**
 - cytoplasmic domain, **33:19–22**
 - ectodomain, **33:14–17**
 - transmembrane domain, **33:17–19**
 - G protein, structure, **29:109–110**
 - L protein, **38:104–109**
 - functional domains, **38:108–109**
 - primary structure, **38:105–108**
 - nucleocapsid proteins, in transcription, **29:108**
- Paramyxoviridae, 39:134, 136**
- genome replication, **39:150–152**
 - transcription, **39:141–142**

- phosphoprotein NS in, **38:109–117**
 picornaviral genomes, **40:144**
 replication
 interferon-induced inhibition,
 38:182–185
 methionine deprivation, **33:340–341**
 RNA polymerase, **38:99–102**
 transcription complex, polypeptide
 composition, **38:100–101**
 transcription reaction, characteristics
 features, **38:101–104**
ts mutants, **26:40**
- Vibrio*, **29:264–265**
 antigenic structures, **29:264**
 kappa phage, **29:295**
 liberation, **29:296–297**
 morphology, **29:296**
 resistance, **29:297**
 NAG, **29:266**
 phage typing, **29:294**
 serotyping, **29:294**
 species, **29:264**
- Vibrio alginolyticus*, **29:264**
Vibrio cholerae, **29:264–266, 288, 304–305**
 bacteriocins, **29:299**
 biotypes, **29:265**
 classical, **29:265**
 classical and El Tor, classification,
 29:272, 277, 291–293
 El Tor, **29:265**
 Celebes-type, **29:294–295, 297**
 Classic-Ubon type, **29:294, 297**
 diagnosis, **29:297**
 kappa-type, **29:294–295**
 oral vaccination, **41:426–427**
 phage-induced mutation, **29:298**
 strains change, **29:298**
- Vibriocins, **29:265, 298–306, see also**
 Bacteriocins; Colicins
 bacteria typing, **29:304**
 chemical properties, **29:302–303**
 detection, **29:299–301**
 diagnostic use, **29:306**
 discovery, **29:299**
 host range, **29:301**
 mode of action, **29:303–304**
 morphology, **29:301–302**
 physical properties, **29:302–303**
 practical use, **29:304–306**
 production, **29:299–300**
 streptomycin-resistant, **29:299–300**
 streptomycin-sensitive, **29:299**
- Vibrio parahaemolyticus*, **29:264, 266**
 morphology groups, **29:284–285**
 phages, **29:283**
- Vibriophage, **29:263–298**
 biological properties, **29:266–267**
 classification, **29:286, 290**
 components, **29:287–290**
 nucleic acids, **29:287–289**
 proteins, **29:288–290**
 dimensions, **29:287–288**
 host range, **29:266–267**
 inactivation, **29:281–282**
 by chemicals, **29:282**
 by heat, **29:278–280**
 pH, **29:283**
 inoviridae, **29:291–292**
 intracellular, **29:272–276**
 lysogenic, **29:294–298**
 biological properties, **29:295–297**
 for diagnosis and tracing of cholera
 El Tor carriers, **29:297–298**
 host range, **29:295**
 liberation of kappa phage, **29:296–297**
 morphology, **29:296**
 practical use, **29:297**
 resistance, **29:297**
 serological properties, **29:295–296**
 for typing of El Tor vibrios, **29:297**
 morphology, **29:283–287**
 multiplication, **29:272, 276**
 myoviridae, **29:286, 291–292**
 phage adsorption, **29:267–272**
 photoreactivation, **29:279–285**
 plaque morphology, **29:267**
 podoviridae, **29:286, 291–292**
 research, historical background,
 29:265–266
 sedimentation properties, **29:287, 289**
 sensitivity to physical and chemical
 agents, **29:278–283**
 serological properties, **29:276–277**
 styloviridae, **29:286, 291–292**
 ultraviolet inactivation, **29:279–285**
 uses, **29:292–294**
 epidemiological, **29:294**
 prophylactic, **29:293**
 therapeutic, **29:293**

- Vicia cryptic virus*, cellular location in plants, 32:192–193
- Vicia faba*, cucumber mosaic virus, 41:314–315
- Victoriocin, 43:343–344
- Vidarabine, carrier-mediated delivery, 35:273, 298
macromolecular carriers, 35:290–291
prodrugs of, 35:280–284
side effects, 35:272
- vif*, in HIV gene expression control, 38:135–136
- Vif protein
feline immunodeficiency virus, 45:235–236
HIV-1, 40:12–13
- vif protein, HIV structure, 39:50, 55
- Vigna sesquipedalis*, leaf protoplasts, virus infection, 29:228
- Vigna sinensis unguiculata*
facultative resistance, 29:340
resistance to viruses, 29:339
virus infection, 29:228
- Vinca rosea*
cell suspension, inoculation with TMV-RNA, 29:239
protoplasts
auxin requirement, 29:224
isolation, 29:225
- Vinculin, alteration in RSV-transformed cells, 32:1115
- 5-Vinyl-1 β -D-arabinofuranosyluracil, antiviral activity, 30:103
- Viral α , synthesis, in HSV replication, 37:90–92
- Viral–bacterial synergistic interaction in respiratory disease
bacterial adherence, 35:222–224
bacterial effects on host defense mechanisms, 35:232–234
control of, 35:237–241
antiviral chemotherapy, 35:239–241
immunomodulators, 35:241
virus vaccines, 35:238–239
general considerations for, 35:219–220, 242–243
immunopathology, 35:236–237
predisposing factors, 35:234–236
respiratory defense mechanisms, 35:224–227
- viral effects
nonspecific host defense mechanisms, 35:227–230
specific host defense mechanisms, 35:230–232
virus infections, 35:220
- Viral–bacterial synergy, bovine herpesvirus role, 45:204–206
- Viral coat protein genes, in viral transport function, 38:230–231
- Viral-coded trans-activator, RSV RNA, 35:13
- Viral demyelination, 42:249–297
AIDS, 42:284–285
animal models, 42:251–252
canine distemper virus, 42:278–280
experimental virus-induced demyelinations, 42:280–281
mouse hepatitis virus, 42:261–265
Semliki Forest virus, 42:270–275
Theiler's virus, 42:266–270
visna virus, 42:275–278
autoimmune mechanisms, 42:294–296
autoreactivity to CNS antigens, 42:296
CNS structure and functional organization, 42:252–256
cross-reactivity between viral and host cell proteins, 42:296
demyelinating viruses, 42:252
epidemics, 42:289
expression of viral proteins, 42:292–293
genetic control of immune response, 42:290
HIV, 42:284–285
HTLV-I-associated, 42:286
initiation of infection, 42:289
mechanisms, 42:291–296
multiple sclerosis, 42:286
mutations in RNA genomes, 42:288
postinfectious encephalomyelitis, 42:281–282
progressive multifocal leukoencephalopathy, 42:283–284
subacute sclerosing panencephalitis, 42:282–283, 287–288
viral-specific T-cell destruction, 42:293–294
virus and host genetics, 42:286–291
- Viral diagnosis, 27:1–69
artifacts in, 27:46–49

- brain tissue, 27:33–38
- breast milk, 27:32
- cell cultures, 27:42–43
- cerebrospinal fluid, 27:32
- clinical applications, 27:42–46
- density gradients, 27:44–45
- by electron microscopy, 27:1–69
- feces, 27:27–32
- gel diffusions, 27:44
- laboratory animals, 27:45–47
- liver tissue, 27:38–40
- nasopharyngeal secretions, 27:23–24
- serum, 27:24–26
- skin and mucous membranes, 27:21–23
- tissues, 27:33–42
 - tumor, 27:40–42
- urine, 27:26–27
- Viral diseases, transmission by arthropod vectors, 33:327–328
- Viral DNA, replication, 37:102–112
- Viral *erbB* gene, in signal transduction, 37:6
- Viral HSV DNA polymerase, properties, 37:104–105
- Viral infection, *see also* Antisense treatment, viral infection
 - acute and persistent, immunological memory impairment, 45:47
 - adeno-associated virus, 25:418–420
 - apoptosis mediated by B cells, 45:30–32
 - cell lysis by TNF- α , 45:28–30
 - effect on target susceptibility to CTL-mediated DNA fragmentation, 45:26–28
 - as public health problem, 44:268
 - transcription during, host regulation, 44:24–25
- Viral oncogenicity, adenovirus, 25:436–437
- Viral penetration stages, 27:143–167, 170–173
 - adenoviruses, 27:191–192
 - endocytosis, 27:151–154
 - fusion, 27:154–159
 - herpesviruses, 27:185–187
 - orthomyxoviruses, 27:167–174
 - papovaviruses, 27:192–195
 - paramyxoviruses, 27:175–176
 - picornaviruses, 27:187–189
 - reoviruses, 27:189–191
 - retroviruses, 27:182–185
 - rhabdoviruses, 27:178–180
 - togaviruses, 27:181–182
- Viral persistence, 46:313–339
 - iridoviruses
 - alternative hosts, 46:398–399
 - in host populations, 46:396–397
 - physical, 46:395
 - requirements
 - avoidance of recognition of infected cells by specific immune response, 46:316–318
 - block of action of nonspecific antiviral defense mechanisms on infected cells, 46:318–319
 - essential, 46:315
 - induction of suppression of host immune response, 46:319–321
 - nonlytic strategy of replication, 46:321–322
 - virus-induced changes in cells, 46:316–321
 - virus-induced alterations, host cellular differentiated functions in absence of cytolysis, 46:323–338
 - experimental evidence, 46:323–324
 - growth hormone deficiency syndrome, 46:324–333
 - neuroendocrine dysfunctions, 46:333–337
 - viral interactions with cytoskeleton, 46:337–338
- Viral products
 - heterologous, HIV expression inhibition, 43:120–121
 - interference
 - association of viral protein with host chromatin, 33:243–247
 - early events in virus-host recognition, 33:241–243
- Viral protein 1, Theiler's murine virus, 39:293, 296
- Viral proteins
 - conformational changes and complex formation, 29:116–118
 - essential for PRD1 DNA replication, 45:303–304
 - HSV DNA replication
 - organization in nucleus, 37:108–111
 - properties, 37:104–106
 - maturation, 29:115–116

- Viral proteins (*cont.*)
 pestiviruses, 41:78–83, 86, 90
 processing, 29:115
 proton motive model, 45:68–70
 purification, 29:118
 quantitation, 29:118
Totivirus, 43:309
- Viral receptors, 42:330–331
 proteins as, 44:204–206
 specificity, 44:203–204
- Viral satellites, symptoms of infection, 33:216, 223
- Viral strains, banana bunchy top virus, 33:309–310
- Viral suspension, killed antiviral vaccines, 39:265–266, 268, 270, 283
- Viral *trans*-activation of cellular transcription, 37:70, 74
- Viral transmission
 by arthropods, 43:13
 pararetroviruses and retroviruses, 44:11–13
- Viral vectors
 gene replacement therapy, 47:303–304
 as probes, 47:304
- Viremia
 hepatitis A virus, 39:219
 lactate dehydrogenase-elevating virus, 41:103–104, 107, 113, 115–116, 123, 154
 lentiviruses, 34:202, 205–207
 pestiviruses, 41:83–84, 90–91
 border disease virus, 41:66
 bovine viral diarrhea virus, 41:60–61, 64–65
 comparisons, 41:69–71
 properties, 41:81
 poliovirus, 34:220–221
 during primary varicella-zoster virus infection, 46:267–271
 simian hemorrhagic fever virus, 41:170, 175–178
 varicella-zoster virus reactivation, 46:271–273
- Virino theory, 35:85; 43:43
- Virion
 bacteriophage ϕ 6, 35:141–151
 bunyaviruses, pathogenesis, 30:302–304
 coat protein, 25:148–150
 composition, 25:148–152
 cucumber mosaic virus, 41:287, 293, 309
 envelope antigens, methods for studying, 25:461–463
 equine arteritis virus, 41:156, 161, 163–168
 FV3
 composition and processing, 30:2–3
 in mRNA transcription, 30:14–15
 human papillomaviruses, properties, 37:127–128
 inoculum, minimal concentration, 25:249–251
in vitro properties, 25:142–144
 iridoviruses, packaging, 46:382–383
 lactate dehydrogenase-elevating virus
 age-dependent poliomyelitis, 41:127
 mice, 41:104, 112, 123–124
 molecular properties, 41:144–150
 morphology, 25:144–148
 nucleic acids, 25:150–152
 paramyxoviridae, structure, 37:213–217
 pestiviruses, 41:72, 79
 purification, 25:138–142
 sap, properties in, 25:137–138
 simian hemorrhagic fever virus, 41:178–179
 translational suppression by retroviruses, 41:194, 197, 202
- Virion assembly
 adeno-associated virus, 25:429–431
 structure, 25:409–416
 coronaviruses, cytopathic effects, 28:79–83
 hepadnaviruses, in hepatocytes, 32:55–56
 in HSV replication, 37:113, 115
 parvovirus, 33:162, 164
 parvovirus proteins, 33:163–164
Totivirus, replication strategy, 43:311–314
- Virion precipitation test, envelope antigens, 25:463
- Virion proteins, human herpesvirus 6, 41:19–21
- Virion protein U, 44:244–245
- Viroids, 28:19, 241–283; 29:256
 bioassay, 28:251
 cell culture systems, 28:250–251
 classification, 28:243–244

- control of diseases caused by, **28:277–278**
- developmental effects, **26:93–97**
- experimental hosts and biological procedures for, **28:249–252**
- functions, **28:260–273**
- identification, **28:251**
- interactions with viruses, **28:248**
- molecular structure, **28:252–260**
- natural diseases, **28:244–249**
- ecology, **28:245–247**
- transmission and symptomatology, **28:247–248**
- nucleotide sequences, **28:253–260**
- nucleus, **33:246**
- pathogenesis, **33:233**
- mechanisms, **28:273**
- plant cell culture infection with, **29:250–251**
- possible animal-type, **28:276–277**
- possible origin, **28:273–276**
- propagation, **28:249–250**
- protoplast infection with, **29:241–242**
- purification, **28:252**
- replication mechanism, **28:261–273**
- enzymes involved, **28:263–264**
- intermediates, **28:265–273**
- RNAs similar to, encapsulated, **28:248–249**
- subcellular location, **28:260**
- and viruses, lack of complementation, **38:238**
- Virology**
- diagnostic, **27:1–69**
- MAbs in, **29:95–130**
- plant, electrotransfection role, **37:339–341**
- Viropexis**, as receptor-mediated endocytosis, **27:151**
- Viroplasms**, **47:213**
- Viroporins**, **45:78–94**
- function, **45:95–96**
- HIV proteins, **45:81–86**
- gp41, **45:82–85**
- Vpu protein, **45:85–86**
- human papillomavirus, **45:91–92, 94**
- hydrophobicity plots, **45:92**
- influenza M2 protein, ionic pore formation, **45:86–89**
- membrane-active protein sequences, **45:93**
- picornavirus 3A protein, **45:79–81**
- pore-forming *vs.* ion-channel-forming proteins, **45:96–98**
- RSV SH protein, **45:91**
- structure, **45:94**
- togavirus 6K protein, **45:89–91**
- Virulence**
- emerging viruses, **41:182**
- equine arteritis virus, **41:156, 162**
- increasing and decreasing, **25:181–182**
- oral vaccination, **41:415, 429, 431–433, 436–437**
- pestiviruses, **41:56, 68, 87**
- simian hemorrhagic fever virus, **41:170–177**
- Virus-antibody interaction**, immunoelectron microscopy, **29:169**
- Virus assembly**, **29:116; 42:203–204**
- adenovirus, **25:393–396**
- Virus-associated RNA**, adenovirus, **39:100, 102**
- Virus binding site**, *Totivirus*, **43:315–317**
- Virus clearance**, simian hemorrhagic fever virus, **41:176–178**
- Virus ecology**, plant viruses in developing countries, **41:349, 351**
- Viruses**, *see also* Nonpersistent viruses;
- Plant viruses**
- antibody detection, **27:51–53**
- architecture, **29:117–118**
- examination, **29:117**
- arthropod transmission, **43:13**
- specificity, **33:328**
- attachment proteins, **27:148–150**
- bacteriophage relationship to, **27:254–260**
- in cell cultures
- mammals compared to, **26:42–47**
- persistence, **26:38–42**
- cell lines, susceptibilities of, **25:229**
- cells infected by, antigen reexpression in, **26:88–93**
- cell transformation by, **26:97–100**
- cellular receptors, **27:143–148**
- chemoprophylaxis, **26:47–49**
- chemotherapy, **26:37–64**
- with continuous (unipartite) genome, **25:35–48**
- defense against, interferon system, **42:90–95**
- as differentiation probes, **26:65–116**

Viruses (*cont.*)

effect on stem cell development, 26:85–88

entry into epithelial cell lines, 42:198–201

entry mechanisms, 45:63–64

gene expression in
intracellular factors affecting, 26:74–84

reprogramming by viruses, 26:84–100

gene organization in, 26:100–105

genetic material, penetration into host cell, 27:141–204

genetic organization, 27:256

genitourinary tract, 42:230–232

glassware, adsorption on, 25:254

glycoproteins, functions, 33:1

heterologous, and HIV expression, 43:107–115

identification, MAbs in, 29:99–104

inocula, storage at low temperatures, 25:226

insect, physical properties, 25:286

interaction with host, questions concerning, 33:330–331

latency, tissue tropisms, 26:69–72

local or systemic infections, polarized epithelial cell role, 42:209–211

as macromolecular assemblies, 28:176–185

in mammals, 26:42–47

morphology, 27:2–14

with multipartite genome, 25:48–68

mutations, 29:118

negative staining, 27:15–16

neutralization on vector cell monolayer, 25:259–262

nonenveloped
glycoproteins, 33:32

vectorial transport and release, 42:204–205

particles
co-entry of macromolecules promoted by, 45:64–68

early membrane permeabilization, 45:65–67

measurement, 27:13–14

passage through nonvector, 25:230

pathogenicity, 29:119–120

persistent infections of

as chemotherapy models, 26:37–64

immunopathogenic mechanisms, 26:45–47

stages, 26:41–42

Plantago, 27:103–140

list, 27:112–116

plant interactions with, 26:201–237

polarity and pathogenesis, 42:207–209

prions *vs.*, 35:85–87

protection with MAbs, 29:121–122

with protein-dependent tripartite genome, 25:48–54

with protein-independent tripartite genome, 25:54–58

purification, 25:223–224

release from polarized epithelial cells, 42:199–205

replication, regulation by defective viruses, 26:45

retroid, 32:35–87

role in infection
alteration in course of, 29:120–121

host range mutants restricted in *Aedes albopictus*, 33:343–347

mutant replication in methionine-starved *Aedes albopictus* cells, 33:358–362

mutants restricted to vertebrate cells, 33:348–358

seroidentification, 27:51

specific infectivities, 25:217–219

with surface projections, 27:9–11

thin sectioning, 27:19–20

transformation-specific proteins, 29:113

transmissibility, loss, vector, 25:217

transmission by vectors, infectivity to, 25:229–230

tumor-causing, *see* Tumor viruses

variants
isolation, 29:119–120

MAB selection, 29:110

vector cell monolayer, 25:198–200

wild-type, *see* Wild-type viruses

Virus-host recognition, early events in, 33:241–243

Virus-induced proteins, 29:332

Virus-like particles
Drosophila retrotransposons
intracellular cycles, 36:60–64

organization, 36:56, 58

- transcription, **36:75**
 formation by retroviruses and pararetroviruses, **44:51–52**
 hepatitis C virus, **40:78**
 hepatitis E virus, **40:87**
- Virus-neutralizing antibodies, oral vaccination, **41:410–414, 424, 438**
- Virus particle protein, of baculoviruses, **25:324**
- Virus-specific informosome-like ribonucleoprotein
 detection, **29:349–350**
 functions, **29:352–358**
 properties, **29:349–350**
 structure, **29:350–353**
- Virus-specific proteins, **29:322**
- Virus-specific ribonucleoprotein particles, **29:314**
- Virus strain, effect on transmissibility, **25:124–126**
- Virus structure, **28:175–240**
 assemblies and symmetry in, **28:181**
 helical symmetry in, **28:181**
 icosahedral designs in, **28:213–219**
 icosahedral symmetry in, **28:183–185**
 nucleoprotein rods and shells in, **28:185–219**
 viral membrane role, **28:219–235**
- Virus theory, **43:43**
- Virus-vector relationship, **25:120–122**
 susceptibility compared to nonvector, **25:230**
- Visna, **35:85**
- Visna virus, **42:275–278, 292**
 demyelination, **42:277–278**
 lentiviruses, **34:189–191**
 structure, **34:191–195**
 virus-host cell interaction *in vitro*, **34:196–199**
 virus-host cell interaction *in vivo*, **34:200–202, 204–208**
 neuropathogenesis, **42:276–277**
 persistent infection, **42:276**
 virology, **42:275–276**
- V-kit* gene in signal transduction, **37:6**
- VP4, viral hemagglutinin, in rotavirus, **38:27–29**
- VPg
 picornaviral genomes, **40:106, 115, 127, 154, 161**
- Theiler's murine encephalomyelitis virus, **39:293**
- VP6 protein, in single-shelled rotavirus particle, **38:5–7**
- vpr* gene
 HIV-1, **40:13**
 in HIV gene expression control, **38:136**
 HIV structure, **39:51, 56**
- V protein, Paramyxoviridae, **39:148**
- Vpr protein, **43:84**
 HIV-1, **40:12–13**
 HIV structure, **39:50**
- vpu* gene, in HIV gene expression control, **38:136**
- Vpu protein
 HIV-1, **40:12–14**
 HIV structure, **39:50, 55**
- VP-1/VP-2 genes, parvoviruses, functions, genetic analysis, **38:436–439**
- vpx protein, HIV structure, **39:50**
- V-rel* oncogene, in signal transduction, **37:17–18**
- vRNP, as possible element of transport function, **38:241**
- v-sis*, as growth factor, **37:4**
- Vulnerability, plant viruses in developing countries, **41:379, 397**

W

- Warts, papillomavirus, **37:128, 130**
- Wasp viruses, and virus-like particles, **31:309–311**
- Wasting syndrome, **46:333**
- Water-borne hepatitis, **39:210, 222, 236–237**
- Watermelon mosaic virus-II, potyvirus coat protein, **36:276, 292, 305**
- WCCV, *see* White clover cryptic virus
- Weeds
 cucumber mosaic virus, **41:336–337**
Plantago spp. as, **27:108–109**
 plant viruses in developing countries, **41:374, 376, 390**
- Western blotting
 prions, **35:112**
 PrP, **35:104**
- Western equine encephalitis virus, vector, **33:329**

- Western equine encephalomyelitis, characteristics and occurrence, **28:389–395**
- Western immunoblots, cucumber mosaic virus, **41:293–295**
- West Nile virus
 animal cells, **36:132–133**
 antigenic relationships, **31:116–117**
 neutralization by MAbs, **31:136**
 serological subgrouping, **31:108**
- Wheat, plant viruses in developing countries, **41:360**
- Wheat streak mosaic virus, **33:242**
- Wheat yellow leaf virus, **25:112–113**
- White clover cryptic virus
 cDNA production for RNA assay, **32:185**
 cellular location in plants, **32:192–193**
 in stolons, partial loss with time, **32:193–194**
 temperate virus, mixture of three viruses, **32:181**
- White clover mosaic virus, furoviruses, **36:21**
- Whitefly
 geminivirus transmission, **30:141–143**
 nonpersistent virus transmission vector, **31:390, 394**
 plant viruses in developing countries
 crop improvement, **41:358–359, 373–374, 376–377**
 remedial action, **41:380**
 transmissible mono- and bipartite closteroviruses, **47:135–136**
- Wild pig, ASF, **35:256**, *see also* African swine fever
- Wild-type viruses
 furoviruses, **36:23–26**
 picornaviruses, **36:153–154**
 genome, **36:162–165**
 protein analysis, **36:157, 160–161**
 recombinants, **36:168, 171**
 revertants, **36:166–168**
 RNA, **36:174**
 vaccine development, **36:176**
- Win 49 321, against poliovirus infection, **30:89**
- Win 41 258–3, HSV uncoating inhibition, **30:89–90**
- WIN compound, HIV structure, **39:21**
- Winter dysentery, torovirus role, **43:257**
- Wistar calf 3, **44:180, 183**
- Woodchuck, hepatitis delta virus-infected, **43:191–192**
- Woodchuck hepatitis B virus
 hepadnavirus, **34:66**
 characterization, **34:79, 85, 90**
 genome organization, **34:69**
 pre-S sequences, **34:98, 109–110**
 replication, **34:72**
 oral vaccination, **41:418, 422, 427**
- Wound tumor virus, **25:219; 29:64; 45:254, 259**
 capsomeres, **29:59**
 cDNA clones, **38:262–269**
 cloning, **38:260–262**
 collection on millipore filters, **25:254–257**
 defective interfering RNAs, genome function, **38:272–276**
 discovery, **29:58**
 enzymatic activities, **29:63**
 exvectorial isolates, **29:74**
 characterization, **29:74–78**
 genome patterns, **29:85**
 resemblance to defective interfering particles, **29:81–85**
 subgenomic RNAs associated with, **29:78–84**
 gene expression in cultured vector cells, **29:71–72**
 genome, **29:59–61**
 segment responsible for tumor induction, **29:88**
 genome organization, **38:260–288**
 growth in vector cell monolayer, **25:243–244**
 growth rate in vector, **29:72–73**
 host passage effects, **25:180**
 infection of plant host, **29:85–88**
 instability in His-Mg tumor extracts, **25:225**
 isolates, **29:73–74**
 KB infectivity standard, **25:226–228**
 loss of transmissibility, **29:73–78, 85**
 molecular biology, **29:57–93**
 physical properties, **29:58–59**
 polypeptides, **29:61–63**
 apparent molecular weights, **29:62, 71**
 encoded by segment 5, identification, **29:78**

- expression
 - in cell-free systems, 29:69–71
 - in cultured vector cells, 29:67–69
 - locations, 29:61
 - molecular weights, 29:61–63
 - outer-protein coat, 29:78
 - purified, stability, 25:225–226
 - regulated infection, in vector cells, 29:89
 - research, 29:89
 - root tumors, 29:85
 - segments, 29:59–60
 - sequence, 38:269–272
 - relationships, 45:262–265
 - specific infectivities, 25:257–259
 - studies, 29:58
 - subvectorial isolates, 29:74–75
 - transcriptase activity, 29:75
 - properties, 29:63–65
 - transcription, 29:63–67, 75
 - transcripts, 29:64–67; 38:277–278
 - isolation, 29:66–67
 - nomenclature, 29:66–67
 - translation, 29:67–72
 - transmission, 29:72–85
 - by leafhopper vector, 29:72–73
 - outer-protein coat polypeptides in, 29:78
 - studies, 29:89
 - tumor induction, 29:85–87, 89
 - role of growth hormones, 29:89–90
 - tumors
 - growth independent of exogenous growth hormone, 29:88
 - tissue culture studies, 29:87–88
 - in vector, growth, 25:246–248
 - in vector cells, regulated infection, 29:72
 - vectorial isolates, 29:74
 - genome patterns, 29:85
 - virion, 29:58–63
- X**
- Xenopus*
 - hepadnavirus, 34:99
 - oocytes
 - alfalfa mosaic virus RNA translation, 25:50
 - membrane permeability, modification, 45:87
 - picornaviral genomes, 40:148
 - X-mRNA, hepatitis B virus transcription, 47:261
 - X promoter, 44:21–22
 - X-ray crystallography
 - hepatitis A virus, 39:224
 - HIV structure, 39:8–10, 25, 31, 53
 - X-ray diffraction, HIV structure, 39:9–10, 56
 - X rays
 - antiviral antibody affinity, 34:299
 - influenza virus, 34:250, 254
 - m*-Xylene diamines, interferon type I induction, 30:119–120
 - Xylo 2'-5'A core, antiviral activity, 30:122
- Y**
- Yeast
 - animal cells, 36:118
 - antiviral system, 43:339–340
 - Drosophila* retrotransposons, 36:35
 - insertional mutagenesis, 36:88
 - intracellular cycles, 36:60, 64, 66
 - organization, 36:50, 59–60
 - scattered repetition, 36:42
 - hepadnavirus, 34:103
 - Yeast killer system, 43:347–356
 - immunity domain, 43:356
 - K1 toxin, functional domains, 43:355–356
 - M dsRNA structure, 43:347–350
 - properties, 43:348
 - toxin
 - mode of action, 43:353–356
 - processing, 43:350–353
 - subunits, 43:355
 - Yellow fever, 43:16
 - Yellow fever virus
 - antigenic relationships, 31:109–113
 - E protein-specific MAb
 - cross-immunofluorescence tests, 31:111
 - hemagglutination inhibition and neutralization titers, 31:112
 - specificity determination, 31:110

- Yellow fever virus (*cont.*)
 geographically defined variations,
 31:118
 isolation from mosquito cells,
 30:31
 picornaviruses, 36:153–154, 165,
 175
 strains, differentiation, MAbs in,
 29:102
 type-specific MAbs
 and cross-reactive MAbs,
 31:155
 reactivity with wild yellow fever
 strains, 31:119
- Yersinia, oral vaccination, 41:414, 427,
 436
- Ying-yang 1, human papilloma-
 virus transcription, 44:336–
 337
- Z**
- Zea mays*, leaf protoplasts, virus infec-
 tion, 29:229
- Zidovudine, 35:273–274; 42:27, 29–30
 HIV structure, 39:4, 30, 33
- Zinc
 furoviruses, 36:14
 hepadnavirus, 34:101
- Zinc levels, bacterial adherence, 35:223
- Zinga virus, study, MAbs in, 29:103
- Zonula adherens, 42:191–192
- Zonula occludens, 42:190–191
- Zoster
 chemotherapy, 28:334–345
 clinical aspects, 28:334
 pathogenesis, 28:330–331
- Zucchini yellow mosaic virus in develop-
 ing countries, 41:371, 377

CONTRIBUTOR INDEX

Boldface numerals indicate volume number

A

Ackermann, Hans-W., **27**:206
Afanasiev, Boris, **47**:303
Agius, Catherine T., **44**:357
Agol, Vadim I., **40**:103
Agranovsky, A. A., **47**:119
Ahlquist, Paul, **32**:215
Air, Gillian M., **31**:53
Altstein, Anatoli D., **25**:451
Anderson, B. N., **32**:129
Anderson, D. K., **28**:141
Anderson, David A., **39**:209
Anderson, Marie J., **46**:2
Ansardi, David, **46**:2
Antoni, Beth Ann, **43**:53
Arif, Basil M., **29**:195
Arnold, Edward, **39**:1
Arnold, Gail Ferstandig, **39**:1
Arrigo, Salvatore J., **38**:125
Arts, Eric J., **46**:99
Arvin, Ann M., **46**:265
Atabekov, J. G., **25**:1; **29**:313
Atabekov, Joseph G., **38**:201

B

Babiuk, Lorne A., **35**:219; **45**:191
Bamford, Dennis H., **45**:281
Bamford, Jaana K. H., **45**:281
Banerjee, Amiya K., **38**:99
Bar-Joseph, M., **25**:93
Baroudy, Bahige M., **40**:57
Bellamy, A. R., **38**:1
Belloncik, Serge, **37**:173
Berns, K. I., **25**:407
Berns, Kenneth I., **32**:243
Bishop, David H.L.(31:1
Black, Jodi B., **41**:1
Black, L. M., **25**:192
Boccardo, Guido, **32**:171
Bohenzky, Roy A., **32**:243; **42**:103
Bos, L., **41**:349
Bose, Jr., Henry R., **37**:1

Both, G. W., **38**:1
Bouloy, Michele, **40**:235
Bour, Stephane, **44**:203
Bove, J. M., **44**:429
Brunt, Alan A., **36**:1
Buchmeier, Michael J., **42**:187
Buck, Kenneth W., **47**:159
Budowsky, E. I., **39**:255
Bujarski, Jozef J., **32**:215; **43**:275
Bukrinskaya, A. G., **27**:141
Bulla, Jr., L. A., **28**:141
Burgyan, Jozsef, **44**:382

C

Caldentey, Javier, **45**:281
Campos, Manuel, **45**:191
Canonic, Peter G., **35**:271
Carlson, Jonathan O., **47**:303
Carrasco, Luis, **45**:61
Carter, Michael J., **29**:95
Caselmann, Wolfgang H., **47**:253
Chapdelaine, Yvan, **44**:1
Chatterjee, S. N., **29**:264
Chattopadhyay, Dhrubajyoti, **38**:99
Cheevers, William P., **34**:189
Chen, Irvin S. Y., **38**:125
Chen-Kiang, Selina, **26**:1
Cohen, Jeffrey I., **36**:153
Compans, Richard W., **42**:187
Consigli, R. A., **28**:141
Corsini, Joe, **47**:303
Cotmore, Susan F., **33**:91
Coulepis, A. G., **32**:129
Crabb, Brendan S., **45**:153
Croizier, G., **26**:118
Cullen, Bryan R., **30**:180; **40**:1

D

Dale, James L., **33**:301
Dall, David J., **38**:249
Davies, J. W., **28**:1

Dawson, William O., 38:307
 De Clercq, Eric, 42:1
 de la Torre, Juan Carlos, 46:313
 de The, Guy, 47:377
 Desselberger, Ulrich, 46:71
 Diener, T. O., 28:241
 Dietzgen, Ralf G., 29:131; 41:282
 Doerfler, Walter, 39:89
 Dorokhov, Yu. L., 29:313

E

Echalier, G., 36:34
 Elder, John H., 45:225
 Engler, W. F., 30:43

F

Fallows, Dorothy A., 46:167
 Fazakerley, John K., 42:187
 Feldmann, Heinz, 47:1
 Field, Anne M., 27:2
 Flasiniski, Stanislaw, 43:275
 Flint, S. J., 31:169
 Francki, Richard I. B., 41:282
 French, Roy, 32:215
 Frey, Teryl K., 44:69
 Fujinami, Robert S., 39:291

G

Gabrielsen, Bjarne, 35:271
 Gahn, Toni A., 40:19
 Galinski, Mark S., 39:129
 Galloway, Denise A., 37:126
 Garnsey, S. M., 25:93
 Geleziunas, Romas, 44:203
 Gessain, Antoine, 47:377
 Ghabrial, Said A., 43:303
 Gilden, Raymond V., 27:281
 Goff, Stephen P., 46:167
 Gonsalves, D., 25:93
 Goorha, R., 30:1
 Granoff, A., 30:1
 Greenberg, Harry B., 36:181
 Greene, Mark I., 42:325
 Griffin, Diane E., 36:255
 Grimstad, Paul R., 28:357
 Gust, I. D., 32:129
 Gust, Ian D., 39:209

H

Hakulinen, Juha, 42:149
 Hammond, John, 27:104
 Harrap, K. A., 25:273
 Harris, Kerry F., 28:113
 Harrison, Stephen C., 28:175
 Hatfield, Dolph L., 41:193
 Hauswirth, W. W., 25:407
 Heinz, Franz X., 31:103
 Helenius, Ari, 36:107
 Herrler, Georg, 40:213
 Hibi, Tadaaki, 37:329
 Hirai, Kanji, 30:225
 Hirth, L., 26:145
 Hiruki, C., 33:257
 Hohn, Thomas, 44:1
 Holland, John J., 40:181
 Holmes, Kathryn V., 28:36
 Horzinek, Marian C., 43:233
 Hovi, Tapani, 37:244
 Huang, C. H., 27:72
 Hull, R., 28:1
 Hull, Roger, 32:35
 Huppert, J., 31:357
 Hyoty, Heikki, 42:149
 Hyypia, Timo, 42:343

I

Igarashi, Akira, 30:21

J

Jahn, Gerhard, 46:197
 Ju, Grace, 30:180

K

Kang, C. Yong, 35:177
 Kantanen, Marja-Leena, 42:149
 Kato, Shiro, 30:225
 Katz, David, 29:169
 Kawai, Sadaaki, 32:97
 Kelly, Thomas J., 34:1
 Kende, Meir, 35:271
 Kent, Stephen B. H., 34:65
 Kielian, Margaret, 45:113
 Kimura, Ikuo, 45:249
 Klenk, Hans-Dieter, 34:247; 40:213; 47:1

Knipe, David M., 37:85
 Koblet, Hans, 38:343
 Koenig, Renate, 31:321
 Kohn, Alexander, 29:169
 Koopmans, Marion, 43:233
 Kozak, Marilyn, 31:229

L

Laver, W. Graeme, 31:53
 Lawman, M. J. P., 35:219
 Lazinski, David W., 43:188
 Lehtinen, Matti, 42:149
 Lehto, Kirsi M., 38:307
 Leinikki, Pauli, 42:149
 Levin, Judith G., 41:193
 Levine, Arnold J., 26:65
 Li, Joachim, 34:1
 Lisa, Vittoria, 32:171
 Longworth, J. F., 26:118
 Luisoni, Enrico, 32:171

M

Mackow, Erich R., 36:181
 Maiti, M., 29:264
 Maltzman, Warren, 26:65
 Marsh, Mark, 36:107
 Martelli, Giovanni P., 44:382
 Martin, Jennifer M., 40:19
 Marusyk, Raymond, 37:211
 Mason, William S., 32:35
 Matsui, Suzanne M., 36:181
 Maxwell, Ian H., 47:303
 Mayo, M. A., 46:416
 Mazzone, H. M., 30:43; 31:293
 McDougall, James K., 37:126
 McGuire, Travis C., 34:189
 McPhee, Dale A., 30:279
 Mebus, Charles A., 35:251
 Mertes, Gabriele, 29:215
 Meyers, Gregor, 47:53
 Middleton, Tim, 40:19
 Milne, Robert G., 32:171
 Mindich, Leonard, 35:137
 Moennig, Volker, 41:53; 99
 Moffat, Jennifer F., 46:265
 Morozov, S. Yu., 25:1
 Morrow, Casey D., 46:2
 Murphy, Frederick A., 43:2
 Murti, K. G., 30:1

N

Nagy, Peter D., 43:275
 Neurath, A. Robert, 34:65
 Nevins, Joseph R., 26:1; 37:35
 Norrby, Erling, 32:1
 Nuss, Donald L., 29:57; 38:249

O

Oediger, H., 30:83
 Offit, Paul A., 44:161
 Ohmann, H. Bielefeldt, 35:219
 Oldstone, Michael B. A., 46:313
 Oroszlan, Stephen, 41:193
 Ostrove, Jeffrey M., 38:45

P

Palm, Peter, 34:143
 Palukaitis, Peter, 41:282
 Paoletti, Enzo, 34:43
 Parkkonen, Paivi, 42:149
 Parrish, Colin R., 38:404
 Parsonson, Ian M., 30:279
 Passens, A., 30:83
 Payne, C. C., 25:273
 Pellett, Philip E., 41:1
 Philipson, Lennart, 25:357
 Phillips, Tom R., 45:225
 Piccini, Antonia, 34:43
 Plachter, Bodo, 46:197
 Plagemann, Peter G. W., 41:53, 99
 Podgwaite, J. D., 31:293
 Porter, Donna C., 46:2
 Porterfield, James S., 31:335
 Prusiner, Stanley B., 29:2; 35:83; 41:241

R

Rabin, Harvey, 27:281
 Rabson, Arnold B., 43:53
 Racaniello, Vincent R., 34:217
 Raccab, B., 31:387
 Ramig, Robert F., 39:164
 Ransohoff, Richard M., 42:57
 Razvi, Enal S., 45:2
 Reanney, Darryl C., 27:206
 Redman, Rebecca, 46:265
 Rein, Alan, 41:193

Reinganum, C., 26:118
 Reiter, Wolf-Dieter, 34:143
 Renaudin, J., 44:429
 Reyes, Gregory R., 40:57
 Richards, K. E., 26:145; 36:1
 Roossinck, Marilyn J., 41:282
 Rosenberg, Naomi, 35:40
 Ross, Bruce C., 39:209
 Rothnie, Helen M., 44:1
 Rott, Rudolf, 34:247
 Rouse, Barry T., 47:353
 Roux, Laurent, 40:181
 Russo, Marcello, 44:382

S

Salmi, Aimo, 37:211
 Sander, Evamarie, 29:131, 215
 Saragovi, Uri H., 42:325
 Sauve, Gordon J., 42:325
 Schlesinger, Milton J., 33:1
 Schlesinger, Sondra, 33:1
 Schodel, Florian, 41:409
 Scott, Thomas W., 37:277
 Scotti, P. D., 26:118
 Sela, Ilan, 26:201
 Sen, Ganes C., 42:57
 Shieh, T. R., 36:315
 Shikata, Eishiro, 45:249
 Shukla, D. D., 36:273
 Simon, Anne E., 40:181
 Sinzger, Christian, 46:197
 Smith, Jean S., 36:215
 Sonenberg, Nahum, 33:175
 Staeheli, Peter, 38:147
 Stanley, John, 30:139
 Stanway, Glyn, 42:343
 Stein, Steven B., 43:53
 Stollar, Victor, 33:327
 Stoltzfus, C. Martin, 35:1
 Storms, Robert W., 37:1
 Streissle, G., 26:37; 30:83
 Studdert, Michael J., 44:357; 45:153
 Sturman, Lawrence S., 28:36
 Sugden, Bill, 40:19

T

Takahashi, Michiaki, 28:286

Taliansky, Mikhail E., 38:201
 Tao, Hung, 35:193
 Tattersall, Peter, 33:91
 Taylor, John M., 32:35; 43:188
 ter Meulen, Volker, 29:95*
 Thiel, Heinz-Jurgen, 47:53
 Tien, Po, 39:321
 Tikoo, Suresh K., 45:191
 Toyoshima, Kumao, 32:97
 Tsiang, Henri, 42:375
 Tucker, Simon P., 42:187
 Turek, Lubomir P., 44:306
 Tweeten, K. A., 28:141

U

Underwood, P. Anne, 34:283
 Uyeda, Ichiro, 45:249

V

Vainionpaa, Raija, 37:211
 van Loon, L. C., 33:205

W

Wainberg, Mark A., 44:203; 46:99
 Ward, C. W., 36:273
 Ward, Richard L., 39:164
 Weaver, Scott C., 37:277
 Welsh, Raymond M., 45:2
 Westaway, E. G., 33:45
 Whitton, J. Lindsay, 44:268
 Wild, T. F., 31:357
 Williams, Trevor, 46:347
 Witte, Owen N., 35:40
 Wold, Marc S., 34:1
 Wray, G., 30:43
 Wu, Gusui, 39:321

Y


Yamada, Masahito, 39:291
 Yamamoto, Masahiro, 41:1
 Yamamoto, Tadashi, 32:97
 Yanagihara, Richard, 43:147
 Yarwood, C. E., 25:169
 Yoshida, Mitsuaki, 32:97

Z

Zack, Jerome A., **38:125**
Zhdanov, Victor M., **25:451**

Ziegler-Graff, V., **46:416**
Zillig, Wolfram, **34:143**
Zurbriggen, Andreas, **39:291**

ISBN 0-12-039849-4



9 780120 398492

90038